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CHAPTER 1
 
General Introduction

INTRODUCTION
Have you ever felt depressed? The answer to this question is usually “YES” and this is not 
unreasonable since most of us have felt depressed once or more in our life-time. Typically, 
“feeling depressed” or “feeling BLUE” is not more than the well-accepted low mood or just 
being temporarily unhappy. On the contrary, clinical depression is a serious neuropsychiatric 
mood disorder that has a leading role in the global burden of diseases causing much of the 
disability world-wide.1,2 Individuals suffering from depression have feelings of guilt, helplessness, 
hopelessness, are occupationally impaired, often have desire for social withdrawal, suffer from 
sleep and concentration disturbances, have a loss of interest in life-pleasures and almost all 
other activities, and suffer from a loss of appetite and sex drive.3 This extensive list of depressive 
symptoms can also include daily experience of suicidal thoughts that can result in a suicidal act.3 
As a matter of fact, depression is a complete contrast to the beauty of the colour BLUE; a colour 
that awakens feelings of tranquillity, stability and inspiration (Yves Klein dedicated a life-time of 
work to the colour blue: “Blue Revolution”).
®“Blue Monochrome (anthropometry)” - Yves Klein 1928-1962
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In the last 15 years a number of successful campaigns took place around the world to raise the 
awareness for depression.4,5 One of the main goals of such campaigns was to reduce the stigma 
of depression and to clarify the differences between being sad and suffering from depressive 
disorders. These goals were mostly achieved and the knowledge over depressive illness among 
the public has increased. More persons have some understanding of the physical and mental 
exhaustion caused by this medical illness. However, the reality is: “We still do not completely 
understand all aspects of depression”! Even though depression may not be an enigma anymore, 
there are many core questions asked by lay people, medical doctors, and academic experts that 
remain unclear. One such question is “What actually causes depression?”! Briefly, this thesis is an 
attempt to unravel some aspects of the aetiology of depression.
IS DEPRESSION the DIABETES OF the BRAIN or a DEMONIC POSSESSION? A brief historical 
aspect
I would first like to quote the famous Chinese philosopher Confucius who said “Study the past 
if you would define the future”. Indeed, if we try to obtain new insights into the aetiology of 
depression and draw conclusions on this illness; and finally define some future perspectives for a 
better understanding of depression, we should certainly understand the history of this disorder. 
Throughout history, depression transformed from the old concept of melancholia to the current 
concept of depression which is mainly viewed as a multifactorial behavioural mental disorder. This 
transition did not occur all of a sudden, but throughout the centuries, many philosophers and 
scientists struggled explaining depression while facing a lot of controversies. This explains why 
studying depression and its aetiology is a great challenge even today.6
It was in the ancient times that the first theories were postulated to define and explain depression: 
Melancholia, a condition characterized by fear, loss-of appetite, and sleeplessness. The humoral 
theory proposed by Hippocrates (370-460 B.C), the father of medicine; explained melancholia.7 
According to the humoral concept melancholia was a condition caused by disequilibrium between 
the four humors and more specifically by an increase in the black bile.7 The core of this theory 
was slightly modified and edited during the centuries to come. It took almost 2,500 years to 
move from Hippocrates melancholia to Emil Kraepelin’s concept of depression (1856 –1926). He 
was the first scientist to propose the use of the term depression, but what made it so difficult to 
progress to defining depression as a disorder?8
In order to define this medical condition as a disorder, depression must be associated with specific 
symptoms and signs that are caused by external factors and internal dysfunctions. Scientists, 
doctors and people described and classified the symptoms of depression to a moderate extent. 
However, they faced difficulties in explaining and understanding what causes depression. 
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Depression was mainly viewed as a mental insanity characterized by personality changes and 
altered/disturbing emotions that did not have a clear cause. This limited understanding in what 
causes depression restrained the process of defining depression as a mental disorder.
In the golden scientific ages of the 19th and the 20th century, mental diseases for the first time, 
were proposed as diseases of the brain by Wilhelm Griesinger (1817-1869).10 Krapelin’s “unitary 
concept of depression” was the first theory to define depression as a unitary endogenous 
disorder.11 Based on clinical observations, this concept emphasized depression as a specific 
psychiatric illness characterized by a combination of several symptoms with a specific organic 
aetiology and pathology. Krapelin’s categorization of mental diseases established the basic tool 
for the widely-used classifications of mental disorders by the American Psychiatric Association 
(DSM-Classification)3 and the World Health Organization (International classification of Disease)12. 
However, these classifications do not account for the aetiology of the disease. A group of 
scientists, e.g. Meyer, refused to regard depression as a biological disease only and proposed to 
view depression as a psychobiological reaction of the human body to stress.13 Whether depression 
is a reactive answer to stress, a systemic disease, or both remains the object of discussion until 
today. Solving the aetiological puzzles would help to disentangle the true causes of depression 
and improve diagnosis.
Over the past 60 years, a large number of scientists spent literally hundreds of thousands of 
research hours, producing and publishing a substantial number of scientific articles on depression. 
This enormous work helped in better understanding the disease. One of the most remarkable 
scientific discovery of the last century (1952) was detecting the presence of serotonin in the 
brain and this discovery started the so-called antidepressant revolution.14 Betty Twarog was 
the first scientist to confirm that indeed depression is the diabetes of the brain and supported 
the biological theory defining depression as a mental disorder caused by an imbalance in brain 
neurotransmitters.15 This start of the era of antidepressant drugs, inspired many researchers to 
reconcile different aetiologic orientations of depression, from social-psychodynamic to biological 
aspects. Due to this work, many questions related to the causes of depression have been 
answered. However, the knowledge over the aetiology of depression remains patchy. Important 
elements in the aetiology of depression are still missing.
What do we really know about the AETIOLOGY OF DEPRESSION? – Epidemiological 
aspects
Depression is generally seen as a bio-psychosocial disease. Thus, there is no single explanation 
of what causes depression, and no minimalist aetiology could capture the complexity of this 
disorder. The academic world widely accepts depression as a complex multifactorial disease that 
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develops as a result of interaction and accumulation of various different psychosocial, biological 
and environmental risk factors. Psychosocial factors such as traumatic early-childhood events16 
such as abuse, socio-economic status17, marital status18, and loss of a partner19 are all established 
aetiologic risk factors involved in the pathogenesis of depression. These factors were observed by 
clinicians and are also related to depression in population-based studies. But these associations 
do not necessarily imply causality between two entities and the typically cross-sectional study 
design may only answer questions such as “Are older persons more likely to be depressed?” On 
the contrary, longitudinal study designs, such as those included in this thesis are more informative 
when we try to infer causality. Specifically, these designs help answer temporal questions: “Do 
events such as abuse precede depression?”. For a factor to be considered causal to depression, 
the time between that factor and the consequence is important and that factor has to precede the 
depressive event. Indeed, this conceptualizes the well-known criterion for temporality by Bradford 
Hill that perhaps is the only criterion which epidemiologists universally agree on and is essential 
to infer causality.20 Longitudinal studies are still relatively rare when studying aetiologic factors 
of depression and therefore most studies presented in this thesis are focused on investigations 
performed within a longitudinal framework.
Various biological factors such as neuroendocrine, neuro-immunological, and genetic, have been 
related to depression and have an important role in the complex aetiology of this disease.21-23 
However, whether these factors are in the causal path to development of depression or they 
appear as a consequence of depression it is still unclear. In this thesis we carefully study few blood 
extracted neuro-inflammatory markers such as interleukin (IL)-6, alpha-1-antichymotrypsin (ACT) 
and C reactive protein (CRP) as well as serum vitamin D levels (a neuroendocrine factor) and their 
impact on the development of depression. These potential biomarkers could reflect a disease 
cause, biological signals of a pathophysiological processes related to extraneous factors, or 
response to a therapeutic intervention specific to depression, or a related condition.21 Determining 
such biomarkers for depression could one day have an influential role in clinical practice and may 
increase the possibility for early detection, treatment and successful management of depression.24
Moreover, psychiatric epidemiology traditionally showed more interest in studying risk factors for 
depression than studying the consequences of depression for health in the general population. 
Taking into account that depression threatens to become the leading global cause of disability2, 
the interest to study the long-term consequences of depression rises. Therefore, one of the studies 
described in this thesis studies the cognitive decline that appears as a long-term consequence in 
persons suffering from depression.
In order to completely understand the biology and the pathophysiology of depression, we need 
to identify genetic loci susceptible of depression, determine the genetic risk, and understand the 
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involvement of those genes in the pathology of depression. The technical development in the last 
years has allowed easy and cheap DNA sequencing, thus studying the genetics of depression on 
a large epidemiologic scale became easily accessible. Many studies aimed to identify common 
genetic variation involved in depression using large scale genome-wide association studies (GWAS) 
were performed.25 Only recently, one study showed that 44 different common genetic variants 
are associated with depression (study under review). Compared to other outcomes studied with 
GWAS medical studies, those studying depression are challenging and with moderate success 
only. Genetic epidemiological research using genotyping arrays approach has detected common 
variants with small effect sizes which may not be appropriate when studying heterogenetic traits 
such as depressive disorder.26 In addition to the common genetic variants, rare variants with 
substantial effect sizes may also be involved in the development of depression. Therefore, exome-
sequencing and exome-chip genotyping methods were proposed as a good solution in order to 
identify rare genetic variants associated with depression.27 This thesis presents two studies that 
employ such methods in discovering rare variants with possible large effects on depression in the 
general population.
Depression is a mental disorder with an estimated heritability from 30 to 40%, and most of 
the risk for depression is explained by environmental factors.22 A complex interplay between 
environment and genetics is conceptualized to increase neurodevelopmental processes involved 
in depression.28 The basis of this hypothesis, as well as the moderate success in determining the 
genetic risk for depression, increased the interest in studying the epigenetics of depression. A few 
investigations in post-mortem depression patients have performed epigenome wide association 
studies (EWAS)29, however a population-based study has not yet been conducted. Such an 
approach is essential in detecting epigenetic associations for psychiatric conditions given the lack 
of prior knowledge.22 Therefore, in Chapter 4 we present the first and the largest population-
based EWAS of depression.
AIMS
This thesis includes several population-based studies that explore the aetiology of depression, 
with a specific interest on biological factors, genetics and epigenetics, and physical health factors 
for depression.
Unravelling the aetiology of depression could potentially answer some remaining questions about 
depression, and finally may explain why we consistently fail to develop effective management 
and treatment tools for depression. Therefore, this thesis aims to apply advanced epidemiological 
studies and to extend the existing knowledge on the aetiology of depression. Using population-
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based data, the studies described in this thesis examine several risk factors and predictors that 
may enlighten the pathophysiological mechanism that underlie the development of depression. 
Specifically, Chapter 2 of this thesis presents longitudinal studies that examine the impact of 
potential biomarkers, such as vitamin D (Chapter 2.1), and inflammatory markers (Chapter 2.2) 
on the occurrence of depression. Chapter 3 of this thesis presents two studies which apply 
advanced genetic epidemiological methods to study the genetics of depression. Chapter 4 
focuses on the epigenetics of depression and presents the largest epigenome wide association 
population-based study so far. Moreover, we dedicated a chapter to the impact of physical health 
conditions such as myocardial infarct on depression (Chapter 5.1) as well as one to the physical 
consequences of depression such as cognitive decline (Chapter 5.2). Finally, Chapter 6 provides 
a more general discussion of the main findings in this thesis and addresses several methodological 
considerations of the studies. Clinical implications of the results in this thesis, and future directions 
are also presented.
SETTING
The studies described in this thesis are large population-based studies of older adults screened 
for depressive symptoms and continuously followed for the occurrence of depressive disorders. 
Data presented in Chapter 4 includes eleven large, population-based cohorts that contributed 
to an epigenome-wide meta-analysis and a replication analysis within the Cohorts for Heart 
and Aging Research in Genomic Epidemiology (CHARGE) Consortium. The remaining chapters 
present studies embedded in the Rotterdam Study, a population-based cohort that enrolled 
14 926 adults aged 45 and older in Rotterdam, the Netherlands.30 Participants underwent cycles 
of extensive home interviews and research examinations every 3 to 4 years. During the home 
interview participants were asked to self-report on the presence of depressive symptoms (using 
the Center for Epidemiologic Studies Depression Scale - CES-D). Those with clinically relevant 
depressive symptoms underwent a semi-structured psychiatric interview (Schedules for Clinical 
assessment in Neuropsychiatry - SCAN) during the research centre visit to diagnose depressive 
disorders. Moreover, participants were continuously monitored for various disorders, among 
which depression, via computerized linkage of data retrieved from pharmacists and general 
practitioner’s reports. Detailed depression assessment was conducted since 1993 onwards.31 A 
diagram of the depression assessment within the Rotterdam Study is presented in Figure 1.
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Figure 1. Diagram of measurements of depression in the Rotterdam Study used in the current thesis.
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CHAPTER 2
 
Biomarkers for depression

CHAPTER 2.1
 
Vitamin D serum levels 
and depression in the elderly
Jovanova Olivera, Aarts Nikkie, Noordam Raymond, Carola Zillikens, 
Hofman Albert, Tiemeier Henning 
ACTA Psychiatrica Scandinavica. 2017 Mar; 135(3):185-194
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ABSTRACT
Objective: The evidence for a prospective association of vitamin D deficiency with the occurrence 
of late-life depression is limited. We aimed to study the long-term association between vitamin D 
serum levels and depression in a large population-based study of older adults.
Method: We included 3 251 participants from the Rotterdam Study, aged 55 and older with 32 
400 person-years follow-up for depression. Baseline 25-Hydroxivitamin D (25(OH)D) serum levels 
were analyzed continuously and categorically. Repeated depressive symptoms questionnaire 
assessments were used to assess the change of depressive symptoms. Semi-structured psychiatric 
interviews, and GP-records were used to assess incident major depressive disorder according to 
DSM-IV criteria.
Results: Low serum vitamin D levels were cross-sectionally associated with more depressive 
symptoms. However, low 25(OH)D serum levels were not prospectively associated with change of 
depressive symptoms (unstandardized beta β = 0.02, 95%CI = -0.23; p = 0.26) or incident MDD 
(hazard ratio HR = 0.95, 95%CI = 0.86; p = 1.05).
Conclusion: We observed a cross-sectional but no prospective association between serum 
vitamin D levels and depression. A cross-sectional association in the absence of the longitudinal 
association can mostly be attributed to reverse causality or residual confounding. Probably, 
vitamin D deficiency is not an independent risk factor for depression but co-occurs with late-life 
depression.
Significant outcomes: 1. Serum vitamin D deficiency and late-life depression are not prospectively 
associated. 2. Only in the cross-sectional analysis we observed that older persons with lower 
vitamin D serum levels were more likely to have more depressive symptoms. 3. This study provides 
further evidence that vitamin D deficiency accompanies late-life depression, but does not suggest 
a causal role of vitamin D deficiency in the development of depression.
Limitations: 1. This study reports analysis of single intra-individual assessment of vitamin D serum 
levels thus variability of vitamin D serum levels over time cannot be observed. 2. This observational 
study design limits the possibility to address reverse causality and draw conclusion about the 
directionality of the association between vitamin D serum levels and depression.
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INTRODUCTION
Chronic/long-standing vitamin D deficiency is a common health risk factor that affects as many 
as one third to half of all elderly people world-wide.1-3 The main sources of this neuro-steroid 
hormone are the synthesis in the skin in response to sunlight exposure and dietary intake. In the 
elderly, the skin capacity to synthesize vitamin D is reduced up to 25%.4 Often the frequency of 
outdoor physical activity and the sunlight exposure are also low, making older people prone to 
vitamin D deficiency.5
Vitamin D deficiency and depression can coexist during late-life. It has been reported that one 
in every five geriatric patients with vitamin D deficiency suffer from depression.6 A growing 
body of epidemiological evidence reports a relationship between low 25(OH)D serum levels and 
depression.7-9 Several studies showed a consistent cross-sectional relationship between low serum 
levels of 25(OH)D and more depressive symptoms in older adults.6,8,10 Yet, few epidemiological 
studies addressed the longitudinal relationship between vitamin D deficiency and late-life 
depression, and yielded inconclusive results, or failed to confirm the possible relationship.7,8,10-13 
Two recently published reviews concluded that the available prospective data is scarce, the 
analysis are not comprehensive, and the reported estimates were not precise.8,14 In order to clarify 
the uncertainty about a prospective association between vitamin D and depression well-designed 
longitudinal studies are needed.8,14
Further, the few available longitudinal studies had limited precision for defining vitamin D 
deficiency and used different cut-offs. Second, their results were mostly based on self-reported 
depressive symptoms, thus the association with well-defined cases of major depression remains 
understudied in prospective research.8,11 Third, three of the previous reports were focused on men 
and one of these was conducted in cardiovascular patients. These studies cannot necessarily be 
considered representative of the general population.7,13,15
Forth, potential confounding bias is a main challenge of all vitamin D studies.8 Serum 25(OH)D 
levels depend on UVB-induced synthesis; thus sunlight exposure, season, and outside activity, are 
all relevant determinants of a person’s serum 25(OH)D levels. Sunlight exposure is correlated with 
both vitamin D serum deficiency and depression and its confounding effect on this relationship 
was previously acknowledged.8 Still, whether sunlight exposure and health-related problems 
influence the prospective association between 25(OH)D serum levels and depression is not well 
understood.8
Importantly, it is uncertain whether vitamin D deficiency is an independent risk factor for 
depression or a marker of poor health status that occurs as a consequence of a prior depression 
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or other chronic diseases.8,10 Earlier studies indicate that vitamin D deficiency may contribute to 
the development of many systemic diseases like cardiovascular diseases, diabetes, and cancer; all 
highly prevalent in elderly population.2,3,16,17
Aims of the study
In conclusion, the cross-sectional association between vitamin D and depression is observed 
consistently. In contrast, the more recently published prospective studies reported inconsistent 
results and failed to establish a longitudinal association. Given the inconclusive evidence of a 
longitudinal association between vitamin D deficiency and depression, additional prospective 
studies are needed. In the current study we sought to clarify whether vitamin D serum levels are 
prospectively associated with depression, using data with a well-defined change of depressive 
symptoms as well as major depression during follow-up. The first aim was to replicate the cross-
sectional relation between vitamin D and depressive symptoms. The second aim was to explore 
whether there is any long-term relationship of the vitamin D serum levels with the change of 
depressive symptoms or with incident major depression. We hypothesized that 25(OH)D serum 
levels are not only cross-sectionally associated with depression but also affect the risk of incident 
depression after carefully controlling for confounders.
METHODS
Study population
The present study was embedded in the Rotterdam Study, a population-based cohort designed to 
investigate diseases and their determinants among people aged 55 years and older. All residents of 
a district in Rotterdam, The Netherlands, were invited to participate.18 Trained research assistants 
collected data on health, medication use, medical and family history, and lifestyle factors in 
extensive home interviews. From March 1997 till December 1999 (baseline of this study), 4 214 
participants visited the research center for clinical examination and blood sampling. Blood serum 
sample of 25(OH)D was available for 3 828 participants. Out of these, 562 participants with 
an Mini-Mental State Examination (MMSE) score < 26 or missing, were excluded.19 Another 15 
participants, with no assessment of baseline depressive symptoms (CES-D - the Dutch version of 
the Centre for Epidemiologic Studies Depression scale) were excluded; leaving 3 251 participants 
in the study population. Women (57% versus 61%, p = 0.03), younger persons (mean age 72 
versus 75 years, p < 0.05); and those with less depressive symptoms (mean CES-D score 4 versus 
5.8, p < 0.05) were more likely to take part in our study.
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The medical ethics committee approved the study (Wet Bevolkingsonderzoek-Population Study 
Act executed by the Ministry of Health, the Netherlands).18 Written informed consent was 
obtained for all participants.
Vitamin D
Vitamin D was measured at baseline only, by assessing serum levels of 25(OH)D. This is the product 
of cutaneous synthesis from sun exposure and dietary sources, and after 25 hydroxylation in the 
liver; it represents the major storage form of vitamin D in the human body.20 In 1997 - 1999, 
fasting blood samples were collected and centrifuged for 20 min. The serum was separated, 
dispensed and frozen within 3 hours at -80° C. Serum total 25(OH)D was quantitatively 
determined using Elecsys vitamin D total assay (COBAS, Roche Diagnostics GmbH, Germany). The 
electrochemiluminescence immunoassay is intended for use on Elecsys and cobas-e immunoassay 
analyzers. The test functional sensitivity was determined to be 10 nmol/L. Limit of quantitation 
was 22.5 nmol/L and intra-and inter-assay coefficients of variation were < 8% and < 11% for 
concentration between 7.5 and 175 nmol/L.21 We analyzed different cut-off points of vitamin D, 
rather than using a single definition of deficiency to reduce the likelihood of chance findings.8
Depressive symptoms
Depressive symptoms were assessed with the Dutch version of the Centre for Epidemiologic 
Studies Depression scale (CES-D).22 The CES-D scale was designed to assess presence and severity 
of self-reported depressive symptoms.23 We asked participants 20 questions that correspond with 
criterion based-symptoms associated with depression, and participants could score from 0 up-to 
60. The screening for depressive symptoms was performed at baseline 1997 - 1999. To assess 
for change of depressive symptoms the screening was reassessed twice; first during examination 
round 2002 until 2004 and second during examination round 2009 until 2011.24
Major depressive disorder
We continuously followed participants for the occurrence of incident major depression from 
baseline 1997 - 1999 until 1 January 2012. The participants were followed for on average 10.0 
years (± 3.5 SD, between 1997 - 2012; for 32 400 person-years) for the occurrence of depression. 
If no depression was identified, participants were censored at the end of follow-up, if they moved 
or at death. Incident events of major depressive disorder (MDD) were identified from two sources 
of information, as reported in detail previously.25 At first, all screen-positive participants identified 
by a CES-D score of 16 or above in each follow-up examination, were interviewed by a clinician 
(psychiatrist, psycho-geriatrician or clinical psychologist) with a semi-structured clinical interview 
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(Dutch version of the Schedules for Clinical Assessment in Neuropsychiatry - SCAN)26 to diagnose 
depressive disorders. Major depressive disorders were classified according to the Statistical Manual 
of Mental Disorders, 4th revised edition (DSM-IV) criteria.
Second, information on occurrence of episodes of MDD were continuously collected from general 
practitioners medical records. The CES-D screening and SCAN interview provided information on 
depressive episodes that are present during a follow-up examination. The medical records data 
identified depressive episodes that occurred and remitted in the intervals between follow-up 
examinations. The Netherlands has a primary physician health-care system, thus all medical records 
(hospital discharge letters, specialists reports, and GP notes) could be extracted and copied by a 
research-assistants looking for potential depressive symptoms. These data were rated/categorized 
by two medical doctors.25 Consensus decisions were made for disagreeing categorizations. Finally, 
incident episodes of MDD were defined as the first event that chronologically occurred in one of 
the two data sources described above.25 In order to control for prevalent baseline depression (both 
clinical and subclinical) we adjusted the longitudinal analysis for baseline depressive symptoms.
Covariates
The following socio-demographic variables, were assessed during the baseline home interview 
and included in the analysis: age, gender, partner status, living independently or in a nursing 
home, and level of education. Partner status was classified as never married or divorced, married, 
and widowed. Education was classified as low, intermediate, or high. Alcohol consumption and 
smoking habits were both assessed at baseline and classified as never, past, or current smoker/
consumer. Self-reported vitamin dietary supplementation was assessed at baseline.27 Everyday 
functional competence was assessed by using the Activities of daily living scale ADL.28 In order to 
assess cognitive performance the MMSE was measured.19 Body mass index BMI (kg/m2), systolic 
blood pressure (mmHg), creatinine and estimated glomerular filtration rate were assessed with 
standard medical and laboratory procedures. Presence of chronic conditions/diseases (stroke, 
diabetes mellitus, cardiovascular disease, liver conditions (based to elevated liver enzymes), and 
Parkinson’s disease) was based on self-report, examination, medical record information, and drug 
utilization. A past diagnosis of cancer was based on self-report only. Latitude, season and sunlight 
exposure are widely accepted as determinants of serum vitamin D.7,29 Therefore, season was 
categorized as blood intake in winter, spring, summer and autumn. Moreover, we used the data 
of the Dutch Royal Meteorological Center KNMI to calculate the individual hours of sunlight in 
the 10 weeks preceding the blood intake.30 Our participants live in one area only thus we did not 
account for latitude.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
30  |  Chapter 2.1
DATA ANALYSIS
Serum 25(OH)D level (nmol/L) was analyzed continuously as a Z-transformed square root variable, 
in order to normalize the distribution and for better interpretation of results. Additionally, we 
analyzed 25(OH)D using two pre-defined cut-offs; a ≤ 37.5 nmol/L, a ≤ 50 nmol/L, and ≤ 75 
nmol/L to define vitamin D serum level deficiency. Also vitamin D was categorized into quartiles, 
within our study sample to explore effects across the range of the continuum. These alternative 
categorizations used in previous research8, facilitate comparison and tests consistency of results 
across cut-off.8
We studied the association between serum 25(OH)D levels and depression both cross-sectionally 
and longitudinally. First, we addressed the cross-sectional association between serum 25(OH)D and 
depressive symptoms (CES-D score) with linear regression. Second, we studied the longitudinal 
association between serum 25(OH)D and change of depressive symptoms (CES-D score) with 
linear regression and generalized estimating equation analysis (GEE). Moreover, we studied the 
longitudinal association between serum 25(OH)D and incident MDD by Cox proportional hazard 
survival analysis. The proportional hazards assumption was assessed by visual inspection of log-
survival curves and by performing an interaction test with time. For all approaches we built two 
models: first, age and sex adjusted (in the longitudinal approach we additionally adjusted for 
baseline depressive symptoms) and second, a fully adjusted model. We included a covariate in 
the model if it changed the estimate of the main determinant by more than 10%, predicted 
depression (p < 0.05) or was an important priory confounder.31 Sex differences in serum 25(OH)
D levels and depression have been described.6,32 Gender interaction-term and possibility of non-
linear relationship were tested. 
Multiple imputations were used in order to account for missing data on potential confounding 
variables (missing values: systolic blood pressure 0.4%, BMI 0.9%, ADL 0.1%, EGRF 0.2%, 
creatinine 0.2% and calcium serum levels 0.1%, education 1.4%, sunlight exposure 0.1%, 
chronic conditions 0.1%, and vitamin dietary supplements 6.7%). All analyses were rerun in the 
complete case and five imputed data sets. In this manuscript we present results from the imputed 
data. All statistical tests were two-sided and p < 0.05 was considered statistically significant. 
Analysis were performed using SPSS Statistics (version 21).
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RESULTS
Baseline characteristics of the cohort are presented in Table 1. The mean age was 71.6 (± 6.6 
SD) years and 57.4% of participants were women. The 3 251 participants had a mean 25(OH)D 
serum level of 49.68 nmol/l. In total, 1 843 (56.7%) individuals had a deficient 25(OH)D serum 
levels (≤ 50 nmol/L), and 1 408 (43.3%) individuals had a sufficient 25(OH)D serum levels (> 50 
nmol/L).
Cross-sectional analysis
The cross-sectional analysis of the relationship between 25(OH)D level serum level and depressive 
symptoms are presented in Table 2. In both continuous and categorical analyses of vitamin D 
we found strong inverse relationship between 25(OH)D serum levels and depressive symptoms. 
After adjustment for age, sex, BMI, baseline CES-D score, ADL score, chronic conditions, sunlight, 
and other lifestyle factors, participants with a lower serum 25(OH)D levels had more depressive 
symptoms unstandardized beta (β) = -0.27, 95% CI = -0.51;-0.04, p = 0.023).
Additionally, we analyzed low 25(OH)D serum levels as a categorical exposure using two different 
cut-off points and quartiles. A serum 25(OH)D level ≤ 37.5 nmol/l was associated with depressive 
symptoms (β = 0.48, 95% CI = -0.01;0.95, p = 0.046) compared to serum 25(OH)D levels > 37.5 
nmol/l. Similarly, when we analyzed the exposure using the cut-off ≤ 75 nmol/L serum 25(OH)
D levels, these were associated with depressive symptoms (β = 0.61, 95% CI = -0.02;1.20, p = 
0.045) compared to levels > 75 nmol/l. When analyzing 25(OH)D serum level quartiles, persons 
in each of the lower quartile groups had more depressive symptoms than those in the reference 
group (> 63.21 nmol/L)(see Table 2.).
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Table 1. Baseline characteristics of the study population  
Total 
sample
Vitamin D deficiency
(<50 nmol/L)
Vitamin D sufficiency
(>50 nmol/L)
N=3251 N=1843 N=1408
Mean (SD)ᵃ
Age (years) 71.6 (6.6) 73 (6.8) 69.7 (5.8)
Female gender, N(%) 1866 (57.4) 1206 (64.6) 660 (35.4)
Systolic blood pressure (mmHg) 143.2 (21) 144.7 (21.4) 141.1 (20.3)
Body mass index (kg/m2) 26.8 (4) 27.3 (4.3) 26.3 (3.4)
Mini mental state examination (score) 28.2 (1.3) 28.1 (1.3) 28.2 (1.2)
Smoking status 
Non smoker, N(%) 1032 (31.7) 653 (63.3) 379 (36.7)
Past smoker, N(%) 1627 (50.0) 830 (51.0) 797 (49.0)
Current smoker, N(%) 592 (18.2) 360 (60.8) 232 (39.2)
Alcohol consumption 
Non consumer, N(%) 319 (9.8) 233 (73.0) 86 (27.0)
Past consumer, N(%) 215 (6.6) 138 (64.2) 77 (35.8)
Current consumer, N(%) 2717 (83.6) 1472 (54.2) 1245 (45.8)
Activities of Daily Living (ADL score) 1.39 (0.5) 1.5 (0.6) 1.3 (0.4)
Creatinine serum levels (nmol/L) 80.5 (27.2) 78.4 (21.2) 83.2 (33.2)
Calcium serum levels (mmol/L) 2.4 (0.1) 2.4 (0.1) 2.4 (0.1)
Estimated glomerular filtration rate 74.6 (15.5) 74.4 (15.8) 74.8 (15.1)
Education 
Low education, N(%) 1788 (55.0) 1079 (60.3) 709 (39.7)
Middle education, N(%) 1055 (32.5) 550 (52.1) 505 (47.9)
High education, N(%) 363 (11.2) 179 (49.3) 184 (50.7)
Marital status
Never married or divorced, N(%) 357 (11.0) 222 (62.2) 135 (37.8)
Married or living with partner, N(%) 2182 (67.1) 1120 (51.3) 1062 (48.7)
Widowed, N(%) 712 (21.9) 501 (70.4) 211 (29.6)
Season of blood intake
Winter, N(%) 1089 (33.5) 548 (50.3) 541 (49.7)
Spring, N(%) 668 (20.5) 420 (62.9) 248 (37.1)
Summer, N(%) 1049 (32.3) 669 (63.8) 380 (36.2)
Autumn, N(%) 442 (13.6) 203 (45.9) 239 (54.1)
Sunlight exposure, (hours)ᵇ 305.6 (120.5) 292.5 (114.6) 322.8 (125.8)
Chronic conditions, N(%)ͨ 1049 (32.3) 671 (64.0) 378 (36.0)
Cancer status, N(%) 235 (7.2) 136 (57.9) 99 (42.1)
Vitamin dietary supplements, N(%) 303 (9.3) 135 (44.6) 168 (55.4)
Baseline CES-D score ͩ
CES-D < 16, N(%) 3047 (93.7) 1714 (56.3) 1333 (43.7)
CES-D ≥ 16, N(%) 204 (6.3) 129 (63.2) 75 (36.8)
Abbreviations: SD, standard deviation; CES-D, Dutch version of the Centre for Epidemiologic Studies 
Depression scale.
ᵃ Unless otherwise is indicated;
ᵇ Sunlight hours during 10 week period preceding the blood drawing;
d Chronic conditions: History of stroke, history of diabetes mellitus, history of Parkinson disease, history of 
liver conditions and history of cardiovascular disease.d Those who score on CES-D ≥ 16 have clinically relevant 
depressive symptoms
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Table 2. Cross-sectional association between serum vitamin D levels and depressive symptoms 
(CES-D) with linear regression (N = 3 251)
Vitamin D 
serum levels
Depressive symptoms (CES-D score)
N Model 1 Model 2
β (95 % CI) p β (95 % CI) p
Continuously
Vitamin D √SD nmol/La 3251 -0.54 (-0.77;-0.30) <0.001 -0.27 (-0.51;-0.04) 0.023
Cut-off
<37.5 nmol/L 1226 0.95 (0.48;1.43) <0.001 0.48 (0.01;0.95) 0.046
>37.5 nmol/L 2025 Reference Reference
<50 nmol/L 1843 0.62 (0.17;1.08) 0.008 0.28 (-0.18;0.73) 0.23
>50 nmol/L 1408 Reference Reference
<75 nmol/L 2748 0.85 (0.24;1.46) 0.006 0.61 (0.02;1.20) 0.045
>75 nmol/L 503 Reference Reference
Quartiles
 <28.57 nmol/L 732 1.48 (0.82;2.15) <0.001 0.74 (0.07;1.41) 0.030
28.58-43.81 nmol/L 819 1.11 (0.49;1.72) <0.001 0.83 (0.22;1.43) 0.008
43.82-63.21 nmol/L 848 0.83 (0.23;1.43) 0.007 0.75 (0.19;1.31) 0.012
>63.21 nmol/L 852 Reference Reference
Abbreviations: SD, standard deviation; CES-D, Dutch version of the Centre for Epidemiologic Studies 
Depression scale; β, unstandardized beta; CI, confidence interval.
Interaction term vitamin D serum levels*gender was tested and showed no statistical significance (p = 0.936).
a Standard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender and age
Model 2. Additionally adjusted for: body mass index, systolic blood pressure, chronic conditions, cancer 
status, smoking habits, alcohol consumption, marital status, level of education, 10 week sunlight exposure 
prior to the blood intake, calcium serum levels, and activity of daily leaving score.
Longitudinal analysis
Next, we studied the longitudinal relationship between 25(OH)D serum levels and change of 
depressive symptoms as well as incident major depressive disorder.
First, (see Table 3.) in contrast to the cross-sectional analysis, low levels of 25(OH)D did not predict 
higher depressive symptoms at the first follow-up (β = 0.01, 95%CI = -0.28;0.29, p = 0.95) or 
second follow-up assessment (β = 0.05, 95%CI = -0.31;0.40, p = 0.80). Moreover, we did not 
found an association between 25(OH)D serum levels and change of depressive symptoms in the 
combined analysis of the two assessment waves (β = 0.02, 95%CI = -0.23;0.26, p = 0.89).
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Second, we assessed the long-term relationship of 25(OH)D serum level and incident MDD. (see 
Table 4.) 32 400 person-years (mean 10.0 ± 3.5 SD, interquartile range 4.1 - 13.8), during which 
150 incident MDD occurred. The serum level of 25(OH)D did not predict long-term risk of incident 
MDD (hazard ratio (HR) = 0.95, 95%CI = 0.86;1.05, p = 0.61).
Table 4. Longitudinal analysis of the association between serum vitamin D levels and incident 
major depressive disorder with Cox regression analysis (N = 2 466)
Vitamin D serum 
levels
Major depressieve disorder
events Model 1 Model 2
HR (95%CI) p HR (95%CI) p
Continuously
Vitamin D √SD nmol/La 150 0.98 (0.81 to 1.18) 0.79 0.95 (0.86 to 1.05) 0.61
Cut-off
<37.5 nmol/L 70 0.96 (0.68 to 1.36) 0.84 1.04 (0.87 to 1.25) 0.81
>37.5 nmol/L 80 Reference Reference
<50 nmol/L 92 0.82 (0.58 to 1.17) 0.27 0.84 (0.70 to 1.01) 0.34
>50 nmol/L 58 Reference Reference
<75 nmol/L 137 1.32 (0.74 to 2.36) 0.35 1.28 (0.95 to 1.73) 0.41
>75 nmol/L 13 Reference Reference
Quartiles
<28,57 nmol/L 38 0.77 (0.52 to 1.14) 0.19 0.82 (0.67 to 1.02) 0.36
28,58-43,81 nmol/L 45 1.13 (0.79 to 1.61) 0.49 1.13 (0.79 to 1.61) 0.51
43,82-63,21 nmol/L 43 1.36 (0.95 to 1.95) 0.10 1.24 (0.87 to 1.78) 0.24
>63.21 nmol/L 24 Reference Reference
Abbreviations: SD, standard deviation; HR, hazard ratio; CI, confidence interval.
Interaction term Vitamin D serum levels*gender was tested and showed no statistical significance (p = 0.160)
aStandard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender, age and baseline depressive symptoms
Model 2. Additionally adjusted for: body mass index, alcohol consumption, smoking status, marital status and 
activity of daily living score.
Sensitivity analysis
Several sensitivity analyses were performed. First, we repeated the analysis of the association 
of 25(OH)D serum levels and incident MDD restricting the analysis to 2 and 5 years follow-up 
(Supplementary material 1). Again we found no indication of a prospective association between 
vitamin D serum levels and incident depression.
Second, sex interaction-term with 25(OH)D serum levels was tested and showed no statistical 
significance (p = 0.94). A quadratic terms of serum 25(OH)D was examined to test for non-linear 
relationship, no evidence for non-linearity was observed.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
36  |  Chapter 2.1
DISCUSSION
In this large population-based cohort of older people, we observed a cross-sectional association 
of both continuously modeled vitamin D serum levels and vitamin D deficiency with depressive 
symptoms, consistent with previous studies.7,8 However low levels of serum vitamin D were not 
prospectively associated with either change of depressive symptoms or incident MDD. Further, 
analyzing vitamin D as a continuous measure did not reveal any prospective association between 
vitamin D serum levels and depression.
Several epidemiological studies explored the cross-sectional relation between vitamin D serum 
levels and depression.6,8 In line with previous investigations6,7,12,33, we found a consistent cross-
sectional relation regardless of whether we analyzed vitamin D serum levels categorically or 
continuously. Older adults with vitamin D deficiency are clearly more likely to have depressive 
symptoms.8 Importantly, the presence of a cross-sectional relationship between vitamin D serum 
levels and depression is not discredited by the absence of long-term risk between them. Yet, 
our findings suggest that if there is a true relationship between low vitamin D serum levels and 
depression this would reflect on a short-term rather than a long-term effect on the development 
of depression.
Our study extends the results of the few earlier studies exploring the prospective relationship with 
conflicting results.10,12,34,35 The three studies showing a prospective association between vitamin 
D and depression13,34,36 were based on selected study populations, i.e. cardiovascular patients or 
men only. In contrast to these findings, Toffanello, et al. and Chan, et al. reported no prospective 
association in men and during relatively short period of 4 years follow-up, respectively.10,12 Our 
results were consistent, none of the analysis provided any statistical evidence for longitudinal 
relationship between vitamin D serum levels and depression, regardless of vitamin D serum level 
cut-offs or severity of depression (depressive symptoms and incident depression). Unlike previous 
studies, we assessed depression using different information sources, and did not rely on self-
report only. Depression was continuously monitored in GP-records over a mean time period of 10 
years. Combining multiple sources of depression reduces ascertainment bias often seen in other 
studies.8
The observed effect estimates present depression rates over 10 years follow-up with respect 
to the vitamin D serum levels measured at baseline. Vitamin D serum levels are highly variable, 
depend on sunlight exposure and diet that changes over time.3 Our report is limited by the single 
intra-individual assessment of vitamin D serum levels. The time-dependent variation of vitamin D 
serum levels may explain why we did not capture an association with depression during follow-
up. Given the within-person variability of vitamin D serum levels, the effect of lower vitamin D 
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serum level is probably diluted when the follow-up period is longer than 5 years.37 Thus, we 
tested different follow-up times of shorter duration. Yet, the findings remained negative. Also, 
studies with other outcomes showed that the variability of vitamin D does not preclude the 
observation of long-term effects. An independent association of vitamin D deficiency with both 
the development of cardiovascular disease and mortality has been reported.16,38
Many authors have speculated that vitamin D activates vitamin D receptors in brain regions related 
to depression, stimulates neurotrophic release, and protects the brain by buffering antioxidant 
and anti-inflammatory defense against vascular injury.3,29 Current pathophysiological theories 
postulate an etiological link between vitamin D and depression. However, whether the cross-
sectional findings reflect such a causal mechanism is questionable. Cherniack, et al. suggested 
that cross-sectional studies may miss sensitive period underlying any plausible association because 
mental illness typically take many months or years to develop.3
We speculate that, if there is any relationship, then vitamin D deficiency rather has a short-term 
than a long-term effect on the development of depression. However, it is very probable that there 
is no causal association between vitamin D deficiency and depression. There are several alternative 
explanations why we observed a cross-sectional association between vitamin D deficiency and 
depression, in the absence of a longitudinal association, in particular residual confounding and 
reverse causality.
The association between vitamin D and depression is complex and likely to be subject of 
residual confounding. This study was embedded in a population-based study, allowing us to use 
prospective measures of outcome and assess a large number of confounding factors. Yet, vitamin 
D deficiency and depression coexist during late-life33 and it is possible that the cross-sectional 
association is due to the higher prevalence of both conditions in the elderly. Chronic diseases 
are common among elderly and convey a high risk of depression. These largely affect the mental 
health by lowering the quality of life, restricting activities, social isolation, and interfering with 
the quality of sleep but also via biological mechanisms such as immune and vascular factors.39 
Hence, we cannot reject the possibility of residual confounding that might bias our results, e.g. 
by physical activity or unmeasured health problems. Indeed Anglin, et al. pointed out that the 
risk of bias due to unmeasured confounding remains high.8 Arguably, vitamin D deficiency is 
partly a marker of chronic nonspecific disease rather than a determinant or a direct contributor 
to the pathogenesis of depression. Sunlight exposure was already acknowledged as an important 
factor that can confound the relationship between vitamin D and depression.8 Assessment of 
sunlight exposure prior to the vitamin D serum level measurement remains a challenge in previous 
studies.7,8 We have tested for confounding by both sunlight exposure 10 week preceding the 
blood intake and season at the time of blood intake, but both measures accounted for a very 
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small part of cross-sectional association. Further, sunlight exposure did not affect the longitudinal 
association. We did not account for parathyroid hormone (PTH) which has been acknowledged 
as a covariate and an intermediate factor with a role in the association between vitamin D and 
depression.34 However, May et al. showed that PTH cannot explain the relation between vitamin 
D and depression.34
Other limitation is the possibility of reverse causality. Depression may precede the vitamin D 
deficiency and reverse causality may explain the observed cross-sectional association between 
depression and vitamin D deficiency. In particular, depressed individuals don not easily go outside 
thus are typically less exposed to sunlight. In this longitudinal study we did not repeatedly assess 
vitamin D and we cannot demonstrate the directionality of the association or rule out that 
depressive symptoms occur prior to any vitamin D deficiency.
Also, we should point out that even though many elderly persons had low levels of vitamin D, the 
analysis of more severe vitamin D insufficiency (≤ 37.5 nmol/L) may not have had optimal power 
to detect an increased risk of incident depression (in contrast to that of continuous depressive 
symptoms) as new onset MDD is not very common in elderly populations.
This study provides further evidence for the cross-sectional association between serum vitamin D 
levels and depression. Clearly, older persons with lower vitamin D serum levels are more likely to 
have more depressive symptoms. However, we observed that vitamin D deficiency and late-life 
depression are not prospectively associated. In conclusion, vitamin D deficiency co-occurs with 
late-life depression, but has no causal role in the development of depression. Although, this is 
an observational study and defining causal mechanisms is not possible, the co-occurrence of 
vitamin D deficiency and late-life depression is a fact that may have clinical implication. Screening 
for vitamin D deficiency in elderly with chronic conditions such as depression remains important 
even if the conditions are not causally related. Vitamin D deficiency is associated with bone 
health, osteoporosis, and increased risk of falls and subsequent fractures.40 Detection of vitamin 
D serum deficiency is easy and treatable. Even if treatment of vitamin D deficiency has no effect 
on depression41, it may prevent other chronic conditions.
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ABSTRACT
Rationale: Evidence suggests that depression is cross-sectionally and longitudinally associated 
with activation of inflammatory response system. Few studies, however, have investigated the 
longitudinal relationship between raised inflammatory biomarkers and persistence of depressive 
symptoms. We examined the temporal relationship between serum levels of inflammatory 
biomarkers and persistence of depressive symptoms among older participants.
Methods: Center for Epidemiologic Studies Depression Scale (CES-D) was used to assess 
depressive symptoms at baseline and at 5 year follow up in 656 participants (233 men, 423 
women) aged > 60 years of the Rotterdam Study. Markers of inflammation interleukin (IL)-6, 
alpha-1-antichymotrypsin (ACT) and C reactive protein (CRP) were assessed at baseline, and all 
participants taking antidepressant medications were excluded from the analysis.
Results: No cross-sectional association was found between IL-6, ACT and CRP with depressive 
symptoms at baseline. However, higher levels of IL-6 and CRP predicted depressive symptoms 
at 5 year follow-up. Adjustment for confounding variables had no impact on the observed 
associations. Similarly, a positive association was found between baseline levels of IL-6 (odds ratio 
[OR], 2.44; p = 0.030) and CRP (OR, 1.81; p = 0.052) and persistence of depressive symptoms 
over 5 years. 
Conclusion: Our data suggest that dysregulation of the inflammatory response system is associated 
with a more severe form of depression more likely to re-occur.
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INTRODUCTION
There is evidence implicating inflammation as a potential etiologic factor for mood disorders. 
Meta-analysis studies have reported higher levels of inflammatory cytokines (such as Interleukin-6, 
(IL)-6) and acute phase proteins (such as C-reactive protein; (CRP)) in the peripheral blood and 
cerebrospinal fluid of patients with major depression.1,2 In addition, inflammation and depressive 
symptoms seem to be associated in large epidemiological cross-sectional studies.3-5
Further evidence stems from prospective studies showing that acute or chronic administration 
of cytokines leads to development of depressive symptoms. Chronic administration of the 
pro-inflammatory cytokine IFN-α for treatment of hepatitis C induced clinically significant 
depression in 30 - 50% of persons with no psychiatric disorders previous to interferon-alpha 
(IFN-α) treatment.6,7 Additional evidence to support an association between elevated immune-
inflammatory cytokines and depressive-like behavioural systems is provided in animal models. 
Elevated immune-inflammatory cytokines induce and exacerbate depressive-like symptoms, 
whereas tumour necrosis factor-alpha (TNF)-α and IL-6 receptor knockout mice show reduced 
behavioural indices of depression.8-13 In humans, fewer large epidemiological studies points 
towards a possible association between activation of inflammatory system and future depressive 
symptoms5,14,15, although controversy still exists.16
A possible explanation for this controversy is the hypothesis that activation of the inflammatory 
system distinguishes a particular subset of patients i.e. those who have a more severe form of 
depression. In agreement, an activation of the inflammatory system was particularly observed in 
major depressive patients who are older17, have recurrent episodes17,18; have comorbid depression 
with other mental and physical illnesses19-21; present earlier onset of the disorder17 and are 
resistant to antidepressant treatment.22,23 Consistent with the hypothesis that inflammation is 
present in a particular subgroup of depressed patients, the anti-inflammatory drug infliximab 
showed antidepressant properties only in treatment resistant depressed patients who have high 
levels of the inflammatory marker C-reactive protein.24
In this study, we take a longitudinal approach to examine the temporal relationship between 
the inflammatory biomarkers IL-6, alpha-1-antichymotrypsin (ACT), CRP at baseline and incident 
depressive symptoms 5 years later or persistent depressive symptoms over 5 years. Participants 
taking antidepressant medications were excluded from the analysis due to the small population 
size.
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METHODS
Study population
The present study is embedded within the Rotterdam Study, a population-based cohort study in 
which all inhabitants age 55 and over living in a defined geographic area of Rotterdam have been 
invited to participate.25 The Medical Ethics Committee approved the study according to the Wet 
Bevolkingsonderzoek: ERGO (Population Study Act: Rotterdam Study) executed by the Ministry 
of Health, Welfare and Sports of the Netherlands. Written informed consent was obtained from 
all participants. During the third survey (1997 – 1999), participants were assessed for depressive 
symptoms. For the present study, of the 3 571 persons who were screened for depressive 
symptoms, only 1 211 had available information on serum level of inflammatory biomarkers. 
Moreover, thirty-seven participants were excluded for being on antidepressants, leaving 1 175 
participants eligible for analysis. In the present analysis, we studied the association of inflammatory 
proteins and depressive symptoms in 656 participants free of antidepressant medications. Out of 
these participants, 102 were on anti-inflammatory medications. In this study, we do not have 
repeated measures of inflammatory cytokines (IL-6, ACT, and CRP), and therefore could not 
analyse whether long-term exposure to high levels of inflammatory markers are associated with 
depression. Sequential exclusions occurred according to the flow chart represented in Figure 1.
Depression assessment
Depressive symptoms were assessed through participant’s completion of the Dutch version of the 
original Center for Epidemiological Studies Depression scale (CES-D) during a home interview.26,27 
The CES-D is a self-reporting 20-item measure of depressive symptoms scored on a scale from 
0 to 3. For the analysis of persistent depressive symptoms, we used a score of 16 as a cut-
off, to indicate clinically significant depressive symptoms in each wave.26,28 Persistent depressive 
symptoms were defined by having CES-D scores ≥ 16 in 1997 - 1999 (baseline) and when re-
assessed in 2002 - 2004 (follow-up).
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Figure 1. Flow chart for sample selection in the study 
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Blood specimens
At baseline, a venepuncture was performed by application of minimal stasis with a 21-gauge 
butterfly needle with tube (Surflo winged infusion set, Terumo). Fasting blood was collected in the 
morning and all tubes were put on ice directly and centrifuged at 2000×g for 10 minutes. Plasma 
was separated and dispensed into two 1.5-ml aliquots and then frozen within 3 hours at - 80°C. 
Both ACT and CRP were assessed by means of a nephelometric method (BN 100, Dade Behring, 
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Marburg, Germany). The IL-6 concentrations were determined with quantitative enzyme-linked 
immunosorbent assay with a test kit from R&D systems (Minneapolis, MN). The intra-assay and 
interassay coefficients for all measurements were < 5% and < 8%, respectively. High-sensitivity 
CRP was measured in a serum, which was stored at - 20°C until performance of the CRP 
measurements, using a Rate Near Infrared Particle Immunoassay (IMMAGE, Immunochemistry 
System, Beckman Coulter, San Diego, CA, detection limit 0.2 mg/L, coefficient of variation (CV) 
3.2%). In this matter a fully automated Hitachi 747 system (Hitachi, Tokyo, Japan, detection limit 
1 mg/L, CV<5%) was used. IL-6 plasma levels were determined using a quantitative enzyme-
linked immunosorbent assay (ELISA) technique (Quantikine HS IL-6 kit, R&D Systems, Oxon, 
UK, detection limit 0.094 pg/mL, CV 8.7%) and ACT plasma levels using kinetic nephelometry 
(Behring Nephelometer BN200, Marburg, Germany, detection limit 1.5 mg/dL, CV 2.8%).
Other measurements
The following variables were considered as possible confounding variables: age, sex, education 
(low, middle, high), physical illness (including prevalent stroke, cardiovascular disease and 
diabetes), cognitive function (as measured by the mini mental-state examination), smoking 
and body mass index (BMI). A history of stroke was obtained through direct questioning and 
computerized linkage with general practitioner medical records.29 Smoking was coded as number 
of cigarettes currently smoked per day and in categories of current, former and never smoker. 
To exclude for obvious sings of inflammation when we analysed IL-6 and ACT, we adjusted for 
acute inflammation as defined by C-reactive protein level > 10mg/L. BMI was defined by > 18.50 
kg/m2 underweight, 18.50-24.99 kg/m2 normal, 25-29.99 kg/m2 overweight, > 30 kg/m2 obese.
DATA ANALYSIS
All data analysis was performed with IBM SPSS Statistics 22. We normalized the distribution 
of IL-6, ACT and CRP by natural logarithmic transformation and used binary logistic regression 
to estimate odds ratios (OR) and 95% confidence intervals (CIs) of inflammatory markers for 
depressive symptoms at baseline (1997 - 1999). We treated inflammatory markers, IL-6, ACT, 
and CRP as continuous variables. To assess the association between the log of the mean IL-6, 
ACT, CRP and depressive symptoms at 5 year follow-up, we performed linear regression analysis 
of the CES-D scores at 5 year follow-up (2002-2004) with adjustment for depressive symptoms 
at baseline (1997-1999). To further explore the association between inflammatory proteins and 
persistent depressive symptoms over the 5 years (1997/1999 - 2002/2004), multinomial binary 
logistic analysis were performed using the CES-D scores (≥ 16) at baseline and at 5 year follow-up.
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Age (continuous) and sex were controlled for in all analyses. To further analyse the effect of 
confounding factors, we added potential confounders to the basic model. If this changed the 
effect estimate meaningfully, the contribution of each variable was individually explored. In 
subgroup analyses, we assessed the age- and sex-adjusted association following exclusion of 
participants with acute inflammation or those with low mini mental state examination (MMSE) 
scores.
RESULTS
Demographic characteristics
Table 1 represents information on socio-demographic and clinical baseline characteristics of the 
participants. The average age of the study participants was 73 years (range 61.1 - 105.8); 59.9% 
of whom were women. Among the study participants, the majority was either classified as being 
overweight or obese (65.3%). Most participants were past smokers 48.4%. Only the minority 
of participants reported history of physical illness (34%) or were screened positive for cognitive 
impairment (13.7%). Mean scores of levels of pro-inflammatory biomarkers in study participants 
are reported.
No association of IL-6, ACT or CRP and depressive symptoms at baseline
To determine if there was a cross-sectional relationship between serum levels of inflammatory 
biomarkers IL-6, ACT, or CRP and current depressive symptoms at baseline, we performed logistic 
regression analysis with CES-D scores at baseline. Our data indicate no association between 
inflammatory proteins IL-6 (OR, 1.08; p = 0.731), ACT (OR, 1.069; p = 0.670) and CRP (OR, 
0.851; p =0.819) and current depressive symptoms at baseline following the adjustments for age 
and gender.
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Table 1. Demographic characteristics of participants in the Rotterdam Study
Demographics Characteristics
Age (years) (mean, range) 73 (61-106)
Gender (%)
Male 40.1
Female 59.9
Education (%)
Low 61.2
Middle 29.1
High 9.7
BMI (kg/m2)
>18.50 0.9
18.50-24.99 33.8
25-29.99 46.4
30-40 18.9
Smoking status (%)
Non-smoker 35.2
Past smoker 48.4
Current smoker 16.4
History of physical illness (%) 34
MMSE score (%)
>26 13.7
≤26 86.3
Interleukin-6 (pg/mL) 4.07 (0.53-80)
α1-Antichymotrypsin (mg/dL) 40.3 (19.5-128.5)
C-Reactive protein (mg/L) 3.39 (0.06-88.8)
BMI body mass index, physical illness stroke, history of cardiovascular disease and diabetes, MMSE mini-
mental state examination.
IL-6 and CRP predict depressive symptoms at 5 year follow-up in older people
To investigate if inflammatory markers are predictive of depressive symptoms at 5-year follow-up, 
stepwise linear regression were performed with the CES-D scores at 5-year follow-up (Table 2). In 
our basic model we corrected for age, gender and depressive symptoms at baseline. Subsequently, 
corrections included acute inflammation, socio-demographic and health characteristics. Our 
data indicate that IL-6 (B, 0.084; p = 0.016) and CRP (B, 0.086; p = 0.013) were significant 
predictors of depressive symptoms at 5-year follow-up and remained so after correction for 
all socio-demographic and health characteristics. ACT (B, 0.057; p = 0.083) showed a trend 
association with depressive symptoms at 5-year follow-up, following adjustment for age, gender 
and depressive symptoms at baseline. The trend association for ACT disappeared after correcting 
for additional socio-demographic and health characteristics including BMI, smoking, physical 
illness, low MMSE scores and acute inflammation (Table 2).
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Table 2. The association between inflammatory proteins and depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) p value
Log IL-6 (per 1 SD increment)α
Model 1 656 0.107 (1.32, 5.38) 0.001
Model 2 650 0.105 (1.16, 5.33) 0.002
Model 3 650 0.084 (0.48, 4.73) 0.016
Log ACT (per 1 SD increment)α
Model 1 655 0.057 (-0.67, 10.76) 0.083
Model 2 650 0.048 (-1.57, 10.04) 0.153
Model 3 650 0.020 (-4.20, 7.75) 0.561
Log CRP (per 1 SD increment)α
Model 1 656 0.090 (0.55, 3.19) 0.006
Model 2 650 0.086 (0.38, 3.16) 0.013
The category “depressive symptoms” includes all subjects who were screened positive. α=levels of 
inflammatory biomarkers from measurements of 1997-1999: new onset of depressive symptoms at 5-years 
follow-up in participants with no depressive symptoms at baseline. Subjects on antidepressant medications 
were excluded from the analysis. Model 1 linear regression analysis adjusted for sex and age. Model 2 as 
model 1 and additionally adjusted for body mass index (BMI), smoking, physical illness (including stroke, 
history of cardiovascular disease and diabetes) and mini-mental state examination (MMSE). Model 3 as model 
2 and additionally adjusted for acute inflammation. No model 3 was created for CRP as acute inflammation 
was calculated as CRP >10 mg/mL; therefore, no adjustment for acute inflammation could be done when 
CRP was used as predictor. IL-6 interleukin-6, ACT α1-antichymotrypsin, CRP C-reactive protein, SD standard 
deviation, B standardized beta, CI cumulative interval.
The contribution of individual covariates in the association between inflammatory 
markers and depressive symptoms at 5 year follow-up
Association with IL-6 and CRP
In the secondary analysis, we included adjustments for individual covariates to further assess 
the effect of each variable on the association between inflammatory markers at baseline and 
depressive symptoms at 5 year follow-up (Table 3 and 4). Our results indicate that the association 
between the levels of IL-6 or CRP and depressive symptoms remained strong and was not 
substantially affected by age, gender, BMI, smoking status, physical illness, low MMSE scores, or 
acute inflammation (specific to IL-6 analysis only), when adjusted individually or in combination. 
As acute inflammation was calculated as CRP >10 mg/mL, no adjustment for acute inflammation 
could be done when CRP was used as a predictor.
In the IL-6 subgroup, exclusion of participants with acute inflammation (B, 0.089; p = 0.010) or 
low MMSE scores (B, 0.170; p = 0.001) did not alter the significance of the association between 
levels of IL-6 and depressive symptoms at 5 year follow-up (Table 3).
Similarly, in the fully adjusted model, IL-6 predicted incident depressive symptoms after 5 years 
following exclusion of CRP values > 10 mg/L (full Model: B, 0.089; p = 0.013; N = 622).
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In contrast to IL-6, associations between CRP and incident depressive symptoms) were no longer 
observed (Full Model: B, 0.044; p = 0.223; N = 622) following exclusion of subjects with CRP 
values > 10 mg/l and adjustments of all covariates.
Table3. The association between levels of IL-6 and depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) p values
Log IL-6 (per 1 SD increment)α
Age, sex 656 0.107 (1.32, 5.38) 0.001
Age, sex, BMI (kg/m2) 652 0.109 (1.31, 5.46) 0.001
Age, sex, smoking status 656 0.105 (1.24, 5.32) 0.002
Age, sex, physical illness 656 0.106 (1.26, 5.34) 0.002
Age, sex, MMSE 654 0.106 (1.27, 5.33) 0.002
Age, sex, acute inflammation 656 0.088 (0.68, 4.83) 0.009
Fully adjusted* 650 0.084 (0.48, 4.73) 0.016
Subgroups (age and sex adjusted)
Excluding those with acute inflammation 627 0.089 (0.68, 4.91) 0.010
Excluding those with MMSE 416 0.170 (2.99, 8.12) 0.001
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who were 
screened positive. α = levels of Il-6 from measurements of 1997-1999: new onset of depressive symptoms 
at 5-year follow-up in participants with no depressive symptoms at baseline. Subjects on antidepressant 
medications were excluded from the analysis. IL-6 interleukin-6, SD standard deviation, B standardized beta, 
CI cumulative interval, BMI body mass index, MMSE mini-mental state examination
Similarly to IL-6, in the CRP subgroup, exclusion of participants with low MMSE scores (B, 0.108; 
p = 0.008), did not affect the association between CRP levels and depressive symptoms (Table 4). 
Our data reported no significant gender and IL-6 or CRP-interaction in the prediction of depressive 
symptoms at 5 year follow-up (following adjustment for age); thus, no further analysis stratified 
for gender were performed.
Table 4. The association between levels of CRP and depressive symptoms after 5 years
Inflammatory proteins No. of cases B (95 % CI) p values
Log CRP (per 1 SD increment)α
Age, sex 656 0.090 (0.55, 3.19) 0.006
Age, sex, BMI (kg/m2) 652 0.090 (0.46, 3.23) 0.009
Age, sex, smoking status 656 0.088 (0.50, 3.15) 0.007
Age, sex, physical illness 656 0.089 (0.51, 3.16) 0.007
Age, sex, MMSE 654 0.089 (0.53, 3.16) 0.006
Fully adjusted* 650 0.086 (0.68, 3.16) 0.013
Subgroups (age and sex adjusted)
Excluding those with MMSE 416 0.108 (0.63, 4.06) 0.008
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who were 
screened positive. α = levels of CRP from measurements of 1997-1999: new onset of depressive symptoms 
at 5-year follow-up in participants with no depressive symptoms at baseline. Subjects on antidepressant 
medications were excluded from the analysis. CRP C-reactive protein, SD standard deviation, B standardized 
beta, CI cumulative interval, BMI body mass index, MMSE mini-mental state examination.
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Association with ACT
As no association was found between ACT and depressive symptoms at 5 year follow-up, no 
further analysis was conducted.
IL-6 and CRP are associated with persistent depressive symptoms over 5 years
To investigate whether there was any association between inflammatory proteins and persistent 
depressive symptoms over 5 years, we generated cut-off scores CES-D > 16 at baseline and at 5 
year follow-up and subsequently performed logistic analysis. In the basic model 1, IL-6 (OR, 2.32; 
p = 0.035) and CRP (OR, 1.79; p = 0.043) were positively associated with persistent depressive 
symptoms over 5 years (Table 5). In model 2, this association remained relatively unchanged 
after adjusting for age, gender, BMI, smoking status, physical illness and low MMSE scores for 
IL-6 (OR, 2.44; p = 0.03) and CRP (OR, 1.81; p = 0.052) respectively. In contrast to the previous 
observations on the depressive symptoms at 5-year follow-up (incident depression-Table 2.), acute 
inflammation largely explained the association between IL-6 and persistent depressive symptoms 
in the fully adjusted model 3 (OR, 2.02; p = 0.107), (Table 5). Levels of ACT (OR, 1.38; p = 0.80) 
were not positively associated with persistent depressive symptoms following adjustment for age 
and gender. No gender interaction was found for IL-6, ACT or CRP in the prediction of persistence 
depressive symptoms over 5 years following adjustment for age, thus no further analysis stratified 
for gender was performed.
Table 5. The association between inflammatory proteins and persistent depressive symptoms over 
5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) p value
Log IL-6
Model 1 656 2.32 (1.06, 5.06) 0.035
Model 2 650 2.44 (1.09, 5.45) 0.030
Model 3 649 2.02 (0.86, 4.77) 0.107
Log ACT
Model 1 654 1.38 (0.12, 16.06) 0.80
Model 2 649 1.23 (0.09, 15.27) 0.871
Model 3 649 0.63 (0.05, 8.81) 0.729
Log CRP
Model 1 655 1.79 (1.02, 3.13) 0.043
Model 2 649 1.81 (0.99,3.29) 0.052
The category “depressive symptoms” includes all subjects who were screened positive: CES-D ≥ 16 at baseline 
and at 5-year follow-up. Subjects on antidepressant medications were excluded from the analysis. Model 1 
multinomial binary logistic regression analysis adjusted for sex and age. Model 2 as model 1 and additionally 
adjusted for body mass index (BMI), smoking, physical illness (including stroke, history of cardiovascular 
disease and diabetes) and mini-mental state examination (MMSE). Model 3 as model 2 and additionally 
adjusted for acute inflammation. No model 3 was created for CRP as acute inflammation was calculated 
as CRP >10 mg/mL; therefore, no adjustment for acute inflammation could be done when CRP was used 
as predictor. IL-6 interleukin-6, ACT α1-antichymotrypsin, CRP C-reactive protein, SD standard deviation, B 
standardized beta, CI cumulative interval.
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The contribution of individual covariates on the association between levels of IL-6 or 
CRP and persistent depressive symptoms over 5 years
Associations with IL-6 and CRP
We further investigated whether the individual covariates could explain the correlation between 
IL-6 or CRP and persistent depressive symptoms during the 5 years (Table 6 and 7). Our results 
indicate that the association between the levels of IL-6 and persistent depressive symptoms was 
little explained by age, gender, BMI, smoking status, physical illness or MMSE, when adjusted 
individually. In contrast, acute inflammation, largely explained the association between the levels 
of IL-6 and persistent depressive symptoms. Indeed correcting for (OR, 1.96; p = 0.113), or 
excluding (OR, 2.19; p = 0.068) participants with acute inflammation reduced this association to 
insignificant levels (Table 6).
However, IL-6 predicted persistent depressive symptoms following exclusion of CRP values > 10 
mg/L and adjustments of all covariates (full model: OR, 2.37; p = 0.049; N = 622). In contrast, 
associations between CRP and persistent depressive symptoms were no longer observed following 
exclusion of subjects with CRP values > 10 mg/l (full model: OR, 1.45; p = 0.310; N = 621). The 
data suggest that the association between depression and inflammation seems to be stronger 
for IL-6 than CRP.
In the subgroup analysis, exclusion of participants with low MMSE scores (OR, 2.64; p = 0.046) 
did not affect the positive relationship between levels of IL-6 and persistent depressive symptoms. 
In contrast to IL-6, association between levels of CRP and persistent depressive symptoms over 
5 years were largely explained by adjustment for physical illness (OR, 1.70; p = 0.067) and by 
exclusion (OR, 1.68; p = 0.138), but not adjustment for low MMSE scores (OR, 1.80; p = 0.042). 
Associations between CRP and depressive symptoms were little explained by age, gender, BMI, 
or smoking status. 
Associations with ACT
As no associations was found between ACT and depressive symptoms at 5 years, no further 
analysis were conducted.
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Table 6. The association between levels of IL-6 and persistent depressive symptoms over 5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) p values
Log IL-6
Age, sex 656 2.32 (1.06, 5.06) 0.035
Age, sex, BMI (kg/m2) 652 2.54 (1.15, 5.60) 0.021
Age, sex, smoking status 656 2.28 (1.04, 5.00) 0.040
Age, sex, physical illness 656 2.23 (1.01, 4.93) 0.048
Age, sex, MMSE 654 2.38 (1.09, 5.18) 0.030
Age, sex, acute inflammation 655 1.96 (0.85, 4.50) 0.113
Fully adjusted* 649 2.02 (0.86, 4.77) 0.107
Subgroups (age and sex adjusted)
Excluding those with acute inflammation 626 2.19 (0.94, 5.01) 0.068
Excluding those with MMSE 416 2.64 (1.02, 6.88) 0.046
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who 
were screened positive: CES-D ≥ 16 at baseline and at follow-up. Subjects on antidepressant medications 
were excluded from the analysis. IL-6 interleukin-6, CI cumulative interval, BMI body mass index, MMSE mini-
mental state examination.
Table 7. The association between levels of CRP and persistent depressive symptoms over 5 years
Inflammatory proteins No. of cases Odds ratio (95 % CI) p values
Log CRP
Age, sex 656 1.79 (1.02, 3.13) 0.043
Age, sex, BMI (kg/m2) 651 1.93 (1.07, 3.49) 0.03
Age, sex, smoking status 655 1.76 (1.01, 3.09) 0.048
Age, sex, physical illness 655 1.70 (0.97, 2.98) 0.067
Age, sex, MMSE 653 1.80 (1.02, 3.16) 0.042
Fully adjusted* 649 1.81 (0.99, 3.29) 0.052
Subgroups (age and sex adjusted)
Excluding those with MMSE 415 1.68 (0.85, 3.35) 0.138
Individual contribution of each covariate. The category “depressive symptoms” includes all subjects who 
were screened positive: CES-D ≥ 16 at baseline and at follow-up. Subjects on antidepressant medications 
were excluded from the analysis. CRP C-reactive protein, CI cumulative interval, BMI body mass index, MMSE 
mini-mental state examination.
DISCUSSION
In this large population based study of elderly persons, we found that the inflammatory 
biomarkers IL-6 and CRP were longitudinally associated with depressive symptoms. Both IL-6 and 
CRP levels predicted persistent depressive symptoms over 5 years independently of age, gender, 
BMI, smoking status or MMSE. Furthermore, we found that IL-6 and CRP predicted incident 
depressive symptoms at 5 year follow-up after adjustment for all socio-demographic and health 
characteristics. In contrast, no longitudinal association was observed between the levels of ACT 
and depressive symptoms. None of the inflammatory biomarkers were associated with depressive 
symptoms at baseline in the cross-sectional analysis.
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To the best of our knowledge, this is the first population-based study to investigate whether 
inflammation predicts persistent depressive symptoms over 5 years. Persistent depressive symptoms 
and inflammation had been previously associated in a small study in individuals who were at 
high risk for coronary heart disease.30 Our results are consistent with the literature suggesting 
that activation of inflammatory response system contributes significantly to the maintenance 
of symptoms of depression, and might be more relevant in people who are more severely ill. 
Inflammation is particularly observed in major depressive patients who are older17, have comorbid 
depression with physical 19,21 and mental illnesses20, present recurrent18 or earlier age of onset of 
the disorder17; and in those who are resistant to antidepressant treatment.22,23 Consistent with 
this hypothesis, we found that the association between inflammation and persistent depression is 
lost when adjusted for physical illnesses. It is possible that inflammation distinguishes a subgroup 
of depressed patients. In line with this idea, Raison et al. showed that the anti-inflammatory drug 
infliximab showed antidepressant properties only in treatment resistant depressed patients who 
have high levels of the inflammatory marker C-reactive protein.24
Secondly, in this study we report a positive longitudinal relationship between IL-6 or CRP levels 
and incident depressive symptoms at 5 year follow-up. Our data is consistent with findings from 
previous literature, which demonstrated a positive longitudinal association between inflammation 
and incident mental health. Similar to our study, Gimeno et al. found a positive association 
between CRP, IL-6 and incident depressive symptoms in healthy participants.31 However, in their 
research only cognitive depressive symptoms were reported; and mental health was conducted 
by using the general health questionnaire (GHQ) which is less specific for depressive symptoms. In 
our study, depressive symptoms were measured using the CES-D scale which is reported to have 
an excellent sensitivity (100%) and specificity (88%) for major depression in a community based 
sample of older subjects.26 Also, in agreement with the present results, Kivimaki et al. showed 
that persistent elevation of IL-6 levels increases risk of common mental disorder.32. Likewise, van 
den Biggelaar and colleagues showed that baseline levels of CRP significantly predicted incident 
depression at five year follow-up in elderly participants of > 85 years old.5
Further investigations on the link between inflammation and incident depression have also been 
conducted in different population groups compared to ours. For example, it has been reported 
that inflammation also predicts depression in females after an accident33 and in middle-aged 
adults4; but not in younger adults16,34 This study does not report a cross-sectional association 
between inflammatory biomarkers and depressive symptoms at baseline. Our data is consistent 
with findings from Matsushima et al. who reported no cross sectional association between 
baseline values of hsCRP and IL-6 and depressive symptoms in a community dwelling older 
participants.35 Our data is also consistent with that of Krogh et al. 2014 who showed no cross-
sectional association between hsCRP and IL-6 levels and depressive symptoms in people with 
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depression.36 The fact that no cross-sectional association was found suggest that the response 
to peripheral infection on producing inflammatory cytokines that act on the brain to cause 
depression might occur only when this inflammatory stimuli is persistent; and might not occur in 
a normal acute and transitional response of the inflammatory system.10
Several mechanisms have been speculated on how inflammation and depression may be 
associated. Both clinical and experimental data strongly point toward the involvement of the 
enzyme indoleamine 2,3 dioxygenase in the development of inflammation-associated major 
depressive disorders.10 Reduced function of the hypothalamus-pituitary-adrenal (HPA) axis 
has been observed in the presence of chronic inflammation in severely ill patients with major 
depression.22,23 Inflammation also induces a reduction in the brain derived-neurotrophic factor 
(BDNF), which negatively influences neurogenesis and neuroplasticity.37-39 Over time, a decrease in 
neurogenesis could contribute to the reduction in hippocampal volume seen in major depression40 
and cognitive dysfunction41 which is positively correlated with a longer duration of depressive 
symptoms in the community.42 Furthermore, it has been suggested that pro-inflammatory 
cytokines can modulate the tryptophan/kynurenine pathway and decrease tryptophan availability 
for serotonin synthesis.10,38,43
We did not find a longitudinal association between levels of ACT and depressive symptoms. Our 
findings seem surprising because ACT is an acute phase serum glycoprotein, which is positively 
associated with CRP.44 A possible explanation for this could be that ACT is a less sensitive marker 
for inflammation than CRP, which signals early inflammation when other clinical parameters are 
yet unchanged and therefore, the latter reveals early inflammation when other clinical parameters 
are equivocal.45-47
This study has several strengths. First, the assessment of depressive symptoms at baseline and at 
5 year follow-up, allowed us to examine the direction of the association between inflammatory 
biomarkers and depressive symptoms. Furthermore, we controlled for several confounding 
factors, which can influence the association between inflammatory markers and depression. 
Several limitations of our study need also to be addressed. First, our study was restricted to 
older population of men and women and thus our findings cannot be generalised for the 
younger population. A second limitation was the fact that we excluded participants who were on 
antidepressants, and thus the findings might be not generalizable for patients more severely ill 
and with clinical depression. Finally, we do not have repeated measures of inflammatory cytokines 
(IL-6, ACT, and CRP), and therefore could not analyse whether long term exposure to high levels 
of inflammatory markers are associated with depression.
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To conclude, our findings indicate that inflammatory biomarkers IL-6 and CRP are longitudinally 
associated with persistence and incident depressive symptoms in older men and women, after 
adjustment for socio-demographic and health characteristics. Inflammation seems to distinguish 
a particular group of people who may benefit from preventive therapies.
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APPENDIX of CHAPTER 2.1
Supplementary material 1
Longitudinal analysis of the association between serum vitamin D levels and incident major 
depressive disorder with Cox regression analysis 5 years follow-up time (N = 2 466)
Vitamin D serum levels Major depressieve disorder
events
Model 1 Model 2
HR (95%CI) p HR (95%CI) P
Continuously
Vitamin D √SD nmol/la 91 0.96 (0.75 to 1.23) 0.77 0.92 (0.80 to 1.05) 0.53
Cut-off
<37.5 nmol/L 45 0.90 (0.58 to 1.41) 0.66 1.03 (0.65 to 1.63) 0.91
>37.5 nmol/L 46 Reference Reference
<50 nmol/L 61 0.90 (0.56 to 1.43) 0.65 0.96 (0.75 to 1.22) 0.86
>50 nmol/L 30 Reference Reference
<75 nmol/L 86 1.65 (0.66 to 4.14) 0.29 1.51 (0.94 to 2.42) 0.37
>75 nmol/L 5 Reference Reference
Quartiles
<28,57 nmol/L 25 0.68 (0.41 to 1.12) 0.13 0.74 (0.44 to 1.27) 0.29
28,58-43,81 nmol/L 29 1.27 (0.81 to 1.98) 0.30 1.31 (0.99 to 1.06) 0.25
43,82-63,21 nmol/L 28 1.62 (1.03 to 2.54) 0.039 1.37 (0.86 to 2.18) 0.20
 >63.21 nmol/L 9 Reference Reference
Abbreviations: SD, standard deviation; HR, hazard ratio; CI, confidence interval.
a Standard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender, age and baseline depressive symptoms; Model 2. Additionally adjusted for: 
body mass index, alcohol consumption, smoking status, marital status and activity of daily living score.
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Longitudinal analysis of the association between serum vitamin D levels and incident major 
depressive disorder with Cox regression analysis 2 years follow-up time (N = 2 466)
Vitamin D serum levels Major depressieve disorder
events
Model 1 Model 2
HR (95%CI) p HR (95%CI) p
Continuously
Vitamin D √SD nmol/la 32 1.10 (0.70 to 1.75) 0.67 0.88 (0.68 to 1.15) 0.63
Cut-off
<37.5 nmol/L 16 0.87 (0.41 to 1.86) 0.72 1.24 (0.81 to 1.91) 0.61
>37.5 nmol/L 16 Reference Reference
<50 nmol/L 21 0.64 (0.28 to 1.47) 0.29 1.1 (0.70 to 1.72) 0.83
>50 nmol/L 11 Reference Reference
<75 nmol/L 30 0.72 (0.16 to 3.22) 0.66 0.70 (0.32 to 1.52) 0.65
>75 nmol/L 2 Reference Reference
Quartiles
<28,57 nmol/L 10 0.77 (0.35 to 1.69) 0.51 1.20 (0.73 to 1.97) 0.71
28,58-43,81 nmol/L 9 0.99 (0.45 to 2.19) 0.99 1.02 (0.46 to 2.27) 0.97
43,82-63,21 nmol/L 10 1.63 (0.74 to 3.61) 0.23 1.33 (0.86 to 2.06) 0.51
 >63.21 nmol/L 3 Reference Reference
Abbreviations: SD, standard deviation; HR, hazard ratio; CI, confidence interval.
a Standard Deviation of the square root of the Vitamin D serum levels (nmol/L)
Model 1. Adjusted for gender, age and baseline depressive symptoms Model 2. Additionally adjusted for: 
body mass index, alcohol consumption, smoking status, marital status and activity of daily living score.
CHAPTER 3
 
The genetics of depression

CHAPTER 3.1
 
A rare Asn396Ser variant in 
the LIPG gene associated with
 depressive symptoms
Amin Najaf, Jovanova Olivera, Adams Hieab, Dehghan Abbas, Kavousi Maryam, et al.
Molecular Psychiatry. 2017 Apr; 22(4):537-543.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
The LIPG gene associated with depressive symptoms  |  67
3
ABSTRACT
Despite a substantial genetic component, efforts to identify common genetic variation underlying 
depression have largely been unsuccessful. In the current study we aimed to identify rare genetic 
variants that might have large effects on depression in the general population. Using high coverage 
exome-sequencing, we studied the exonic variants in 1 265 individuals from the Rotterdam 
study (RS) who were assessed for depressive symptoms. We identified a missense Asn396Ser 
mutation (rs77960347) in the endothelial lipase (LIPG) gene, occurring with an allele frequency 
of 1% in the general population, that was significantly associated with depressive symptoms 
(p value = 5.2*10-08, β = 7.2). Replication in three independent datasets (N = 3 612) confirmed 
the association of Asn396Ser (p value = 7.1*10-03, β = 2.55) with depressive symptoms. LIPG is 
predicted to have enzymatic function in steroid biosynthesis, cholesterol biosynthesis and thyroid 
hormone metabolic processes. The Asn396Ser variant is predicted to have a damaging effect on 
the function of LIPG. Within the discovery population, carriers also showed an increased burden 
of white matter lesions (p value = 3.3*10-02) and a higher risk of Alzheimer’s disease (odds ratio 
= 2.01; p value = 2.8*10-02) compared to the non-carriers. Together, these findings implicate the 
Asn396Ser variant of LIPG in the pathogenesis of depressive symptoms in the general population.
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INTRODUCTION
Depression is a common psychiatric illness with a substantial heritability (h2 = 40-50%).1 Despite 
decades of research, its genetic origin remains largely obscure. Previously candidate gene studies 
suggested a role of various genes in the monoaminergic neurotransmission pathways. These 
include MTHFR, 5-HTTLPR, HTR1A, HTR2A, TPH1 and BDNF. However, these findings were not 
replicated in recent large case-control studies based on array-based genome-wide association 
studies (GWAS). The hypothesis-free large-scale GWAS have led to the discovery of hundreds of 
genetic variants contributing to the risk of a wide diversity of common human traits and diseases2,3, 
however, the Psychiatric Genetics Consortium (PGC) Working Group for Major Depressive 
Disorder (MDD) did not identify a genome-wide significant locus for depression that could be 
replicated.3 Also PGC could not replicate the two common genetic variants that were recently 
implicated in MDD in a GWAS in the Han-Chinese population.4,5 The failure to elucidate the 
genes underlying MDD is mainly attributed to the fact that MDD is more common, less heritable 
and more heterogeneous compared to other psychiatric diseases like Schizophrenia6, genes for 
which were successfully identified by the same consortium.7 High heterogeneity of the disease 
phenotype and inclusion of a substantial number of non-genetic patients that develop a major 
depression due to life-events dilutes the effects of the genetic variants and diminishes statistical 
power.3 To overcome the issues with statistical power relating to heterogeneity, large-scale 
GWAS (N > 30 000) of sub-domains of depression and quantitative endophenotypes have been 
performed.8,9 Endophenotypes are heritable quantitative factors10,11, that have been successfully 
used to unravel the genetics of other heterogeneous diseases with major misclassification such as 
hypertension.12 For depression, however, these were also not successful.8,9
Two important lessons learned from the array-based GWAS in general. First, common variants 
have small effects and consortia of mega-sizes are needed to detect these. Second, a substantial 
part of the heritability is not accounted for by the common variants. The variance of MDD 
explained by common genomic variation across the entire genome is estimated to be ~21%6,13 
and 4% for quantitative outcomes.8 These estimates suggest there may be various alternative 
genetic mechanisms that explain the heritability such as rare variants. Also the search for rare 
variants has a long history starting with linkage analysis – a method studying co-segregation 
of chromosomal regions with the disease in families. These regions presumably harbour rare-
causal variants that have relatively large effects on the disease risk.14 The identified linked regions 
are followed up with various fine-mapping techniques to identify the putative causal variant.14 
Linkage of depression has been reported to large genomic regions including 15q2515,16, 17p17, 
7p18, 8p17, 12q2319,20, 18q18, 1p3620 and 13q311,20. The presumed underlying rare-causal variants 
were never identified. Notably such rare variants are usually not present on microarrays used 
for large-scale GWAS and despite recent improvements in genotype imputation methods and 
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the reference haplotypes used for genetic imputations21, are difficult to impute with sufficient 
confidence. An alternative approach is next generation sequencing (NGS). This is a highly effective 
method for identifying rare variants with relatively large effects. Such variants may be anticipated 
in exonic or coding regions.
In this study, we performed exome sequencing in a large population-based cohort to search 
for rare exonic variants associated with depressive symptoms measured using the Centre for 
Epidemiologic Studies Depression (CES-D)22, as an endophenotype of MDD. Findings were 
replicated in three independent studies. As endophenotypes are not 1:1 related to disease, we 
further studied the relation of the variants associated with depressive symptoms to a range of 
other diseases including Alzheimer’s disease, changes in the brain structure, thyroid pathology, 
and metabolic changes.
METHODS
Study populations
Our discovery population consists of subjects from the Rotterdam study (RS). RS is a prospective, 
population-based study from the well-defined district of Ommoord within the city of Rotterdam, 
designed to investigate the occurrence and determinants of diseases in the elderly.23 The RS 
cohort was initially defined in 1990 among 7 983 persons who underwent a home interview 
and extensive physical examination at baseline and during follow-up examinations occurring 
every 3 - 4 years (RS-I). The cohort was further extended in 2000 (RS-II) and 2005 (RS-III), 
establishing a total of 14 926 participants.23 The Rotterdam Study was approved by the Medical 
Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the 
Netherlands. All participants provided written informed consent to participate in the study and to 
obtain information from their treating physicians.
Participants from RS-I were assessed for depressive symptoms using the 20-item version of the 
CES-D scale. CES-D is a self-report measure of symptoms experienced during the prior week. It 
has shown to be relatively stable over time (82% of older adults had stable CES-D scores over four 
measurement rounds in 10 years)9,24,25 and covers the following major dimensions of depression: 
depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, 
psychomotor retardation, loss of appetite, and sleep disturbance.9 The total score ranges from 
0 - 60, with higher scores indicating a greater burden of depressive symptoms. The heritability 
of the CES-D is estimated to be 0.2426 and it detects current MDD cases with high sensitivity and 
specificity.27,28 A score of >16 is considered to indicate a possible clinical depression.29 In order to 
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maximize the number of eligible participants, data from the third follow-up visit was used in this 
study.
Since 2005, magnetic resonance imaging (MRI) of the brain has been acquired at 1.5 Tesla during 
RS study examinations. The MRI protocol incorporates several sequences, including a T1-weighted 
sequence, a proton density weighted sequence, and a fluid-attenuated inversion recovery (FLAIR) 
sequence. These sequences were automatically processed using custom-developed multimodal 
algorithms to quantify brain tissue volumes.30,31 The processed images distinguished between 
grey matter, white matter, white matter lesions, and cerebrospinal fluid, and the volumes of each 
of these tissues were calculated by multiplying the number of voxels with that label with the 
volume of an individual voxel, expressed in ml.
Various other disease related to depressive systems have been characterized in the discover cohort. 
Alzheimer’s disease (AD) was characterized using the National Institute of Neurological Disorders 
and Stroke–Association Internationale pour la Recherche et l’Enseignement en Neurosciences - 
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA).32 Thyroid stimulating 
hormone (TSH) and free thyroxine (FT4) measurements were performed in serum samples stored 
at - 80°C in samples collected between 1997 and 2000. Thyroxine, thyrotropin, and thyroid 
perioxidase antibodies were quantified by electrochemiluminescence immunoassay (ECLIA, 
Roche).33
Independent replications were performed in the Erasmus Rucphen Family (ERF) study. ERF is a 
family-based study that includes inhabitants of a genetically isolated community in the South-
West of the Netherlands, ascertained as part of the Genetic Research in Isolated Population 
(GRIP) program.34 The ERF cohort includes approximately 3 000 living descendants of 22 founder 
couples who had at least six children baptized in the community church. All data were collected 
between 2002 and 2005. The population shows minimal immigration and high inbreeding and 
therefore the frequency of many rare alleles is increased in this population.34 All participants 
provided informed consent. The Medical Ethical Committee of the Erasmus University Medical 
Centre approved the ERF study. All study participants were assessed for depressive symptoms 
using Hospital Anxiety and Depression Scale (HADS) and CES-D. HADS is a 14-item scale of which 
7 items relate to anxiety and 7 items to depression. For depression, the total score ranges from 0 
to 21, with higher scores indicating a greater burden of depressive symptoms. A cut off of ≥ 8 is 
considered indicative of likely clinical depressive episodes.35
Subjects were extensively profiled for metabolomics using either plasma or serum samples 
collected at the time of visit and stored at - 80°C. Metabolic profiling was performed either by 
mass spectrometry (MS) or nuclear magnetic resonance (NMR), using five metabolite platforms: 
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one set by the AbsoluteIDQTM p150 Kit (Biocrates Life Sciences AG) (N = 937)36, two sets by 
either liquid chromatography coupled MS or Electro-Spray Ionization coupled MS37,38 (N = 2 416 
and N = 822 respectively), two sets measured by NMR using small molecular compounds39 (N = 
2 416, measured by Center for Proteomics and Metabolomics, Leiden University Medical Center, 
Leiden, the Netherlands) and lipoprotein extraction windows (N = 2 609, measured by Center 
for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands and 
deconvoluted by the commercial algorithm of Bruker Corporation NMR service protocol). The 
majority of the blood samples (97%) were obtained during fasting. In total, 2 864 participants 
from the ERF study were profiled for metabolomics on at least one of the five platforms and 563 
metabolites were annotated, which consisted of lipoprotein sub-particles, amino acids, a large 
array of (lyso)phosphatidylcholines, sphingolipids, ceramides, triglycerides and low-molecular-
weight compounds.
Exome sequencing
In the Rotterdam study, exomes of randomly selected subset of 2 628 individuals from the RS-I 
population were sequenced at the Human Genotyping facility of the department of Internal 
Medicine, at Erasmus MC, the Netherlands. The sequencing was performed at an average depth 
of 54x using the Nimblegen SeqCap EZ V2 capture kit on an Illumina Hiseq2000 sequencer 
using the TrueSeq Version 3 protocol. The sequence reads were aligned to hg19 using Burrows-
Wheeler Aligner (BWA).40 Subsequently, the aligned reads were processed further using Picard’s 
MarkDuplicates, SAMtools41 and the Indel Realignment and Base Quality Score Recalibration tools 
from Genome Analysis Toolkit (GATK).42 Genetic variants were called using the HaplotypeCaller 
from GATK. Samples with low concordance to genotyping array (< 95%), or that differed 4 
standard deviations from the mean on either the number of detected variants per sample, 
transition to transversion ratio or high heterozygote to homozygote ratio and low call rate (< 
90%) were removed from the data. Single Nucleotide Variants (SNVs) with a low call rate (< 
90%) and out of Hardy-Weinberg equilibrium (HWE; p-value < 10-8) were also removed from 
the data. The final dataset consisted of 600 806 SNVs in 2 356 individuals. Of these, 1 265 were 
assessed for depressive symptoms and were used in this study. The average age at examination 
was 72.3 years and the majority were women (59%; Supplementary Table 1). File handling and 
formatting was done using VCFtools43 and PLINK44. Annotation of the variants was performed 
using SeattleSeq annotation138 (http://snp.gs.washington.edu/SeattleSeqAnnotation138/). 
Exomes of 1 336 randomly selected individuals from the ERF study cohort were sequenced at 
the Center for Biomics of the Cell Biology department, at the Erasmus MC, The Netherlands. 
Sequencing was done at a median depth of 57x using the Agilent version V4 capture kit, on an 
Illumina Hiseq2000 sequencer, using the TruSeq Version 3 protocol. The sequence reads were 
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aligned to the human genome build 19 (hg19), using Burrows-Wheeler Aligner (BWA) and 
the NARWHAL pipeline.40,45 Subsequently, the aligned reads were processed further, using the 
IndelRealigner, MarkDuplicates and Table Recalibration tools from the Genome Analysis Toolkit 
(GATK)42 and Picard (http://picard.sourceforge.net). This was necessary to remove systematic 
biases and to recalibrate the PHRED quality scores in the alignments. After processing, genetic 
variants were called, using the Unified Genotyper tool from the GATK.42 For each sample, at 
least 4 Gigabases of sequence was aligned to the genome. Functional annotations were also 
performed using the SeattleSeq annotation 138 database. About 1.4 million SNVs were called. 
After removing variants with a low quality, out of HWE (p value < 10-6) and low call rate (< 99%), 
and samples with a low call rate (< 90%), we retrieved 543 954 very high quality SNVs in 1 327 
individuals. Of these, 1 247 individuals (60% women, mean age = 48.5 years) were assessed for 
depressive symptoms and included in the replications analysis.
Exome-chip genotyping
Study participants from the ERF cohort whose exomes were not sequenced (N = 1 527) were 
genotyped on the Illumina Infinium HumanExome BeadChip, version 1.1, which contains over 
240 000 exonic variants selected from multiple sources together spanning 12 000 samples from 
multiple ethnicities. Calling was performed with GenomeStudio. We removed subjects with a call 
rate < 0.95, IBS > 0.99 and heterozygote ratio > 0.60. Ethnic outliers identified using a principal 
component analysis with 1 000 Genomes data (Supplementary Figure 1) and individuals with sex 
discrepancies were also removed. The SNVs that were monomorphic in our sample or had a call 
rate < 0.95 were removed. After quality control we retrieved about 70 000 polymorphic SNVs in 
1 515 subjects. Of these, 840 individuals (54% women, mean age = 50 years) were assessed for 
depressive symptoms and included in the replication analysis.
In the RS cohort, 3 163 (1 949 independent) samples were genotyped using the Illumina Human 
Exome BeadChip v1.0. Genotype calling was performed according to the CHARGE joint calling 
protocols.46 For replication, we used 1 525 individuals (52.6% women, mean age = 73.7 years) 
who were assessed for depressive symptoms but not exome sequenced.
DATA ANALYSIS
Single variant quantitative trait association analysis of depressive symptoms was performed 
using the seqMeta (v1.4) library of the R software in RS. We included only missense, nonsense, 
frameshift, or essential splice site bi-allelic variants that had a minor allele count > 7 in the RS 
discovery set. In the ERF replication samples, for sequence data we used a linear mixed effects 
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model in seqMeta (V1.4) using the kinship matrix estimated from the pedigree data in the 
kinship2 library of R. For the exome-chip data, we used FamScore test implemented in RVtests 
(http://zhanxw.github.io/rvtests/) using the kinship matrix estimated from the genotyped data 
to adjust for familial relationships. Analysis of the RS exome-chip data was performed using 
seqMeta library of the R software. All analyses were adjusted for age and sex. Meta-analysis 
of the replication studies was performed in R using the library rmeta. Association analyses with 
other dichotomous and quantitative traits were performed using logistic and linear regression 
analysis respectively, adjusted for age and sex in PLINK v1.0744 (http://pngu.mgh.harvard.edu/
purcell/plink/) or SPSS v21. Analysis of the metabolomics data in the ERF cohort was performed 
using linear regression adjusted for age and sex. Skewed metabolites were transformed using 
either natural logarithm or inverse-normal transformation. We used polygenic residuals of the 
metabolites after regressing out the effect of relationships in a linear mixed model in GenABEL. 
We used Bonferroni corrected p-value thresholds in ERF (0.05/563 metabolites = 8.8*10-05) to 
declare significance.
RESULTS
Genome-wide association and quantile-plots are provided in Supplementary Figures 2 and 
3. We observed significant association of depressive symptoms with a low frequency variant 
(rs77960347-G; MAF = 1%, N (carriers) = 60; p value = 5.2*10-08) on chromosome 18 (Table 1a, 
Figure 1). The estimated additive effect of the minor allele (G) on depressive symptoms was large 
(β = 7.2) (Figures 2 and 3), suggesting that each allele yields an increase of depressive symptoms 
by 7.2 units. Rs77960347 is a highly conserved missense variant in the LIPG gene (Asn396Ser 
phastCons = 1) and predicted to be damaging (polyPhen = 1). In the replication cohort ERF, 
rs77960347-G was observed with a similar frequency to the discovery sample. The replication 
sample demonstrated a significant association (p value = 7.1*10-03) of rs77960347-G with the 
depressive symptoms, and also a large effect (β = 2.55) (Table 1b, Figure 3). 
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Apart from having large effects on depressive symptoms, the carriers of rs77960347-G on 
average had a smaller brain volume (both white and grey matter) and a higher burden of white 
matter lesions (p value = 3.3*10-02; based on the subset of 10/60 carriers with an MRI available), 
compared to non-carriers (Table 2).
Table 2. Brain imaging characteristics of carriers and non-carriers of Asn396Ser
  A/A (N=398) A/G (N=10) p value
Demographics
Age, years 79.0 (4.8) 79.0 (4.8) 0.97
Females 222 (55.8%) 7 (70.0%) 0.37
Brain volumetry, mL
Intracranial volume 1137.2 (119.6) 1136.5 (93.8) 0.99
Grey matter volume 508.6 (52.1) 501.2 (49.8) 0.66
White matter volume 378.9 (55.1) 377.9 (51.1) 0.96
Cerebrospinal fluid volume 247.4 (51.2) 255.0 (47.8) 0.64
White matter lesion volume 8.3 (3.9 - 17.1) 24.6 (5.4 - 34.5) 0.03
Figure 1. Regional association plot for the top hit (Asn396Ser). 
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Figure 2. Box plot for the carriers and non-carriers of the minor allele (G). 
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Vertical axis shows the CES-D score. Purple box region shows the interquartile range. The horizontal bar in the 
box indicates the median. Lower and upper whiskers indicate the first and the fourth quartiles respectively. 
Circles indicate outliers and stars indicate extreme values.
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Figure 3. Forest plot for the top hit (Asn396Ser). 
Effect
Po
pu
lat
ion
−2 0 2 4 6 8 10
RSseq (Discovery; N=1265)
ERFseq (Replication; N=1247)
ERFchip (Replication; N=840)
RSchip (Replication; N=1525)
Pooled
Asn396Ser
Effect
Po
pu
lat
ion
−2 0 2 4 6 8 10
RSseq (Discovery; N=1265)
ERFseq (Replication; N=1247)
ERFchip (Replication; N=840)
RSchip (Replication; N=1525)
Pooled
Asn396Ser
Vertical axis represents all the studies. Horizontal axis shows the size of the effect of the variant. Size of 
the blue boxes indicates the precision. The horizontal lines adjacent the blue boxes indicate the confidence 
interval for the study. The red diamond indicates the summary effect estimate. The width of the diamond 
indicates the confidence interval for the summary effect. 
Given that the LIPG gene is expressed in the thyroid gland and has been implicated in several 
cardiometabolic disorders, including dyslipidemia47, atherosclerosis48,49, cardiovascular diseases50, 
and inflammation51, we additionally tested the association of Asn396Ser with these conditions 
and their related phenotypes (Table 3). No association with thyroid functioning, cardiovascular 
outcomes, inflammation, atherosclerosis, or hypertension was observed (Table 3). Total cholesterol 
was increased in carriers (p value = 5.3*10-03; Table 3). The association of Asn396Ser with 
depressive symptoms was relatively decreased after adjusting for total cholesterol (adjusted β = 
7.0, adjusted p value = 5.3*10-06), using a slightly reduced sample size (N = 1 112). Furthermore, 
we observed a two-fold increase in the prevalence of Alzheimer’s disease (AD) in carriers of 
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the minor allele (14/60 carriers) compared to non-carriers (p value = 2.8*10-02; Table 3). The 
association of Asn396Ser with depressive symptoms remained significant (p value = 3.7*10-
08) after adjusting for AD. However, the association with AD disappeared (p value = 0.46) 
after adjusting for depressive symptoms. Metabolomic profiles of carriers and non-carriers of 
Asn396Ser in the ERF study demonstrated significantly increased levels of high density lipoprotein 
(HDL) sub-particles and Apolipoprotein A1 (APOA1) (p value < 6.7*10-05; Supplementary Table 2).
Table 3. Association results of various diseases with Asn396Ser
Disease Phenotype Effect (OR)§ SE p value
Cardiovascular
Myocardial infarction (MI) -0.32 0.48 0.51
Coronary heart disease (CHD) -0.18 0.49 0.72
Coronary artery calcification (CAC) -0.27 0.58 0.64
Inflammation
C-reactive protein (CRP) -0.06 0.13 0.65
Thyroid function
Thyroid stimulating hormone (TSH) 0.05 0.17 0.79
Free Thyroxine (FT4; pmol/l) -0.72 0.49 0.14
Cholesterol
High density lipoprotein (HDL; mg/dl) 6.96 2.94 0.02
Low density lipoprotein (LDL; mg/dl) 15.16 7.42 0.04
Total cholesterol (TC; mg/dl) 21.09 7.57 5.0*10-03
Triglycerides (TG; mg/dl) -0.05 0.10 0.59
Atherosclerosis
Intima media thickness (IMT) -0.03 0.03 0.31
Hypertension
Diastolic blood pressure 0.20 2.29 0.93
Systolic blood pressure 0.01 4.21 0.99
Hypertension 0.27(1.31) 0.52 0.60
Neurological
Alzheimer’s disease (AD) 0.70(2.01) 0.32 0.03
Cognitive function (G-factor) -0.10 0.28 0.72
§ all effects/ORs are reported for the minor allele (G) 
DISCUSSION
Using a comprehensive exome-based association study of depressive symptoms, we have 
identified a rare (MAF = 1%) Asn396Ser coding variant (rs77960347-G) in the LIPG gene in 
chromosome 18q21. This variant is conserved and predicted to have damaging effects on the 
LIPG protein. The estimated effect of Asn396Ser on depressive symptoms is large and significantly 
replicates in three independent samples. Carriers of the rare allele (G) manifest smaller brains and 
more white-matter lesions compared to non-carriers. When considering pleiotropic effects, the 
variant is nominally associated with blood cholesterol levels and an increased risk of AD.
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Rs77960347 is relatively less frequent in the general population (1000Genomes MAF = 0.5%; 
10/2174 alleles) compared to the cohorts used in this study. Comparing across ethnicities, it 
is more frequent in non-Finnish Europeans (1.35% in non-Finnish Europeans versus 0.35% in 
Finnish and 0.18% in Africans). In the RS cohort, we observed 60 carriers of the minor allele 
(G). The variant overlaps both transcripts of the endothelial lipase (LIPG) gene. Common variants 
in LIPG have consistently been associated with blood cholesterol levels.52 Previous reports on 
the association of cholesterol levels with depression have been contradictory.53 In our study, we 
observed significantly increased levels of serum cholesterol in carriers of Asn396Ser compared to 
non-carriers. Notably however, the association with cholesterol was not nearly as strong as with 
the depressive symptoms. Furthermore, the lipidomics/metabolomics profiles of the carriers and 
non-carriers in the ERF cohort demonstrated significantly increased levels of HDL sub-particles 
and plasma APOA1. 
Carriers of rs77960347-G had a higher burden of white matter lesions than non-carriers. White 
matter lesions in patients with depression have been well recognized in the elderly.54-57 The 
severity of subcortical white matter lesions in the elderly has been associated with the presence 
of depressive symptoms and to a history of late-onset depression.57 White matter lesions are 
also frequently found in AD patients.58-60 In this context, the higher prevalence of AD in carriers 
of Asn396Ser is interesting. Depression is also one of the most widely studied risk factors for 
AD.61 Previous reports suggest that the one-month prevalence of major depressive episodes in 
AD patients is as high as 25%.61 While there is a general consensus about the existing complex 
relationship between the two diseases, the direction of causality remains unclear. However, a 
few longitudinal epidemiological studies suggest that people with a history of depression are 
at an increased risk of AD.62,63 It is of interest that the association of genetic variant loses its 
significance after adjusting from depressive symptoms but its association to depressive symptoms 
remains significant when adjusting for AD. This findings is compatible with a mechanism in which 
the depressive symptoms are an intermediate in the association between Asn396Ser and AD. 
Given the marginal level of significance of the association to AD, this hypothesis requires further 
confirmation in other cohort studies.
LIPG is highly expressed in the thyroid gland (AUC = 0.96, p value = 1*10-49) and is predicted 
to be involved in the metabolism of steroids, cholesterol, thyroid hormone, tryptophan, 
butanoate (butyrate), vitamins A and D, and the platelet amyloid precursor protein (APP) 
pathway (http://129.125.135.180:8080/GeneNetwork/?gene=LIPG).64 Hypothalamus-pituitary-
thyroid (HPT) axis abnormalities have been documented in some depressed patients.65 Thyroid 
dysfunction, including both hypothyroidism and hyperthyroidism, are known to be associated 
with mood disorders.66-68 In our study we did not find evidence of thyroid function abnormalities 
in the carriers of the minor allele. The predicted involvement of LIPG in the metabolism of 
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butanoate (butyrate) and tryptophan is notable given that tryptophan is a precursor of serotonin 
and depletion in plasma tryptophan has been previously reported in depressed individuals.69,70 
Sodium butyrate is also known to reverse depressive-like behaviors in animals.71
Our study is the first to have used exome-sequencing on a large scale with a specific aim to 
identify rare variants with large effects on depressive symptoms. One of the strengths of this 
study is the use of a quantitative depression scale for gene discovery. The CES-D detects cases of 
MDD with high sensitivity and specificity28 and has proven to be relatively stable over time.25,72 In 
association studies quantitative endophenotypes provide an improved power to detect genetic 
variants compared to a dichotomous trait. This is likely to be especially true for trait such as MDD, 
for which the severity and duration of illness can be highly heterogeneous.73 Another strength of 
our study is the use of high coverage sequencing (> 50 x on average) necessary to reliably detect 
rare variants.
In conclusion, we have discovered a novel missense variant rs77960347-G (Asn396Ser) in the 
LIPG gene that confers a large effect on depressive symptoms in the general population. We 
have also confirmed that this association is not confounded or mediated by the presence of an 
underlying somatic disorder. Moreover, the combination of the predicted functioning of LIPG, 
the association of rs77960347-G with white matter lesions, and its pleiotropic effects on various 
phenotypes linked with major depressive disorder substantiates LIPG as a candidate gene for 
depression that warrants further genetic and functional investigation.
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ABSTRACT
Background: Despite high heritability, little success was achieved in mapping genetic determinants 
of depression-related traits by means of genome-wide association studies (GWAS).
Methods: To identify genes associated with depressive symptomology, we performed a gene-
based association analysis of non-synonymous variation captured using exome-sequencing and 
exome-chip genotyping in a genetically isolated population from the Netherlands (N = 1 999). 
Finally, we reproduced our significant findings in an independent population-based cohort (N = 
1 604).
Results: We detected significant association of depressive symptoms with a gene NKPD1 (p 
value = 3.7 × 10-08). Non-synonymous variants in the gene explained 0.9% of sex-age-adjusted 
variance of depressive symptoms in the discovery study, which is translated into 3.8% of the total 
estimated heritability (h2 = 0.24). Significant association of depressive symptoms with NKPD1 
gene was also observed (N = 1 604, p value = 1.5 x 10-03) in the independent replication sample 
despite little overlap with the discovery cohort in the set of non-synonymous genetic variants 
observed in the NKPD1 gene. Meta-analysis of the discovery and replication studies improved the 
association signal (p value = 1.0 x 10-09).
Conclusion: Our study suggests that non-synonymous variation in the gene NKPD1 affects 
depressive symptoms in the general population. NKPD1 is predicted to be involved in the de-novo 
synthesis of sphingolipids, which have been implicated in the pathogenesis of depression.
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INTRODUCTION
Major depressive disorder (MDD) is the most prevalent psychiatric disease1 and is known to be 
influenced by both genetic and non-genetic factors. The heritability of MDD is estimated to be ~ 
40%.1-3 Up until recently all efforts to identify common genetic variation involved in depression 
using large scale genome-wide association studies (GWAS) were unsuccessful.4,5 Two common 
variants on chromosome 10 were detected, one near the SIRT1-DNAJC12 locus (minor allele 
frequency (MAF) = 0.45; p value = 2.4 × 10-10), the other in an intron of the LHPP gene (MAF = 
0.26; p value = 6.4 × 10-12), each with a small effect on the disease risk (odds ratios of 1.15 and 
0.84). Despite successful replication in an independent sample of Chinese origin, the two variants 
could not be reproduced in the European MDD case/control samples.6,7
The limited success of GWAS in case of depression has been attributed to the specifics of the 
disease.1 The patients with MDD have heterogeneous phenotypes, they differ from one another 
in frequency, severity and the duration of episodes of MDD.5 Those with a family history of 
MDD more often have clinically severe illness, earlier age of onset, and suffer higher rates of 
recurrence.8 Because MDD is more prevalent and less heritable than other psychiatric traits, for 
instance, schizophrenia1, it has been speculated that common genetic variants involved in MDD 
have effects even smaller than the effects of genetic variants observed for schizophrenia.1,9 The 
proportion of variance of MDD explained by common genetic variants is estimated to be 21%10 
asking for a sample size of more than 75K for the discovery of such variants.1
One of the approaches that was successfully followed for other complex and prevalent outcomes 
that are liable to misclassification (e.g., hypertension) is to study the genetics of quantitative traits 
of liability (e.g. blood pressure).11 Following this reasoning, large-scale attempts were made to 
identify common genetic variants associated with depressive symptoms and somatic complaints 
in depression (N > 30 000). However, these efforts also failed.2,12 Of note is that, the percentage 
of variance explained by common genetic variation was estimated to be rather low (< 4%).12
Besides common variants, rare variants may be involved in MDD. Recently, two studies identified 
rare variants in a gene ZNF3413 and Cav2-adaptor gene set14 to be nominally associated with 
depression. As these variants may be private to individual (sub-) families even at a single locus, 
different variants in the same gene may be involved in the disease (allelic heterogeneity). Statistical 
approaches to aggregate rare variants across genes can help overcome the problem of allelic 
heterogeneity.15 Further increase in power of statistical association analysis may be achieved by 
using founder populations for gene discovery.15 Because of their unique characteristics including 
genetic, environmental and cultural homogeneity, and enrichment of some rare alleles due to 
genetic drift, founder populations are considered more powerful than general populations for 
the discovery of rare variants.15,16
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In the current study we aim to identify genetic variants implicated in depressive symptomology using 
exome-sequencing and exome-chip genotyping in a genetically isolated European population. 
We conduct single variant and gene-based analyses to discover variants and genes associated 
with depressive symptoms and replicate our findings into a population-based prospective cohort 
study from the same source population.
METHODS
Discovery population
The Erasmus Rucphen Family (ERF) study is a cross-sectional cohort including 3 000 living 
descendants (age range 18 - 96 years) of 22 couples who lived in the middle of 18th century in 
an isolated village in the Southwest of the Netherlands and had at least 6 children baptized in 
the community church. Until the last few decades descendants of these founders have lived in 
social isolation with minimal immigration (less than 5%). From the year 1848, the population 
has expanded from 700 up to 20 000 inhabitants.17 77% of the fathers and 79% of the 
mothers in this population have inbreeding coefficient greater than zero. The participants are 
not selected for any disease or outcome. Detailed information regarding the ERF isolate can 
be found elsewhere.17-19 The study protocol was approved by the medical ethics board of the 
Erasmus MC Rotterdam, the Netherlands. Written informed consents were provided by all the 
subjects participating in the study. Symptoms of depression were assessed with the Center for 
Epidemiological Studies Depression Scale (CES-D) in 2,353 participants.20 The questionnaire is a 
valid and reliable self-report measure of current symptoms of depression.20,21 The scale consists 
of 20 items with total scores ranging from 0 to 60. Higher scores correspond to more depressive 
symptoms. A CES-D score of >16 is indicative of possible depression.20 The descriptive data of ERF 
study are provided in Supplementary Table 1.
Exome sequencing
Exomes of 1 336 participants from the ERF pedigree were sequenced at the Center for Biomics, 
Erasmus MC Rotterdam, the Netherlands. Sequencing was performed at a median depth of 57 x 
(mean depth = 74x) using Agilent SureSelect V4 capture kit on an Illumina Hiseq2000 sequencer 
and the TruSeq Version 3 protocol. Sequence reads were aligned to the human genome build 19, 
using Burrows-Wheeler Aligner22 and the NARWHAL pipeline.23 Subsequently, the aligned reads 
were processed further, using the IndelRealigner, MarkDuplicates and Table Recalibration tools 
from the Genome Analysis Toolkit (GATK). For each sample, at least 4 Gigabases of sequence 
was aligned to the genome. Genetic variants were called using the Unified Genotyper tool from 
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the GATK24 v2.3. About 1.4 million Single Nucleotide Variants (SNVs) were called. Genotype 
concordance checks were performed with the available genome-wide array data. The SeattleSeq 
annotation 138 database (http://snp.gs.washington.edu/SeattleSeqAnnotation138/) was used to 
perform functional annotations of the identified SNVs. After removal of individuals with low 
concordance, inconsistent genomic and pedigree kinship estimate and ethnic-outliers detected 
using principal components analysis (Supplementary Figure 1), and filtering out variants with low 
quality (QUAL < 30), > 5% Mendelian errors per sample and out of Hardy-Weinberg equilibrium 
(p value < 10-08) we retrieved 528 617 polymorphic SNVs in 1 308 individuals. Of these, 1 209 
had depressive symptoms measured.
Exome chip
Study participants from the ERF cohort whose exomes were not sequenced (N = 1 527) were 
genotyped on the Illumina Infinium HumanExome BeadChip, version 1.1, which contains over 
240 000 exonic variants selected from multiple sources together spanning 12 000 samples from 
multiple ethnicities. Calling was performed with GenomeStudio and the ZCall variant calling 
tool25(Broad Institute). We removed subjects with a call rate < 0.95, IBS > 0.99, heterozygote 
ratio > 0.60, XXY individuals and ethnic-outliers (Supplementary Figure 1). SNPs that were 
monomorphic in our sample or had a call rate < 0.95 were removed from the dataset. After 
quality control we retrieved 71 320 genetic variants in 1 512 individuals. Of these, 794 had 
depressive symptoms measured and 62 246 variants were polymorphic within this sample.
DATA ANALYSIS
Single variant association analysis of depressive symptoms was performed using a linear-
mixed model (mmscore function) in GenABEL (30) incorporating genomic kinship matrix to 
account for relatedness. Gene-based association analysis of depressive symptoms including 
only nonsynonymous variants (missense, missense near splice, stop-gained, stop-gained near 
splice, stop-lost, stop-lost near splice mutations) was performed using the famSKAT-O test in 
the FFBSKAT function of the FREGAT R-package26 (http://mga.bionet.nsc.ru/soft/FREGAT/). 
FamSKAT-O is a powerful tool for family-based analyses.27 It combines a sequence kernel 
association test (SKAT) with a classical burden test and retains the advantages of both. SKAT 
compares the average similarity of a set of genetic variants in the analyzed region for each pair 
of individuals with pairwise phenotypic similarities. Pairwise genetic similarity is measured by 
using a kernel weighting function, which reduces the information on multiple genetic variants 
for a pair of individuals into a single scalar factor. Weights for genetic variants were assigned as a 
standard function of the MAF with β distribution parameters of (1, 25)28 and the range for ρ was 
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set from 0 to 1 with an increment of 0.1.29 Genomic kinship was used to correct for relatedness. 
The kinship matrix was calculated with the IBS function of GenABEL 30 using autosomal genetic 
variants with a MAF ≥ 5%. Since the two ERF subsamples had little overlapping in individuals 
(4 individuals in common) they were analyzed separately. Of 88 565 nonsynonymous variants in 
exome sequence data, 85 858 formed 13 707 gene regions with > 1 polymorphic genetic variants 
(ranging from 2 to 222 variants, median 5). In exome chip data, 47 469 nonsynonymous variants 
were present and 43 563 of them were within 9 677 gene regions with > 1 polymorphic genetic 
variants (ranging from 2 to 123 variants, median 3). Meta-analysis of the two ERF subsamples (as 
well as of the discovery and replication samples) was performed using Fisher’s method 31, which 
has been shown to have a high power in regional meta-analysis.32 All analyses were adjusted for 
age and sex (Supplementary Table 2). Exome-wide significance for gene-based analysis was set at 
p value < 2.5×10-6 corresponding to a Bonferroni correction for ~20 000 protein-coding genes in 
the genome.33 The proportion of total variance explained by a single region was estimated with 
the ‘return.variance.explained’ option of FFBSKAT.
Replication study
Significant findings from the discovery population were selected for replication in the independent 
population-based Rotterdam Study (RS) study. RS is a prospective, population-study from a well-
defined district in Rotterdam (Ommoord) that investigates the occurrence and determinants of 
diseases in the elderly.34 The cohort was initially defined in 1990 among approximately 7 900 
persons who underwent a home interview and extensive physical examination at the baseline and 
during follow-up rounds every 3-4 years. The cohort was extended in 2000 and 2005. RS is an 
outbred population, predominantly of Dutch origin. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, approved the study. Written informed consent was obtained from 
all study participants. Participants from RS-I are assessed at four follow-up visits for depressive 
symptoms using the 20 item version of the CES-D scale. Because of maximum participation, data 
from the third visit was used in this study.
Exomes of 2 628 individuals from the RS-I population were sequenced at the Human Genotyping 
facility of the Internal Medicine department, at the Erasmus MC, the Netherlands, at an average 
depth of 54x using the Nimblegen SeqCap EZ V2 capture kit on an Illumina Hiseq2000 sequencer 
and the TruSeq Version 3 protocol. The sequenced reads were aligned to human genome build 
19 using Burrows-Wheeler Aligner.22 The aligned reads were processed further using Picard’s 
MarkDuplicates, SAMtools35, and the Indel Realignment and Base Quality Score Recalibration 
tools from GATK.24 Genetic variants were called using the HaplotypeCaller and genotypeGVCFs 
tools of GATK. Samples with low concordance to genotyping array (< 95%), or that were 4 
standard deviations from mean on either the number of detected variants per sample, transition to 
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transversion ratio or heterozygous to homozygous ratio and low call rate (< 90%) were removed 
from the data. Initial variant QC was done using the Variant Quality Score Recalibration tool from 
GATK, additionally SNVs with a low call rate (< 90%) and out of HWE (p value < 10-08) were also 
removed from the data. The final dataset consisted of 600,806 SNVs in 2,356 individuals. File 
handling and formatting was done using vcftools and PLINK36 (http://pngu.mgh.harvard.edu/
purcell/plink/). Annotation of the variants was performed using SeattleSeq annotation 138.
The SeqMeta library (https://cran.r-project.org/web/packages/seqMeta/index.html) for the R 
statistical analysis software was used to perform gene-based SKAT analysis of depressive symptoms 
for the genes identified in the discovery cohort. As in the discovery cohort only nonsynonymous 
mutations were used in the SKAT analysis. The analysis was adjusted for age and sex.
RESULTS
The discovery sample (ERF) included 1 999 individuals. The percentage of women (57%) and 
the mean age (49 years) were similar to that of the whole ERF study (Supplementary Table 1). 
The heritability of depressive symptoms was estimated at 0.24. Results of the single variant and 
gene-based analysis are illustrated in Figure 1 and quantile-quantile (QQ) plots are provided 
in Supplementary Figure 2. None of the single variants surpassed the standard genome-wide 
significance threshold (Figure 1). Genome-wide results of gene-based analysis are provided in 
Supplementary Table 3. Significant association of depressive symptoms was observed with the 
gene NKPD1 (p value = 3.7 x 10-08) (Supplementary Table 3). Nine non-synonymous variants 
were observed in the NKPD1 gene in the ERF study (Supplementary Table 4). Except for one 
variant, minor alleles of all non-synonymous variants were associated with higher CES-D scores 
(Supplementary Table 4). Two variants were relatively frequent (rs28469095, MAF = 0.11 and 
rs117934605, MAF = 0.13). The variant that showed the lowest p value (rs75291769, p value 
= 2.5 x 10-04) was four times more frequent in ERF (MAF = 0.046) compared to 1 000 genomes 
(0.012). The region covering the NKPD1 showed good coverage in sequencing with a mean read 
depth of 46.5x. Non-synonymous variants in NKPD1 gene explained 0.9% of the age- and sex-
adjusted variance of CES-D in the ERF sample, which is translated into 3.8 % of the estimated 
heritability (0.24).
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Significant association of NKPD1 with depressive symptoms was also observed in the replication 
cohort (RS) (p value = 1.5 x 10-03). A total of 15 nonsynonymous variants were tested in the 
NKPD1 gene in the RS with MAFs varying from 0.03% to 0.7%. (Supplementary Table 5). The 
association signal improved to p value = 2.9 x 10-05 when we limited the analyses to mutations 
that were predicted damaging by PolyPhen (10 mutations (9 missense, 1 stop-gained) within 
NKPD1 gene; Supplementary Table 5). Figure 2 compares the results of exome single-point and 
gene-based analysis for NKPD1 in the two samples. Different variants were identified within 
NKPD1 gene in ERF and RS. In ERF, the second NKPD1 exon gave the strongest association signal 
while the third and fourth exons contained only modest signals. In the replication, association 
signals were present in the fourth exon only but the p values were stronger compared to that seen 
in ERF. When meta-analyzing the discovery and replication studies the significance of association 
increased to a p value of 1.0 x 10-09. 
Figure 2. Single-point and gene-based association signals of NKPD1 gene in the discovery sample 
(ERF, blue) and the replication sample (RS, pink).
Dotted blue and red lines indicate the regional statistically significant levels for discovery and replication, 
respectively. Size of the points is proportional to the MAF.
None of the previously identified genes i.e., SIRT-DNAJC12, LHPP, ZSNF34 or Cav2 adaptor genes 
showed evidence of association in our study (see Supplementary Table 3).
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DISCUSSION
We have identified and replicated association of (rare) non-synonymous variants in NKPD1 gene 
with depressive symptoms. These coding variants explained 0.9% of the age- and sex-adjusted 
variance and 3.8% of heritability of depressive symptoms in the ERF population. To our knowledge 
this is the first study that explores the gene-based association of non-synonymous variants for 
depressive symptoms using large scale whole exome-sequencing.
To date, little success was achieved in mapping genetic determinants of depression-related 
traits by means of GWAS and whole genome/exome sequencing.1,2,4 We did not find evidence 
of association of previously reported genes including SIRT-DNAJC12, LHPP, ZSNF34 and Cav2 
adaptor gene set in our study. In previously published GWAS of MDD and depressive symptoms, 
only five intronic variants were mapped on to the NKPD1 gene, of which three showed modest 
association signals (p value < 0.1; Supplementary Tables 6-7). These variants may be in low linkage 
disequilibrium with coding variants not typed in these studies.
Our study had several strengths that ultimately led to the discovery of a novel gene associated 
with depressive symptoms. In association studies, quantitative measurements give better chances 
to detect genetic variants compared to the dichotomous trait, especially for traits like depression, 
which represents an arbitrarily selected extreme of the continuum of varying severity and 
duration.37 Secondly, we used high coverage exome sequencing (average depth = 74x) in a large 
discovery set that allowed us to determine rare variants with high precision. Finally, our discovery 
is based within a genetically isolated population. Samples from genetic isolates are expected to 
have reduced genetic variation and shifted allele frequencies due to long-time genetic drift.19 Rare 
alleles can accumulate in large numbers in these populations, thus empowering the association 
analysis.15 In our study, the missense variant that showed the strongest association within the 
NKPD1 gene (rs75291769/exm1479956, p value = 2.5 x 10-04) had a frequency of 4.6% in ERF 
(Supplementary Table 3) but was monomorphic in RS despite the fact that both populations go to 
the same source population. Yet, several other variants within NKPD1 showed modest associations 
with depressive symptoms in RS, with the strongest signal in exon 4 of NKPD1, 6K apart from the 
strongest signal obtained in ERF. None of these single-point association signals achieved genome-
wide significance, illustrating the advantage of a regional gene-based association analysis over a 
single point study of rare variants. 
NKPD1 encodes NTPase KAP family P-loop domain–containing protein 1, and it was found to 
express strongly in skin and, to a lesser extent, in cerebellum, other brain tissues and thyroid 
(http://www.gtexportal.org/home/gene/NKPD1).38 NTPases are nucleoside-triphosphatases 
that hydrolyze nucleoside triphosphates to nucleoside diphosphates. It has been shown that 
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membrane NTPase activity is substantially altered in Lesch–Nyhan disease fibroblasts.39 Lesch–
Nyhan syndrome (also known as juvenile gout) is caused by a defect of the purine metabolism 
and its symptoms include mental retardation, dystonia, spasticity, delayed motor development 
and a compulsive form of self-injurious behavior.40 Functional prediction of NKPD1 suggests that 
this gene is involved in the de novo biosynthesis of sphingolipids (http://129.125.135.180:8080/
GeneNetwork/?gene=NKPD1). De novo synthesis of sphingolipids results in the formation of 
ceramides.41-46 Sphingolipid metabolism is also proposed to be a therapeutic target for MDD.47,48 
Some antidepressants (amitriptyline and fluoxetine) are known to inhibit sphingomyelin 
phosphodiesterase 1 acid lysosomal (SMPD1).49 SMPD1 is a membrane protein facing the lysosomal 
lumen that converts sphingomyelin into ceramide.47,49 Earlier, we found various sphingomyelin 
levels in the blood to be associated with depressive symptoms.50 
In summary, we have discovered association of non-synonymous variation in the gene NKPD1 
with depressive symptoms in the general population. The variants explain 0.9% of the age- 
and sex-adjusted variance of depressive symptoms, which translates into 3.8% of the estimated 
genetic variance of depressive symptoms. The predicted involvement of NKPD1 in the biosynthesis 
of sphingolipids corroborate the possible role of NKPD1 in depression.
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APPENDIX of CHAPTER 3
Exome-sequencing in a large population-based study reveals a rare Asn396Ser variant in the LIPG 
gene associated with depressive symptoms
Supplementary Figure 1. 
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Supplementary Figure1: Ethnicity information provided by the principal components analysis. Black circles represent the samples analyzed, red: Caucasian, blue: Chinese, green: African, yellow: Colombian (AMR), cyan: Mexican (AMR), coral: Puerto Rican (AMR), brown: African (AMR).  
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Ethnicity information provided by the principal components analysis. Black circles represent the samples 
analyzed, red: Caucasian, blue: Chinese, green: African, yellow: Colombian (AMR), cyan: Mexican (AMR), 
coral: Puerto Rican (AMR), brown: African (AMR). 
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Genome-wide association plot. Horizontal axis shows all chromosomes. Vertical axis shows the strength of 
association in terms of negative principal logarithm of the association p-value. Each dot represents a SNV. The 
horizontal red dotted line indicates the genome-wide significance threshold. 
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Supplement Table 1
RS (seqeunce) RS (exomechip) ERF (sequence) ERF (exomechip)
N 1265 1525 1247 840
Age mean(SD) 72.3 (7.1) 73.7 (7.2) 48.5 (14.6) 50.0 (15.8)
% women 59.1 52.6 60 54
CES-D mean(SD) 4.5 (6.9) 4.7 (7.1) 11.7 (10.3) 9.2 (9.0)
Supplement Table 2
Name BETA SE t-value p-value N
M-HDL-ApoA1 2.8811 0.6684 4.31 1.70E-05 2186
L-HDL-cholesterol 1.2789 0.3148 4.06 5.01E-05 2187
M-HDL-phospholipids 2.3569 0.5854 4.03 5.86E-05 2187
HDL-phospholipids 9.0311 2.2490 4.02 6.13E-05 2186
plasma-ApoA1 9.7158 2.4312 4.00 6.65E-05 2186
L-HDL-phospholipids 2.2543 0.5746 3.92 9.01E-05 2186
M-HDL-Free cholesterol 0.2622 0.0679 3.86 0.000116 2188
L-HDL-Free cholesterol 0.3130 0.0813 3.85 0.000121 2188
M-HDL-cholesterol 1.1438 0.3017 3.79 0.000154 2187
L-HDL-ApoA1 2.3032 0.6189 3.72 0.000203 2186
XL-HDL-Free cholesterol 0.7118 0.1937 3.67 0.000244 2177
Ethanol -0.2681 0.0731 -3.67 0.000249 1991
HDL-cholesterol 5.0928 1.4056 3.62 0.000298 2186
L-HDL-ApoA2 0.4994 0.1394 3.58 0.000346 2186
XL-HDL-phospholipids 0.1480 0.0415 3.57 0.000369 2178
Phosphatidylcholine diacyl (38:7) 0.2853 0.0825 3.46 0.00055 2258
HDL-ApoA1 9.0328 2.6479 3.41 0.000658 2185
M-HDL-ApoA2 0.6115 0.1831 3.34 0.000852 2185
Phosphatidylcholine diacyl (36:4) 0.8600 0.2624 3.28 0.001061 2262
S-VLDL-cholesterol 0.2625 0.0830 3.16 0.001583 2187
HDL-Free cholesterol 1.1654 0.3752 3.11 0.001921 2186
S-VLDL-phospholipids 0.2874 0.0947 3.03 0.002441 2181
Ceramide C24:1 0.3180 0.1059 3.00 0.002766 648
Phosphatidylcholine diacyl (40:4) 0.0147 0.0050 2.95 0.003218 2251
Phosphatidylethanolamine 38:4 1.4875 0.5070 2.93 0.003463 647
HDL-APOA2 1.6880 0.5989 2.82 0.004871 2185
Lysophosphatidylcholine(18:2) -0.2889 0.1049 -2.75 0.005927 2258
Phosphatidylethanolamine(38:4) 0.0361 0.0134 2.69 0.00715 2254
Phosphatidylcholine diacyl (32:0) 0.0441 0.0164 2.69 0.007191 2260
Sphingomyeline C 16:0 22.8932 8.4976 2.69 0.007241 647
Phosphatidylcholine diacyl C 38:0 1.9246 0.7309 2.63 0.008662 649
M-VLDL-cholesterol 0.9207 0.3597 2.56 0.010539 2181
Isoleucine -8489.8937 3340.3312 -2.54 0.011108 2009
Sphingomyeline C 16:1-OH 1.0739 0.4217 2.55 0.011114 651
XL-HDL-ApoA2 0.1398 0.0552 2.53 0.01134 2172
XL-LDL-triglycerides 0.1755 0.0702 2.50 0.012455 2186
Glycine 57814.1927 23167.4814 -2.50 0.012659 1995
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Name BETA SE t-value p-value N
Phosphatidylcholine diacyl (34:3) 0.0700 0.0281 2.49 0.01276 2259
Phosphatidylcholine diacyl C42:4 0.0265 0.0108 2.45 0.014385 794
Phosphatidylethanolamine 38:5 0.4631 0.1887 2.45 0.014397 647
glutamine -991.2650 409.1073 -2.42 0.015481 2015
Ornithine -178.3774 73.9146 -2.41 0.015898 2006
L-VLDL-cholesterol 0.1080 0.0449 2.40 0.016391 2178
Lysophosphatidylcholine(22:6) -0.0120 0.0050 -2.40 0.016637 2255
XL-HDL-cholesterol 0.1235 0.0516 2.39 0.016766 2173
Phosphatidylethanolamine 38:2 0.0397 0.0167 2.39 0.017297 647
Lysophosphatidylcholine(18:1) -0.1436 0.0609 -2.36 0.018419 2256
Lysine -177.0992 75.8465 -2.33 0.019643 2014
Phosphatidylcholine diacyl (34:2) 0.8670 0.3737 2.32 0.020426 2261
Phosphatidylethanolamine 36:4 0.2993 0.1336 2.24 0.02542 648
Phosphatidylethanolamine 34:2 0.2988 0.1355 2.21 0.02779 647
Phosphatidylcholine diacyl C 38:1 3.0173 1.3726 2.20 0.028281 651
M-VLDL-Free cholesterol 0.2980 0.1361 2.19 0.02863 2182
Phosphatidylcholine alkyl-acyl C42:5 0.3665 0.1674 2.19 0.028907 648
Hexadecenoylcarnitine 0.0050 0.0023 2.19 0.029 794
Phosphatidylcholine diacyl C34:3 2.3860 1.0976 2.17 0.030018 794
S-LDL-Free cholesterol -0.3569 0.1645 -2.17 0.030139 2185
M-LDL-Free cholesterol -0.5330 0.2460 -2.17 0.030399 2187
plasma-Free cholesterol 2.4840 1.1572 2.15 0.031931 2188
Phosphatidylcholine diacyl (34:4) 0.0055 0.0026 2.14 0.03224 2251
Phosphatidylcholine diacyl (36:3) 0.4598 0.2146 2.14 0.032254 2263
Phosphatidylethanolamine 38:6 0.3097 0.1444 2.14 0.032328 648
Phosphatidylcholine diacyl C40:5 1.5985 0.7519 2.13 0.033813 791
Lysophosphatidylcholine(O-16:1) -0.0037 0.0018 -2.12 0.034018 2260
Phosphatidylcholine diacyl (38:4) 0.3551 0.1692 2.10 0.035946 2262
Leucine -4708.2738 2255.4395 -2.09 0.036967 2014
S-LDL-cholesterol -1.6397 0.7943 -2.06 0.039114 2185
Lysophosphatidylcholine(O-18:1) -0.0029 0.0014 -2.05 0.040424 2257
Phosphatidylcholine diacyl C38:5 6.8767 3.3750 2.04 0.041927 792
XS-VLDL-phospholipids 0.0422 0.0208 2.03 0.042923 2186
Phosphatidylcholine diacyl (34:1) 0.6373 0.3152 2.02 0.043282 2260
XXL-LDL-cholesterol 163.1383 80.9920 2.01 0.044106 2182
Phosphatidylcholine diacyl (32:1) 0.1196 0.0596 2.01 0.044668 2249
Lysophosphatidylcholine(18:0) -0.1969 0.0980 -2.01 0.044669 2262
plasma-ApoA2 1.0394 0.5181 2.01 0.04495 2186
XXL-LDL-Free cholesterol 162.9651 81.4730 2.00 0.045598 2185
Phosphatidylcholine diacyl C 34:4 -0.5293 0.2647 -2.00 0.045958 651
Phosphatidylethanolamine 34:1 0.2943 0.1474 2.00 0.046312 648
XXL-LDL-ApoB 151.1427 76.2554 1.98 0.047598 2186
Decadienylcarnitine 0.0057 0.0029 1.98 0.0477 793
Phosphatidylethanolamine(34:2) 0.1340 0.0677 1.98 0.047836 2204
Phosphatidylethanolamine alkyl-acyl 40:3 0.1621 0.0819 1.98 0.048181 648
Phosphatidylethanolamine 40:6 0.2902 0.1466 1.98 0.048245 646
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Name BETA SE t-value p-value N
Phosphatidylethanolamine 40:5 0.2829 0.1432 1.98 0.048645 648
IDL-ApoB 0.3683 0.1871 1.97 0.049135 2182
M-LDL-cholesterol -1.7971 0.9265 -1.94 0.052548 2187
Phosphatidylcholine alkyl-acyl C40:5 0.5589 0.2880 1.94 0.052754 650
Sphingomyeline C 18:0 3.8163 1.9669 1.94 0.052775 651
L-VLDL-Free cholesterol 0.0783 0.0406 1.93 0.05388 2180
Phosphatidylcholine diacyl (38:2) 0.0119 0.0062 1.93 0.054025 2259
Phosphatidylcholine diacyl C32:2 0.5833 0.3035 1.92 0.05496 794
Hydroxytetradecenoylcarnitine 0.0020 0.0010 1.92 0.055369 792
XXL-LDL-triglycerides 123.5163 64.6331 1.91 0.056131 2180
IDL-Free cholesterol 0.3210 0.1681 1.91 0.056353 2187
Phosphatidylcholine diacyl C 42:5 0.1727 0.0907 1.90 0.05733 650
Phosphatidylethanolamine 36:2 0.2449 0.1288 1.90 0.057706 648
S-LDL-phospholipids -0.8458 0.4468 -1.89 0.058478 2184
Sphingomyeline C 18:2 0.3667 0.1937 1.89 0.05877 650
Sphingomyeline C 24:1 9.8264 5.2068 1.89 0.059578 649
Phosphatidylcholine diacyl C40:6 4.0630 2.1548 1.89 0.059717 792
plasma-cholesterol 8.8493 4.7207 1.87 0.060986 2188
M-VLDL-phospholipids 0.5778 0.3095 1.87 0.062069 2183
Ceramide C23:0 0.1458 0.0783 1.86 0.063143 648
Phosphatidylcholine alkyl-acyl C42:6 0.2532 0.1368 1.85 0.064659 651
Phosphatidylcholine diacyl C36:5 0.1639 0.0890 1.84 0.065981 790
XL-HDL-triglycerides 0.1156 0.0629 1.84 0.066065 2170
XXL-LDL-phospholipids 146.5294 79.9350 1.83 0.066923 2180
Phosphatidylethanolamine 42:7 0.2279 0.1247 1.83 0.068173 645
Phosphatidylcholine diacyl C 40:1 0.2408 0.1321 1.82 0.068711 651
Phosphatidylethanolamine 36:3 0.2568 0.1410 1.82 0.068956 650
Phosphatidylethanolamine 40:4 0.0392 0.0216 1.82 0.069951 648
Lysophosphatidylcholine C 18:3 -0.1599 0.0883 -1.81 0.070663 650
Phosphatidylcholine diacyl C42:5 0.0496 0.0276 1.80 0.072586 792
Phosphatidylcholine diacyl C40:4 0.4455 0.2481 1.80 0.072998 792
Phosphatidylethanolamine 38:1 0.0364 0.0204 1.79 0.073877 649
Phosphatidylcholine diacyl (38:5) 0.1528 0.0858 1.78 0.0753 2257
Phosphatidylcholine diacyl C 34:2 66.9234 37.6360 1.78 0.075844 648
M-HDL-triglycerides 0.0839 0.0472 1.78 0.07592 2182
Pimelylcarnitine 0.0058 0.0033 1.76 0.078856 794
Hydroxysphingomyeline C22:2 -0.9502 0.5416 -1.75 0.079769 794
Phosphatidylcholine diacyl C 40:3 0.2123 0.1223 1.74 0.083094 650
L-HDL-triglycerides 0.0753 0.0435 1.73 0.083145 2175
Phosphatidylcholine diacyl C 36:4 28.5307 16.5341 1.73 0.0849 650
Lysophosphatidylcholine 16:1 -0.4205 0.2441 -1.72 0.085425 648
S-LDL-ApoB -0.6864 0.3994 -1.72 0.085814 2186
Hydroxybutyrate_2 141.3856 82.4395 1.72 0.086496 2005
IDL-phospholipids 0.6283 0.3705 1.70 0.090089 2187
Methylglutarylcarnitine 0.0028 0.0017 1.70 0.090163 783
Valine 22356.0277 13187.6231 -1.70 0.090187 2013
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
The LIPG gene associated with depressive symptoms  |  105
3
Name BETA SE t-value p-value N
XL-HDL-ApoA1 0.2082 0.1251 1.66 0.096193 2175
S-VLDL-Free cholesterol 0.0473 0.0285 1.66 0.09699 2187
IDL-cholesterol 1.3646 0.8228 1.66 0.097369 2183
Phosphatidylcholine diacyl (32:2) 0.0133 0.0080 1.66 0.0979 2257
Methionine -3860.7325 2344.4098 -1.65 0.099759 2014
Lysophosphatidylcholine(20:3) -0.0109 0.0067 -1.62 0.104468 2256
Phosphatidylcholine diacyl C42:6 0.0573 0.0356 1.61 0.107882 790
Decenoylcarnitine 0.0259 0.0161 1.61 0.107923 791
Phosphatidylethanolamine 36:1 0.2314 0.1442 1.61 0.108925 649
Phosphatidylcholine alkyl-acyl C34:0 0.3015 0.1899 1.59 0.112722 650
M-LDL-phospholipids -0.8264 0.5275 -1.57 0.117373 2187
Creatinine 3421.9775 2224.6016 1.54 0.124147 2005
Lysophosphatidylcholine C 20:3 -0.4603 0.3033 -1.52 0.129503 647
Phosphatidylcholine alkyl-acyl C36:2 1.7172 1.1367 1.51 0.131344 648
Sphingomyeline C 16:1 2.2652 1.5040 1.51 0.132524 648
S-VLDL-triglycerides 0.0863 0.0574 1.50 0.132933 2186
lysoPhosphatidylcholine acyl C18:2 -3.3201 2.2083 -1.50 0.13312 792
Hydroxytetradecadienylcarnitine 0.0010 0.0007 1.50 0.134354 794
Alpha-ketoglutarate 140.5460 93.9052 1.50 0.134634 2007
Phosphatidylcholine diacyl C 34:3 -2.9436 1.9661 -1.50 0.134845 649
Phosphatidylethanolamine 34:3 0.2035 0.1374 1.48 0.13897 646
Phosphatidylcholine diacyl C32:0 0.8981 0.6076 1.48 0.139798 793
Phosphatidylcholine diacyl C36:6 0.1238 0.0849 1.46 0.145278 791
L-VLDL-phospholipids 0.0728 0.0501 1.45 0.146333 2182
Phosphatidylethanolamine 42:5 0.0084 0.0058 1.45 0.146905 648
Phosphatidylcholine acyl-alkyl C42:0 0.0355 0.0246 1.44 0.149189 793
Glutaconylcarnitine 0.0018 0.0012 1.44 0.150427 793
Phosphatidylethanolamine 38:3 0.1137 0.0797 1.43 0.154356 645
lysoPhosphatidylcholine acyl C18:1 -1.7766 1.2508 -1.42 0.15589 793
Creatine -107.2443 75.7401 -1.42 0.156945 2014
Phosphatidylcholine alkyl-acyl C38:4 1.1903 0.8465 1.41 0.160173 648
Lysophosphatidylcholine C15:0 -0.1681 0.1196 -1.41 0.160322 650
Phosphatidylcholine diacyl C34:4 0.2012 0.1446 1.39 0.164438 794
Triglycerides(54:1) -0.0162 0.0117 -1.38 0.167058 2237
lysoPhosphatidylcholine acyl C17:0 -0.1123 0.0812 -1.38 0.167282 794
PE-plasmologen 18:0/18:2 0.5911 0.4284 1.38 0.16814 650
XL-LDL-phospholipids 0.8290 0.6038 1.37 0.169927 2187
Sphingomyeline C 24:2 3.6515 2.6928 1.36 0.175559 650
Phosphatidylcholine diacyl C38:3 4.1113 3.0512 1.35 0.17823 794
Phosphatidylcholine diacyl (36:5) 0.0810 0.0604 1.34 0.179706 2242
Phosphatidylcholine diacyl C 34:1 29.0610 21.7588 1.34 0.182149 647
Phosphatidylcholine alkyl-acyl C38:5 1.4855 1.1193 1.33 0.184943 647
Sphingomyeline C 23:0 1.8779 1.4273 1.32 0.188718 651
Phosphatidylcholine diacyl C24:0 -0.0702 0.0533 -1.32 0.188782 732
Methanol -0.0700 0.0534 -1.31 0.19043 2011
M-LDL-ApoB -0.4892 0.3767 -1.30 0.194213 2187
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Name BETA SE t-value p-value N
Phosphatidylcholine alkyl-acyl C38:3 0.5011 0.3857 1.30 0.194315 650
PE-plasmologen 16:0/18:2 0.3073 0.2406 1.28 0.201867 648
Sphingomyeline C 14:0 1.4318 1.1269 1.27 0.204338 650
Phosphatidylcholine diacyl C34:1 12.5520 9.9108 1.27 0.205706 793
Carnitine -98.4857 77.9250 -1.26 0.206429 2011
lysoPhosphatidylcholine acyl C24:0 -0.0208 0.0166 -1.25 0.210078 794
Phosphatidylcholine alkyl-acyl C34:3 1.0013 0.7990 1.25 0.210552 650
Alanine 28500.7753 22802.4272 -1.25 0.211481 2014
M-VLDL-triglycerides 0.5922 0.4742 1.25 0.21185 2182
Phosphatidylcholine diacyl C30:0 0.3928 0.3157 1.24 0.213793 793
Phosphatidylcholine alkyl-acyl C36:4 1.6566 1.3316 1.24 0.213923 648
Phosphatidylcholine diacyl C 40:2 0.1421 0.1143 1.24 0.213948 647
Ceramide C24:0 0.2999 0.2417 1.24 0.215263 648
Hexadecadienylcarnitine 0.0009 0.0007 1.23 0.21772 793
Serine -5.2465 4.2630 -1.23 0.218797 794
Phosphatidylcholine diacyl C38:6 6.4927 5.2831 1.23 0.219451 793
Phosphatidylethanolamine 36:5 0.1543 0.1258 1.23 0.220495 646
Phosphatidylcholine diacyl C36:1 3.4804 2.8498 1.22 0.222347 792
Sphingomyeline C 23:1 1.5702 1.2873 1.22 0.223007 650
HDL-Triglycerides 0.1254 0.1033 1.21 0.224612 2181
Phosphatidylcholine diacyl C 38:7 0.3707 0.3055 1.21 0.225516 649
Phosphatidylcholine alkyl-acyl C40:6 0.4005 0.3318 1.21 0.227858 650
Phosphatidylcholine diacyl (38:3) 0.0851 0.0708 1.20 0.229341 2261
S-HDL-Free cholesterol 0.1211 0.1015 1.19 0.232627 2183
Sphingomyeline C 22:1 2.9411 2.4818 1.19 0.23643 650
1,5-Anhydrosorbitol -246.0655 209.3522 -1.18 0.239987 2012
Phosphatidylcholine diacyl C 32:2 -0.7894 0.6719 -1.17 0.240492 648
Lysophosphatidylcholine C 20:4 -0.1275 0.1085 -1.17 0.240499 646
Tryptophan -2.9284 2.4992 -1.17 0.241656 794
VLDL-cholesterol 1.6616 1.4209 1.17 0.242357 2178
Lactate -9454.6311 8112.9518 -1.17 0.244006 2008
Phosphatidylcholine alkyl-acyl C36:1 0.8637 0.7434 1.16 0.245757 648
Lysophosphatidylcholine(20:4) -0.0211 0.0184 -1.15 0.250424 2260
Phosphatidylcholine acyl-alkyl C44:6 0.0722 0.0637 1.13 0.257079 793
Phosphatidylcholine diacyl C36:3 7.7691 6.8679 1.13 0.258307 794
Hydroxysphingomyeline C14:1 -0.2966 0.2624 -1.13 0.258645 794
Phosphatidylcholine diacyl C36:4 10.2810 9.1160 1.13 0.259742 794
Lysophosphatidylcholine C 22:5 -0.0729 0.0653 -1.12 0.264636 647
Hydroxybutyrate_2 0.1030 0.0935 1.10 0.270762 1983
Decanoylcarnitine 0.0829 0.0754 1.10 0.272104 789
Lysophosphatidylcholine C 22:4 -0.1038 0.0945 -1.10 0.272391 650
Hydroxyhexadecenoylcarnitine 0.0009 0.0009 1.09 0.27388 782
Phosphatidylcholine acyl-alkyl C38:0 0.1570 0.1435 1.09 0.274208 792
LDL-Triglycerides 0.7844 0.7175 1.09 0.274425 2185
XL-LDL-ApoB 0.3159 0.2902 1.09 0.27651 2188
Spingomyeline C16:1 -0.7776 0.7164 -1.09 0.278095 794
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Name BETA SE t-value p-value N
Lipids (CH=CH*CH2CH2) -80.2993 74.1875 -1.08 0.279213 2000
Phosphatidylcholine diacyl C38:4 6.2041 5.7969 1.07 0.284834 793
Sphingomyeline C dih 22:0 95.4900 89.4785 1.07 0.286286 649
lysoPhosphatidylcholine acyl C20:3 -0.1631 0.1540 -1.06 0.289769 794
Phosphatidylcholine diacyl C40:3 0.0364 0.0345 1.05 0.291782 791
Betaine 1400.0068 1334.6173 1.05 0.294306 2012
Hydroxyhexadecanoylcarnitine 0.0006 0.0006 1.05 0.294761 792
Glutamine -20.3888 19.4510 -1.05 0.29486 794
TMAO_Betaine 78.7771 76.2238 1.03 0.301495 2007
Sphingomyeline C dih 23:0 81.9513 79.3116 1.03 0.301855 651
Phosphatidylcholine diacyl C 30:0 -0.6958 0.6735 -1.03 0.301949 650
Hexenoylcarnitine 0.0010 0.0010 1.03 0.303113 794
PE-plasmologen 18:1/18:1 0.0744 0.0725 1.03 0.305148 651
S-HDL-ApoA2 -0.3972 0.3873 -1.03 0.305208 2184
Octenoylcarnitine 0.0131 0.0128 1.02 0.308574 785
Phosphatidylcholine diacyl C 36:3 11.6641 11.4826 1.02 0.3101 649
Phosphatidylcholine diacyl C40:1 0.0187 0.0184 1.02 0.310131 793
Phosphatidylcholine diacyl C 36:2 22.3630 22.0639 1.01 0.311173 648
Phosphatidylcholine diacyl C42:0 0.0319 0.0315 1.01 0.311565 794
Ceramide Glu C16:0 0.0330 0.0332 0.99 0.320287 648
PE-plasmologen 18:0/18:1 0.0984 0.0989 0.99 0.320344 651
Hydroxybutyrylcarnitine 0.0034 0.0034 0.99 0.320506 775
Phosphatidylcholine diacyl C32:1 0.0990 0.1002 0.99 0.323103 788
Formate -0.0367 0.0372 -0.99 0.323332 2006
Phosphatidylcholine acyl-alkyl(O-34:3) 0.0116 0.0118 0.98 0.325258 2259
Phosphatidylcholine diacyl C 32:0 1.2006 1.2219 0.98 0.326184 649
Phosphatidylcholine alkyl-acyl C32:1 -0.2789 0.2847 -0.98 0.327617 650
Phosphatidylethanolamine(38:2) 0.1365 0.1399 0.98 0.32941 2258
Phosphatidylcholine diacyl C 38:4 9.4543 9.7055 0.97 0.330362 649
Threonine -4.9665 5.1092 -0.97 0.331314 794
Hydroxysphingomyeline C16:1 -0.1327 0.1368 -0.97 0.332164 794
Tyrosine -3.0380 3.1432 -0.97 0.334073 794
S-HDL-phospholipids 0.4825 0.5000 0.96 0.334696 2185
Phosphatidylcholine diacyl C34:2 11.3734 11.8155 0.96 0.336049 794
S-LDL-triglycerides -0.0468 0.0487 -0.96 0.336649 2183
Phosphatidylcholine diacyl C 38:6 6.8689 7.2302 0.95 0.34245 650
VLDL-ApoB 0.2725 0.2876 0.95 0.343335 2181
Lysophosphatidylcholine(16:0) -0.2401 0.2538 -0.95 0.344153 2262
Phosphatidylcholine diacyl C38:1 0.1023 0.1083 0.94 0.344977 794
Ceramide C16:0 0.0748 0.0792 0.94 0.34533 650
Sphingomyeline C 18:1 1.1630 1.2321 0.94 0.345566 651
Phosphatidylethanolamine 32:2 0.1064 0.1128 0.94 0.345996 650
Hydroxysphingomyeline C24:1 -0.0697 0.0745 -0.94 0.349675 794
Triglycerides(54:2) -0.0510 0.0548 -0.93 0.352231 2245
Phosphatidylcholine alkyl-acyl C36:3 0.5918 0.6371 0.93 0.353257 648
Lysophosphatidylcholine C 20:5 -0.0612 0.0661 -0.93 0.354892 647
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Tyrosine -1013.0963 1095.8059 -0.92 0.355326 2014
L-VLDL-triglycerides 0.0727 0.0790 0.92 0.357169 2181
Phosphatidylethanolamine(36:3) 0.0013 0.0014 0.92 0.358499 2254
Acetylcarnitine 0.4078 0.4482 0.91 0.363168 794
lysoPhosphatidylcholine acyl C28:1 -0.0203 0.0224 -0.91 0.365177 792
Sphingomyeline C 15:0 0.5819 0.6483 0.90 0.369739 650
XL-LDL-Free cholesterol 0.2323 0.2589 0.90 0.369799 2188
XL-VLDL-cholesterol 0.2079 0.2319 0.90 0.370136 2184
Lysophosphatidylcholine C 22:6 -0.0627 0.0707 -0.89 0.376067 646
Phosphatidylcholine alkyl-acyl C34:1 0.7240 0.8297 0.87 0.383226 649
Triglycerides(56:2) -0.0041 0.0047 -0.86 0.388454 2236
Phosphatidylcholine acyl-alkyl(O-44:5) 0.0020 0.0024 0.86 0.392304 2259
Glycine -14.1780 16.6154 -0.85 0.393748 787
Phosphatidylcholine diacyl C 32:1 -0.1200 0.1415 -0.85 0.396773 648
Phosphatidylcholine acyl-alkyl C32:1 0.0983 0.1161 0.85 0.397347 794
Phosphatidylcholine acyl-alkyl(O-38:7) -0.0019 0.0023 -0.84 0.398223 2256
Lysophosphatidylcholine C 18:2 -3.0736 3.6445 -0.84 0.399337 650
Spingomyeline C24:0 1.0422 1.2376 0.84 0.399976 793
plasma-Triglycerides 0.0368 0.0439 0.84 0.402157 2177
Phosphatidylcholine diacyl C 40:7 0.5245 0.6292 0.83 0.40477 650
XL-LDL-cholesterol 0.7663 0.9225 0.83 0.406276 2188
Phosphatidylcholine diacyl C 38:5 4.3620 5.2496 0.83 0.406325 649
Phosphatidylethanolamine 32:0 0.0145 0.0175 0.83 0.406514 647
Phosphatidylcholine acyl-alkyl C42:2 0.0261 0.0316 0.83 0.40845 794
Sphingomyeline C 20:0 1.9004 2.2998 0.83 0.408903 650
Phosphatidylcholine acyl-alkyl(O-36:6) -0.0411 0.0499 -0.83 0.409286 2244
lysoPhosphatidylcholine acyl C20:4 -0.3328 0.4112 -0.81 0.418531 793
Hydroxyoctadecenoylcarnitine 0.0006 0.0007 0.81 0.418969 794
Phosphatidylcholine diacyl C 30:1 0.1613 0.1994 0.81 0.419051 648
XL-VLDL-Free cholesterol 0.0324 0.0402 0.81 0.419238 2183
Lysophosphatidylethanolamine(18:0) -0.0077 0.0095 -0.81 0.42 2252
Phosphatidylcholine diacyl (40:6) -0.0437 0.0543 -0.80 0.421561 2251
Sphingomyeline C 22:0 2.6844 3.3666 0.80 0.425526 649
Phosphatidylcholine acyl-alkyl(O-36:5) 0.0162 0.0204 0.80 0.425807 2260
Lysophosphatidylcholine(16:1) -0.0064 0.0081 -0.79 0.429678 2248
Ceramide(d18:1/24:0) 0.0059 0.0075 0.79 0.431545 2261
Octadecadienylcarnitine 0.0034 0.0043 0.79 0.432248 794
Phosphatidylcholine diacyl C 42:4 0.0771 0.0991 0.78 0.436625 650
Spingomyeline C20:2 -0.0332 0.0428 -0.78 0.438471 794
Ceramide C18:0 0.0141 0.0183 0.77 0.44146 649
Ceramide Glu C24:1 0.0331 0.0438 0.75 0.450606 649
Lysophosphatidylcholine(14:0) -0.0041 0.0055 -0.75 0.451357 2261
Triglycerides(51:4) 0.0043 0.0057 0.75 0.453446 2248
PE-plasmologen 18:1/20:4 -0.3952 0.5304 -0.75 0.456418 650
Phosphatidylcholine diacyl C40:2 0.0155 0.0209 0.74 0.456985 791
Spingomyeline C26:0 -0.0095 0.0127 -0.74 0.457176 793
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PE-plasmologen 18:1/18:2 0.1514 0.2040 0.74 0.458306 650
Acetate -0.0420 0.0568 -0.74 0.459246 1977
Phosphatidylcholine acyl-alkyl C34:1 0.3079 0.4166 0.74 0.460141 793
Phosphatidylcholine diacyl C 40:4 0.3484 0.4720 0.74 0.460747 649
Phosphatidylcholine acyl-alkyl C42:4 0.0322 0.0438 0.74 0.461432 794
Phosphatidylcholine diacyl C36:2 7.7112 10.4923 0.73 0.462594 794
Triglycerides(54:7) 0.0101 0.0137 0.73 0.463333 2246
Lipids (CH2) -55.1358 75.4446 -0.73 0.46498 2001
Methionine -1.1058 1.5218 -0.73 0.467651 794
Sphingomyeline(d18:1/20:1) -0.0038 0.0052 -0.73 0.468248 2263
Myoinositol -56.8363 78.7998 -0.72 0.470824 2009
Phosphatidylcholine diacyl C42:1 0.0103 0.0143 0.72 0.471821 794
XS-VLDL-cholesterol 0.0078 0.0109 0.72 0.472844 2187
Spingomyeline C18:1 -0.4150 0.5809 -0.71 0.475098 794
Hydroxysphingomyeline C22:1 -0.4984 0.7032 -0.71 0.478706 794
Proline 7.4088 10.5659 0.70 0.483387 789
Triglycerides(56:7) 0.0435 0.0626 0.69 0.487798 2246
Phosphatidylcholine diacyl C 38:2 0.6817 0.9963 0.68 0.494078 651
Sphingomyeline(d18:1/18:2) 0.0011 0.0016 0.68 0.49474 2260
Phosphatidylcholine acyl-alkyl C34:0 0.0471 0.0692 0.68 0.496504 794
Tetradecadienylcarnitine 0.0022 0.0032 0.68 0.49868 789
Ceramide C22:0 0.0630 0.0936 0.67 0.501078 649
Phosphatidylcholine diacyl C26:0 0.0167 0.0249 0.67 0.501168 731
Triglycerides(46:1) -0.0194 0.0289 -0.67 0.502614 2211
Phosphatidylcholine acyl-alkyl(O-34:1) 0.0039 0.0059 0.67 0.506041 2259
lysoPhosphatidylcholine acyl C14:0 0.0644 0.0970 0.66 0.507031 793
Triglycerides(52:1) -0.0500 0.0761 -0.66 0.510788 2242
Phosphatidylcholine acyl-alkyl C44:4 0.0116 0.0176 0.66 0.512032 794
XS-LDL-ApoB 0.4366 0.6696 0.65 0.514404 2183
Nonaylcarnitine 0.0482 0.0741 0.65 0.515314 791
VLDL-Free cholesterol 0.3656 0.5673 0.64 0.519371 2182
Lysophosphatidylcholine C 18:1 -1.4611 2.2729 -0.64 0.520543 648
Arginine -2.4807 3.8999 -0.64 0.524899 794
Triglycerides(53:1) -0.0023 0.0037 -0.63 0.530546 2207
XXL-VLDL-triglycerides -0.0580 0.0933 -0.62 0.534289 2174
L-LDL-triglycerides -0.0254 0.0414 -0.61 0.539607 2185
Phosphatidylcholine diacyl (38:6) 0.0850 0.1389 0.61 0.540482 2254
Dodecenoylcarnitine 0.0053 0.0086 0.61 0.542218 788
Triglycerides(54:6) 0.0385 0.0635 0.61 0.544317 2246
Phosphatidylcholine diacyl (40:5) 0.0085 0.0141 0.60 0.545483 2256
Proline -509.4497 845.3949 -0.60 0.546831 2010
Phosphatidylcholine diacyl C28:1 -0.0960 0.1596 -0.60 0.547744 794
Triglycerides(50:3) 0.0418 0.0697 0.60 0.548103 2251
Triglycerides(52:4) 0.0358 0.0604 0.59 0.553434 2253
Phosphatidylcholine alkyl-acyl C32:0 0.1918 0.3237 0.59 0.553767 650
Phosphatidylcholine acyl-alkyl C36:4 -0.5615 0.9509 -0.59 0.555019 793
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Triglycerides(51:3) 0.0376 0.0644 0.58 0.559294 2239
Sphingomyeline(d18:1/24:0) 0.0128 0.0222 0.58 0.565135 2260
Glutarylcarnitine 
(Hydroxyhexanoylcarnitine)
0.0010 0.0017 0.57 0.565601 788
Lipids_CH2CO -44.0181 76.6504 -0.57 0.565849 2001
Sphingomyeline C 20:1 44.9383 78.4664 0.57 0.567041 650
Phosphatidylethanolamine 32:1 0.0841 0.1480 0.57 0.569939 644
Triglycerides(50:2) 0.0387 0.0683 0.57 0.571087 2256
XL-VLDL-phospholipids 0.0330 0.0583 0.57 0.571338 2182
lysoPhosphatidylcholine acyl C28:0 -0.0281 0.0501 -0.56 0.57447 789
Leucine / Isoleucine -5.6052 10.1280 -0.55 0.580119 793
Phosphatidylcholine diacyl (36:2) 0.1515 0.2756 0.55 0.582477 2262
Dimethylglycine 42.0366 77.2745 0.54 0.586508 2009
S-HDL-ApoA1 -0.5308 0.9847 -0.54 0.589925 2188
VLDL-phospholipids 0.7279 1.3644 0.53 0.593733 2182
Acetone 0.0277 0.0520 0.53 0.594045 2006
Sphingomyeline C 24:3 -0.4168 0.7847 -0.53 0.595494 651
Sphingomyeline(d18:1/23:1) -0.0047 0.0091 -0.52 0.603933 2262
Phosphatidylethanolamine 40:3 0.0043 0.0083 0.52 0.606339 647
Phosphatidylcholine acyl-alkyl C38:5 -0.4371 0.8491 -0.51 0.606833 794
Phenylalanine -0.9544 1.9295 -0.49 0.620986 794
Lipids_CH3 -36.2720 74.0097 -0.49 0.624118 2004
Spingomyeline C16:0 -2.0123 4.1675 -0.48 0.62933 794
Phosphatidylcholine diacyl (36:1) 0.0367 0.0762 0.48 0.63038 2254
Octadecenoylcarnitine 0.0242 0.0502 0.48 0.630581 792
Phosphatidylethanolamine 42:6 -0.0033 0.0068 -0.48 0.630713 650
Ornithine -1.9861 4.1330 -0.48 0.630966 794
Sphingomyeline C dih 18:0 -0.1815 0.3783 -0.48 0.631499 651
Sphingomyeline(d18:1/17:0) -0.0010 0.0022 -0.48 0.632139 2253
Phosphatidylcholine acyl-alkyl C38:2 0.0483 0.1011 0.48 0.633098 794
Hexose -90.3905 190.0176 -0.48 0.634422 792
Dodecanedioylcarnitine 0.0009 0.0018 0.47 0.635353 792
lysoPhosphatidylcholine acyl C26:0 0.0321 0.0678 0.47 0.636075 788
plasma ApoB 0.7405 1.6156 0.46 0.646764 2188
lysoPhosphatidylcholine acyl C18:0 -0.6846 1.4943 -0.46 0.646978 794
Triglycerides(56:5) 0.0227 0.0498 0.46 0.648325 2125
Phosphatidylcholine diacyl C 40:6 1.4246 3.1226 0.46 0.648383 649
Triglycerides(48:2) -0.0453 0.1000 -0.45 0.650715 2244
Sphingomyeline C dih 24:0 -40.0546 88.4365 -0.45 0.650758 649
Phosphatidylcholine acyl-alkyl C40:0 0.1407 0.3151 0.45 0.655347 792
Phosphatidylcholine alkyl-acyl C36:5 0.4329 0.9732 0.44 0.6566 650
Hydroxypropionylcarnitine 8.9460 20.1257 0.44 0.656798 789
Sphingomyeline(d18:1/22:1) -0.0091 0.0206 -0.44 0.657658 2263
Phosphatidylcholine acyl-alkyl C30:0 0.0087 0.0198 0.44 0.659196 794
Phosphatidylcholine alkyl-acyl C34:2 0.4665 1.0574 0.44 0.65923 650
Propenoylcarnitine 0.0002 0.0005 0.44 0.662192 794
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Phosphatidylcholine diacyl C 40:5 0.5817 1.3474 0.43 0.666077 647
Spingomyeline C24:1 -0.9208 2.1338 -0.43 0.666183 794
XS-VLDL-triglycerides 0.0136 0.0319 0.43 0.670875 2183
Phosphatidylcholine acyl-alkyl(O-36:2) -0.0015 0.0035 -0.42 0.672867 2259
Lysophosphatidylcholine C 22:0 0.0302 0.0729 0.41 0.678915 651
Pyruvate_Oxaloacetate 4071.9179 9939.2325 0.41 0.682083 2010
Phosphatidylethanolamine(O-38:5) -0.0054 0.0131 -0.41 0.6829 2253
XXL-VLDL-phospholipids -0.0266 0.0660 -0.40 0.686687 2177
Triglycerides(54:5) 0.0229 0.0570 0.40 0.688598 2247
Triglycerides(52:3) 0.0181 0.0458 0.39 0.692943 2260
LDL-cholesterol -1.4978 3.8434 -0.39 0.696798 2188
Phosphatidylcholine acyl-alkyl(O-34:2) -0.0051 0.0131 -0.39 0.699704 2255
Ceramide C20:0 0.0054 0.0143 0.38 0.705939 649
Hydroxyhexadecadienylcarnitine -0.0003 0.0007 -0.38 0.706733 794
Triglycerides(56:8) 0.0087 0.0233 0.37 0.709907 2249
Sphingomyeline(d18:1/24:1) -0.0202 0.0544 -0.37 0.710105 2261
lysoPhosphatidylcholine acyl C16:0 -1.4995 4.0408 -0.37 0.710679 794
IDL-Triglycerides 0.0197 0.0532 0.37 0.710729 2178
L-LDL-Free cholesterol 0.0965 0.2650 0.36 0.7158 2188
PE-plasmologen 18:1/22:6 0.0685 0.1883 0.36 0.716139 650
Phosphatidylcholine diacyl C 36:5 1.1213 3.1010 0.36 0.717769 645
Phosphatidylcholine acyl-alkyl C42:1 0.0072 0.0206 0.35 0.724643 794
PE-plasmologen 16:0/20:4 -0.2042 0.5801 -0.35 0.724947 648
Phosphatidylcholine acyl-alkyl C30:1 0.0049 0.0139 0.35 0.726045 791
Triglycerides(46:2) -0.0048 0.0136 -0.35 0.726556 2223
Phosphatidylcholine alkyl-acyl C40:4 0.0731 0.2099 0.35 0.727829 648
Triglycerides(50:4) 0.0250 0.0717 0.35 0.727955 2250
Phosphatidylcholine diacyl (40:7) 0.0026 0.0073 0.35 0.728051 2252
Hydroxyisobutyrate_3 -321.4775 925.3928 -0.35 0.728331 2005
PE-plasmologen 18:0/22:6 0.1055 0.3051 0.35 0.729713 648
Sphingomyeline(d18:1/25:0) 0.0004 0.0012 0.34 0.730474 2258
Sphingomyeline(d18:1/18:1) -0.0030 0.0090 -0.34 0.734911 2259
Phosphatidylcholine acyl-alkyl C36:2 -0.2273 0.6772 -0.34 0.737227 794
PE-plasmologen 18:0/20:4 -0.3108 0.9327 -0.33 0.739019 649
Phosphatidylcholine acyl-alkyl C30:2 -0.0021 0.0064 -0.33 0.740243 794
Spingomyeline C26:1 -0.0090 0.0278 -0.32 0.746477 794
Spingomyeline C18:0 -0.3357 1.0451 -0.32 0.748156 794
Triglycerides(52:5) 0.0210 0.0655 0.32 0.74873 2250
Phosphatidylcholine acyl-alkyl(O-38:6) -0.0027 0.0083 -0.32 0.74907 2260
Dimethylamine -27.6135 86.7613 -0.32 0.750313 2010
Phosphatidylcholine acyl-alkyl C42:5 0.0275 0.0893 0.31 0.758343 794
Phosphatidylethanolamine alkyl-acyl 38:7 -0.0059 0.0193 -0.31 0.759982 647
L-LDL-cholesterol 0.3414 1.1199 0.30 0.76054 2188
XL-VLDL-triglycerides 0.0297 0.0975 0.30 0.760755 2181
Sphingomyeline(d18:1/16:1) -0.0032 0.0109 -0.30 0.765331 2262
Ceramide(d18:1/24:1) -0.0014 0.0048 -0.30 0.767937 2255
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Valine -4.0565 13.7895 -0.29 0.768701 794
Phosphatidylcholine acyl-alkyl C38:3 -0.0559 0.1927 -0.29 0.771753 794
Phosphatidylcholine acyl-alkyl C40:1 0.0214 0.0756 0.28 0.777053 794
XS-LDL-phospholipids -0.1554 0.5548 -0.28 0.779398 2182
XXL-VLDL-cholesterol -0.1516 0.5422 -0.28 0.779781 2176
Hydroxyvalerylcarnitine 
(Methylmalonylcarnitine)
-0.0005 0.0017 -0.28 0.780933 791
Triglycerides(46:0) -0.0055 0.0199 -0.28 0.781351 2157
Phosphatidylcholine acyl-alkyl C40:4 0.0293 0.1069 0.27 0.783972 794
Phosphatidylcholine acyl-alkyl C40:2 -0.0240 0.0882 -0.27 0.785219 794
Carnitine -0.4899 1.8088 -0.27 0.786592 794
VLDL-Triglycerides -1.3683 5.1113 -0.27 0.788947 2176
Tetradecenoylcarnitine 0.0018 0.0069 0.27 0.789881 790
Phosphatidylcholine diacyl C 38:3 1.2547 4.7558 0.26 0.791992 647
Phosphatidylcholine acyl-alkyl C38:4 -0.1667 0.6320 -0.26 0.792033 794
Phosphatidylcholine diacyl C 36:1 1.0831 4.1101 0.26 0.792239 647
Succinate -21.7916 83.8768 -0.26 0.795041 2006
LDL-phospholipids 0.5059 1.9634 0.26 0.79669 2188
Phosphatidylcholine acyl-alkyl C36:3 -0.1038 0.4031 -0.26 0.796911 794
Phosphatidylcholine diacyl C42:2 -0.0035 0.0138 -0.26 0.796979 787
Triglycerides(58:8) 0.0026 0.0101 0.25 0.799365 2235
Phosphatidylcholine alkyl-acyl C38:2 -0.0928 0.3688 -0.25 0.80141 651
Phosphatidylcholine acyl-alkyl C42:3 0.0091 0.0378 0.24 0.809781 794
LDL-Free cholesterol 0.2666 1.1139 0.24 0.810893 2188
PE-plasmologen 18:1/20:5 -0.0353 0.1511 -0.23 0.815332 650
Citrate -16.3810 70.3089 -0.23 0.815796 2014
Phosphatidylcholine diacyl C 36:0 0.1048 0.4568 0.23 0.818696 650
Triglycerides(50:0) -0.0213 0.0935 -0.23 0.819562 2232
Phosphatidylcholine acyl-alkyl C32:2 -0.0077 0.0338 -0.23 0.820224 794
lysoPhosphatidylcholine acyl C26:1 -0.0081 0.0359 -0.22 0.822359 794
Phosphatidylcholine diacyl C36:0 0.0335 0.1492 0.22 0.822634 794
L-LDL-ApoB -0.0767 0.3432 -0.22 0.823214 2187
Triglycerides(50:5) -0.0013 0.0058 -0.22 0.828031 2242
Sphingomyeline(d18:1/24:2) -0.0053 0.0245 -0.22 0.828094 2262
Phosphatidylcholine diacyl C 40:0 -0.0453 0.2089 -0.22 0.828306 647
Triglycerides(50:1) -0.0158 0.0748 -0.21 0.83305 2253
lysoPhosphatidylcholine acyl C16:1 0.0428 0.2042 0.21 0.833967 790
Phosphatidylcholine acyl-alkyl(O-36:3) 0.0007 0.0032 0.21 0.835596 2257
Sphingomyeline C 24:0 0.4460 2.1962 0.20 0.839133 649
Phosphatidylcholine alkyl-acyl C36:0 0.0325 0.1606 0.20 0.83947 650
Sphingomyeline(d18:1/22:0) 0.0069 0.0342 0.20 0.839647 2262
Phosphatidylcholine acyl-alkyl(O-36:4) -0.0040 0.0202 -0.20 0.843835 2255
S-HDL-cholesterol -0.0848 0.4409 -0.19 0.84753 2183
PE-plasmologen 16:0/22:5 -0.0273 0.1430 -0.19 0.848578 650
Octanoylcarnitine 0.0029 0.0151 0.19 0.849731 788
Phosphatidylcholine alkyl-acyl C38:1 0.0633 0.3344 0.19 0.850008 651
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Sphingomyeline(d18:1/20:0) 0.0028 0.0152 0.19 0.8514 2263
PE-plasmologen 16:0/20:5 0.0284 0.1532 0.19 0.85289 643
Triglycerides(51:2) -0.0127 0.0688 -0.19 0.853036 2247
Phosphatidylcholine diacyl C38:0 0.0349 0.1900 0.18 0.85408 794
Phenylalanine -45.4450 249.6529 -0.18 0.855575 2015
Phosphatidylcholine acyl-alkyl(O-38:5) -0.0027 0.0152 -0.18 0.860024 2260
Phosphatidylethanolamine(O-38:7) -0.0024 0.0136 -0.18 0.860276 2241
Triglycerides(56:3) -0.0093 0.0534 -0.17 0.861199 2238
Phosphatidylethanolamine 34:0 0.0042 0.0263 0.16 0.873179 649
Phosphatidylcholine acyl-alkyl C36:0 -0.0056 0.0375 -0.15 0.881088 792
Triglycerides(48:3) -0.0139 0.0939 -0.15 0.882245 2241
Phosphatidylcholine acyl-alkyl C36:1 -0.0552 0.3730 -0.15 0.882348 793
Phosphatidylcholine diacyl C 26:0 0.0237 0.1648 0.14 0.885881 648
Triglycerides(51:1) -0.0021 0.0145 -0.14 0.886137 2232
Triglycerides(58:9) -0.0013 0.0093 -0.14 0.887377 2230
PE-plasmologen 16:0/18:1 0.0103 0.0738 0.14 0.888968 650
Sphingomyeline(d18:1/15:0) 0.0006 0.0043 0.14 0.889676 2255
Phosphatidylcholine acyl-alkyl C36:5 0.0826 0.6147 0.13 0.89308 792
L-LDL-phospholipids -0.0737 0.5607 -0.13 0.895395 2187
Phosphatidylcholine diacyl (36:6) 0.0002 0.0015 0.13 0.895829 2239
Butenylcarnitine 0.0001 0.0010 0.13 0.899509 794
Glycerol -10.2162 81.2641 -0.13 0.899969 2007
LDL-ApoB -0.1633 1.3267 -0.12 0.902052 2188
Phosphatidylcholine acyl-alkyl C44:3 -0.0009 0.0071 -0.12 0.902938 794
Tiglylcarnitine -0.0002 0.0014 -0.12 0.906041 794
Phosphatidylcholine acyl-alkyl C34:2 -0.0711 0.6043 -0.12 0.906316 794
Lysophosphatidylcholine C 20:0 8.8906 78.3525 0.11 0.909694 649
Phosphatidylcholine acyl-alkyl C34:3 -0.0429 0.4192 -0.10 0.918444 794
Phosphatidylcholine acyl-alkyl C44:5 0.0081 0.0792 0.10 0.918814 794
Phosphatidylcholine acyl-alkyl(O-38:4) 0.0007 0.0073 0.10 0.922692 2260
Triglycerides(56:6) 0.0054 0.0578 0.09 0.92536 2233
XS-LDL-Free cholesterol 0.0231 0.2501 0.09 0.92629 2184
XS-LDL-cholesterol 0.1048 1.1674 0.09 0.92846 2186
Glutamate -6.5508 75.4108 -0.09 0.930785 2008
XXL-VLDL-Free cholesterol 0.0052 0.0600 0.09 0.930978 2178
Phosphatidylcholine diacyl C32:3 -0.0025 0.0311 -0.08 0.935986 794
Sphingomyeline(d18:1/14:0) 0.0006 0.0081 0.08 0.937455 2259
Phosphatidylcholine acyl-alkyl C38:6 0.0365 0.4652 0.08 0.937534 793
Sphingomyeline(d18:1/18:0) 0.0015 0.0191 0.08 0.938558 2260
Histidine 0.2177 2.8664 0.08 0.939469 793
PE-plasmologen 16:0/22:6 0.0204 0.3044 0.07 0.9467 646
Phosphatidylethanolamine(O-36:5) 0.0006 0.0096 0.06 0.952598 2253
S-HDL-triglycerides 0.0089 0.1514 0.06 0.953293 2187
Glucose -0.0010 0.0178 -0.06 0.953938 2004
Triglycerides(48:0) 0.0022 0.0408 0.05 0.956873 2154
Triglycerides(48:1) 0.0030 0.0586 0.05 0.959147 2231
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Name BETA SE t-value p-value N
Phosphatidylcholine diacyl C 34:0 -0.0317 0.6225 -0.05 0.959342 651
Phosphatidylcholine acyl-alkyl C38:1 -0.0024 0.0486 -0.05 0.960266 794
Triglycerides(54:4) 0.0028 0.0580 0.05 0.960843 2251
Sphingomyeline C 22:2 4.3857 89.2959 0.05 0.960843 649
XS-LDL-triglycerides -0.0085 0.1740 -0.05 0.961046 2182
Alpha-ketoisovalerate 18.3234 397.6434 0.05 0.963251 2014
Sphingomyeline C dih 16:0 0.0304 0.6692 0.05 0.963774 649
PE-plasmologen 18:0/20:5 -0.0073 0.1706 -0.04 0.965662 648
Triglycerides(58:10) 0.0002 0.0040 0.04 0.968962 2200
Lysophosphatidylcholine C 16:0 -0.3769 10.0728 -0.04 0.970164 650
Phosphatidylcholine acyl-alkyl C40:3 -0.0017 0.0500 -0.03 0.973658 794
Sphingomyeline(d18:1/23:0) -0.0004 0.0131 -0.03 0.973792 2262
Sphingomyeline(d18:1/21:0) 0.0002 0.0054 0.03 0.977014 2259
lysoPhosphatidylcholine acyl C6:0 0.0001 0.0018 0.03 0.977302 792
Triglycerides(52:2) -0.0013 0.0473 -0.03 0.977692 2262
Sphingomyeline(d18:1/25:1) -0.0001 0.0025 -0.03 0.978594 2256
Phosphatidylcholine acyl-alkyl C40:6 0.0063 0.2606 0.02 0.980731 794
Phosphatidylcholine acyl-alkyl C40:5 0.0042 0.1736 0.02 0.980733 794
Triglycerides(52:6) 0.0008 0.0616 0.01 0.990163 2248
Lysophosphatidylcholine C 18:0 -0.0364 3.9873 -0.01 0.992723 649
Sphingomyeline(d18:1/16:0) -0.0007 0.0831 -0.01 0.99333 2261
M-LDL-triglycerides 0.0000 0.0549 0.00 0.99938 2188
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APPENDIX of CHAPTER 3.2
Non-synonymous Variation in NKPD1 Increases Depressive Symptoms in the European Populations
Supplement 1
Table S1. Descriptive data of ERF study (N = 2 353)
Characteristics Median (Range) Mean (SD)
Sex (% women) 56
Age, Years 48.84 (18 – 96) 48.73 (14.96)
CES-D 8.24 (0 – 59) 10.74 (9.65)
Table S2. Association of depressive symptoms (CES-D) with age
Intercept Age
Estimate ± s.e. p value Estimate ± s.e. p value
Males 2.893 ± 0.928 0.0019 0.131 ± 0.018 8.40x10-13
Females 4.802 ± 0.916 1.85x10-07 0.145 ± 0.018 1.74x10-15
Table S3. Genome-wide results of gene-based analysis
Provided online see URL: http://www.biologicalpsychiatryjournal.com/article/S0006-3223(16)32669-5/addons
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Figure S1. 
Ethnicity information provided by the principal components analysis. Black circles represent the samples 
included in this study, red: Caucasian, blue: Chinese, green: African, yellow: Colombian (AMR), cyan: Mexican 
(AMR), coral: Puerto Rican (AMR), brown: African (AMR). 
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Figure S2. 
Quantile-quantile (QQ) plots of the single-variant and gene-based association analysis. Observed distribution 
is depicted on the vertical axis and expected distribution is depicted on the horizontal axis.  
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The epigenetics of depression
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ABSTRACT
Depression is determined by the interplay between environmental and genetic risk. Epigenetic 
mechanisms, like DNA methylation, can mediate the association between depression and it’s 
environmental and genetic risk factors. By performing the largest (N = 11 256) cross-ethnic 
epigenome-wide association study of depressive symptoms, we identified hypermethylation of 
cg04987734 (p value = 1.51 × 10-8, CDC42BPB gene), cg12325605 (p value = 5.24 × 10-09, 
ARHGEF3 gene) and cg14023999 (p value = 5.99 × 10-08, intergenic) associated with depressive 
symptoms. These candidate loci for depression are involved in the regulation of serotonin and 
dopamine levels in the brain, sphingolipid metabolism, synaptic plasticity, and inflammation.
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INTRODUCTION
Depression is one of the most common mental health disorders that results in major disability and 
shorter life-expectancy1,2, and it is projected to play a leading role in disease burden by the year 
2030.3,4 Limited understanding of the molecular mechanisms underlying depression is a major 
bottleneck in the development of innovative treatment, prognostic markers, and prevention 
strategies.
Studying depression is challenging as it is a heterogeneous disorder with a multifactorial etiology, 
including genetic and environmental risk factors.5,6 The contribution of genetics to the risk of 
depression is substantial with heritability estimates of 40 to 50%.7 Genome-wide association 
studies (GWASs) have recently identified numerous rare and common genetic variants associated 
with depression and related traits.8-12 However, genetic sequence variation alone does not 
completely explain an individual’s risk for developing depression. Among environmental factors, 
adverse life-events and stress are major risk factors for depression.13-15 Converging evidence 
from animal and human studies suggest that psychosocial stressors trigger depression onset 
by inducing elevations in pro-inflammatory cytokines.16 These environmental and psychosocial 
stressors are also known to influence epigenetic mechanisms, such as DNA methylation.17 These 
stress-triggered DNA methylation changes can drive sustained changes in gene expression that 
may link stress exposures with mental health outcomes.18,19 Thus, an increasing interest in the role 
of DNA methylation in depression has emerged.20
DNA methylation may be global or tissue-specific.20,21 Tissues likely to be involved in complex 
psychiatric disorders, such as brain, are not directly accessible from living patients. The, use of 
post-mortem brain tissue to study DNA methylation is a possible solution, although obtaining a 
sufficient sample size is challenging.22,23 To study differential DNA methylation associated with 
mental health symptoms on a large scale, peripheral tissues such as blood constitutes a useful 
proxy for detecting trans-tissue changes and the most appropriate tissue for biomarkers.22,24 
Moderate correlation has been demonstrated between blood and brain tissues at non-tissue 
specific regulatory regions across the methylome.25 To date, several studies have assessed the 
correlation between depression and blood DNA methylation.26,27 However, these studies have 
been limited to a small number of DNA methylation sites (CpGs) and/or small samples. For 
instance, the largest published epigenome-wide association study (EWAS) assessed brain DNA 
methylation in 76 cases persons who died during a depressive episode and 45 controls.28
In the current study, we performed an EWAS of depressive symptoms using whole blood samples 
of 7 948 individuals of European ethnicity from the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium. We replicated our findings in 3 308 individuals of 
African-American and European ancestry. Finally, to identify the affected genes, we performed 
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a genome-wide gene expression analysis followed by pathway analyses of the differentially 
methylated and expressed genes.
METHODS
Study populations
The study sample for the discovery analysis included a total of 7 948 participants of European 
ancestry from nine population-based cohorts of the CHARGE consortium (Table 1): Cardiovascular 
Health Study (CHS)29, Framingham Heart Study (FHS)30, Helsinki Birth Cohort Study (HBCS)31, 
Cooperative Health Research in the Augsburg Region (KORA) study32, two sub-cohorts from 
Lothian Birth-Cohort born in 1921 (LBC1921)33 and 1936 (LBC1936)34, two sub-cohorts from 
Rotterdam Study (RS-III and RS-BIOS)35 and Generation Scotland: Scottish Family Health Study 
(GS) study.36 These cohorts included community dwelling individuals, who were not selected 
based on disease status. Informed consent was obtained from all participants. The protocol for 
each study was approved by the institutional review board of each institution.
Table 1. Characteristics of the individuals in the discovery (N = 7 948) and replication cohorts (N = 
3 308)
Study N Female
(%)
Mean Age
(SD)
Current 
smokers*
(%) 
Depressive 
symptoms 
Antidepressant 
medication use 
(%)
Discovery
CHS 323 194 (60.1) 75.6 (5.2) 173 (53.6) CES-D (0-30) 19 (5.9)
FHS 2,722 1,508 (53.6) 58.5 (11.6) 948 (34.8) CES-D (0-20) 251 (16.1)
HBCS 122 0 (0) 65.2 (2.7) 24 (19.7) CES-D (0-20) 11 (9.0)
KORA 1,727 882 (51.1) 61.0 (8.9) 250 (14.5) PHQ-9 82 (4.7)
LBC 1921 432 261 (60.4) 79.1 (0.6) 194 (44.9) HADS 15 (3.5)
LBC 1936 916 452 (49.3) 69.6 (0.8) 504 (55) HADS 30 (3.3)
RS III 722 391 (54.2) 59.8 (8.1) 167 (23.1) CES-D (0-20) 38 (5.3) 
RS BIOS 757 319 (42.1) 67.6 (5.9) 78 (10.3) CES-D (0-20) 51 (6.7)
GS 227 151 (64.5) 52.4 (8.1) 46 (19.7) SCID¥ 44 (18.8)
Total 7,948 4,158 (48.4) 65.4 (5.8) 2,384 (30.6) - 541 (8.1)
Replication
ARIC 2,297 1,445 (63) 56.1 (5.7) 584 (25.4) 21-MQ 74 (3.3)
WHI-EMPC 1,011 1,011 (100) 64.6 (7.1) 509 (50.3) CES-D/DIS 61 (6.0)
Total 3,308 2,456 (74.2) 60.3 (6.4) 1,093 (37.9) - 135 (4.7)
Characteristics are depicted as mean (SD), unless otherwise specified.
CHC Cardiovascular health cohort, FHS Framingham Heart Study, HBCS Helsinki Birth Cohort Study, KORA 
Cooperative Health Research in the Augsburg Region, LBC Lothian Birth Cohort, RS Rotterdam Study, GS 
Generation Scotland Study, and ¥CASE-CONTROL STUDY, ARIC Atherosclerosis Risk in Communities Study 
and WHI-EMPC the Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated Cardiovascular 
disease; “(in brackets we state number of item of the questionnaires)”. * Represents former or current smoker
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The replication sample included 3 308 participants from the Atherosclerosis Risk in Communities 
Study (ARIC)37 and the Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated 
Cardiovascular disease (WHI-EMPC).38,39 More detailed information for each cohort can be found 
in the Supplementary Text.
Depressive symptoms assessment
Depressive symptoms were measured using self-reported questionnaires or structured interview 
performed by a trained researcher, psychologist, or psychiatrist at the same time point when blood 
samples were obtained for DNA methylation quantification (Table 1). Four cohorts (FHS, HBCS, 
RS-III, and RS-BIOS) assessed depressive symptoms using the 20-item Centre for Epidemiologic 
Studies Depression (CES-D) scale40, while CHS used the 10-item CES-D scale. Participants could 
score from zero to 60 (or 30 for CHS) points, where higher scores indicate more depressive 
symptoms. WHI-EMPC used a cohort specific CES-D/DIS screening instrument, which is described 
in detail in the Supplementary Text. The LBC1921 and LBC1936 assessed self-reported depressive 
symptoms using the Hospital Anxiety and Depression Scale-depression subscale (HADS-D),41 
which consists of seven items. Participants could score from zero to 21. The KORA study used 
the self-administered Patient Health Questionnaire (PHQ-9)42 representing a depression module 
that scores each of the nine Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
(DSM-IV) criteria for depression from zero to three. The GS study assessed life-time history 
of depression using the Structured Clinical Interview for DSM-IV Disorders (SCID).43 The ARIC 
study assessed depressive symptoms using the 21-item Maastricht Questionnaire (21-MQ). In all 
cohorts depressive symptoms were analyzed as continuous variable except for GS, which studied 
depression status as binary trait.
DNA methylation sample and measurement
In all cohorts, DNA was extracted from whole blood and methylation levels were assessed using 
the Illumina-Infinium Human Methylation 450K BeadChip (Illumina Inc, San Diego, CA, USA) 
using standard manufacturer’s protocols. The 450K array includes more than 450,000 CpGs and 
is enriched for genic regions, covering 99% of all genes. DNA methylation data pre-processing, 
including quality control (QC) and normalization, was conducted per cohort using study-specific 
methods. In all cohorts, DNA methylation levels were quantified as β-values, which range from 
zero to one, and indicate the proportion of DNA strands in a sample methylated at a specific CpG. 
Detailed information about cohort specific DNA extraction, bisulfite conversion, DNA methylation 
profiling, normalization and QC is described in detail in the Supplementary Text.
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Gene expression
For the expression analyses, data from the RS-III cohort was used where whole-blood was 
collected (PAXGene Tubes – Becton Dickinson). All RNA samples with an RNA Quality Score > 7 
were amplified, labelled (Ambion TotalPrep RNA), and hybridized to the Illumina HumanHT12v4 
Expression Beadchips as described by the manufacturer’s protocol. All samples were scanned 
on the Illumina iScan System (combined with an AutoLoader) using Illumina iScan image data 
acquisition software. Illumina GenomeStudio software (version 1.9.0) was used to generate 
output files for statistical analysis using R. In R Probes were quantile normalized to the median 
distribution, log2-transformed, and centered to the mean. Further, a sample Z transformation 
(mean = 0, standard deviation = 1) was applied. 44 877 probes measured over the whole 
genome. All probes that showed a detection p value < 0.05 in > 10% of samples were retained 
for the analysis (N = 21 238).44
DATA ANALYSIS
Epigenome-wide association analysis
In all cohorts, the association between depressive symptoms and CpG sites was assessed using 
linear regression analysis in the R software. In the regression analyses, DNA methylation β values at 
each CpG site was specified as the dependent variable and the depressive symptoms/depression 
as the predictor of interest. Further, as DNA methylation patterns significantly associate with 
age45, sex46 and smoking47, the regression analysis included these as covariates in addition to 
methylation batch effects and white blood cell composition (imputed or directly measured, 
depending on availability within each cohort). All cohorts used principal components estimated 
using genome-wide genotype data to control for population stratification. Familial relationships 
were also accounted for in the model when applicable (FHS). Cohort specific details of these 
analyses are provided in the Supplementary Text.
It is unclear whether antidepressant medication use confounds the association between depressive 
symptoms and DNA methylation.48,49 Therefore, we performed sensitivity analyses by adjusting 
the initial model additionally for antidepressant medication use at the time of sample collection.
Finally, we performed sample-size weighted meta-analysis of the cohort-specific results using 
METAL.50 Due to the variability of available CpG sites after quality control steps, we excluded 
CpG sites missing in more than three of the participating cohorts. In total, 484 516 probes were 
available for meta-analysis. In addition to the gene annotation provided by Illumina based on 
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RefSeq database for the intergenic sites, the UCSC database (GRCh37/hg19) was explored to 
further annotate the CpGs. Bonferroni correction was applied to adjust for multiple testing giving 
a genome-wide significance threshold of 0.05/484 516 methylation sites = 1.03 × 10-7. All CpG 
sites suggestive of association (p value ≤ 10-5) were tested for association in the independent 
replication cohort using the same model as used in the discovery EWAS. Finally, a sample size 
weighted meta-analysis was performed for all cohorts included in the discovery and replication 
phases in METAL.
Gene pathway analysis
Pathway analysis was performed for genes containing one or more nominally significant CpG 
sites from the meta-analysis of discovery and replication cohorts with PANTHER (see URLs). 
Genes that were included in the pathway analysis are provided in the Supplementary Table 1. 
Pathway analysis was performed using PANTHER51 over-representation test using annotations 
from Reactome version 58 release 2016-12-07. In total 1 775 pathways were tested for over 
representation resulting in a Bonferroni corrected significance threshold of 0.05/1 775 = 2.82 × 
10-05.
Gene expression analysis
Linear regression analysis was used to associate identified methylation sites with each of the 21 
238 expression probes using probes as dependent, CpG site as the independent variable, and 
age, sex, fasting state, blood cell counts and technical covariates (plate ID and RNA quality score) 
as covariates. Correction for multiple testing was performed using false discovery rate using 
Benjamini-Hochberg method implemented the stats library of R. Finally, pathway analysis of all 
significantly associated genes with CpG sites was performed in PANTHER.51
RESULTS 
The characteristics of each individual cohort included in this meta-analysis are summarized in 
Table 1. The mean age in the discovery cohorts ranged from 52.4 years (SD = 8.1) in GS to 79.1 
years (SD = 0.57) in LBC1921. Forty-eight percent of the total discovery sample were female. 
The replication cohort comprised 74% women and had an average age of 60.3 years (SD = 6.4) 
(Table 1).
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Epigenome-wide association analysis
In the meta-analysis of depressive symptoms of European ancestry, we identified one CpG site 
on chromosome 14q32.32 (cg04987734, CDC42BPB, p value = 4.93 × 10-8) that passed the 
Bonferroni threshold for significance (Table 2, Supplementary Figure 1). Suggestive association 
was observed at 19 additional CpG sites (Table 2). Adjusting for anti-depressive medication use 
did not meaningfully change the results (Supplementary Table 2). No inflation in the test statistic 
was observed (λ = 1.03, Supplementary Figure 2). We tested all 20 CpG sites for association 
in the replication sample. The top CpG site from the discovery sample (cg04987734) showed 
nominal association (p value = 0.048) with depressive symptoms in the validation data set (Table 
2). In addition, significant association of a CpG site (cg12325605; p value = 9.17 ×10-05, Table 
2) annotated to the ARHGEF3 gene with depressive symptoms was observed in the replication 
sample.
Meta-analysis of discovery and replication cohorts showed a significant association of both 
cg04987734 (p value = 1.51 × 10-08) and cg12325605 (p value = 5.24 × 10-09) with depressive 
symptoms (Table 2; Figures 1 & 2). Also, an additional intergenic CpG site (cg14023999; p value 
= 5.99 × 10-08) at chromosome 15q26.1 locus showed genome-wide significant association with 
depressive symptoms (Supplementary Table 3). Top results from the meta-analysis of discovery 
and replication cohorts are provided in the Supplementary Table 3. Genome-wide results are 
illustrated in Supplementary Figures 3 & 4.
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Figure 1: Regional association plot for the top CpG site, Genome 19 (cg04987734). 
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Figure 2: Regional association plot for the top CpG site, Genome 19 (cg12325605). 
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From blood to brain
Since the brain is the most relevant tissue for psychiatric disorders like depression, we checked 
the correlation between methylation in blood and various brain regions at the three identified 
sites using a web-based tool, BECon.25 Methylation at cg04987734 in the CDC42BPB gene was 
highly correlated (r = 0.81) between blood and the Brodmann area 7 that spans the medial 
and lateral walls of the parietal cortex (Supplementary Figure 5). Methylation at the other two 
sites was negatively correlated with methylation in the Brodmann area 10 than spans anterior 
prefrontal cortex (cg12325605, r = -0.39; cg14023999, r = -0.42) suggesting strong but reverse 
methylation patterns in blood and brain (Supplementary Figures 6 & 7).
Gene pathway analysis
Pathway analysis of all genes annotated to at least one nominally significant CpG site (p < 0.05) 
showed significant over-representation of genes involved in axon guidance (1.41 fold increase, 
p value = 5.2 × 10-07), nerve growth factor (NGF) signaling (1.42 fold increase, p value = 1.31 × 
10-05), platelet-derived growth factor (PDGF) signaling (1.47 fold increase, p value = 4.5 × 10-09) 
and developmental biology (1.32 fold increase, p value = 3.95 × 10-06) (Supplementary Table 4).
Gene expression analysis
Methylation at cg04987734 was significantly associated with increased expression of four 
genes (Supplementary Table 5). Methylation at cg12325605 was significantly associated with 
differential expression of 422 genes (Supplementary Table 6) and methylation at cg14023999 
was significantly associated with differential expression of two genes (Supplementary Table 7). 
Pathway analysis of the 422 differentially expressed genes revealed only one significant pathway: 
immune system (fold enrichment = 2.56, p value = 6.93 × 10-10) and more specifically the adaptive 
immune system (fold enrichment = 2.99, p value = 7.37 × 10-07) rather than the innate immune 
system (fold enrichment = 2.53, p value = 1.77 × 10-03) (Supplementary Table 8). Results were 
more significant when we added the other six genes that were differentially associated with 
cg04987734 and cg14023999 (Supplementary Table 9).
DISCUSSION
In this large-scale EWAS of depressive symptoms, we identified hypermethylation of three CpG 
sites (cg04987734, cg12325605 and cg14023999) associated with depressive symptoms. 
Cg04987734 is annotated to the CDC42BPB gene, cg12325605 to the ARHGEF3 gene, and 
cg14023999 lies in an intergenic region on chromosome 15q26.1 locus. Pathway analyses of 
genes harboring all nominally associated methylation sites suggest over representation of genes 
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involved in axon guidance, nerve growth factor (NGF) and platelet-derived growth factor (PDGF) 
signaling. The three CpG sites were significantly associated with the differential expression of 
428 genes. Pathway analysis of the differentially expressed genes show significant enrichment of 
genes involved in regulating the immune system.
CDC42BPB encodes a serine/threonine protein kinase that plays a role in the regulation of 
cytoskeleton reorganization, cell migration and regulation of neurite outgrowth52 and is 
highly expressed in the brain. Further, gene co-expression network suggests that it is involved 
in the synthesis, recycling, salvage and regulation of tetrahydrobiopterin (BH4) and cytotoxic 
T-lymphocyte-associated protein 4 (CTLA4) inhibitory signaling (see URLs). BH4 is an essential 
co-factor for the aromatic-amino-acid-hydroxylases and glyceryl-ether mono-oxygenase and 
regulates nitric-oxide synthase (NOS) activity.53 BH4 deficiency leads to dopamine and serotonin 
deficiency in the brain54, a characteristic pathophysiological hallmark of depression.55 BH4 has also 
been reported as an intrinsic regulator of inflammatory pain sensitivity and chronicity in animal 
studies56 and implicated in immune response.57 Inflammation-induced increases in inducible 
NOS activity can usurp available BH4, resulting in NOS uncoupling and increased oxidative stress 
affecting dopamine synthesis.58 Further, CTLA4 is a member of the immunoglobulin superfamily 
that is expressed by activated T-cells59 and soluble CTLA4 has been suggested as a biomarker 
for inflammation.60 Interestingly, methylation levels at this CpG site (cg04987734) in CDC42BPB 
gene were also previously associated with C-reactive protein (CRP) levels in blood61; a marker for 
inflammation. Hyper-methylation of cg04987734 has been associated with increased expression of 
CDC42BPB in blood (see URLs).62 Consistent with such an involvement in inflammatory processes, 
hyper-methylation of cg04987734 was also identified as an epigenetic marker associated with 
cigarette smoking.47 Life-style factors such as smoking and alcohol consumption reflect additional 
environmental effects that may induce epigenetic changes. In our study, however, we controlled 
for smoking in the regression model; therefore the association between depression and DNA 
methylation of this CpG site may be independent of smoking habits.
ARHGEF3 encodes for Rho Guanine Nucleotide Exchange Factor 3 protein. The gene is highly 
expressed in adrenal glands, brain and uterus (see URLs). Genetic variants in ARHGEF3 have 
been associated with platelet volume (see URLs). Functional analysis of ARHGEF3 (see URLs) 
suggests that this gene is involved in the regulation of innate immune response and sphingolipid 
metabolism. Earlier we identified rare missense variants in a gene NKPD111, a gene also predicted 
to be involved in de novo synthesis of sphingolipids, and plasma sphingolipid levels associated 
with depressive symptomology.63
The third associated CpG site, cg14023999 lies in an intergenic region on chromosome 15q26.1. 
Hypermethylation of cg14023999 is associated with decreased expression of SEMA4B gene in 
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blood (see URLs). SEMA4B gene encodes for Semaphorin 4B protein. Semaphorins are implicated 
in axon guidance, regulation of cell migration, angiogenesis and immune response.64-68 Sema4B is 
believed to function through a direct interaction with post-synaptic density protein PSD-9569-71 to 
promote synapse maturation.69,72,73 The knock-down of Sema4B causes a decrease in GABAergic 
synapse number72 suggesting a role in the assembly of excitatory and inhibitory postsynaptic 
specializations.73
Interestingly, all the three top hits are connected directly or through regulatory effects to genes 
involved in the immune pathway. Further, the pathway analysis of all the differentially expressed 
genes associated with these three top hits point towards the immune pathway. Together these 
findings are compatible with the hypothesis that environmental stressors may trigger depression 
by inducing elevations in pro-inflammatory cytokines16. Testing this hypothesis, however, 
requires further work, as our cross-sectional design does not allow us to establish the direction 
of association. We can only carefully speculate, whether the epigenetic factors mediate the 
relation between some environmental exposure(s) and depression, whether the epigenetic factors 
mediate the relation between the genome and depression; or whether the epigenetic variants are 
biomarkers of depression but not causally related to the disorder. In contrast to the expression 
data of our top hits, in the formal pathway analysis of the methylation data, we did not observe 
a significant overrepresentation of genes involved in the immune pathway (see Supplementary 
Table 4). Rather, these pathway analysis suggested significant enrichment of genes involved in 
axon-guidance and growth factor signaling.
This is the largest epigenome-wide study of depressive symptoms reported to date. Our major 
strength is the sample size that enabled detection of a replicable epigenome-wide significant 
locus, which suggests that in blood, DNA methylation signatures associated with depression 
may be subtle and will require large samples to be detected. Using peripheral blood tissue 
for DNA methylation profiling is a limitation of this study, as DNA methylation is known to be 
tissue specific.20 While peripheral blood is not considered to be the most relevant tissue for 
the pathophysiology of depression, some sites show correlated methylation profiles between-
tissues.20,21 The three sites identified in our study show moderate to high correlation between 
methylation in blood and various brain regions. Previous studies have also reported epigenetic 
changes with similar effects in both peripheral tissue and brain.48 Secondly, we replicated our 
top hits in the African-American samples. This suggests that depression related differences 
in DNA methylation may be similar across ethnicities.74-76 However, the use of a multi-ethnic 
predominantly African-American replication sample may also have resulted in false negatives due 
to different genetic background. Third, in these analysis we mostly used quantitative measures 
of depressive symptoms. Quantitative endo-phenotypes provide powerful alternatives for several 
complex outcomes, for example, hypertension.77 This is likely to be especially true for a trait such as 
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depressive symptoms, for which the severity and duration of illness can be highly heterogeneous.78 
Studies that use depression as an arbitrary selected extreme of the continuum of varying severity, 
are highly susceptible to misclassification, resulting in the loss of the statistical power. Genome-
wide studies of depressive traits, using quantitative endo-phenotypes, have been suggested to 
improve statistical power.78 The majority of the cohorts used the CES-D depression scale to assess 
depressive symptoms in our study. However, the use of different phenotypic measures by different 
samples typically implies some loss of statistical power due to the heterogeneity in the phenotype 
assessment. Finally, although we adjusted for potential confounders, the possibility of residual 
confounding cannot be excluded. Antidepressant medication indicate treated depression but itself 
may result in epigenetic modifications involved in depression pathophysiology.49 Antidepressants 
can thus mediate or confound the relation between DNA methylation and depression. However, 
in sensitivity analysis additionally adjusted for antidepressant medication, our results did not 
change.
To summarize, we report the first EWAS of depressive symptoms. We identified hypermethylation 
of three sites in the genome significantly associated with depressive symptoms. The identified 
loci are implicated in axon guidance, nerve growth factor, regulation of serotonin and dopamine 
levels in the brain, sphingolipid metabolism, synaptic plasticity and inflammation. Our findings 
provide new insights into the molecular mechanisms underlying the complex pathophysiology of 
depression.
URLs. The expression of genes in various brain regions is available through the genome browser: 
http://genenetwork.org/webqtl/main.py. The associations between methylation of cg04987734 
with the expression of the CDC42BPB gene is available at http://genenetwork.nl/biosqtlbrowser/. 
The expression of the ARHGEF3 gene is available at https://www.gtexportal.org/home/gene/
ARHGEF3#geneExpression. The association between gene variants of ARHGEF3 and platelet 
activation is available at https://www.ebi.ac.uk/gwas/search?query=arhgef3. Functional analysis 
of ARHGEF3 are available at http://129.125.135.180:8080/GeneNetwork/?gene=ARHGEF3. 
Association between methylation of cg14023999 with expression of SEMA4B gene in blood is 
available at http://genenetwork.nl/biosqtlbrowser/. Pathway analysis was performed using the 
web based tool PANTHER (www.pantherdb.org). Correlation between methylation in blood and 
brain was assessed using BECon (https://redgar598.shinyapps.io/BECon/).
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APPENDIX of CHAPTER 4
Supplementary Text
Cardiovascular Health Study Cohort
Description
The Cardiovascular Health Study Cohort (CHS) is a population-based cohort study of risk factors 
for coronary heart disease and stroke in adults ≥ 65 years conducted across four field centers.1 
The original predominantly European ancestry cohort of 5 201 persons was recruited in 1989 - 
1990 from random samples of the Medicare eligibility lists. CHS was approved by institutional 
review committees at each field center and individuals in the present analysis had available DNA 
and gave informed consent including consent to use of genetic information for the study of 
cardiovascular disease.
DNA methylation was measured on a randomly selected subset of 323 European descent 
participants from study year. The samples were randomly selected among participants without 
presence of coronary heart disease, congestive heart failure, peripheral vascular disease, valvular 
heart disease, stroke or transient ischemic attack at study baseline or lack of available DNA at 
study year 5.
Methylation measurements were performed at the Institute for Translational Genomics and 
Population Sciences at the Harbor-UCLA Medical Center Institute for Translational Genomics and 
Population Sciences using the Infinium HumanMethylation450 BeadChip (Illumina Inc, San Diego, 
CA). Quality control was performed in in the minfi R package.2-4 (version 1.12.0, http://www.
bioconductor.org/packages/release/bioc/html/minfi.html). Samples with low median intensities of 
below 10.5 (log2) across the methylated and un-methylated channels, samples with a proportion 
of probes falling detection of greater than 0.5%, samples with QC probes falling greater than 
3 standard deviation from the mean, sex check mismatches, or failed concordance with prior 
genotyping were removed. Methylation values were normalized using the SWAN quantile 
normalization method.3 Since white blood cell proportions were not directly measured in CHS 
they were estimated from the methylation data using the Houseman method.5 All association 
analyses were performed in R using linear mixed models with DNA methylation beta values as 
the outcome. Analyses adjusted for age, gender, current smoking status and antidepressant 
medication. Additionally chip, chip row and column were adjusted for as random effects.
CHS was approved by institutional review committees at each field center and individuals in 
the present analysis had available DNA and gave informed consent including consent to use of 
genetic information for the study of cardiovascular disease.
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Framingham Heart Study
Description
The Framingham Heart Study (FHS) is a population-based, prospective study. In 1948, the 
Original cohort of 5 209 individuals were recruited from Framingham, MA.6 The offspring 
cohort was recruited in 1971, including 5 124 offspring and spouses of offspring of the FHS 
Original cohort.7 Offspring participants underwent examinations every four years (except eight 
years between the first and the second examinations).7 Peripheral whole blood samples were 
collected from these participants at the eighth examination (2005 - 2008). Buffy coat fractions 
were obtained and genomic DNA was extracted using the Gentra Puregene DNA extraction kit 
(Qiagen, Venlo, Netherlands). Bisulfite conversion of genomic DNA was performed with the EZ 
DNA Methylation Kit (Zymo Research, Irvine, CA). DNA methylation was measured by Infinium 
HumanMethylation450 BeadChip (Illumina, CA) in two separate labs. All participants provided 
written consent for genetic study.
QC procedures were performed. Bad samples were excluded if the samples were outliers 
in multidimensional scaling (MDS) analysis, high missing rate (> 1%), poor matching to SNP 
genotype. Low quality probes were excluded if these probes had high missing rate (> 20%), 
were mapped to multiple locations, had SNP (MAF > 5% in EUR 1000G) at CpG site or ≤ 10 
bp of Single Base Extension.8 About 440,000 probes remain in ~2,600 FHS participants. A total 
of 1 680 Offspring participants had both DNA methylation and CES-D phenotype. The sample 
characteristics are displayed in Table 1 in the manuscript.
Analysis
Two models of association were tested. In order to reduce the batch effects, we analyzed the 
DNA methylation in each lab: residuals were obtained by regressing a CpG against the batch 
effects (plate, row and col numbers) and lab-specific principle components that were related 
to the outcome. Residuals from two labs were put together and then regressed against the 
CES-D, adjusting for covariates and family structure. Plate ID and family structures were treated 
as random effects in linear mixed models.
Model 1. Resid (CpG ~ Batch effects + PCs) (lab-specific)
Pooled residuals from two labs ~ CES-D + Gender + Age + smoking + WBC + family structure
Model 2. Resid (CpG ~ Batch effects + PCs) (lab-specific)
Pooled residuals from two labs ~ CES-D + Gender + Age + smoking + WBC + deprx8 + family 
structure
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Helsinki Birth Cohort Study (HBCS)
Description
The Helsinki Birth Cohort Study (HBCS) comprises 13 345 individuals (6 370 women and 6 975 
men), born as singletons between 1934 and 1944 in one of the two main maternity hospitals in 
Helsinki and who were living in Finland in 1971 when a unique personal identification number 
was allocated to each member of the Finnish population. The HBCS, which has been described 
in detail elsewhere, has been approved by the Ethics Committee of the National Public Health 
Institute. Register data were linked with permission from the Finnish Ministry of Social Affairs and 
Health and the Finnish National Archives.
In 2001 – 2004 at an average age of 61.5 years (SD = 2.9 and range = 56.7 – 69.8 years), a 
randomly selected subsample of the cohort comprising 2 003 individuals (1 075 women and 928 
men) was invited to a clinical examination including collection of a blood sample for genetic, 
epigenetic and biochemical studies and a psychological survey including a measure of depressive 
symptoms. For 283 participants, extraction of DNA was not successful, or DNA showed gender 
discrepancy or close relatedness. From the remaining sample of 1 720 individuals, 115 women 
and 97 men had been evacuated to Sweden or Denmark during the World War II according to 
the Finnish National Archives’ register. To study the effects of early separation from parents on 
methylome, we selected 83 evacuated men with data on age at and length of evacuation and 
of father’s occupational status and 83 non-evacuated controls matched for sex, birth year and 
father’s occupational status in childhood for the methylation typing. In this study, the analyses are 
based on 62 evacuated men and 60 non-evacuated controls with full data on CES-D depressive 
symptoms, covariates, and methylation profiles. For this group the mean age was 63.5 years (SD 
= 2.8).
DNA methylation sample, measurement, normalization and quality control
DNA methylation analysis was performed at the Genetics Core of the Wellcome Trust Clinical 
Research Facility (Edinburgh, UK). Bisulphite conversion of 500 ng input DNA was carried out using 
the EZ DNA Methylation Kit (Zymo Research, Freiburg, Germany). Four microlitres of bisulphite-
converted DNA was processed using the Infinium HD Assay for Methylation. This was performed 
using the Illumina Methylation 450 k beadchip and Infinium chemistry (Illumina, Inc., San Diego, 
CA, USA). Each sample was interrogated on the arrays against 485 000 methylation sites. The 
arrays were imaged on the Illumina HiScan platform and genotypes were called automatically 
using GenomeStudio Analysis software version 2011.1.
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Quality control pipeline was set up using the R-package minfi, including intensity read outs, 
normalization, cell type composition estimation, β- and M-value calculation. We excluded 
samples with low intensity (badSampleCutoff < 10.6) or deviant beta distribution based on 
visual inspection (N = 5). We did not detect any gender discrepancy. Data were normalized with 
functional normalization (FunNorm). Of the probes, we excluded those with detection p value > 
0.01 in > 50% of samples9, non-autosomal and non-specific binding probes as well as probes with 
SNPs in the interval for which the Illumina probe is designed to hybridize and if they were located 
close (10bp from query site) to a SNP which had a minor allele frequency of ≥ 0.05. Probes located 
in the X and Y chromosome were also excluded. This yielded a total number of probes of 424 
844. Batch effects were identified by inspecting the association of principal components of the 
methylation levels with possible technical batches using linear regressions and visual inspection 
of PCA plots using the Bioconductor R package shinyMethyl (version 0.99.3). Identified batch 
effects (i.e. array column) were removed using the Empirical Bayes’ (EB) method ComBat10. Batch 
corrected M-values after ComBat were used for all further statistical analyses.
Depressive symptoms assessment
Frequency of depressive symptoms were self-reported with the 20-item Centre for Epidemiologic 
Studies Depression scale (CES-D). 
Covariates
Age, sex, current smoking status, evacuation status (evacuated in childhood or not), and 
antidepressant medication (Model 2) were self-reported at the clinical visit. Blood cell proportions 
were estimated with the Houseman method. First three genotype MDS components were derived 
from genome-wide genotype data.
Analysis
A linear regression of the CES-D depressive symptoms score and covariates on each individual 
methylation probe in the array was performed in R.
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Cooperative Health Research in the Augsburg Region
Description
The Cooperative Health Research in the Region of Augsburg (KORA) study is an independent 
population-based cohort from the region of Augsburg, Southern Germany. Whole blood samples 
were obtained from the KORA F4 survey (examination 2006-2008), a seven-year follow-up study 
of the KORA S4 cohort. Participants gave written informed consent and the study was approved 
by the local ethics committee (Bayerische Landesärztekammer). 
DNA methylation sample, measurement, normalization and quality control
Whole blood genomic DNA was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo 
Research, Orange, CA, USA) according to the manufacturer’s procedure, with the alternative 
incubation conditions recommended when using the Illumina Infinium Methylation Assay. Raw 
methylation data were extracted using the Illumina GenomeStudio software (version 2011.1, 
Methylation module 1.9.0). Preprocessing was performed using R (version 3.0.1). Probes with 
signals from less than three functional beads, and probes with a detection p-value > 0.01 were 
defined as low-confidence probes. Probes that covered SNPs (MAF in Europeans > 5%) were 
excluded from the data set. A color bias adjustment was performed using the R package lumi 
(version 2.12.0) through smooth quantile normalization and background correction based on 
the negative control probes present on the Infinium HumanMethylation BeadChip. This was 
performed separately for the two color channels and chips. β-values corresponding to low-
confidence probes were set to missing. A 95% call rate threshold was applied on samples and CpG 
sites. Beta-mixture quantile normalization (BMIQ) was applied using the R package wateRmelon, 
version 1.0.3. Because KORA F4 samples were processed on 20 96-well plates in 9 batches, plate 
and batch effects were investigated using principal component analysis and eigenR2 analysis.
Depressive symptoms assessment
Depressive symptoms were assessed using the German version of the self-administered Patient 
Health Questionnaire (PHQ-9).11 PHQ-9 represents a depression module that scores each of the 
nine Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for 
depression from zero to three. PHQ-9 scores of 5, 10, 15, and 20 represents mild, moderate, 
moderately severe and severe depression. It is used to monitor the severity of the depressive 
symptoms. PHQ scores higher or equal to 10 have been shown to have a sensitivity of 88% and 
a specificity of 88% for major depression. PHQ-9 is recommended by the American Psychiatric 
Association (APA) working group for DSM-V as instrument to evaluate the severity of major 
depressive disorder according to the new DSM-V criteria.
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Covariates
The association between DNA methylation level as the outcome and depression as the 
independent variable was performed using linear regression models, adjusting for age, sex, 
smoking, antidepressants, white blood cell count, and technical covariates (analytic plate and 
chip position on plate).
Information on sociodemographic variables including sex, age, smoking status and use of 
antidepressants was collected by trained medical staff during a standardized interview. The 
estimated white blood cell proportions were obtained using the method by Houseman et al.5
Lothian Birth Cohorts of 1921 (LBC1921) and 1936 (LBC1936)
Description
The LBC1921 and LBC1936 represent relatively healthy older individuals, mostly living in the 
Lothian region of Scotland, born in 1921 and 1936, respectively. They have been involved in 
longitudinal assessments of psychological and medical traits from the age of 79 (LBC1921) or 70 
(LBC1936) years.12, 13 Here, we report the first wave, with the largest sample size: 433 (60.3% 
female) participants with a mean age of 79.1 ± 0.6 years (range = 77 - 80) in the LBC1921; 920 
(49.5% female) participants with a mean age of 69.6±0.8 years (range = 67 - 71) in the LBC1936.
DNA methylation sample, measurement, normalization and quality control
514 whole blood samples in LBC1921 and 1 004 samples in LBC1936 were taken and DNA 
extracted using standard methods at, respectively, MRC Technology, Western General Hospital, 
Edinburgh and the Wellcome Trust Clinical Research Facility (WTCRF), Western General Hospital, 
Edinburgh. 485 512 methylation probes were typed at the WTCRF. The R minfi package was 
used to background correct raw intensity data and to generate methylation beta-values.2 Probes 
with a low (< 95%) detection rate (at p < 0.01) were removed and manual quality control via 
inspection of the array control probe signals was used to locate and exclude low quality samples 
(e.g. samples with inadequate hybridisation, bisulfite conversion, nucleotide extension or staining 
signal). Samples with a low call rate (samples with < 450,000 probes detected at p < 0.01) 
were excluded based on the Illumina-recommended thresholds. Because the LBC samples had 
previously been genotyped (Illumina 610-Quadv1), genotypes derived from the 65 SNP control 
probes on the methylation array using the wateRmelon package14 were compared to those on 
the genotyping array. Exclusions were made for samples with a low match of genotypes with SNP 
control probes, potentially indicative of sample contamination or mix-up (N = 9). Additionally, 
8 subjects whose predicted sex, based on XY probes, did not align with reported sex were 
eliminated.
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Depressive symptoms assessment
Depressive symptoms were assessed with the Hospital Anxiety Depression Scale15, containing 
seven items each for anxiety and depression. The total score of the seven depression items was 
used. Self-reported smoking behavior (current, former and never) and medication use was also 
ascertained in the clinical testing session. The Anatomical Therapeutical Chemical-Code was used 
to code anti-depressants for current- and non-users.
Covariates
Age, sex, the first four principal components obtained from genotyping array data to index 
population substructure, B cells, monocytes, CD8T cells, CD4T cells, NK cells, position on 
BeadChip, methylation sample plate, BeadChip, hybridization date (and smoking for model 2). 
White blood cell counts were imputed from the methylation array using the Houseman method.5
Analysis
A linear regression of the HADS depression score and covariates on each individual methylation 
probe in the array was performed in R (v3.2.3).
The Rotterdam Study
Description
The Rotterdam Study (RS) is a prospective population based cohort study in a well-defined suburb 
in the city of Rotterdam, the Netherlands. The design and prospective of the Rotterdam Study 
has been described in details elsewhere.16 For the current analysis we used data from individuals 
aged 45 years and older that participated in the third cohort of the Rotterdam Study. Samples 
were obtained in two stages. First stage included participants of the first visit of the third cohort 
(RS-III-1). Second stage was obtained as a part of the BBMRI-NL (Biobanking and Biomolecular 
Research Infrastructure Netherlands) – BIOS project and included participants of the fifth visit 
of the first cohort (RS-I-5), third visit of the second cohort (RS-II-3) and second visit of the third 
cohort (RS-III-2). The subsets from the two stages were analyzed individually and then meta-
analyzed, together with other cohorts. 
DNA methylation sample, measurement, normalization and quality control
In both subsets of in total 1 479 individuals a whole blood DNA methylation was quantified 
utilizing same methods. DNA was extracted from whole peripheral blood, stored in EDTA tubes, 
by standardized salting out methods. The genome-wide DNA-methylation levels were determined 
using the Illumina HumanMethylation 450K array (Illumina, Inc., San Diego, CA, USA).17 In short, 
samples (500ng of DNA per sample) were first treated with bisulfite using the Zymo EZ-96 DNA-
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methylation kit (Zymo Research, Irvine, CA, USA). Next, in accordance with the manufacturers’ 
protocol the samples were hybridized to the arrays. The methylation percentage of a CpG site 
was reported as a β-value ranging between 0 for no methylation and 1 for full methylation.
Quality control (QC) of the samples was carried out using Illumina Genome Studio software 
(v2011.1, methylation module version 1.9.0; Illumina). During QC samples with incomplete bisulfite 
treatment, with a low detection rate (< 99%), or gender swaps, were excluded. Also, probes with 
a detection p value > 0.01 in > 1% samples, were filtered out. In total of 474 528 probes passed 
the QC in the first subset and 419 937 in the BIOS subset (excluding sex chromosome).Filtered 
β values were than normalized with DASEN implemented in the wateRmelon package of the R 
statistical software.14 
Depressive symptoms assessment
Depressive symptoms were assessed with the Dutch version of the Centre for Epidemiologic 
Studies Depression scale (CES-D).18 The CES-D scale was designed to assess presence and severity 
of self-reported depressive symptoms.19 Participants were asked 20 questions that correspond 
with criterion based-symptoms associated with depression, and they could score from 0 - 60. The 
screening for depressive symptoms was performed during the home interview by trained research 
assistants. 
Covariates
Age, sex, current smoking status and antidepressant medication were measured using standard 
cohort specific protocols at the time DNA samples were collected. During this interview participants 
reported on their smoking behavior (current, former and never) and psychotropic medication 
use. Moreover, to confirm the self-reported use of antidepressants prescription, the Anatomical 
Therapeutical Chemical-Code20 data was collected from pharmacies linked records. Exposure to 
an antidepressant was defined as current user and non-user of any antidepressant as described 
in detail elsewhere.20 White blood cells counts (monocytes, granulocytes and lymphocytes) were 
measured immediately at the research center using a standard hematology analyzer (Beckman 
Coulter, Pasadena, CA, USA).
Analysis
An epigenome-wide linear regression was performed per DNA methylation probe with CES-D 
depression score adjusting for covariates in R. Model 1 was adjusted for age, sex, smoking status, 
batch effects and cell composition, while Model 2 was additionally adjusted for antidepressant 
medication use.
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Generation Scotland Study
Description
Generation Scotland: Scottish Family Health Study (GS:SFHS) is a population- and family-based 
cohort comprising ~24 000 individuals from the Scottish population. The cohort has been described 
in detail previously.21 Two hundred and twenty-seven individuals (118 cases, 109 controls) were 
included in the current study. These individuals are of European descent and were aged 40 years 
or over at the time of recruitment to GS:SFHS. Antidepressant usage was determined by self-
report at the time of recruitment. Blood samples for DNA extraction were obtained at the time 
of recruitment to GS:SFHS.
DNA methylation sample, measurement, normalization and quality control
Whole blood genomic DNA (500 ng) was treated with sodium bisulphite using the EZ-96 DNA 
Methylation Kit (Zymo Research, Irvine, California), according to the manufacturer’s instructions. 
DNA methylation was assessed using the Infinium HumanMethylation450 BeadChip (Illumina 
Inc., San Diego, California), according to the manufacturers protocol. Samples were assigned to 
slides such that gender was counter-balanced. Methylation array processing was carried out at 
the Wellcome Trust Clinical Research Facility, The University of Edinburgh.
Raw intensity (.idat) files were read into R using the minfi package2, which was used to perform 
initial quality control assessments by assessing signal from the array’s internal control probes. All 
samples were deemed to have performed well based on the output of the control probes.
Probe and sample filtering was performed using the pfilter function in wateRmelon.14 Probes 
were excluded if they had a detection p value ≥ 0.05 in more than 5% samples (N = 1000) or had 
a beadcount of less than 3 in more than 5% samples (N = 466). All samples satisfied an inclusion 
criterion of having no more than 5% probes with a detection p value ≥ 0.01. The final dataset 
comprised 484 145 probes measured in 227 individuals.
The raw data (β values) were normalized using the dasen function in wateRmelon.14
Assessment of depression
Diagnoses of depression were established by trained researchers who administered the screening 
questions of the Structured Clinical Interview for DSM-IV (SCID)22 to all GS:SFHS participants. 
Those who screened positive were subsequently assessed using the mood disorder sub-sections 
of the SCID. Major depressive disorder (MDD) was diagnosed in those meeting the criteria for 
MDD whose symptoms could not be better explained by bipolar disorder, a general medical 
condition or substance abuse.
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Covariates
The following variables were included as covariates: sex, age, current smoking status, family, 
estimated blood cell counts, batch (methylation slide ID), and methylation-based principal 
components. Antidepressant usage was additionally included as a covariate in a sensitivity analysis 
carried out to assess the contribution of antidepressant use to depression-associated methylation 
differences.
Smoking status was determined by self-report at the time of blood sample collection and was 
recorded as a binary variable (current smokers vs. non-smokers (never smokers and ex-smokers)). 
Antidepressant usage was also determined by self-report at the time of blood sample collection. 
No data on antidepressant usage was available for seven individuals.
Estimated proportions of six blood cell types (monocytes, granulocytes, CD4+ T-cells, CD8+ T-cells, 
B-cells and natural killer cells) were obtained using the estimateCellCounts function in minfi.5, 23 
In order to avoid collinearity, one cell type, natural killer cells, was excluded from the analyses.
Methylation-based principal components were identified using prcomp without scaling. PCA 
was performed on the matrix of residualised β-values obtained after residualising for the other 
covariates included in the model used to identify differentially methylated positions (principal 
components were estimated separately for Model 1 and Model 2). Principal components that 
individually accounted for at least 1% of the variance were included as covariates. For both 
models, this resulted in the inclusion of the first six principal components.
As our sample comprised related individuals (100 discordant sib pairs and 27 singletons), it was 
necessary to account for relatedness. This was achieved using the duplicateCorrelation function 
in limma24, 25 to fit family as a random effect.
Atherosclerosis Risk In Communities (ARIC) Study
DNA methylation sample, measurement, normalization and quality control
DNA methylation analysis was conducted with the Infinium HumanMethylation450 BeadChip 
(HM450) array (Illumina Inc., San Diego, CA) on genomic DNA extracted from blood samples 
collected at ARIC Visit 2. Assay were performed on participants who had not restricted use 
of their DNA and for whom at least 1 μg of DNA and genome-wide genotyping data were 
available. Details of assay and QC procedures have been previously published.27 Briefly, genomic 
DNA was treated with sodium bisulfite using the EZ-96 DNA methylation kit (Zymo Research 
Corporation, Irvine, CA) following the manufacturer’s protocol. Bisulfite converted DNA was 
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amplified, enzymatically fragmented, purified and hybridized to the HM450 array in accordance 
with the manufacturer’s directions. Methylation typing at 485 577 CpG sites was performed 
using GenomeStudio 2011.1 (Illumina Inc., San Diego, CA). Methylation level for each probe was 
derived as a beta value representing the fractional level of methylation at that location. Quality 
control analysis was performed using the wateRmelon R package.14 Probe data were excluded 
if they had a low detection rate (< 95% at p < 0.01) and a high missing rate (greater than 1% 
across all samples). Sample data were excluded based on the following criteria: (1) greater than 
5% missing values across all probes; (2) possible gender mismatch based on principal component 
analysis; (3) genotype mismatch based on 24 SNPs present on the HM450 array. Methylation 
values were normalized using the Beta MIxture Quantile dilation (BMIQ) method.28 All ARIC Study 
participants have provided written informed consent for genomic studies and this work was 
conducted in compliance with the Helsinki Declaration. The Committee for the Protection of 
Human Subjects at the University of Texas Health Science Center at Houston has approved this 
research.
Depressive symptoms assessment
Depressive symptoms were assessed at visit 2 using the 21-item Maastricht Questionnaire.29 
Responses to the questionnaire are coded as yes = 2, don’t know = 1, and no = 0. Two items, 
questions 9 and 14, are reversed coded (yes = 0, don’t know = 1, no = 2). Responses are summed 
to obtain an overall vital exhaustion score, which ranges from 0 to 42, with higher scores 
representing more exhaustion. Cronbach alpha for internal consistency has been reported as 
0.89.29 Although designed to measure vital exhaustion, the 21-item Maastricht Questionnaire 
has been shown to correlate with measures of depressive symptoms30 and was previously used to 
assess depressive symptoms.31, 32
Covariates
Age, sex, current smoking status and antidepressant medication were measured using standard 
cohort specific protocols at visit 2. Blood cell proportions were imputed using the Houseman 
method.5 Genotype principal components were derived from genome-wide genotype data 
(Affymetrix 6.0).
Analysis
Analysis was performed according to a pre-specified analysis plan adjusting for biological and 
technical covariates (see attached spreadsheet for details).
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Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated CVD
Description
Women’s Health Initiative - Epigenetic Mechanisms of PM-Mediated CVD (WHI-EMPC) is an 
ancillary study of epigenetic mechanisms underlying associations between ambient particulate 
matter (PM) air pollution and cardiovascular disease (CVD) in the Women’s Health Initiative clinical 
trials (CT) cohort. It is funded by the National Institute of Environmental Health Sciences (R01-
ES020836).33
The WHI-EMPC study population is a stratified, random sample of 2 200 WHI CT participants 
who were examined between 1993 and 2001; had available buffy coat, core analytes, 
electrocardiograms, and ambient concentrations of PM; but were not taking anti-arrhythmic 
medications at the time.
As such, WHI-EMPC is representative of the larger, multiethnic WHI CT population from which 
it was sampled: N = 68 132 participants aged 50 - 79 years who were randomized to hormone 
therapy, calcium / vitamin D supplementation, and / or dietary modification in 40 U.S. clinical 
centers at the baseline exam (1993 - 1998) and re-examined in the fasting state one, three, six, 
and nine years later.34
During participant visits, data on age, race/ethnicity, smoking status, depressive symptoms, and 
antidepressant medication use were obtained. Current analyses were in European Americans 
and involved information collected at the first visit with available DNA methylation (DNAm) data. 
DNA Methylation
Genome-wide DNAm at CpG sites was measured using the Illumina 450K Infinium Methylation 
BeadChip, quantitatively represented by beta (the percentage of methylated cytosines over the 
sum of methylated and unmethylated cytosines), and quality controlled using the following 
filters:  detection p values > 0.01 in > 10% of samples, detection p values > 0.01 in > 1% of 
probes, yielding values of beta at 484,220 sites. DNAm data was normalized using BMIQ28, then 
stage- and plate-adjusted using ComBat.10 Modeled epigenome-wide associations also adjusted 
for principal components for ancestral admixture, cell subtype proportions (CD8-T, CD4-T, B cell, 
natural killer, monocyte, and granulocyte)5, and technical covariates including array, row, and 
column.
Depressive symptoms ascertainment
Depressive symptoms were obtained on the day of DNAm collection using a short screening 
instrument developed by Burnman et al.35 that combines six items from the CES-D that highly 
correlate with the full instrument (r = 0.88)36 with two items from the Diagnostic Interview 
Schedule (DIS). This CES-D/DIS screening instrument ranges from 0 to 1 with a higher score 
indicating a greater likelihood of depression.
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Supplementary Figure 2: Quantile-quantile plots for the discovery EWAS. 
Horizontal axis depicts the expected negative logarithm of the association p-value, while the vertical axis 
shows the observed negative logarithm of the association p-value (λ = 1.030).
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Supplementary Figure 4: Quantile-quantile plot of the meta-analysis of discovery and replication 
EWAS (λ = 1.088). 
Horizontal axis depicts the expected negative logarithm of the association p-value, while the vertical axis 
shows the observed negative logarithm of the association p-value.
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Supplementary Figure 5. Correlation between blood and brain methylation at cg04987734.
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Supplementary Figure 6: Correlation between blood and brain methylation at cg12325605. 
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Supplementary Figure 7: Correlation between blood and brain methylation at cg14023999.
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Supplementary Table 1. List of genes used in pathway analysis
HTR2B
MARCH1
MARCH3
MARCH4
MARCH6
MARCH7
MARCH8
SEPT4
SEPT5
SEPT6
SEPT8
SEPT9
T12
A1BG
A2BP1
A2M
A2ML1
A4GALT
A4GNT
AAA1
AACS
AADACL4
AAK1
AANAT
AARS
AARS2
AASDH
AATF
AATK
ABAT
ABCA1
ABCA12
ABCA13
ABCA17P
ABCA2
ABCA3
ABCA4
ABCA5
ABCB1
ABCB7
ABCB8
ABCB9
ABCC1
ABCC2
ABCC3
ABCC5
ABCC6
ABCC6P1
ABCC6P2
ABCC8
ABCC9
ABCD3
ABCD4
ABCE1
ABCF1
ABCF2
ABCG1
ABCG4
ABCG5
ABCG8
ABHD1
ABHD10
ABHD12
ABHD12B
ABHD14B
ABHD15
ABHD2
ABHD3
ABHD8
ABI1
ABI3
ABL1
ABL2
ABLIM1
ABLIM2
ABLIM3
ABP1
ABR
ABTB2
ACAA1
ACAA2
ACACB
ACAD10
ACAD11
ACADS
ACAN
ACAP1
ACAP2
ACAP3
ACBD3
ACBD4
ACBD7
ACCN1
ACCN2
ACCN3
ACCN4
ACCN5
ACE
ACE2
ACER3
ACHE
ACLY
ACMSD
ACN9
ACO1
ACOT11
ACOT13
ACOT2
ACOT4
ACOT7
ACOX1
ACOX3
ACOXL
ACP5
ACP6
ACPL2
ACR
ACRBP
ACRC
ACRV1
ACSBG1
ACSF2
ACSF3
ACSL1
ACSL3
ACSL4
ACSL5
ACSL6
ACSM1
ACSM5
ACSS3
ACTA1
ACTA2
ACTC1
ACTG1
ACTL6B
ACTL7B
ACTL9
ACTN1
ACTN2
ACTN3
ACTN4
ACTR1A
ACTR1B
ACTR2
ACTR3C
ACTRT2
ACVR1B
ACVRL1
ACY1
ACY3
ADAD1
ADAL
ADAM11
ADAM12
ADAM15
ADAM17
ADAM19
ADAM21
ADAM21P1
ADAM32
ADAM33
ADAM5P
ADAM7
ADAM8
ADAMDEC1
ADAMTS1
ADAMTS10
ADAMTS13
ADAMTS15
ADAMTS16
ADAMTS17
ADAMTS2
ADAMTS20
ADAMTS3
ADAMTS7
ADAMTS8
ADAMTS9
ADAMTSL1
ADAMTSL3
ADAMTSL4
ADAP1
ADAP2
ADAR
ADARB1
ADARB2
ADAT1
ADC
ADCK5
ADCY1
ADCY10
ADCY2
ADCY3
ADCY4
ADCY5
ADCY7
ADCY8
ADCY9
ADCYAP1R1
ADD1
ADD2
ADD3
ADH4
ADH6
ADH7
ADHFE1
ADIPOR1
ADIPOR2
ADK
ADM
ADO
ADORA1
ADORA2A
ADORA3
ADPGK
ADPRH
ADPRHL1
ADRA1A
ADRA1B
ADRA2B
ADRA2C
ADRB2
ADRB3
ADRBK1
ADRBK2
ADRM1
ADSSL1
AEBP1
AEBP2
AFAP1
AFAP1L1
AFAP1L2
AFF1
AFF2
AFF3
AFMID
AFTPH
AGA
AGAP1
AGAP11
AGAP2
AGAP3
AGAP5
AGAP6
AGAP8
AGBL1
AGBL2
AGBL3
AGBL4
AGBL5
AGFG1
AGFG2
AGL
AGPAT1
AGPAT2
AGPAT3
AGPAT4
AGPAT5
AGPAT6
AGRN
AGRP
AGTRAP
AGXT
AGXT2
AGXT2L2
AHCY
AHCYL1
AHCYL2
AHDC1
AHNAK
AHNAK2
AHRR
AIFM1
AIFM2
AIFM3
AIG1
AIM1
AIM1L
AIM2
AIMP1
AIP
AIRE
AJAP1
AK1
AK2
AK3L1
AK5
AKAP1
AKAP12
AKAP13
AKAP2
AKAP6
AKAP8
AKD1
AKIRIN1
AKNA
AKR1A1
AKR1B15
AKR1C2
AKR1D1
AKR1E2
AKT1
AKT1S1
AKT2
AKT3
ALB
ALCAM
ALDH16A1
ALDH18A1
ALDH1L1
ALDH2
ALDH3A1
ALDH3B1
ALDH3B2
ALDH4A1
ALDH5A1
ALDH7A1
ALDOB
ALG1
ALG10B
ALG12
ALG13
ALG14
ALG1L2
ALG3
ALG5
ALG8
ALG9
ALK
ALKBH1
ALKBH4
ALKBH5
ALKBH6
ALKBH7
ALLC
ALOX12
ALOX12B
ALOX12P2
ALOX15
ALOX15B
ALOX5
ALOXE3
ALPI
ALPK3
ALPL
ALS2CL
ALS2CR11
ALS2CR4
ALX1
ALX3
ALX4
AMAC1L3
AMBRA1
AMD1
AMDHD1
AMDHD2
AMH
AMHR2
AMIGO1
AMIGO3
AMMECR1
AMOTL1
AMOTL2
AMPD2
AMPD3
AMPH
AMT
AMZ1
ANAPC1
ANAPC13
ANAPC5
ANAPC7
ANGPTL2
ANK1
ANK2
ANK3
ANKAR
ANKDD1A
ANKFN1
ANKFY1
ANKH
ANKHD1
ANKLE2
ANKMY1
ANKRD10
ANKRD11
ANKRD12
ANKRD13A
ANKRD13B
ANKRD13D
ANKRD20B
ANKRD22
ANKRD23
ANKRD24
ANKRD28
ANKRD30A
ANKRD31
ANKRD33B
ANKRD34C
ANKRD45
ANKRD46
ANKRD52
ANKRD53
ANKRD54
ANKRD57
ANKRD58
ANKRD6
ANKRD9
ANKS1A
ANKS1B
ANKS3
ANKS6
ANKZF1
ANLN
ANO1
ANO2
ANO4
ANO7
ANO8
ANO9
ANP32A
ANP32B
ANP32E
ANPEP
ANTXR1
ANTXR2
ANXA11
ANXA4
ANXA5
ANXA6
ANXA7
ANXA9
AOAH
AOC3
AOX1
AP1B1
AP1G1
AP1G2
AP1S2
AP1S3
AP2A1
AP2A2
AP2B1
AP2M1
AP3B2
AP3D1
AP3M1
AP3M2
AP4E1
AP4S1
APBA2
APBB1IP
APBB2
APBB3
APC
APC2
APCDD1
APCDD1L
APCS
APEH
APEX1
APEX2
APH1B
APITD1
APLP2
APOB48R
APOBEC3A
APOBEC3B
APOBEC3F
APOBEC3G
APOC1
APOD
APOL4
APOL6
APOLD1
APOM
APOOL
APP
APPBP2
APPL2
AQP1
AQP12A
AQP12B
AQP2
AQP5
AQP6
AQP9
AR
ARAP1
ARAP2
ARAP3
ARF1
ARF5
ARF6
ARFGAP2
ARFIP1
ARFRP1
ARGLU1
ARHGAP1
ARHGAP10
ARHGAP12
ARHGAP15
ARHGAP18
ARHGAP19
ARHGAP20
ARHGAP22
ARHGAP23
ARHGAP24
ARHGAP25
ARHGAP26
ARHGAP27
ARHGAP28
ARHGAP29
ARHGAP5
ARHGAP6
ARHGAP8
ARHGAP9
ARHGDIA
ARHGEF10
ARHGEF10L
ARHGEF12
ARHGEF16
ARHGEF17
ARHGEF18
ARHGEF19
ARHGEF2
ARHGEF3
ARHGEF4
ARHGEF6
ARHGEF7
ARID1A
ARID1B
ARID2
ARID3A
ARID3C
ARID5B
ARIH1
ARL1
ARL11
ARL15
ARL16
ARL17A
ARL3
ARL4A
ARL4C
ARL4D
ARL5C
ARL6
ARL6IP4
ARL6IP6
ARMC1
ARMC10
ARMC2
ARMC8
ARMCX1
ARMCX2
ARMCX3
ARNT2
ARNTL
ARNTL2
ARPC1A
ARPC1B
ARPC3
ARPM1
ARPP-21
ARR3
ARRB1
ARRB2
ARRDC2
ARRDC5
ARSA
ARSB
ARSD
ARSG
ARSI
ARSJ
ART1
ART3
ART4
ARTN
ARVCF
ARX
AS3MT
ASAH1
ASAH2
ASAH2B
ASAM
ASAP1
ASAP2
ASB10
ASB13
ASB14
ASB18
ASB2
ASB9
ASCC1
ASCC3
ASCL1
ASCL2
ASF1B
ASFMR1
ASGR1
ASGR2
ASH2L
ASIP
ASPG
ASPH
ASPHD1
ASPHD2
ASPSCR1
ASS1
ASTN2
ASXL1
ASZ1
ATAD1
ATAD3A
ATAD3C
ATAD5
ATE1
ATF2
ATF3
ATF4
ATF5
ATF6
ATF6B
ATF7
ATG16L1
ATG16L2
ATG3
ATG4B
ATG4D
ATG5
ATG7
ATG9B
ATHL1
ATM
ATN1
ATOH1
ATOH8
ATOX1
ATP10A
ATP10B
ATP11A
ATP11B
ATP1A1
ATP1A3
ATP1A4
ATP1B1
ATP1B2
ATP2A2
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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ATP2A3
ATP2B1
ATP2B2
ATP2B3
ATP2B4
ATP2C1
ATP2C2
ATP4B
ATP5A1
ATP5B
ATP5E
ATP5G1
ATP5G2
ATP5H
ATP5J
ATP5J2
ATP5L
ATP5S
ATP5SL
ATP6V0A1
ATP6V0A2
ATP6V0A4
ATP6V0B
ATP6V0C
ATP6V0D1
ATP6V0D2
ATP6V0E2
ATP6V1B2
ATP6V1C1
ATP6V1C2
ATP6V1H
ATP7A
ATP8A2
ATP8B1
ATP8B2
ATP8B3
ATP8B4
ATP9B
ATPAF2
ATPBD4
ATPGD1
ATR
ATRIP
ATXN1
ATXN10
ATXN3
ATXN7
ATXN7L1
ATXN7L2
AURKB
AURKC
AUTS2
AVEN
AVP
AVPI1
AVPR1B
AVPR2
AWAT2
AXIN1
AXIN2
AXL
AZI1
AZI2
AZU1B2M
B3GALNT2
B3GALT4
B3GALTL
B3GAT1
B3GAT2
B3GNT2
B3GNT4
B3GNT7
B3GNT9
B3GNTL1
B4GALNT1
B4GALNT3
B4GALT1
B4GALT2
B4GALT3
B4GALT5
B9D1
B9D2
BAALC
BACE1
BACE2
BACH2
BAG2
BAG4
BAGE4
BAGE5
BAHCC1
BAHD1
BAI1
BAI3
BAIAP2
BAIAP2L1
BAIAP3
BAK1
BAMBI
BANF1
BANK1
BANP
BAP1
BARHL2
BARX2
BASP1
BAT1
BAT2
BAT2L1
BAT3
BAT4
BAT5
BAZ1A
BAZ1B
BAZ2B
BBC3
BBOX1
BBS5
BBS7
BBS9
BBX
BCAN
BCAP29
BCAP31
BCAR1
BCAR3
BCAS1
BCAS3
BCAS4
BCAT1
BCAT2
BCKDHA
BCKDHB
BCKDK
BCL10
BCL11A
BCL11B
BCL2
BCL2L1
BCL2L10
BCL2L14
BCL2L15
BCL2L2
BCL3
BCL6
BCL7A
BCL7B
BCL7C
BCL9
BCL9L
BCLAF1
BCOR
BCORL1
BCR
BCYRN1
BDH1
BDH2
BDKRB1
BDKRB2
BDNF
BDNFOS
BDP1
BEAN
BECN1
BEGAIN
BEND3
BEND4
BEND5
BEND6
BEST4
BET1
BEX4
BEX5
BEYLA
BFAR
BFSP2
BGN
BHLHB9
BHLHE23
BHLHE40
BHLHE41
BHMT
BHMT2
BICC1
BICD1
BICD2
BIK
BIN1
BIN2
BIN3
BIRC5
BIRC7
BIVM
BLCAP
BLK
BLMH
BLOC1S2
BLVRA
BMF
BMP1
BMP2K
BMP4
BMP6
BMP7
BMP8A
BMP8B
BMPER
BMPR2
BNC1
BNC2
BNIP1
BNIP2
BNIP3L
BOC
BOLA1
BOP1
BPGM
BPHL
BPIL1
BRAF
BRD1
BRD2
BRD3
BRD4
BRE
BRF1
BRF2
BRIP1
BRP44
BRP44L
BRPF1
BRPF3
BRS3
BRUNOL4
BRUNOL5
BRUNOL6
BRWD1
BSCL2
BSDC1
BSG
BSN
BSPRY
BST1
BST2
BSX
BTAF1
BTBD1
BTBD11
BTBD12
BTBD17
BTBD18
BTBD19
BTBD2
BTBD7
BTBD8
BTBD9
BTF3
BTG2
BTG3
BTG4
BTN2A1
BTN3A1
BTN3A3
BTNL2
BTNL9
BUB3
BUD13
BUD31
BVES
BZRAP1
BZW1
BZW2
C10orf105
C10orf107
C10orf11
C10orf114
C10orf116
C10orf119
C10orf122
C10orf125
C10orf128
C10orf129
C10orf140
C10orf2
C10orf26
C10orf27
C10orf4
C10orf46
C10orf47
C10orf54
C10orf55
C10orf57
C10orf58
C10orf62
C10orf68
C10orf71
C10orf72
C10orf75
C10orf76
C10orf79
C10orf81
C10orf82
C10orf90
C10orf91
C10orf95
C10orf99
C11orf1
C11orf17
C11orf31
C11orf34
C11orf41
C11orf45
C11orf46
C11orf49
C11orf54
C11orf57
C11orf58
C11orf63
C11orf66
C11orf67
C11orf71
C11orf73
C11orf75
C11orf80
C11orf82
C11orf84
C11orf85
C11orf87
C11orf88
C11orf9
C11orf90
C11orf91
C11orf93
C12orf11
C12orf12
C12orf23
C12orf26
C12orf27
C12orf34
C12orf35
C12orf4
C12orf42
C12orf43
C12orf48
C12orf49
C12orf5
C12orf51
C12orf54
C12orf56
C12orf60
C12orf67
C12orf72
C12orf75
C12orf76
C13orf15
C13orf16
C13orf27
C13orf36
C13orf37
C13orf38
C14orf1
C14orf104
C14orf106
C14orf118
C14orf119
C14orf126
C14orf132
C14orf135
C14orf143
C14orf148
C14orf159
C14orf162
C14orf167
C14orf178
C14orf179
C14orf181
C14orf183
C14orf184
C14orf19
C14orf2
C14orf21
C14orf23
C14orf34
C14orf37
C14orf4
C14orf43
C14orf45
C14orf49
C14orf50
C14orf64
C14orf68
C14orf70
C14orf72
C14orf73
C14orf93
C15orf17
C15orf2
C15orf23
C15orf27
C15orf28
C15orf29
C15orf33
C15orf38
C15orf40
C15orf41
C15orf42
C15orf43
C15orf53
C15orf58
C15orf60
C15orf61
C16orf11
C16orf13
C16orf35
C16orf38
C16orf42
C16orf45
C16orf46
C16orf5
C16orf52
C16orf62
C16orf65
C16orf67
C16orf68
C16orf7
C16orf70
C16orf72
C16orf73
C16orf74
C16orf75
C16orf81
C16orf86
C16orf87
C16orf90
C16orf92
C17orf101
C17orf102
C17orf104
C17orf108
C17orf42
C17orf46
C17orf49
C17orf51
C17orf57
C17orf59
C17orf60
C17orf62
C17orf64
C17orf66
C17orf68
C17orf70
C17orf74
C17orf75
C17orf76
C17orf77
C17orf81
C17orf82
C17orf85
C17orf87
C17orf88
C17orf89
C17orf90
C17orf91
C17orf93
C17orf96
C17orf97
C17orf98
C18orf1
C18orf10
C18orf18
C18orf2
C18orf20
C18orf26
C18orf32
C19orf10
C19orf12
C19orf18
C19orf21
C19orf23
C19orf24
C19orf25
C19orf28
C19orf29
C19orf34
C19orf36
C19orf40
C19orf41
C19orf43
C19orf45
C19orf46
C19orf48
C19orf50
C19orf51
C19orf52
C19orf53
C19orf6
C19orf60
C19orf63
C19orf71
C19orf77
C1GALT1C1
C1orf100
C1orf103
C1orf106
C1orf107
C1orf113
C1orf115
C1orf122
C1orf123
C1orf124
C1orf130
C1orf14
C1orf141
C1orf144
C1orf146
C1orf151
C1orf159
C1orf163
C1orf170
C1orf172
C1orf175
C1orf177
C1orf187
C1orf189
C1orf190
C1orf192
C1orf198
C1orf21
C1orf213
C1orf216
C1orf220
C1orf228
C1orf229
C1orf25
C1orf26
C1orf31
C1orf43
C1orf49
C1orf51
C1orf52
C1orf53
C1orf56
C1orf57
C1orf58
C1orf59
C1orf61
C1orf63
C1orf64
C1orf66
C1orf69
C1orf70
C1orf83
C1orf84
C1orf86
C1orf88
C1orf89
C1orf9
C1orf91
C1orf92
C1orf94
C1orf96
C1orf97
C1QBP
C1QL2
C1QL4
C1QTNF1
C1QTNF2
C1QTNF3
C1QTNF4
C1QTNF7
C1RL
C20orf103
C20orf108
C20orf111
C20orf112
C20orf117
C20orf12
C20orf123
C20orf135
C20orf160
C20orf165
C20orf166
C20orf177
C20orf195
C20orf196
C20orf199
C20orf24
C20orf26
C20orf3
C20orf30
C20orf43
C20orf46
C20orf54
C20orf56
C20orf70
C20orf72
C20orf85
C20orf95
C20orf96
C21orf119
C21orf122
C21orf129
C21orf130
C21orf29
C21orf33
C21orf34
C21orf59
C21orf62
C21orf63
C21orf66
C21orf67
C21orf7
C21orf70
C21orf71
C21orf81
C21orf91
C22orf15
C22orf24
C22orf25
C22orf26
C22orf32
C22orf34
C22orf42
C22orf43
C22orf45
C22orf46
C22orf9
C2CD2
C2CD2L
C2CD4A
C2CD4B
C2CD4C
C2orf18
C2orf28
C2orf29
C2orf34
C2orf39
C2orf42
C2orf48
C2orf50
C2orf54
C2orf55
C2orf57
C2orf61
C2orf63
C2orf65
C2orf68
C2orf7
C2orf70
C2orf71
C2orf73
C2orf74
C2orf76
C2orf78
C2orf81
C2orf86
C2orf89
C2orf90
C3orf15
C3orf17
C3orf20
C3orf21
C3orf23
C3orf25
C3orf26
C3orf30
C3orf31
C3orf38
C3orf39
C3orf48
C3orf50
C3orf52
C3orf54
C3orf57
C3orf59
C3orf74
C3orf75
C3orf77
C3P1
C4BPA
C4orf10
C4orf22
C4orf23
C4orf26
C4orf27
C4orf31
C4orf32
C4orf33
C4orf34
C4orf37
C4orf42
C4orf46
C4orf49
C4orf50
C5
C5orf13
C5orf15
C5orf20
C5orf27
C5orf30
C5orf32
C5orf33
C5orf35
C5orf36
C5orf37
C5orf38
C5orf39
C5orf4
C5orf42
C5orf45
C5orf49
C5orf53
C5orf56
C5orf58
C6
C6orf1
C6orf10
C6orf103
C6orf106
C6orf108
C6orf118
C6orf120
C6orf123
C6orf126
C6orf129
C6orf130
C6orf132
C6orf134
C6orf136
C6orf141
C6orf145
C6orf153
C6orf168
C6orf174
C6orf176
C6orf186
C6orf191
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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C6orf195
C6orf204
C6orf208
C6orf221
C6orf222
C6orf226
C6orf227
C6orf27
C6orf35
C6orf48
C6orf52
C6orf57
C6orf64
C6orf70
C6orf72
C6orf94
C6orf97
C7orf10
C7orf13
C7orf16
C7orf20
C7orf23
C7orf25
C7orf27
C7orf29
C7orf30
C7orf41
C7orf42
C7orf43
C7orf47
C7orf49
C7orf50
C7orf51
C7orf55
C7orf57
C7orf58
C7orf60
C7orf63
C7orf68
C7orf70
C8A
C8orf12
C8orf34
C8orf42
C8orf51
C8orf59
C8orf71
C8orf73
C8orf75
C8orf84
C8orf85
C9orf100
C9orf119
C9orf128
C9orf152
C9orf153
C9orf163
C9orf167
C9orf171
C9orf24
C9orf25
C9orf3
C9orf47
C9orf50
C9orf57
C9orf64
C9orf68
C9orf69
C9orf75
C9orf86
C9orf89
C9orf93
C9orf96
CA1
CA10
CA12
CA13
CA3
CA4
CA5A
CA5B
CA6
CA7
CAB39
CAB39L
CABC1
CABIN1
CABLES1
CABLES2
CABP1
CABP2
CABP4
CABP5
CABP7
CACHD1
CACNA1A
CACNA1B
CACNA1C
CACNA1D
CACNA1E
CACNA1G
CACNA1H
CACNA1I
CACNA2D1
CACNA2D2
CACNA2D3
CACNA2D4
CACNB1
CACNB2
CACNB3
CACNB4
CACNG2
CACNG3
CACNG4
CACNG8
CADM1
CADM2
CADM3
CADPS
CADPS2
CALCA
CALCB
CALCOCO2
CALCR
CALD1
CALHM1
CALHM2
CALHM3
CALM1
CALM3
CALML4
CALML5
CALML6
CALN1
CALR
CALU
CALY
CAMK1D
CAMK2D
CAMK2G
CAMK4
CAMKK1
CAMKK2
CAMKV
CAMSAP1
CAMSAP1L1
CAMTA1
CAND1
CAND2
CANT1
CAP2
CAPG
CAPN1
CAPN10
CAPN12
CAPN13
CAPN14
CAPN2
CAPN3
CAPN5
CAPN8
CAPN9
CAPNS1
CAPRIN1
CAPRIN2
CAPS
CAPZA1
CAPZB
CARD11
CARD14
CARD8
CARKD
CARM1
CARS
CARS2
CARTPT
CASC1
CASC2
CASC3
CASC4
CASK
CASKIN1
CASKIN2
CASP10
CASP4
CASP5
CASP8AP2
CASQ2
CASR
CASS4
CAST
CASZ1
CATSPER2
CATSPER3
CATSPERB
CATSPERG
CAV1
CAV2
CBFA2T3
CBLC
CBLL1
CBLN3
CBR1
CBR4
CBS
CBWD1
CBWD2
CBX3
CBX4
CBX6
CBX7
CBX8
CBY1
CC2D2B
CCDC101
CCDC102A
CCDC102B
CCDC105
CCDC106
CCDC108
CCDC109A
CCDC109B
CCDC11
CCDC110
CCDC111
CCDC112
CCDC113
CCDC114
CCDC116
CCDC124
CCDC127
CCDC130
CCDC134
CCDC136
CCDC137
CCDC138
CCDC140
CCDC141
CCDC142
CCDC146
CCDC148
CCDC15
CCDC152
CCDC154
CCDC159
CCDC160
CCDC163P
CCDC18
CCDC19
CCDC22
CCDC23
CCDC24
CCDC27
CCDC28A
CCDC33
CCDC34
CCDC37
CCDC40
CCDC42
CCDC43
CCDC46
CCDC52
CCDC55
CCDC57
CCDC59
CCDC6
CCDC62
CCDC63
CCDC64
CCDC66
CCDC68
CCDC69
CCDC7
CCDC71
CCDC74B
CCDC75
CCDC81
CCDC85A
CCDC85C
CCDC87
CCDC88B
CCDC88C
CCDC92
CCDC93
CCDC94
CCDC96
CCDC97
CCHCR1
CCK
CCKBR
CCL1
CCL13
CCL17
CCL2
CCL22
CCL25
CCL26
CCL27
CCL28
CCM2
CCNA2
CCNC
CCND1
CCND2
CCND3
CCNE1
CCNF
CCNG1
CCNH
CCNI
CCNJ
CCNJL
CCNL1
CCNL2
CCNO
CCNY
CCR1
CCR10
CCR5
CCR6
CCR7
CCR8
CCR9
CCRL2
CCRN4L
CCS
CCT2
CD109
CD151
CD160
CD163
CD164L2
CD180
CD19
CD1B
CD1C
CD1D
CD1E
CD200
CD244
CD247
CD248
CD274
CD300C
CD300LG
CD302
CD36
CD38
CD3E
CD4
CD40
CD44
CD46
CD47
CD48
CD55
CD58
CD7
CD79B
CD80
CD81
CD82
CD86
CD8A
CD9
CD97
CD99L2
CDAN1
CDC14A
CDC2
CDC20B
CDC25C
CDC27
CDC42
CDC42BPB
CDC42BPG
CDC42EP2
CDC42EP3
CDC42EP5
CDC6
CDC7
CDC73
CDCA2
CDCA4
CDCA5
CDCA7
CDCA7L
CDCP2
CDGAP
CDH1
CDH11
CDH12
CDH13
CDH15
CDH17
CDH18
CDH22
CDH23
CDH3
CDH4
CDH5
CDH7
CDH9
CDK10
CDK11B
CDK12
CDK13
CDK14
CDK15
CDK16
CDK17
CDK19
CDK20
CDK2AP1
CDK5
CDK5R1
CDK5R2
CDK5RAP1
CDK6
CDK7
CDKL2
CDKN1B
CDKN1C
CDKN2AIP
CDKN2BAS
CDKN2C
CDKN3
CDO1
CDON
CDR2
CDR2L
CDRT15
CDRT15P
CDS2
CDSN
CDT1
CDX1
CDX2
CDYL
CDYL2
CEACAM21
CEACAM4
CEACAM6
CEBPA
CEBPE
CEBPG
CEBPZ
CECR1
CECR2
CECR4
CECR5
CELSR3
CEMP1
CENPA
CENPBD1
CENPF
CENPH
CENPK
CENPM
CENPP
CENPT
CENPV
CEP120
CEP164
CEP350
CEP55
CEP57
CEP68
CEP72
CEPT1
CERCAM
CERKL
CES7
CES8
CETN1
CETP
CFB
CFDP1
CFI
CFL2
CFLAR
CFP
CGB
CGB2
CGB8
CGGBP1
CGRRF1
CHADL
CHAF1A
CHCHD3
CHCHD5
CHCHD6
CHD1L
CHD2
CHD3
CHD5
CHD7
CHD8
CHDH
CHEK2
CHFR
CHGB
CHI3L1
CHI3L2
CHIA
CHIC2
CHID1
CHIT1
CHKB-CPT1B
CHL1
CHMP1A
CHMP2A
CHMP2B
CHMP4B
CHMP4C
CHMP6
CHODL
CHP2
CHPF2
CHRDL1
CHRM2
CHRM3
CHRM4
CHRM5
CHRNA10
CHRNA3
CHRNA5
CHRNA6
CHRNA7
CHRNB1
CHRNE
CHRNG
CHST1
CHST10
CHST11
CHST12
CHST13
CHST15
CHST2
CHST3
CHST4
CHST6
CHST7
CHST8
CHST9
CHSY1
CHSY3
CHUK
CIAO1
CIAPIN1
CIB4
CIC
CIDEA
CIDECP
CIITA
CILP
CILP2
CIR1
CISD3
CISH
CIT
CITED1
CITED2
CITED4
CIZ1
CKAP4
CKAP5
CKLF
CLASP1
CLASP2
CLC
CLCN1
CLCN4
CLCN5
CLCN6
CLCN7
CLCNKB
CLDN10
CLDN11
CLDN14
CLDN15
CLDN16
CLDN18
CLDN22
CLDN23
CLDN6
CLDN7
CLDND1
CLEC16A
CLEC17A
CLEC1A
CLEC2A
CLEC2B
CLEC2D
CLEC2L
CLEC3B
CLEC4F
CLEC4G
CLEC4GP1
CLEC9A
CLGN
CLIC1
CLIC2
CLIC3
CLIC5
CLIP1
CLIP2
CLIP3
CLK1
CLK2
CLK4
CLMN
CLN3
CLN5
CLN6
CLN8
CLNK
CLNS1A
CLP1
CLPB
CLPP
CLPS
CLPTM1
CLPTM1L
CLRN1
CLRN2
CLRN3
CLSPN
CLSTN1
CLTB
CLTC
CLU
CLUAP1
CLYBL
CMBL
CMC1
CMIP
CMKLR1
CMPK1
CMTM1
CMTM2
CMTM5
CNBD1
CNDP2
CNFN
CNGA3
CNGB1
CNGB3
CNIH
CNIH2
CNKSR2
CNKSR3
CNN1
CNN3
CNNM1
CNNM2
CNNM3
CNNM4
CNOT1
CNOT10
CNOT3
CNOT6
CNP
CNPY1
CNPY3
CNR1
CNR2
CNRIP1
CNST
CNTD2
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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CNTF
CNTFR
CNTN1
CNTN2
CNTN4
CNTN6
CNTNAP2
CNTNAP4
CNTNAP5
COBL
COBRA1
COCH
COG2
COG3
COG5
COG6
COG7
COG8
COIL
COL11A1
COL11A2
COL12A1
COL13A1
COL14A1
COL15A1
COL16A1
COL17A1
COL18A1
COL19A1
COL1A2
COL20A1
COL22A1
COL23A1
COL24A1
COL25A1
COL27A1
COL29A1
COL2A1
COL3A1
COL4A1
COL4A2
COL4A3BP
COL4A5
COL5A1
COL5A3
COL6A1
COL6A2
COL6A3
COL6A4P2
COL6A6
COL8A2
COL9A1
COL9A3
COLEC11
COLQ
COMMD10
COMMD5
COMMD7
COMMD8
COMP
COMT
COPB2
COPG
COPS3
COPS6
COPS7A
COPS8
COPZ1
COPZ2
COQ10A
COQ2
COQ5
COQ6
CORIN
CORO1B
CORO1C
CORO2A
CORO2B
CORO6
CORO7
CORT
COTL1
COX10
COX18
COX19
COX4NB
COX5A
COX7A2
COX7B2
COX8C
CP
CPA2
CPA4
CPA5
CPAMD8
CPEB1
CPEB2
CPLX1
CPLX2
CPLX3
CPN1
CPN2
CPNE2
CPNE4
CPNE5
CPNE6
CPNE7
CPNE9
CPO
CPPED1
CPSF1
CPSF3L
CPSF4
CPSF4L
CPSF6
CPT1A
CPT1C
CPT2
CPVL
CPXM2
CR1L
CR2
CRABP1
CRABP2
CRADD
CRAMP1L
CRB1
CRB2
CRB3
CRBN
CRCP
CREB1
CREB3
CREB3L1
CREB3L2
CREB3L3
CREB5
CREBBP
CREG1
CRELD1
CRELD2
CRH
CRHR1
CRHR2
CRIM1
CRIP1
CRIP3
CRK
CRLF1
CRMP1
CRNKL1
CROCC
CROCCL1
CROCCL2
CRTAM
CRTC1
CRY1
CRY2
CRYAB
CRYBA2
CRYBB2
CRYBB3
CRYGB
CRYGD
CRYGN
CRYL1
CRYM
CS
CSDAP1
CSDE1
CSE1L
CSF1
CSF2
CSF3
CSF3R
CSGALNACT1
CSH2
CSHL1
CSK
CSMD1
CSMD2
CSMD3
CSNK1A1
CSNK1D
CSNK1E
CSNK1G1
CSNK1G2
CSNK2A1
CSNK2A2
CSNK2B
CSPG4
CSPP1
CSRNP1
CSRP1
CSRP3
CST1
CST11
CST2
CST5
CST7
CST8
CST9L
CSTF2
CSTF3
CT45A6
CT62
CTAGE1
CTBP1
CTBP2
CTDP1
CTDSP1
CTDSPL
CTDSPL2
CTF1
CTGF
CTNNA2
CTNNAL1
CTNNBIP1
CTNND2
CTNS
CTPS2
CTRB2
CTRC
CTRL
CTSB
CTSD
CTSE
CTSG
CTSO
CTSS
CTSZ
CTTN
CTTNBP2
CTTNBP2NL
CTU1
CTXN2
CUBN
CUEDC1
CUEDC2
CUGBP2
CUL1
CUL3
CUL4A
CUL4B
CUL5
CUTA
CUX1
CUX2
CUZD1
CWC22
CWF19L2
CWH43
CX3CR1
CXADR
CXADRP3
CXCL1
CXCL12
CXCL13
CXCL14
CXCL16
CXCL17
CXCL2
CXCL5
CXCL6
CXCL9
CXCR1
CXCR3
CXCR4
CXCR6
CXCR7
CXorf1
CXorf36
CXorf40B
CXorf41
CXorf48
CXorf56
CXorf57
CXorf58
CXorf64
CXXC4
CXXC5
CYB561
CYB561D1
CYB561D2
CYB5B
CYB5R1
CYB5R3
CYBA
CYBB
CYBRD1
CYC1
CYCS
CYFIP1
CYFIP2
CYGB
CYHR1
CYP11A1
CYP11B1
CYP11B2
CYP17A1
CYP19A1
CYP1A1
CYP1A2
CYP1B1
CYP20A1
CYP24A1
CYP26A1
CYP26C1
CYP27A1
CYP2A13
CYP2A7
CYP2D7P1
CYP2F1
CYP2J2
CYP2S1
CYP2U1
CYP2W1
CYP39A1
CYP3A5
CYP46A1
CYP4A22
CYP4F11
CYP4F12
CYP4V2
CYP4X1
CYP7B1
CYS1
CYSLTR2
CYTH1
CYTH2
CYTH3
CYTIP
CYTSA
CYTSB
D2HGDH
DAAM2
DAB1
DAB2
DAB2IP
DACH1
DAG1
DAGLA
DAGLB
DAK
DALRD3
DAND5
DAOA
DAP
DAPK1
DAPK2
DAPK3
DAPP1
DAXX
DAZAP1
DAZL
DBC1
DBF4B
DBI
DBNDD1
DBNDD2
DBNL
DBT
DBX1
DBX2
DCAF12
DCAF12L2
DCAF13
DCAKD
DCBLD1
DCC
DCHS1
DCHS2
DCLRE1B
DCLRE1C
DCP1A
DCP1B
DCPS
DCST1
DCTD
DCTN1
DCTN2
DCTN3
DCTN6
DCTPP1
DCUN1D1
DCUN1D2
DCUN1D3
DCUN1D5
DCXR
DDAH1
DDAH2
DDB2
DDC
DDHD1
DDI2
DDIT4
DDIT4L
DDR1
DDRGK1
DDX11
DDX17
DDX18
DDX20
DDX23
DDX25
DDX26B
DDX31
DDX39
DDX3X
DDX4
DDX46
DDX47
DDX5
DDX50
DDX51
DDX55
DDX60
DEAF1
DECR1
DECR2
DEDD
DEF6
DEF8
DEFA10P
DEFA4
DEFB1
DEFB107A
DEFB110
DEFB119
DEFB122
DEFB124
DEFB125
DEFB126
DEFB133
DEFB136
DEGS1
DEGS2
DEM1
DENND1A
DENND1B
DENND2A
DENND2D
DENND3
DENND4B
DENND5A
DENND5B
DENR
DEPDC1
DEPDC1B
DEPDC6
DERA
DERL1
DES
DFFB
DFNA5
DFNB31
DGAT1
DGAT2
DGCR14
DGCR2
DGCR5
DGCR9
DGKA
DGKB
DGKD
DGKG
DGKH
DGKI
DGKQ
DGKZ
DHCR7
DHDDS
DHDH
DHRS12
DHRS2
DHRS3
DHRS4
DHRS4L1
DHRS7
DHRS7B
DHTKD1
DHX15
DHX16
DHX29
DHX30
DHX32
DHX34
DHX37
DHX38
DHX40P
DHX57
DHX58
DHX9
DIABLO
DIAPH1
DIAPH2
DIAPH3
DIDO1
DIMT1L
DIO3
DIP2C
DIRAS1
DIRAS3
DIRC1
DIRC2
DIRC3
DIS3L
DISP1
DISP2
DIXDC1
DKC1
DKFZP434H168
DKFZP686I15217
DKFZp686O24166
DKFZp761E198
DKK4
DLC1
DLEC1
DLEU7
DLG2
DLG3
DLG4
DLG5
DLGAP1
DLGAP2
DLGAP3
DLGAP4
DLGAP5
DLK1
DLL1
DLL3
DLL4
DLST
DLX1
DLX3
DLX4
DLX5
DLX6AS
DMAP1
DMBT1
DMBX1
DMD
DMKN
DMP1
DMPK
DMRT1
DMRT3
DMRTA2
DMXL1
DNAH10
DNAH11
DNAH14
DNAH17
DNAH2
DNAH5
DNAH7
DNAH9
DNAI2
DNAJA2
DNAJA3
DNAJA4
DNAJB12
DNAJB13
DNAJB2
DNAJB6
DNAJC1
DNAJC10
DNAJC11
DNAJC13
DNAJC14
DNAJC15
DNAJC16
DNAJC17
DNAJC18
DNAJC19
DNAJC2
DNAJC24
DNAJC3
DNAJC30
DNAJC4
DNAJC5
DNAJC5B
DNAJC6
DNAJC7
DNAJC8
DNAJC9
DNALI1
DNASE1L2
DNASE1L3
DNASE2
DND1
DNER
DNHD1
DNM1
DNM1P35
DNM2
DNM3
DNMBP
DNMT1
DNMT3A
DNMT3B
DNPEP
DNTT
DNTTIP2
DOC2A
DOC2B
DOCK1
DOCK10
DOCK2
DOCK3
DOCK4
DOCK5
DOCK9
DOK1
DOK2
DOK3
DOK5
DOK6
DOK7
DOLPP1
DOM3Z
DONSON
DOPEY1
DOPEY2
DOT1L
DPCR1
DPEP1
DPEP2
DPF3
DPH2
DPP10
DPP4
DPP6
DPP8
DPP9
DPPA3
DPPA4
DPT
DPY19L1
DPY19L2P4
DPYD
DPYSL2
DPYSL4
DPYSL5
DQX1
DR1
DRAM1
DRAM2
DRD1
DRD2
DRD4
DRG1
DRG2
DRP2
DSC3
DSCAM
DSCAML1
DSCC1
DSCR8
DSE
DSG4
DSN1
DSP
DSPP
DST
DSTN
DSTYK
DTHD1
DTNA
DTNB
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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DTNBP1
DTX1
DTX4
DTYMK
DULLARD
DUOX1
DUS2L
DUS3L
DUSP1
DUSP10
DUSP11
DUSP16
DUSP19
DUSP2
DUSP22
DUSP26
DUSP27
DUSP28
DUSP3
DUSP4
DUSP5
DUSP5P
DUSP6
DUXA
DVL1
DYDC2
DYNC1H1
DYNC1I1
DYNC1LI2
DYNC2H1
DYNLL1
DYNLL2
DYNLRB2
DYNLT3
DYRK1B
DYRK2
DYRK3
DYSF
DZIP1L
E2F2
E2F7
E2F8
E4F1
EARS2
EBAG9
EBF1
EBF3
EBF4
EBP
ECD
ECE1
ECE2
ECHDC1
ECHDC2
ECHDC3
ECSCR
ECSIT
EDA
EDAR
EDC3
EDC4
EDEM2
EDEM3
EDF1
EDIL3
EDN1
EDN2
EDN3
EDNRB
EED
EEF1A2
EEF1D
EEF1DP3
EEF2
EEF2K
EEFSEC
EFCAB1
EFCAB2
EFCAB3
EFCAB4A
EFCAB4B
EFCAB5
EFCAB6
EFCAB8
EFEMP1
EFEMP2
EFHC1
EFHC2
EFHD1
EFHD2
EFNA2
EFNA3
EFNA4
EFNA5
EFNB1
EFNB3
EFR3A
EFR3B
EFS
EGF
EGFL6
EGFL7
EGFL8
EGFLAM
EGFR
EGLN1
EHBP1
EHBP1L1
EHD1
EHD2
EHD3
EHD4
EHF
EHMT1
EHMT2
EI24
EID3
EIF2AK2
EIF2AK3
EIF2AK4
EIF2B2
EIF2B4
EIF2B5
EIF2C1
EIF2C2
EIF2S3
EIF3A
EIF3B
EIF3D
EIF3E
EIF3G
EIF3I
EIF3K
EIF3L
EIF3M
EIF4A1
EIF4A3
EIF4E3
EIF4EBP1
EIF4EBP3
EIF4ENIF1
EIF4G1
EIF4G2
EIF4H
EIF5
EIF5A
EIF5A2
EIF5AL1
EIF5B
ELAC1
ELAC2
ELANE
ELAVL1
ELAVL3
ELAVL4
ELF1
ELF2
ELF4
ELF5
ELFN1
ELFN2
ELK3
ELK4
ELL
ELL2
ELMO1
ELMO2
ELMO3
ELMOD1
ELMOD2
ELMOD3
ELOF1
ELOVL1
ELOVL3
ELOVL4
ELOVL5
ELOVL6
ELP2P
ELP4
ELSPBP1
EMB
EME1
EMID1
EMID2
EMILIN2
EML2
EML6
EMP1
EMP2
EMP3
EMR2
EMX1
EMX2
EMX2OS
EN1
EN2
ENAH
ENC1
ENG
ENGASE
ENHO
ENOSF1
ENOX1
ENOX2
ENPP1
ENPP3
ENPP4
ENPP5
ENPP6
ENPP7
ENTPD1
ENTPD2
ENTPD3
ENTPD6
ENTPD7
ENTPD8
EOMES
EP300
EP400
EP400NL
EPAS1
EPB41
EPB41L1
EPB41L2
EPB41L3
EPB41L4A
EPB42
EPB49
EPC2
EPCAM
EPDR1
EPHA1
EPHA10
EPHA4
EPHA5
EPHA8
EPHB2
EPHB3
EPHB6
EPHX1
EPHX3
EPM2A
EPN1
EPN2
EPOR
EPPK1
EPRS
EPS15L1
EPS8L1
EPS8L2
EPSTI1
EPX
ERAL1
ERAS
ERBB2
ERBB2IP
ERBB3
ERBB4
ERC1
ERC2
ERCC1
ERCC2
ERCC4
ERCC6
ERCC8
ERGIC1
ERGIC2
ERH
ERI2
ERI3
ERICH1
ERLIN1
ERMAP
ERMN
ERN1
ERN2
ERRFI1
ESAM
ESPN
ESPNL
ESPNP
ESR1
ESR2
ESRP1
ESRP2
ESRRB
ESRRG
ESX1
ESYT2
ETF1
ETFA
ETNK2
ETS1
ETV3
ETV4
ETV5
ETV6
EVC2
EVI5
EVI5L
EVL
EVPL
EVX1
EVX2
EWSR1
EXD2
EXD3
EXO1
EXOC2
EXOC3
EXOC3L
EXOC3L2
EXOC4
EXOC8
EXOSC10
EXOSC7
EXT1
EXT2
EXTL3
EYA4
EYS
EZH1
EZR
F10
F11R
F12
F2RL1
F2RL3
F7
F8
F9
FAAH
FABP1
FABP2
FABP3
FABP6
FABP9
FADS2
FAH
FAHD2A
FAHD2B
FAIM
FAIM3
FAM100B
FAM101B
FAM102B
FAM103A1
FAM105A
FAM107B
FAM109B
FAM110A
FAM111B
FAM113B
FAM116A
FAM117A
FAM118A
FAM120A
FAM122B
FAM122C
FAM123B
FAM123C
FAM124A
FAM125B
FAM126A
FAM126B
FAM127B
FAM128A
FAM129A
FAM129B
FAM129C
FAM131A
FAM131C
FAM132A
FAM134B
FAM136A
FAM13A
FAM149A
FAM151B
FAM153B
FAM155A
FAM155B
FAM159A
FAM159B
FAM160A1
FAM160A2
FAM160B1
FAM160B2
FAM162A
FAM163A
FAM164C
FAM166B
FAM167A
FAM167B
FAM168A
FAM168B
FAM169B
FAM170A
FAM170B
FAM171A1
FAM171A2
FAM172A
FAM173B
FAM176A
FAM177B
FAM178B
FAM179A
FAM180B
FAM181A
FAM181B
FAM184A
FAM184B
FAM185A
FAM186A
FAM188B
FAM189A1
FAM18A
FAM190A
FAM190B
FAM192A
FAM193B
FAM195A
FAM195B
FAM196B
FAM19A1
FAM19A2
FAM19A3
FAM19A4
FAM19A5
FAM20A
FAM20B
FAM20C
FAM21A
FAM22D
FAM25A
FAM26D
FAM27C
FAM27L
FAM32A
FAM36A
FAM38A
FAM3B
FAM3C
FAM3D
FAM40A
FAM41C
FAM43A
FAM43B
FAM45B
FAM46A
FAM46B
FAM46C
FAM47A
FAM47E
FAM48A
FAM49A
FAM50B
FAM53B
FAM53C
FAM54A
FAM55C
FAM55D
FAM57B
FAM58A
FAM58B
FAM59A
FAM5B
FAM60A
FAM63A
FAM63B
FAM64A
FAM65A
FAM65B
FAM65C
FAM66B
FAM69A
FAM69C
FAM71E2
FAM73B
FAM76A
FAM78A
FAM81A
FAM82A1
FAM82A2
FAM82B
FAM83A
FAM83B
FAM83H
FAM84B
FAM89A
FAM91A1
FAM92A1
FAM96A
FAM96B
FAM98C
FAM9A
FANCA
FANCC
FANCD2
FANCI
FANK1
FAP
FAR2
FARP1
FARS2
FARSA
FARSB
FAS
FASN
FASTK
FASTKD1
FAT1
FAT3
FATE1
FBLIM1
FBLL1
FBLN1
FBLN2
FBLN7
FBN1
FBN2
FBN3
FBP1
FBRS
FBRSL1
FBXL12
FBXL15
FBXL16
FBXL17
FBXL18
FBXL19
FBXL2
FBXL20
FBXL21
FBXL3
FBXL6
FBXL7
FBXL8
FBXO11
FBXO16
FBXO17
FBXO21
FBXO24
FBXO25
FBXO28
FBXO3
FBXO31
FBXO32
FBXO34
FBXO4
FBXO41
FBXO42
FBXO44
FBXO45
FBXO46
FBXO6
FBXO8
FBXO9
FBXW11
FBXW7
FBXW8
FBXW9
FCAMR
FCAR
FCER2
FCGBP
FCGR2B
FCGR3A
FCGRT
FCHO1
FCHSD1
FCHSD2
FCN2
FCRL2
FCRL4
FCRLA
FDFT1
FDX1
FDXACB1
FDXR
FECH
FEM1A
FEM1B
FEN1
FER
FER1L5
FERMT2
FERMT3
FES
FEV
FEZ1
FEZ2
FEZF2
FGB
FGD1
FGD4
FGD6
FGF1
FGF11
FGF12
FGF13
FGF14
FGF17
FGF20
FGF22
FGF23
FGF3
FGF4
FGF8
FGF9
FGFBP1
FGFR1
FGFR1OP
FGFR2
FGFR3
FGFR4
FGFRL1
FGGY
FGR
FHAD1
FHDC1
FHIT
FHL1
FHL2
FHL3
FHL5
FHOD1
FHOD3
FIBIN
FICD
FIGLA
FIGN
FIS1
FITM1
FIZ1
FKBP10
FKBP14
FKBP15
FKBP1A
FKBP5
FKBP9L
FKBPL
FLAD1
FLCN
FLI1
FLII
FLJ10357
FLJ10661
FLJ11235
FLJ12825
FLJ13197
FLJ22536
FLJ23834
FLJ25006
FLJ26850
FLJ30058
FLJ31306
FLJ32063
FLJ32810
FLJ33360
FLJ35024
FLJ35390
FLJ36031
FLJ37453
FLJ39582
FLJ39609
FLJ39653
FLJ40330
FLJ40434
FLJ41350
FLJ41941
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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FLJ42709
FLJ43663
FLJ43950
FLJ44606
FLJ44817
FLJ45079
FLJ45244
FLJ45340
FLJ45983
FLJ90757
FLNA
FLNB
FLNC
FLOT1
FLOT2
FLRT2
FLRT3
FLT1
FLT3
FLT3LG
FLT4
FLVCR1
FLVCR2
FLYWCH1
FLYWCH2
FMN2
FMNL1
FMNL2
FMO1
FMO3
FMR1NB
FN3KRP
FNBP1
FNDC1
FNDC3A
FNDC3B
FNDC4
FNDC7
FNIP1
FNIP2
FNTA
FOLH1
FOLH1B
FOLR2
FOLR3
FOS
FOSB
FOSL1
FOSL2
FOXA3
FOXB2
FOXC1
FOXC2
FOXD3
FOXE3
FOXF1
FOXF2
FOXG1
FOXH1
FOXI2
FOXI3
FOXJ2
FOXJ3
FOXK1
FOXK2
FOXM1
FOXN3
FOXN4
FOXO1
FOXO3
FOXP1
FOXP2
FOXP3
FOXP4
FOXR1
FPR1
FPR2
FRAS1
FRAT1
FRAT2
FREM2
FREM3
FREQ
FRK
FRMD1
FRMD4A
FRMD4B
FRMD5
FRMPD1
FRMPD2
FRMPD4
FRS2
FRS3
FRY
FRZB
FSCB
FSCN2
FSD1
FSTL1
FSTL4
FTH1
FTHL17
FTL
FTMT
FTSJ1
FTSJD1
FUBP3
FUCA2
FUK
FUNDC2
FUS
FUT10
FUT11
FUT3
FUT4
FUT5
FUT6
FUT8
FUZ
FXN
FXR1
FXYD1
FXYD4
FXYD5
FXYD6
FYCO1
FYN
FZD2
FZD3
FZD4
FZD5
FZD7
FZD8
FZD9
FZR1
G0S2
G2E3
G3BP1
G3BP2
G6PC
G6PC3
GAA
GAB4
GABARAP
GABBR1
GABBR2
GABPB2
GABRA1
GABRA2
GABRA3
GABRA5
GABRA6
GABRB1
GABRB2
GABRB3
GABRD
GABRG2
GABRG3
GABRP
GABRQ
GABRR1
GABRR2
GAD1
GADD45A
GADD45GIP1
GAGE10
GAGE2A
GAK
GAL
GAL3ST4
GALE
GALK1
GALK2
GALNS
GALNT10
GALNT12
GALNT14
GALNT2
GALNT5
GALNT7
GALNT9
GALNTL2
GALNTL4
GALNTL5
GALNTL6
GALP
GANAB
GAP43
GAPVD1
GAR1
GARNL3
GARS
GAS1
GAS2L2
GAS7
GAST
GATA1
GATA2
GATA3
GATA4
GATA5
GATA6
GATAD2A
GATAD2B
GATM
GATS
GATSL1
GBA
GBE1
GBF1
GBGT1
GBP4
GBP7
GBX1
GC
GCA
GCAT
GCDH
GCET2
GCG
GCK
GCLC
GCLM
GCM1
GCM2
GCN1L1
GCNT2
GCNT7
GDAP1
GDAP1L1
GDAP2
GDE1
GDEP
GDF1
GDF2
GDF5
GDF6
GDF7
GDF9
GDI1
GDNF
GDPD1
GDPD5
GEFT
GEM
GEN1
GFAP
GFI1
GFOD2
GFPT1
GFPT2
GFRA1
GFRA2
GFRA3
GFRA4
GGA2
GGCX
GGN
GGNBP2
GGPS1
GGT1
GGT7
GGT8P
GHRL
GHRLOS
GIGYF1
GIMAP1
GIMAP4
GIMAP8
GIN1
GINS1
GIPC1
GIPC3
GIPR
GIT1
GIT2
GJA3
GJA4
GJA5
GJB5
GJB6
GJC1
GJD3
GJD4
GK5
GLA
GLB1L
GLB1L3
GLDC
GLDN
GLG1
GLI2
GLI3
GLIS1
GLIS2
GLIS3
GLOD4
GLOD5
GLP2R
GLRA1
GLRA3
GLRX2
GLRX3
GLRX5
GLS2
GLT1D1
GLT25D1
GLT25D2
GLT8D1
GLTP
GLTPD1
GLTPD2
GLTSCR1
GLUD2
GLUL
GLYATL3
GLYCTK
GLYR1
GM2A
GMCL1
GMCL1L
GMDS
GMEB1
GMEB2
GMFB
GML
GMPR
GMPR2
GMPS
GNA11
GNA12
GNAL
GNAO1
GNAQ
GNAS
GNAT1
GNAT2
GNAZ
GNB1
GNB1L
GNB2
GNB2L1
GNB3
GNB5
GNG12
GNG2
GNG4
GNG7
GNL1
GNL2
GNL3
GNL3L
GNLY
GNMT
GNPDA1
GNPTAB
GNRHR
GOLGA2
GOLGA2L1
GOLGA3
GOLGA4
GOLGA6A
GOLGA7B
GOLGA8B
GOLIM4
GOLM1
GOLPH3
GOLSYN
GOLT1A
GOPC
GORASP1
GOSR2
GOT1
GP1BB
GP2
GP5
GP9
GPATCH4
GPBAR1
GPBP1L1
GPC2
GPC3
GPC4
GPC6
GPD1
GPD1L
GPD2
GPHN
GPI
GPIHBP1
GPKOW
GPLD1
GPM6A
GPN1
GPN2
GPNMB
GPR101
GPR109A
GPR111
GPR114
GPR120
GPR123
GPR124
GPR132
GPR133
GPR135
GPR137
GPR137B
GPR142
GPR143
GPR155
GPR156
GPR157
GPR158
GPR160
GPR161
GPR172A
GPR173
GPR176
GPR177
GPR182
GPR183
GPR19
GPR25
GPR27
GPR3
GPR31
GPR35
GPR39
GPR4
GPR45
GPR50
GPR56
GPR62
GPR63
GPR68
GPR77
GPR78
GPR85
GPR88
GPR89B
GPR98
GPRASP2
GPRC5B
GPRC5C
GPRIN2
GPSM1
GPSM2
GPSM3
GPT
GPT2
GPX1
GPX6
GPX7
GRAMD1A
GRAMD1B
GRAMD3
GRAMD4
GRAPL
GRASP
GRB10
GRB2
GRB7
GREM2
GRHL1
GRHL2
GRHL3
GRIA2
GRID1
GRID2
GRID2IP
GRIK1
GRIK3
GRIK4
GRIN1
GRIN2A
GRIN2B
GRIN2C
GRIN2D
GRIN3A
GRINA
GRIP1
GRIP2
GRK1
GRK4
GRK5
GRK6
GRK7
GRM1
GRM4
GRM6
GRM7
GRM8
GRP
GRPR
GRRP1
GRSF1
GRTP1
GRWD1
GRXCR2
GSC
GSC2
GSDMB
GSDMD
GSG1
GSG1L
GSK3A
GSN
GSPT1
GSR
GSTA4
GSTCD
GSTM3
GSTO2
GSX1
GTDC1
GTF2A1
GTF2A2
GTF2B
GTF2E2
GTF2F1
GTF2F2
GTF2H3
GTF2H4
GTF2H5
GTF2IRD2B
GTF3A
GTF3C1
GTF3C2
GTPBP1
GTPBP10
GTPBP3
GTPBP8
GUCA2B
GUCY1A2
GUCY1B2
GUCY1B3
GUCY2C
GUCY2D
GUCY2E
GUF1
GUK1
GULP1
GUSB
GUSBL1
GXYLT1
GXYLT2
GYG1
GYLTL1B
GYPA
GYPC
GYS1
GZMM
H19
H1F0
H1FNT
H1FX
H2AFJ
H2AFY2
H3F3B
H6PD
HABP2
HADH
HAGH
HAL
HAMP
HAND1
HAND2
HAP1
HAPLN1
HAPLN2
HAPLN3
HAPLN4
HAR1B
HARS2
HAS1
HAS2AS
HAS3
HAT1
HAUS2
HAUS3
HAUS4
HAUS5
HAX1
HBA1
HBB
HBM
HBP1
HBS1L
HCCA2
HCCS
HCFC1
HCFC1R1
HCG18
HCG22
HCG27
HCG2P7
HCG4
HCG9
HCK
HCLS1
HCN1
HCN3
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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HCN4
HCRT
HCRTR2
HDAC1
HDAC11
HDAC2
HDAC3
HDAC4
HDAC6
HDAC7
HDAC9
HDC
HDGF
HDGF2
HDGFL1
HDGFRP3
HDLBP
HDX
HEATR1
HEATR2
HEATR7A
HECA
HECW1
HECW2
HEG1
HELLS
HELT
HELZ
HEMK1
HEPACAM
HEPH
HEPHL1
HERC2
HERC3
HERC5
HES1
HES3
HES7
HEXDC
HEXIM1
HEY2
HEYL
HFM1
HGC6.3
HGS
HGSNAT
HHAT
HHEX
HHIPL1
HIAT1
HIBADH
HIC1
HIC2
HIF1A
HIGD1A
HIGD1B
HINFP
HINT1
HINT2
HIP1
HIP1R
HIPK1
HIPK2
HIPK3
HIPK4
HIRIP3
HIST1H1A
HIST1H1D
HIST1H2AI
HIST1H2AM
HIST1H2BC
HIST1H2BD
HIST1H2BE
HIST1H2BH
HIST1H2BK
HIST1H2BN
HIST1H3A
HIST1H3D
HIST1H3E
HIST1H3G
HIST1H3H
HIST1H4D
HIST1H4G
HIST1H4L
HIST2H2AB
HIST2H2AC
HIST2H2BF
HIVEP1
HIVEP2
HIVEP3
HK1
HK2
HK3
HKDC1
HLA-A
HLA-B
HLA-DMB
HLA-DOA
HLA-DOB
HLA-DPA1
HLA-DPB1
HLA-DPB2
HLA-DQA2
HLA-DQB1
HLA-DQB2
HLA-DRA
HLA-E
HLA-F
HLA-G
HLA-H
HLA-J
HLA-L
HLTF
HLX
HM13
HMBOX1
HMBS
HMCN1
HMG20A
HMGA2
HMGB1
HMGB2
HMGB3
HMGB3L1
HMGCLL1
HMGN4
HMHA1
HMHB1
HMOX2
HMP19
HMSD
HMX2
HNF1B
HNF4A
HNMT
HNRNPA1
HNRNPA1L2
HNRNPA2B1
HNRNPA3
HNRNPAB
HNRNPC
HNRNPD
HNRNPF
HNRNPH1
HNRNPK
HNRNPU
HNRNPUL1
HNRPA1L-2
HOMER3
HOOK1
HOOK3
HOTAIR
HOXA1
HOXA10
HOXA11AS
HOXA13
HOXA2
HOXA3
HOXA4
HOXA7
HOXB13
HOXB2
HOXB3
HOXB7
HOXB8
HOXC10
HOXC11
HOXC12
HOXC13
HOXC4
HOXC9
HOXD1
HOXD10
HOXD13
HOXD3
HOXD4
HOXD8
HOXD9
HPCA
HPCAL4
HPDL
HPRT1
HPS3
HPSE2
HPYR1
HRASLS5
HRC
HRH1
HRH3
HRK
HRNBP3
HS2ST1
HS3ST1
HS3ST2
HS3ST3A1
HS3ST3B1
HS3ST4
HS3ST5
HS6ST1
HS6ST2
HS6ST3
HSBP1
HSBP1L1
HSD11B1
HSD11B1L
HSD11B2
HSD17B1
HSD17B10
HSD17B13
HSD17B2
HSD17B4
HSD3B2
HSD3B7
HSF1
HSF4
HSF5
HSFYP1
HSP90AA1
HSP90AB1
HSPA12B
HSPA13
HSPA1A
HSPA1B
HSPA1L
HSPA2
HSPA4
HSPA6
HSPA7
HSPA8
HSPB1
HSPB2
HSPB6
HSPB8
HSPBAP1
HSPBP1
HSPC072
HSPC159
HSPD1
HSPE1
HSPG2
HTATIP2
HTATSF1
HTR1E
HTR1F
HTR2A
HTR2B
HTR2C
HTR3A
HTR3C
HTR3D
HTR5A
HTR6
HTR7P
HTRA1
HTRA3
HTT
HULC
HUWE1
HYAL1
HYAL2
HYAL3
HYDIN
HYLS1
HYMAI
IAH1
IARS2
IBSP
IBTK
ICA1
ICA1L
ICAM3
ICAM5
ICK
ICOS
ID1
ID4
IDH1
IDH3G
IDO2
IDS
IDUA
IER2
IER3
IER5
IER5L
IFFO1
IFFO2
IFI27
IFI27L1
IFI27L2
IFI44L
IFIH1
IFIT1
IFIT5
IFLTD1
IFNA8
IFNAR1
IFRD2
IFT122
IFT140
IFT74
IFT88
IGDCC3
IGDCC4
IGF1R
IGF2BP1
IGF2BP2
IGF2BP3
IGFBP2
IGFBP3
IGFBP4
IGFBP5
IGFBP6
IGFBP7
IGFL2
IGFN1
IGHMBP2
IGLL3
IGLON5
IGSF10
IGSF11
IGSF21
IGSF22
IGSF3
IGSF8
IGSF9
IGSF9B
IHH
IKBIP
IKBKE
IKBKG
IKZF1
IKZF5
IL10RB
IL11
IL12A
IL12B
IL12RB2
IL13
IL13RA1
IL15
IL15RA
IL16
IL17B
IL17C
IL17F
IL17RA
IL17RC
IL17RD
IL17RE
IL18BP
IL19
IL1A
IL1B
IL1R2
IL1RAP
IL1RAPL1
IL1RL1
IL1RL2
IL20
IL20RA
IL21R
IL23A
IL27
IL27RA
IL28RA
IL2RB
IL31
IL4
IL4I1
IL4R
IL5RA
IL6
IL6R
IL7
IL9
ILDR1
ILDR2
ILF2
ILF3
ILKAP
IMMP2L
IMP3
IMPA2
IMPG1
IMPG2
INADL
INCA1
INF2
ING1
ING5
INHBC
INMT
INO80
INO80D
INO80E
INPP1
INPP4A
INPP4B
INPP5A
INPP5B
INPP5D
INPP5F
INPP5K
INPPL1
INSC
INSIG1
INS-IGF2
INSL3
INSL6
INSM1
INSR
INTS1
INTS12
INTS3
INTS4
INTS4L1
INTS5
INTS6
INTS7
INTS8
IP6K1
IP6K3
IPCEF1
IPMK
IPO11
IPO13
IPO4
IPO9
IPW
IQCA1
IQCB1
IQCC
IQCD
IQCE
IQCF6
IQCG
IQCJ
IQGAP2
IQSEC1
IQSEC2
IQSEC3
IQUB
IRAK1BP1
IRAK2
IRAK3
IREB2
IRF2
IRF2BP1
IRF2BP2
IRF3
IRF4
IRF5
IRF6
IRF7
IRF8
IRS1
IRS2
IRS4
IRX1
IRX2
IRX3
IRX4
IRX5
ISG20
ISL1
ISL2
ISLR2
ISM1
ISPD
ITFG3
ITGA1
ITGA2
ITGA2B
ITGA5
ITGA7
ITGA8
ITGA9
ITGAE
ITGAL
ITGAM
ITGB1
ITGB1BP2
ITGB1BP3
ITGB2
ITGB3
ITGB4
ITGB6
ITGB7
ITGB8
ITIH5
ITIH5L
ITK
ITLN1
ITM2A
ITM2B
ITM2C
ITPK1
ITPKA
ITPKB
ITPR1
ITPR2
ITPR3
ITPRIP
ITSN1
ITSN2
IVD
IYD
JAG1
JAG2
JAK1
JAK2
JAK3
JAKMIP1
JAKMIP2
JAKMIP3
JAM3
JARID2
JAZF1
JDP2
JMJD1C
JMJD5
J M J D 7 -
PLA2G4B
JOSD1
JPH2
JPH3
JRK
JRKL
JUB
JUN
JUP
KAAG1
KALRN
KANK2
KANK3
KAT2A
KAT2B
KAT5
KATNAL1
KATNAL2
KAZALD1
KBTBD10
KBTBD11
KBTBD3
KBTBD5
KCNA10
KCNA2
KCNA3
KCNA4
KCNA7
KCNAB2
KCNB1
KCNC1
KCNC2
KCNC3
KCNC4
KCND3
KCNE1
KCNE1L
KCNF1
KCNG2
KCNG3
KCNG4
KCNH1
KCNH2
KCNH3
KCNH4
KCNH6
KCNIP1
KCNIP2
KCNIP3
KCNIP4
KCNJ1
KCNJ10
KCNJ11
KCNJ12
KCNJ14
KCNJ15
KCNJ16
KCNJ2
KCNJ5
KCNJ6
KCNJ8
KCNJ9
KCNK1
KCNK12
KCNK13
KCNK16
KCNK17
KCNK2
KCNK3
KCNK4
KCNK7
KCNK9
KCNMA1
KCNMB2
KCNMB3
KCNMB4
KCNN1
KCNN2
KCNN3
KCNN4
KCNQ1
KCNQ1OT1
KCNQ2
KCNQ3
KCNQ4
KCNQ5
KCNRG
KCNS1
KCNS3
KCNT1
KCP
KCTD1
KCTD11
KCTD12
KCTD13
KCTD15
KCTD18
KCTD2
KCTD5
KCTD6
KCTD8
KDM1B
KDM2A
KDM2B
KDM4A
KDM4B
KDM6A
KDM6B
KDSR
KEAP1
KEL
KHDC1
KHDC1L
KHDRBS2
KHK
KHNYN
KHSRP
KIAA0020
KIAA0040
KIAA0090
KIAA0101
KIAA0146
KIAA0182
KIAA0195
KIAA0196
KIAA0226
KIAA0247
KIAA0284
KIAA0319L
KIAA0355
KIAA0391
KIAA0406
KIAA0415
KIAA0430
KIAA0467
KIAA0494
KIAA0495
KIAA0528
KIAA0556
KIAA0562
KIAA0564
KIAA0586
KIAA0652
KIAA0664
KIAA0892
KIAA0895
KIAA0895L
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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KIAA0907
KIAA0913
KIAA0922
KIAA1009
KIAA1012
KIAA1024
KIAA1026
KIAA1147
KIAA1161
KIAA1191
KIAA1199
KIAA1211
KIAA1217
KIAA1244
KIAA1257
KIAA1274
KIAA1279
KIAA1310
KIAA1324
KIAA1324L
KIAA1377
KIAA1407
KIAA1409
KIAA1429
KIAA1467
KIAA1468
KIAA1486
KIAA1529
KIAA1530
KIAA1543
KIAA1549
KIAA1598
KIAA1614
KIAA1632
KIAA1688
KIAA1712
KIAA1737
KIAA1751
KIAA1841
KIAA1875
KIAA1949
KIAA1984
KIAA2013
KIAA2018
KIDINS220
KIF11
KIF13A
KIF13B
KIF14
KIF15
KIF16B
KIF18B
KIF19
KIF1A
KIF1B
KIF1C
KIF20B
KIF21B
KIF25
KIF26A
KIF26B
KIF3A
KIF3C
KIF4A
KIF5A
KIF5C
KIF6
KIF7
KIFAP3
KIFC1
KIFC3
KIR3DL2
KIR3DL3
KIRREL
KIRREL2
KIRREL3
KISS1
KIT
KITLG
KLB
KLC2
KLC4
KLF1
KLF10
KLF12
KLF13
KLF14
KLF15
KLF16
KLF2
KLF3
KLF6
KLF7
KLF9
KLHDC1
KLHDC10
KLHDC3
KLHDC7B
KLHDC8A
KLHDC9
KLHL10
KLHL13
KLHL14
KLHL15
KLHL17
KLHL2
KLHL21
KLHL23
KLHL25
KLHL26
KLHL29
KLHL30
KLHL32
KLHL33
KLHL34
KLHL35
KLHL7
KLHL8
KLK10
KLK15
KLKBL4
KLRAQ1
KLRG2
KMO
KNDC1
KNG1
KPNA2
KPNA4
KPNA6
KPNA7
KPNB1
KPTN
KRAS
KRBA1
KRBA2
KRCC1
KREMEN1
KRR1
KRT2
KRT23
KRT24
KRT26
KRT28
KRT3
KRT31
KRT33A
KRT39
KRT6A
KRT7
KRT72
KRT75
KRT79
KRT81
KRT86
KRTAP10-3
KRTAP12-4
KRTAP1-3
KRTAP13-1
KRTAP15-1
KRTAP19-1
KRTAP19-5
KRTAP20-1
KRTAP20-2
KRTAP24-1
KRTAP4-1
KRTAP5-9
KRTAP6-3
KRTAP9-2
KRTDAP
KSR1
KSR2
KTN1
KY
L1CAM
L1TD1
L3MBTL
LACTB
LAG3
LAIR1
LAMA3
LAMA4
LAMA5
LAMB1
LAMB2
LAMB3
LAMB4
LAMC1
LAMC2
LAMC3
LAMP2
LAMP3
LANCL2
LANCL3
LAPTM4A
LAPTM4B
LAPTM5
LARP1
LARP4B
LARS2
LASP1
LASS1
LASS2
LASS4
LASS5
LASS6
LAT
LAT2
LATS1
LATS2
LAYN
LBP
LBX1
LBX2
LBXCOR1
LCAT
LCE1E
LCE3E
LCK
LCLAT1
LCMT1
LCN10
LCN15
LCN8
LCOR
LCP1
LCTL
LDB1
LDB2
LDHA
LDHAL6B
LDHB
LDHC
LDLR
LDLRAD2
LDLRAD3
LDLRAP1
LDOC1L
LEAP2
LECT1
LEF1
LEFTY1
LEFTY2
LEMD3
LENG1
LENG8
LEO1
LEP
LEPR
LEPRE1
LEPREL1
LEPROTL1
LETM1
LETM2
LETMD1
LEUTX
LFNG
LGALS12
LGALS13
LGALS3
LGALS7
LGALS7B
LGALS8
LGALS9C
LGI2
LGI3
LGI4
LGMN
LGR4
LGR5
LGR6
LGTN
LHB
LHFP
LHFPL2
LHFPL3
LHFPL5
LHPP
LHX1
LHX2
LHX4
LHX6
LHX8
LHX9
LIFR
LIG4
LILRA2
LILRA4
LILRA6
LILRB1
LILRB3
LILRP2
LIMA1
LIMCH1
LIMD1
LIMD2
LIMK2
LIMS2
LIN28
LIN37
LIN7A
LINGO1
LINGO3
LINS1
LIPA
LIPE
LIPH
LITAF
LIX1
LIX1L
LLGL2
LMAN2
LMBR1L
LMBRD1
LMF1
LMNA
LMO2
LMO3
LMO4
LMO7
LMOD2
LMTK2
LMTK3
LMX1A
LMX1B
LNP1
LNPEP
LNX1
LOC100101938
LOC100125556
LOC100128164
LOC100128239
LOC100128292
LOC100128542
LOC100128640
LOC100128675
LOC100128731
LOC100128788
LOC100128811
LOC100128977
LOC100129550
LOC100129637
LOC100129716
LOC100130093
LOC100130274
LOC100130331
LOC100130581
LOC100130691
LOC100130776
LOC100130872
LOC100130872-
SPON2
LOC100130987
LOC100132215
LOC100132963
LOC100133091
LOC100133161
LOC100133308
LOC100133612
LOC100133893
LOC100133957
LOC100133991
LOC100134259
LOC100134368
LOC100134713
LOC100134868
LOC100144603
LOC100144604
LOC100169752
LOC100188947
LOC100188949
LOC100190939
LOC100192378
LOC100268168
LOC100271715
LOC100271836
LOC100272217
LOC100286844
LOC100302401
LOC100302652
LOC100329109
LOC113230
LOC116437
LOC121952
LOC127841
LOC134466
LOC139201
LOC144776
LOC145474
LOC145663
LOC145814
LOC145837
LOC145845
LOC146880
LOC148696
LOC150185
LOC150527
LOC150568
LOC150622
LOC151174
LOC151534
LOC152217
LOC153328
LOC158376
LOC221710
LOC222699
LOC253724
LOC254559
LOC256880
LOC257358
LOC283050
LOC283999
LOC284009
LOC284688
LOC284749
LOC284788
LOC284798
LOC284805
LOC285033
LOC285205
LOC285375
LOC285401
LOC285419
LOC285456
LOC285501
LOC285548
LOC285550
LOC285593
LOC285692
LOC285780
LOC285796
LOC285830
LOC285954
LOC286016
LOC286238
LOC338799
LOC339290
LOC339524
LOC339674
LOC340074
LOC340094
LOC344595
LOC344967
LOC375196
LOC387646
LOC388428
LOC388789
LOC388796
LOC389332
LOC389333
LOC389493
LOC389634
LOC390594
LOC390858
LOC391322
LOC399959
LOC400657
LOC400696
LOC400759
LOC400794
LOC400804
LOC400927
LOC400931
LOC400940
LOC401010
LOC401097
LOC401127
LOC401463
LOC404266
LOC407835
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
172  |  Appendix 4.1
LOC440173
LOC440461
LOC440839
LOC441046
LOC441204
LOC441208
LOC442308
LOC492303
LOC494141
LOC541473
LOC554203
LOC619207
LOC641367
LOC642006
LOC642587
LOC642597
LOC643719
LOC643837
LOC644538
LOC644649
LOC645323
LOC645961
LOC646498
LOC646627
LOC646762
LOC646982
LOC647288
LOC647979
LOC648691
LOC650368
LOC650623
LOC651250
LOC652276
LOC653113
LOC727677
LOC728264
LOC728276
LOC728392
LOC728448
LOC728554
LOC728613
LOC728743
LOC728855
LOC729080
LOC729082
LOC729375
LOC729384
LOC729991-MEF2B
LOC730668
LOC731275
LOC731779
LOC731789
LOC84740
LOC84931
LOC90246
LOC91316
LOC91948
LOH12CR1
LONP1
LONRF1
LONRF3
LOX
LOXHD1
LOXL1
LOXL2
LOXL3
LPA
LPAR1
LPAR3
LPAR4
LPAR5
LPAR6
LPCAT1
LPGAT1
LPHN1
LPHN2
LPHN3
LPIN1
LPIN2
LPL
LPO
LPP
LPPR2
LPPR3
LPPR4
LPPR5
LRAT
LRCH1
LRCH3
LRDD
LRFN5
LRG1
LRIG1
LRIG2
LRIG3
LRIT2
LRP1
LRP11
LRP3
LRP4
LRP5
LRP5L
LRP6
LRP8
LRPAP1
LRPPRC
LRRC1
LRRC10
LRRC10B
LRRC14B
LRRC15
LRRC16A
LRRC18
LRRC20
LRRC23
LRRC24
LRRC27
LRRC28
LRRC29
LRRC3
LRRC30
LRRC33
LRRC36
LRRC37A3
LRRC37B
LRRC37B2
LRRC41
LRRC43
LRRC47
LRRC49
LRRC4B
LRRC6
LRRC61
LRRC66
LRRC69
LRRC7
LRRC8A
LRRC8B
LRRC8D
LRRC8E
LRRFIP1
LRRFIP2
LRRIQ3
LRRIQ4
LRRK1
LRRN1
LRRN2
LRRN3
LRRN4
LRRN4CL
LRSAM1
LRTM1
LRTM2
LSAMP
LSM12
LSM14B
LSM2
LSM5
LSM6
LSP1
LST1
LTA
LTB4R
LTB4R2
LTBP1
LTBP4
LTF
LTK
LUC7L
LUC7L2
LUC7L3
LUZP1
LUZP2
LUZP6
LVRN
LXN
LY6D
LY6E
LY6G5C
LY6G6E
LY75
LY86
LY9
LYAR
LYN
LYPD5
LYPD6B
LYPLA2
LYRM2
LYRM4
LYRM5
LYRM7
LYSMD2
LYSMD3
LYST
LYZL2
LZTFL1
LZTR1
LZTS2
M6PR
MAB21L1
MACF1
MACROD1
MACROD2
MAD1L1
MAD2L1BP
MADD
MAEA
MAEL
MAFB
MAFF
MAFG
MAFK
MAG
MAGEA5
MAGEA6
MAGEB10
MAGEB18
MAGEB2
MAGEB3
MAGEB4
MAGEB6
MAGEC1
MAGEC2
MAGEC3
MAGED1
MAGED2
MAGEE1
MAGEE2
MAGEH1
MAGI1
MAGI2
MAGI3
MAGIX
Magmas
MAGOH
MAGT1
MAL
MAL2
MALAT1
MALL
MAMDC4
MAML1
MAML2
MAML3
MAMSTR
MAN1A2
MAN1C1
MAN2A2
MAN2B2
MANBA
MANBAL
MANEAL
MANF
MAOB
MAP1A
MAP1D
MAP1LC3B2
MAP1LC3C
MAP1S
MAP2
MAP2K1
MAP2K2
MAP2K3
MAP2K4
MAP2K6
MAP2K7
MAP3K10
MAP3K11
MAP3K15
MAP3K3
MAP3K4
MAP3K5
MAP3K6
MAP3K7
MAP3K7IP2
MAP3K8
MAP3K9
MAP4
MAP4K1
MAP4K2
MAP4K3
MAP4K4
MAP4K5
MAP6
MAP7D1
MAPK10
MAPK11
MAPK12
MAPK15
MAPK4
MAPK7
MAPK8IP2
MAPK8IP3
MAPK9
MAPKAP1
MAPKAPK3
MAPKAPK5
MAPKBP1
MAPRE1
MAPRE2
MAPRE3
MAPT
MARK1
MARK2
MARK3
MARS
MARS2
MARVELD2
MARVELD3
MAS1L
MASP1
MAST1
MAST2
MAST3
MAST4
MAT2B
MATK
MATN1
MATN2
MATN3
MATN4
MATR3
MAVS
MAX
MAZ
MBD2
MBD3
MBD6
MBIP
MBLAC1
MBNL2
MBOAT2
MBOAT7
MBP
MC1R
MC3R
MC4R
MCART6
MCAT
MCC
MCCC1
MCF2
MCF2L
MCF2L2
MCHR2
MCM2
MCM3
MCM5
MCM7
MCM8
MCM9
MCOLN1
MCPH1
MCTP1
MCTS1
MDC1
MDFI
MDGA1
MDGA2
MDH2
MDK
MDM1
MDP1
ME3
MECOM
MECR
MED1
MED11
MED12L
MED13L
MED14
MED15
MED19
MED20
MED21
MED23
MED24
MED28
MED30
MED9
MEF2C
MEF2D
MEFV
MEG3
MEG8
MEGF10
MEGF11
MEGF6
MEGF8
mei-01
MEIG1
MEIS2
MELK
MEMO1
MEN1
MEOX2
MEPCE
MERTK
MESDC1
MESP1
MESP2
MEST
MESTIT1
MET
METAP2
METRN
METRNL
METT10D
METT5D1
METTL10
METTL14
METTL2A
METTL2B
METTL5
METTL7B
METTL8
METTL9
MEX3A
MEX3B
MEX3C
MFAP1
MFAP2
MFAP3L
MFAP4
MFHAS1
MFI2
MFN1
MFN2
MFSD1
MFSD11
MFSD2B
MFSD3
MFSD4
MFSD5
MFSD6
MFSD7
MFSD9
MGA
MGAT3
MGAT4B
MGAT4C
MGAT5
MGC14436
MGC15885
MGC16121
MGC16275
MGC16384
MGC23284
MGC26597
MGC27382
MGC42105
MGC45800
MGC57346
MGC70857
MGC87042
MGEA5
MGLL
MGMT
MGRN1
MGST1
MIA
MIA3
MIB2
MICA
MICAL1
MICAL2
MICAL3
MICALCL
MICALL2
MICB
MID1IP1
MIER2
MIF4GD
MIMT1
MINK1
MINPP1
MIPEP
MIR100
MIR1182
MIR1185-2
MIR1205
MIR1229
MIR1237
MIR124-2
MIR124-3
MIR1256
MIR1259
MIR125A
MIR1266
MIR127
MIR128-2
MIR1289-2
MIR1306
MIR132
MIR138-1
MIR141
MIR143
MIR1468
MIR152
MIR153-2
MIR1539
MIR182
MIR1826
MIR183
MIR1908
MIR1909
MIR191
MIR1912
MIR1913
MIR192
MIR193A
MIR193B
MIR194-2
MIR196A2
MIR196B
MIR19A
MIR2052
MIR21
MIR2110
MIR219-2
MIR30A
MIR320D1
MIR328
MIR329-2
MIR330
MIR33A
MIR340
MIR345
MIR365-1
MIR365-2
MIR376B
MIR377
MIR384
MIR410
MIR423
MIR487A
MIR492
MIR493
MIR494
MIR495
MIR505
MIR507
MIR508
MIR510
MIR514-2
MIR515-2
MIR516A1
MIR516B2
MIR517C
MIR519B
MIR519E
MIR520B
MIR525
MIR548A2
MIR548F3
MIR548F5
MIR548H4
MIR548N
MIR574
MIR589
MIR596
MIR598
MIR600
MIR611
MIR645
MIR654
MIR665
MIR670
MIR675
MIR708
MIR711
MIR7-3
MIR760
MIR888
MIR922
MIR9-3
MIRLET7C
MIRLET7G
MIRLET7I
MITF
MIXL1
MKL1
MKL2
MKLN1
MKNK2
MKRN2
MKRN3
MKX
MLC1
MLEC
MLF1IP
MLH1
MLL
MLL3
MLL4
MLL5
MLLT1
MLLT3
MLLT4
MLNR
MLX
MLXIP
MLXIPL
MLYCD
MMACHC
MMADHC
MMD
MME
MMEL1
MMGT1
MMP1
MMP14
MMP15
MMP17
MMP23A
MMP25
MMP28
MMP3
MMP9
MMRN2
MND1
MNDA
MNT
MOBKL1A
MOBKL1B
MOBKL2A
MOBKL2B
MOBKL2C
MOBKL3
MOG
MOGAT3
MOGS
MON1A
MON1B
MORC4
MORF4
MORN1
MOSC1
MOSC2
MOV10
MOXD1
MOXD2
MPDU1
MPEG1
MPG
MPHOSPH8
MPHOSPH9
MPL
MPND
MPO
MPP1
MPP2
MPP6
MPPE1
MPPED1
MPRIP
MRAP
MRAP2
MRAS
MRC2
MRE11A
MREG
MRGPRD
MRGPRG
MRM1
MRO
MRPL13
MRPL15
MRPL16
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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MRPL19
MRPL20
MRPL21
MRPL22
MRPL23
MRPL32
MRPL33
MRPL38
MRPL48
MRPL52
MRPS11
MRPS12
MRPS14
MRPS16
MRPS17
MRPS18A
MRPS18B
MRPS22
MRPS23
MRPS26
MRPS27
MRPS33
MRPS35
MRPS36
MRS2
MRTO4
MRVI1
MS4A13
MS4A2
MS4A3
MS4A6A
MSC
MSH2
MSH3
MSH6
MSI1
MSI2
MSL2
MSL3
MSL3L2
MSLN
MSN
MSRA
MSRB3
MST1R
MST4
MSX1
MT1DP
MT1E
MT1F
MT1G
MT1H
MT1X
MT2A
MT4
MTA1
MTCH1
MTCH2
MTERF
MTERFD2
MTERFD3
MTF1
MTFR1
MTG1
MTHFD1L
MTHFR
MTHFS
MTHFSD
MTIF3
MTM1
MTMR10
MTMR12
MTMR15
MTMR4
MTMR6
MTMR8
MTMR9
MTMR9L
MTNR1A
MTNR1B
MTP18
MTSS1
MTSS1L
MTUS1
MTUS2
MTVR2
MTX1
MTX2
MTX3
MUC12
MUC15
MUC2
MUC21
MUC4
MUC5B
MUC6
MUC7
MUL1
MUM1
MUM1L1
MUPCDH
MURC
MUS81
MUSTN1
MVD
MXD4
MXRA5
MXRA7
MXRA8
MYADM
MYADML
MYB
MYBBP1A
MYBL2
MYBPC1
MYBPC2
MYBPC3
MYBPH
MYCBP2
MYCBPAP
MYCL1
MYCN
MYEOV2
MYF5
MYH10
MYH11
MYH14
MYH15
MYH16
MYH3
MYH4
MYH6
MYH7
MYH7B
MYL1
MYL12A
MYL2
MYL3
MYL5
MYL6
MYL6B
MYL9
MYLIP
MYLK
MYLK4
MYNN
MYO10
MYO15A
MYO15B
MYO16
MYO18A
MYO18B
MYO1B
MYO1C
MYO1D
MYO1E
MYO1F
MYO1G
MYO1H
MYO3B
MYO5B
MYO5C
MYO7A
MYO7B
MYO9B
MYOCD
MYOD1
MYOF
MYOG
MYOM2
MYOM3
MYOT
MYOZ2
MYOZ3
MYPN
MYPOP
MYST2
MYST4
MYT1
MYT1L
MZF1
N4BP2
N4BP2L1
N4BP2L2
N4BP3
N6AMT2
NAA15
NAA16
NAA20
NAA30
NAA40
NAA50
NAAA
NAALADL1
NAALADL2
NAB1
NACAD
NACAP1
NACC1
NACC2
NADK
NADSYN1
NAE1
NAF1
NAGA
NAGPA
NAGS
NAMPT
NANOS3
NAP1L1
NAP1L4
NAPA
NAPEPLD
NARF
NARFL
NARS2
NAT1
NAT10
NAT14
NAT15
NAT2
NAT8L
NAV1
NAV2
NAV3
NBEAL1
NBEAL2
NBL1
NBLA00301
NBN
NBPF14
NBPF3
NCAM1
NCAN
NCAPD2
NCAPD3
NCAPG2
NCAPH
NCBP2
NCCRP1
NCDN
NCF2
NCK1
NCK2
NCKAP5
NCKAP5L
NCL
NCLN
NCOA1
NCOA2
NCOA4
NCOA6
NCOR1
NCOR2
NCR1
NCRNA00081
NCRNA00087
NCRNA00092
NCRNA00094
NCRNA00095
NCRNA00110
NCRNA00111
NCRNA00114
NCRNA00115
NCRNA00119
NCRNA00120
NCRNA00160
NCRNA00162
NCRNA00164
NCRNA00167
NCRNA00171
NCRNA00173
NCRNA00174
NCRNA00175
NCRNA00176
NCRNA00181
NCRNA00188
NCRNA00200
NCRNA00207
NCSTN
NDE1
NDEL1
NDFIP1
NDN
NDRG1
NDRG2
NDRG4
NDST1
NDST2
NDUFA13
NDUFA4L2
NDUFA5
NDUFA6
NDUFA7
NDUFA9
NDUFAF2
NDUFB1
NDUFB10
NDUFB11
NDUFB3
NDUFB5
NDUFB8
NDUFC1
NDUFC2
NDUFS2
NDUFS3
NDUFS4
NDUFS6
NDUFS7
NDUFV1
NDUFV2
NEBL
NECAB1
NECAB2
NECAP1
NEDD4
NEDD4L
NEDD9
NEFL
NEFM
NEGR1
NEIL1
NEIL2
NEIL3
NEK1
NEK10
NEK11
NEK5
NEK6
NELF
NELL1
NELL2
NEO1
NEU1
NEU2
NEU4
NEURL
NEURL1B
NEURL2
NEURL3
NEURL4
NEUROD1
NEUROD2
NEUROD6
NEUROG1
NEUROG2
NEXN
NF1
NF2
NFAM1
NFASC
NFAT5
NFATC1
NFATC2
NFATC4
NFE2L2
NFE2L3
NFIA
NFIC
NFIL3
NFIX
NFKB1
NFKB2
NFKBIA
NFKBIE
NFKBIL1
NFKBIL2
NFKBIZ
NFRKB
NFU1
NFXL1
NFYA
NFYB
NFYC
NGDN
NGEF
NGF
NGFR
NGFRAP1
NHEDC1
NHEDC2
NHEJ1
NHLH1
NHLH2
NHLRC3
NHLRC4
NHP2
NHP2L1
NHS
NHSL1
NHSL2
NID1
NID2
NIF3L1
NIN
NINJ2
NIPAL2
NIPAL3
NIPAL4
NIPBL
NIPSNAP1
NIPSNAP3A
NISCH
NIT1
NIT2
NKAIN2
NKAIN3
NKAIN4
NKAP
NKD1
NKD2
NKPD1
NKTR
NKX1-2
NKX2-1
NKX2-2
NKX2-4
NKX2-5
NKX3-1
NKX6-1
NKX6-2
NKX6-3
NLGN1
NLGN2
NLGN3
NLGN4X
NLRC3
NLRC5
NLRP1
NLRP11
NLRP12
NLRP3
NLRP6
NLRP7
NMB
NMD3
NME1
NME2
NME5
NME7
NMI
NMNAT1
NMNAT2
NMRAL1
NMT1
NMT2
NMUR1
NNAT
NNMT
NOD1
NOD2
NODAL
NOL11
NOL12
NOL3
NOL4
NOL7
NOM1
NOMO1
NONO
NOP14
NOP16
NOP56
NOP58
NOS1
NOS1AP
NOS2
NOS3
NOSTRIN
NOTCH1
NOTCH2
NOTCH3
NOTCH4
NOTO
NOTUM
NOV
NOVA1
NOXA1
NPAS1
NPAS2
NPAS3
NPAS4
NPBWR2
NPC1L1
NPEPPS
NPFF
NPFFR1
NPFFR2
NPHP1
NPHP4
NPHS2
NPL
NPLOC4
NPM1
NPM3
NPNT
NPPA
NPPB
NPPC
NPR1
NPTN
NPTX1
NPTX2
NPY
NPY1R
NPY2R
NPY5R
NQO1
NR0B2
NR1D1
NR1D2
NR1H2
NR1H3
NR1I2
NR1I3
NR2C1
NR2E1
NR2F1
NR2F6
NR3C1
NR4A1
NR4A3
NR5A1
NR5A2
NR6A1
NRAP
NRARP
NRBF2
NRBP1
NRBP2
NRCAM
NRD1
NRF1
NRG1
NRG2
NRG3
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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NRG4
NRGN
NRIP2
NRN1
NRP2
NRSN1
NRSN2
NRXN1
NRXN2
NRXN3
NSA2
NSD1
NSFL1C
NSL1
NSMCE2
NSMCE4A
NSUN2
NSUN4
NSUN6
NSUN7
NT5DC1
NT5DC2
NTAN1
NTF3
NTF4
NTHL1
NTM
NTN1
NTN4
NTN5
NTNG1
NTRK1
NTRK3
NTS
NTSR1
NTSR2
NUAK1
NUAK2
NUB1
NUBP1
NUBP2
NUBPL
NUCB2
NUCKS1
NUDC
NUDCD1
NUDCD3
NUDT10
NUDT16
NUDT16P
NUDT18
NUDT19
NUDT3
NUDT6
NUDT9P1
NUF2
NUMA1
NUMB
NUMBL
NUP107
NUP133
NUP188
NUP205
NUP210
NUP210L
NUP43
NUP50
NUP54
NUP62
NUP62CL
NUP85
NUP93
NUPL1
NUPL2
NUPR1
NUS1
NUSAP1
NWD1
NXF5
NXN
NXNL1
NXPH1
NXPH2
NXPH3
NXPH4
NXT1
NYNRIN
OAS1
OAS2
OAZ1
OAZ2
OAZ3
OBFC1
OBFC2A
OBSCN
OBSL1
OCA2
OCIAD2
OCLN
OCM
OCM2
OCRL
ODC1
ODF2L
ODF3L2
ODZ2
ODZ3
ODZ4
OGDH
OGDHL
OGFR
OGFRL1
OGT
OLA1
OLFM1
OLFM3
OLFM4
OLFML1
OLFML2B
OLFML3
OLIG1
OLIG2
OMA1
ONECUT1
ONECUT2
ONECUT3
OPA1
OPA3
OPALIN
OPCML
OPLAH
OPN1LW
OPN3
OPN5
OPRK1
OPRL1
OPTC
OPTN
OR10A3
OR10A5
OR10A7
OR10AG1
OR10G4
OR10G8
OR10H1
OR10H4
OR10H5
OR10J1
OR10V1
OR11L1
OR12D2
OR12D3
OR14J1
OR1A1
OR1A2
OR2B2
OR2C1
OR2C3
OR2G2
OR2H1
OR2J2
OR2L13
OR2L1P
OR2M1P
OR2T3
OR2T34
OR2T6
OR2W1
OR2Y1
OR4A47
OR4K2
OR4N3P
OR51T1
OR52A4
OR52B4
OR52B6
OR52J3
OR52K2
OR52W1
OR56A1
OR56A5
OR5A1
OR5AC2
OR5C1
OR5E1P
OR5H1
OR5L2
OR5T3
OR6B1
OR6B3
OR6K2
OR6T1
OR7C1
OR7E37P
OR7G1
OR7G2
OR7G3
OR8A1
OR8G2
OR8H1
ORAI2
ORC3L
ORC4L
ORC6L
ORMDL2
ORMDL3
OSBP2
OSBPL10
OSBPL1A
OSBPL2
OSBPL3
OSBPL5
OSBPL8
OSCAR
OSCP1
OSGIN1
OSR1
OSR2
OSTalpha
OSTBETA
OSTC
OSTCL
OSTM1
OTOA
OTOF
OTOL1
OTOP1
OTOP2
OTOP3
OTP
OTUB1
OTUD3
OTUD4
OTUD5
OTUD7B
OTX1
OTX2
OTX2OS1
OVCA2
OVCH2
OVOL1
OXA1L
OXCT1
OXER1
OXGR1
OXR1
OXSR1
OXT
P2RX1
P2RX3
P2RX4
P2RX5
P2RX6
P2RX7
P2RY1
P2RY6
P4HA1
P4HA2
P4HB
P4HTM
PA2G4
PA2G4P4
PABPC1
PABPC4
PABPC4L
PABPN1
PACRG
PACS1
PACS2
PACSIN1
PACSIN2
PADI1
PADI3
PADI6
PAEP
PAF1
PAFAH1B1
PAFAH1B2
PAG1
PAGE2
PAGE2B
PAGE3
PAICS
PAIP1
PAIP2
PAIP2B
PAK1
PAK2
PAK3
PAK4
PAK6
PALB2
PALLD
PALM
PALM2
PAMR1
PAN2
PANK3
PANK4
PANX1
PANX2
PAOX
PAPD4
PAPD5
PAPL
PAPLN
PAPOLA
PAPOLB
PAPOLG
PAPPA
PAPSS2
PAQR5
PARD3
PARD3B
PARD6A
PARD6B
PARD6G
PARK7
PARM1
PARN
PARP1
PARP10
PARP14
PARP16
PARP6
PARP9
PARS2
PART1
PARVA
PARVB
PARVG
PASD1
PATL2
PAWR
PAX1
PAX2
PAX3
PAX4
PAX5
PAX6
PAX7
PAX8
PAX9
PBRM1
PBX1
PBX2
PBX3
PBX4
PBXIP1
PC
PCBD2
PCBP1
PCBP2
PCBP3
PCBP4
PCCA
PCDH1
PCDH10
PCDH15
PCDH19
PCDH21
PCDH24
PCDH7
PCDH8
PCDH9
PCDHA2
PCDHA6
PCDHA7
PCDHAC1
PCDHB10
PCDHB11
PCDHB15
PCDHB17
PCDHB18
PCDHB5
PCDHGA1
PCDHGA2
PCDHGA4
PCF11
PCGF1
PCGF2
PCGF3
PCGF5
PCIF1
PCLO
PCM1
PCMT1
PCMTD2
PCNA
PCNT
PCNXL2
PCNXL3
PCOTH
PCP2
PCSK1
PCSK1N
PCSK5
PCSK6
PCSK7
PCSK9
PCYT1A
PCYT1B
PCYT2
PDCD1
PDCD11
PDCD5
PDCD6
PDCL2
PDE10A
PDE11A
PDE12
PDE1A
PDE1B
PDE1C
PDE2A
PDE3A
PDE3B
PDE4A
PDE4B
PDE4C
PDE4D
PDE4DIP
PDE5A
PDE6A
PDE6B
PDE6G
PDE7B
PDE8A
PDE8B
PDGFA
PDGFB
PDGFD
PDGFRA
PDGFRL
PDHA2
PDHB
PDHX
PDIA2
PDIA3
PDIA4
PDIA6
PDK2
PDK3
PDK4
PDLIM3
PDP1
PDPK1
PDPN
PDS5A
PDS5B
PDSS2
PDX1
PDXDC1
PDXK
PDYN
PDZD2
PDZD4
PDZD7
PDZRN3
PDZRN4
PEAR1
PEBP4
PECR
PEF1
PEG10
PEG3
PELI1
PELI2
PELI3
PELP1
PEMT
PENK
PEPD
PER1
PER2
PERP
PES1
PET112L
PEX10
PEX11G
PEX14
PEX19
PEX5
PF4V1
PFAS
PFDN1
PFDN4
PFKFB1
PFKFB2
PFKFB3
PFKFB4
PFKL
PFKM
PFKP
PFN2
PFN3
PGAM5
PGAP2
PGAP3
PGBD4
PGBD5
PGCP
PGGT1B
PGK1
PGK2
PGLS
PGLYRP1
PGLYRP2
PGM1
PGM5
PGRMC2
PGS1
PHACTR1
PHACTR2
PHACTR3
PHACTR4
PHB
PHB2
PHC3
PHEX
PHF1
PHF10
PHF11
PHF12
PHF13
PHF14
PHF15
PHF17
PHF21A
PHF21B
PHF23
PHF6
PHGDH
PHGR1
PHIP
PHKA1
PHKA2
PHKB
PHLDA2
PHLDB1
PHLDB2
PHLDB3
PHLPP1
PHOX2A
PHOX2B
PHRF1
PHTF2
PHYH
PHYHIP
PHYHIPL
PI15
PI4K2A
PI4KA
PI4KAP1
PI4KB
PIAS1
PIAS3
PIAS4
PICK1
PID1
PIF1
PIGA
PIGC
PIGG
PIGM
PIGO
PIGQ
PIGR
PIGU
PIGV
PIGW
PIGX
PIGY
PIGZ
PIH1D2
PIK3C2B
PIK3C2G
PIK3CA
PIK3CB
PIK3CD
PIK3CG
PIK3IP1
PIK3R1
PIK3R2
PIK3R3
PIK3R5
PIK3R6
PIKFYVE
PILRA
PILRB
PIM1
PIN1
PINX1
PIP4K2A
PIP5K1A
PIP5K1B
PIP5K1C
PIP5KL1
PIPOX
PISD
PITPNA
PITPNC1
PITPNM1
PITPNM2
PITPNM3
PITRM1
PITX1
PITX2
PITX3
PIWIL2
PJA2
PKD1
PKD1L1
PKD1L3
PKD2L2
PKHD1
PKHD1L1
PKLR
PKM2
PKN3
PKNOX2
PKP1
PKP3
PKP4
PL-5283
PLA2G12A
PLA2G15
PLA2G2A
PLA2G2E
PLA2G4C
PLA2G4D
PLA2G4E
PLA2G6
PLA2G7
PLAC1
PLAC2
PLAC8
PLAGL1
PLAT
PLAUR
PLBD1
PLBD2
PLCB4
PLCD1
PLCD3
PLCD4
PLCE1
PLCH1
PLCH2
PLCL1
PLCL2
PLCXD2
PLCZ1
PLD1
PLD2
PLD4
PLD5
PLD6
PLDN
PLEC1
PLEK
PLEK2
PLEKHA1
PLEKHA2
PLEKHA5
PLEKHA7
PLEKHA9
PLEKHF1
PLEKHG1
PLEKHG3
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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PLEKHG4
PLEKHG4B
PLEKHG5
PLEKHG7
PLEKHH1
PLEKHH2
PLEKHH3
PLEKHM1
PLEKHN1
PLEKHO1
PLEKHO2
PLIN1
PLIN2
PLIN3
PLK1S1
PLK2
PLK5P
PLLP
PLOD2
PLP2
PLS3
PLTP
PLXDC1
PLXNA1
PLXNA3
PLXNA4
PLXNB1
PLXNB2
PLXNB3
PLXNC1
PLXND1
PMEPA1
PMF1
PMFBP1
PML
PMM1
PMP22
PMPCB
PMS2CL
PMS2L11
PMS2L3
PMS2L5
PNCK
PNKD
PNLDC1
PNLIPRP1
PNLIPRP2
PNMA1
PNMA2
PNMA5
PNMAL1
PNMAL2
PNN
PNOC
PNP
PNPLA2
PNPLA6
PNPLA7
PNRC1
PNRC2
PODN
PODNL1
PODXL
POF1B
POFUT1
POGZ
POLA1
POLA2
POLD1
POLDIP2
POLDIP3
POLE
POLE2
POLE3
POLE4
POLG
POLG2
POLI
POLK
POLL
POLN
POLQ
POLR1A
POLR1B
POLR1E
POLR2B
POLR2E
POLR2H
POLR2I
POLR2J
POLR3A
POLR3B
POLR3E
POLR3F
POLR3GL
POLR3K
POLRMT
POLS
POM121
POM121C
POM121L12
POM121L2
POM121L9P
POMC
POMGNT1
POMP
POMT2
POMZP3
POP1
POP4
POP7
POR
PORCN
POTEE
POTEF
POU2F1
POU2F2
POU2F3
POU3F2
POU3F3
POU3F4
POU4F1
POU6F2
PP14571
PPA1
PPA2
PPAP2A
PPAP2B
PPAP2C
PPAPDC1A
PPAPDC1B
PPARA
PPARD
PPARG
PPARGC1B
PPAT
PPBPL1
PPFIA1
PPFIA3
PPFIA4
PPFIBP1
PPFIBP2
PPHLN1
PPIC
PPID
PPIH
PPIL1
PPIL2
PPIL4
PPIL5
PPL
PPM1E
PPM1F
PPM1H
PPM1K
PPM1L
PPM1M
PPME1
PPP1CA
PPP1CC
PPP1R10
PPP1R11
PPP1R12B
PPP1R12C
PPP1R13L
PPP1R14A
PPP1R14B
PPP1R16B
PPP1R2P1
PPP1R2P3
PPP1R3B
PPP1R3C
PPP1R3E
PPP1R3F
PPP1R3G
PPP1R7
PPP1R8
PPP1R9A
PPP2CA
PPP2R2A
PPP2R2B
PPP2R2C
PPP2R2D
PPP2R3A
PPP2R5A
PPP2R5C
PPP2R5D
PPP2R5E
PPP3CB
PPP3CC
PPP3R1
PPP4C
PPP4R1L
PPPDE1
PPRC1
PPT1
PPT2
PPTC7
PPY
PPY2
PQLC1
PQLC2
PRAM1
PRAME
PRAMEF20
PRB3
PRB4
PRCC
PRCD
PRCP
PRDM1
PRDM10
PRDM11
PRDM13
PRDM15
PRDM16
PRDM2
PRDM4
PRDM6
PRDM7
PRDM8
PRDX1
PRDX2
PRDX5
PREB
PRELP
PREP
PREPL
PREX1
PREX2
PRG2
PRG4
PRH1
PRHOXNB
PRIC285
PRICKLE1
PRICKLE2
PRICKLE3
PRICKLE4
PRIM2
PRKAB1
PRKACA
PRKAG2
PRKAR1B
PRKAR2A
PRKAR2B
PRKCA
PRKCB
PRKCD
PRKCE
PRKCH
PRKCI
PRKCQ
PRKCZ
PRKD2
PRKDC
PRKG1
PRKRA
PRKRIP1
PRKRIR
PRKX
PRLH
PRLHR
PRM1
PRM2
PRM3
PRMT1
PRMT10
PRMT5
PRMT7
PRMT8
PRND
PRNP
PRNT
PROC
PROCA1
PROCR
PROKR1
PROM2
PROX1
PRPF18
PRPF31
PRPF38B
PRPF39
PRPF8
PRPS1L1
PRPS2
PRPSAP1
PRPSAP2
PRR12
PRR18
PRR24
PRR25
PRR3
PRR4
PRRC1
PRRG3
PRRT1
PRRT2
PRRT3
PRRX1
PRRX2
PRSS12
PRSS22
PRSS23
PRSS27
PRSS36
PRSS37
PRSS38
PRSS8
PRTN3
PRX
PSAP
PSAPL1
PSCA
PSD2
PSD3
PSD4
PSEN1
PSEN2
PSENEN
PSG2
PSG8
PSIP1
PSKH1
PSKH2
PSMA4
PSMA5
PSMA6
PSMA7
PSMB10
PSMB11
PSMB4
PSMB5
PSMB6
PSMB7
PSMB8
PSMB9
PSMC1
PSMC2
PSMC3IP
PSMC5
PSMD1
PSMD12
PSMD13
PSMD14
PSMD2
PSMD3
PSMD5
PSMD6
PSMD8
PSMD9
PSME1
PSME2
PSME3
PSMG2
PSMG3
PSORS1C1
PSORS1C3
PSPN
PSRC1
PSTPIP1
PSTPIP2
PTBP1
PTCD1
PTCD2
PTCH1
PTCH2
PTCHD1
PTCHD2
PTCRA
PTDSS2
PTEN
PTF1A
PTGDR
PTGDS
PTGER1
PTGER2
PTGER3
PTGES
PTGS2
PTH
PTH1R
PTK2B
PTK6
PTK7
PTN
PTOV1
PTP4A1
PTP4A3
PTPDC1
PTPLA
PTPLB
PTPN1
PTPN11
PTPN12
PTPN14
PTPN18
PTPN3
PTPN5
PTPN6
PTPN7
PTPRA
PTPRB
PTPRC
PTPRCAP
PTPRE
PTPRF
PTPRG
PTPRJ
PTPRK
PTPRM
PTPRN
PTPRN2
PTPRO
PTPRQ
PTPRR
PTPRS
PTPRU
PTRF
PTRH1
PTS
PUF60
PUM1
PURG
PUS1
PUS10
PUS7
PUSL1
PVALB
PVR
PVRL1
PVRL3
PVRL4
PVT1
PWP2
PWWP2B
PXDN
PXDNL
PXK
PXMP2
PXMP3
PXMP4
PXN
PYCARD
PYCR1
PYCR2
PYCRL
PYGM
PYY
PYY2
QARS
QPCT
QPRT
QRICH1
QRICH2
QRSL1
QSOX1
QSOX2
QTRT1
R3HCC1
R3HDM1
R3HDML
RAB11A
RAB11FIP1
RAB11FIP3
RAB11FIP4
RAB11FIP5
RAB12
RAB15
RAB19
RAB1A
RAB1B
RAB20
RAB21
RAB22A
RAB23
RAB27B
RAB28
RAB2B
RAB30
RAB31
RAB35
RAB37
RAB39
RAB39B
RAB3C
RAB3D
RAB3GAP1
RAB3GAP2
RAB3IP
RAB40AL
RAB40B
RAB40C
RAB42
RAB43
RAB4A
RAB4B
RAB6A
RAB6B
RAB7A
RAB8B
RAB9B
RABAC1
RABEP1
RABGEF1
RABGGTA
RABL2A
RAC1
RAC3
RACGAP1
RAD17
RAD18
RAD21
RAD51AP2
RAD51L1
RAD52
RAD54L
RAD9A
RAD9B
RADIL
RAE1
RAET1E
RAET1G
RAF1
RAG1AP1
RAGE
RAI1
RAI14
RALA
RALB
RALBP1
RALGAPA2
RALGDS
RALGPS2
RALYL
RAMP1
RAMP3
RANBP17
RANBP3
RANBP9
RANGAP1
RANGRF
RAP1A
RAP1B
RAP1GAP
RAP1GAP2
RAP1GDS1
RAPGEF3
RAPGEF4
RAPGEF5
RAPGEF6
RAPGEFL1
RAPSN
RARA
RARB
RARG
RARRES2
RASA1
RASA3
RASAL1
RASAL2
RASAL3
RASD1
RASD2
RASGEF1A
RASGEF1B
RASGEF1C
RASGRF1
RASGRF2
RASGRP1
RASGRP2
RASL10A
RASL10B
RASL11B
RASSF1
RASSF2
RASSF3
RASSF4
RASSF5
RASSF6
RASSF7
RAVER1
RAX
RB1
RBBP6
RBCK1
RBL1
RBM10
RBM12B
RBM14
RBM15
RBM15B
RBM16
RBM17
RBM18
RBM19
RBM20
RBM22
RBM24
RBM25
RBM26
RBM28
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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RBM33
RBM34
RBM38
RBM39
RBM4
RBM41
RBM42
RBM44
RBM47
RBM4B
RBM5
RBM6
RBM9
RBMS1
RBMS2
RBMS3
RBMX
RBMXL1
RBMXL3
RBP1
RBP2
RBP4
RBP7
RBPJ
RBPMS
RBPMS2
RBX1
RC3H2
RCAN1
RCC2
RCCD1
RCHY1
RCN1
RCN2
RCOR1
RCOR2
RCSD1
RCVRN
RD3
RDBP
RDH10
RDH12
RDH14
RDX
RECQL4
RECQL5
REEP1
REEP2
REEP3
REEP4
REEP5
REEP6
REG1A
REG3G
REL
RELA
RELL1
RELN
RELT
REM1
REM2
RENBP
REP15
REPIN1
REPS1
RER1
RERE
RERG
RESP18
REST
RET
RETN
REV1
REXO1
REXO1L2P
REXO2
RFC1
RFC4
RFC5
RFESD
RFPL3S
RFPL4A
RFPL4B
RFTN2
RFWD2
RFWD3
RFX1
RFX4
RFX5
RFX7
RG9MTD2
RGAG1
RGL1
RGL2
RGL3
RGMA
RGN
RGNEF
RGS10
RGS12
RGS13
RGS14
RGS18
RGS19
RGS2
RGS20
RGS3
RGS5
RGS7
RGS9
RHBDD2
RHBDD3
RHBDF1
RHBDF2
RHBDL2
RHBG
RHCG
RHEB
RHOB
RHOBTB2
RHOBTB3
RHOD
RHOG
RHOT1
RHOU
RHOV
RHPN1
RHPN2
RIBC1
RIC8A
RICH2
RICS
RICTOR
RIF1
RILPL1
RIMBP2
RIMBP3
RIMKLA
RIMKLB
RIMS1
RIMS2
RIMS4
RIN1
RIN2
RIN3
RING1
RINL
RIPK1
RIPK3
RIPK4
RIPPLY2
RIT2
RLF
RMND5A
RNASE10
RNASE4
RNASE9
RNASEH1
RNASEK
RNF113A
RNF125
RNF126P1
RNF128
RNF13
RNF135
RNF138
RNF139
RNF14
RNF144A
RNF144B
RNF145
RNF149
RNF165
RNF166
RNF169
RNF17
RNF170
RNF182
RNF183
RNF185
RNF186
RNF19B
RNF2
RNF208
RNF212
RNF213
RNF216
RNF220
RNF222
RNF24
RNF25
RNF31
RNF34
RNF39
RNF4
RNF41
RNF44
RNF5
RNF6
RNFT1
RNFT2
RNGTT
RNLS
RNMTL1
RNPEPL1
RNU11
RNU5E
RNU6ATAC
ROBLD3
ROBO1
ROBO2
ROBO3
ROCK1
ROCK2
ROPN1B
ROR1
ROR2
RORA
RORC
ROS1
RP1
RP1L1
RP2
RPA1
RPA2
RPAIN
RPAP3
RPE
RPE65
RPF1
RPGR
RPGRIP1
RPH3A
RPH3AL
RPIA
RPL10
RPL10A
RPL13
RPL13AP17
RPL13AP20
RPL13AP5
RPL14
RPL17
RPL18AP3
RPL19
RPL19P12
RPL21
RPL22
RPL22L1
RPL23A
RPL23AP82
RPL23P8
RPL24
RPL26
RPL28
RPL29
RPL3
RPL36AL
RPL38
RPL39
RPL41
RPL5
RPLP0
RPLP1
RPN1
RPN2
RPP14
RPP21
RPP40
RPRD2
RPRM
RPS10
RPS11
RPS15
RPS18
RPS19
RPS19BP1
RPS23
RPS24
RPS29
RPS5
RPS6KA1
RPS6KA2
RPS6KA3
RPS6KA4
RPS6KB2
RPS6KC1
RPS6KL1
RPS8
RPS9
RPSA
RPSAP58
RPTOR
RPUSD2
RRAD
RRBP1
RREB1
RRM1
RRN3P1
RRN3P3
RRP1
RRP12
RRP7B
RSAD1
RSAD2
RSL24D1
RSPH1
RSPH10B
RSPH9
RSPO1
RSPO2
RSPO3
RSRC2
RSU1
RTBDN
RTDR1
RTF1
RTKN
RTN1
RTN4
RTN4IP1
RTN4R
RTN4RL2
RTP1
RTP2
RUFY1
RUFY4
RUNDC1
RUNDC3A
RUNX1
RUNX1T1
RUNX3
RUSC1
RUSC2
RWDD1
RXFP3
RXFP4
RXRA
RXRB
RYK
RYR1
RYR2
RYR3
S100A13
S100A2
S100A3
S100A4
S100A5
S100A6
S100A8
S100P
S100PBP
S1PR1
S1PR2
S1PR5
SAC3D1
SACS
SAFB
SAFB2
SAG
SALL1
SALL2
SAMD12
SAMD13
SAMD14
SAMD4A
SAMD5
SAMD9
SAMM50
SAP130
SAP18
SAP25
SAP30L
SAPS2
SAR1B
SARDH
SARM1
SARNP
SARS
SARS2
SASH1
SASH3
SAT1
SAT2
SATB1
SATB2
SAV1
SBF1
SBF2
SBK1
SBK2
SBNO2
SC4MOL
SCAF1
SCAI
SCAMP1
SCAMP3
SCAMP4
SCAND1
SCAND3
SCAP
SCAPER
SCARB1
SCARB2
SCARF1
SCARF2
SCARNA11
SCCPDH
SCD5
SCFD2
SCG2
SCG5
SCGB2A1
SCGB2A2
SCGN
SCHIP1
SCMH1
SCML1
SCML2
SCN11A
SCN1B
SCN2B
SCN3B
SCN4A
SCN4B
SCN5A
SCNM1
SCNN1B
SCOC
SCPEP1
SCRIB
SCRN1
SCRT1
SCRT2
SCTR
SCUBE1
SCUBE2
SDAD1
SDC1
SDC2
SDCBP
SDCBP2
SDCCAG10
SDCCAG8
SDF2
SDF2L1
SDF4
SDHA
SDHAP1
SDHAP2
SDK1
SDK2
SDR16C6
SDR9C7
SEC1
SEC13
SEC14L1
SEC14L3
SEC14L4
SEC14L5
SEC16A
SEC22B
SEC23A
SEC23IP
SEC24B
SEC24C
SEC24D
SEC31A
SEC31B
SEC61A1
SEC61A2
SEC61G
SEC63
SECISBP2L
SECTM1
SEL1L
SEL1L2
SEL1L3
SELI
SELK
SELO
SELP
SELPLG
SEMA3A
SEMA3B
SEMA3C
SEMA3G
SEMA4B
SEMA4C
SEMA4F
SEMA4G
SEMA5A
SEMA5B
SEMA6A
SEMA6B
SEMA6C
SEMA6D
SEMA7A
SEMG1
SENP1
SENP2
SENP3
SEPHS2
SEPN1
SEPP1
SEPSECS
SEPX1
SERAC1
SERBP1
SERF2
SERGEF
SERINC2
SERINC3
SERINC4
SERP2
SERPINA1
SERPINA11
SERPINA12
SERPINA13
SERPINA3
SERPINA4
SERPINA7
SERPINB11
SERPIND1
SERPINE1
SERPINF1
SERPINF2
SERPING1
SERPINH1
SERPINI1
SERPINI2
SERTAD2
SERTAD3
SESN2
SESTD1
SET
SETBP1
SETD1A
SETD1B
SETD2
SETD3
SETD4
SETD7
SETDB2
SETMAR
SEZ6
SEZ6L2
SF1
SF3A1
SF3A2
SF3B1
SF3B4
SFMBT1
SFMBT2
SFN
SFRP1
SFRP2
SFRP4
SFRP5
SFRS12
SFRS13A
SFRS13B
SFRS18
SFRS2B
SFRS3
SFRS4
SFRS5
SFRS6
SFRS8
SFT2D1
SFT2D2
SFTA2
SFTA3
SFTPA1
SFXN2
SFXN3
SGCB
SGCD
SGCE
SGCZ
SGEF
SGIP1
SGK1
SGK269
SGK3
SGMS1
SGOL1
SGPP1
SGPP2
SGSH
SGSM1
SGSM2
SGTA
SGTB
SH2B1
SH2B2
SH2B3
SH2D1A
SH2D2A
SH2D3C
SH2D4B
SH2D6
SH2D7
SH3BGRL
SH3BGRL2
SH3BP2
SH3BP4
SH3BP5
SH3BP5L
SH3D20
SH3GL1
SH3GLB2
SH3KBP1
SH3PXD2A
SH3PXD2B
SH3RF1
SH3RF2
SH3RF3
SH3TC1
SH3TC2
SH3YL1
SHANK1
SHANK2
SHANK3
SHARPIN
SHC1
SHC2
SHC3
SHC4
SHD
SHF
SHH
SHISA3
SHISA4
SHISA6
SHISA7
SHISA9
SHMT1
SHMT2
SHOC2
SHOX2
SHQ1
SHROOM1
SHROOM2
SHROOM3
SHROOM4
SIAE
SIDT1
SIGIRR
SIGLEC1
SIGLEC10
SIGLEC12
SIGLEC6
SIGLEC9
SIGMAR1
SIK3
SIL1
SIM1
SIM2
SIN3A
SIN3B
SIPA1
SIPA1L1
SIPA1L2
SIRPA
SIRPB2
SIRPG
SIRT2
SIRT5
SIRT6
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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SIRT7
SIT1
SIX3
SIX4
SIX6
SKA2
SKAP2
SKI
SKIL
SKINTL
SKIV2L
SKP1
SKP2
SLA2
SLAIN1
SLAIN2
SLAMF1
SLAMF8
SLAMF9
SLBP
SLC10A2
SLC10A4
SLC10A6
SLC10A7
SLC11A1
SLC11A2
SLC12A1
SLC12A2
SLC12A4
SLC12A5
SLC12A6
SLC12A7
SLC12A8
SLC13A4
SLC15A1
SLC15A3
SLC15A4
SLC16A10
SLC16A13
SLC16A2
SLC16A3
SLC16A4
SLC16A5
SLC16A6
SLC16A7
SLC16A8
SLC16A9
SLC17A5
SLC17A6
SLC17A7
SLC18A1
SLC18A2
SLC19A1
SLC19A3
SLC1A2
SLC1A4
SLC1A6
SLC1A7
SLC20A2
SLC22A1
SLC22A11
SLC22A12
SLC22A13
SLC22A16
SLC22A17
SLC22A18
SLC22A18AS
SLC22A20
SLC22A23
SLC22A24
SLC22A4
SLC22A6
SLC22A8
SLC22A9
SLC23A1
SLC23A3
SLC24A1
SLC24A4
SLC25A10
SLC25A13
SLC25A15
SLC25A16
SLC25A17
SLC25A20
SLC25A21
SLC25A22
SLC25A23
SLC25A25
SLC25A26
SLC25A29
SLC25A30
SLC25A31
SLC25A33
SLC25A35
SLC25A37
SLC25A39
SLC25A42
SLC25A44
SLC25A45
SLC25A46
SLC26A10
SLC26A11
SLC26A2
SLC26A4
SLC26A5
SLC26A8
SLC27A1
SLC27A3
SLC28A3
SLC29A1
SLC29A2
SLC29A3
SLC29A4
SLC2A1
SLC2A12
SLC2A13
SLC2A14
SLC2A2
SLC2A3
SLC2A5
SLC2A6
SLC2A7
SLC2A9
SLC30A1
SLC30A2
SLC30A4
SLC30A8
SLC33A1
SLC34A2
SLC35A1
SLC35B1
SLC35B3
SLC35C1
SLC35C2
SLC35D1
SLC35E3
SLC35E4
SLC35F1
SLC35F3
SLC36A1
SLC36A2
SLC36A4
SLC37A1
SLC37A4
SLC38A1
SLC38A10
SLC38A3
SLC38A4
SLC38A5
SLC38A6
SLC38A7
SLC38A8
SLC38A9
SLC39A14
SLC39A4
SLC39A6
SLC39A7
SLC39A8
SLC3A1
SLC40A1
SLC41A3
SLC43A1
SLC43A2
SLC44A2
SLC44A4
SLC44A5
SLC45A1
SLC45A4
SLC46A1
SLC46A2
SLC46A3
SLC47A1
SLC4A1
SLC4A2
SLC4A3
SLC4A4
SLC4A5
SLC4A8
SLC5A1
SLC5A10
SLC5A11
SLC5A5
SLC5A7
SLC5A8
SLC5A9
SLC6A1
SLC6A12
SLC6A15
SLC6A16
SLC6A19
SLC6A20
SLC6A3
SLC6A4
SLC6A5
SLC6A9
SLC7A13
SLC7A2
SLC7A5
SLC7A5P2
SLC7A7
SLC7A8
SLC8A1
SLC8A2
SLC8A3
SLC9A1
SLC9A11
SLC9A2
SLC9A3
SLC9A3R1
SLC9A3R2
SLC9A5
SLC9A6
SLC9A7
SLC9A8
SLC9A9
SLCO1A2
SLCO1B3
SLCO2A1
SLCO3A1
SLCO4A1
SLCO5A1
SLCO6A1
SLFN11
SLFN12L
SLFN13
SLFN14
SLIT1
SLIT2
SLIT3
SLITRK1
SLITRK3
SLITRK4
SLITRK6
SLMO1
SLTM
SMAD3
SMAD4
SMAD5
SMAD6
SMAD7
SMAD9
SMAGP
SMAP2
SMARCA1
SMARCA2
SMARCA4
SMARCAL1
SMARCC1
SMARCD3
SMARCE1
SMC2
SMC3
SMC5
SMCHD1
SMCR5
SMCR7L
SMEK1
SMEK2
SMEK3P
SMG6
SMG7
SMOC1
SMOC2
SMOX
SMPD1
SMPD3
SMPDL3B
SMPX
SMR3A
SMTN
SMTNL2
SMYD1
SMYD3
SMYD4
SNAI1
SNAP25
SNAP29
SNAP47
SNAP91
SNAPC1
SNAPC2
SNAPC3
SNAPC5
SNAPIN
SNAR-D
SND1
SNED1
SNHG3-RCC1
SNHG4
SNHG5
SNHG6
SNHG8
SNORA21
SNORA26
SNORA27
SNORA30
SNORA38
SNORA39
SNORA69
SNORD105
SNORD113-2
SNORD113-6
SNORD114-1
SNORD114-25
SNORD114-30
SNORD115-11
SNORD115-13
SNORD115-14
SNORD115-15
SNORD115-35
SNORD115-4
SNORD116-15
SNORD116-4
SNORD119
SNORD12
SNORD18A
SNORD2
SNORD24
SNORD27
SNORD30
SNORD43
SNORD45C
SNORD56B
SNORD63
SNORD87
SNORD89
SNORD93
SNPH
SNRNP200
SNRNP35
SNRNP40
SNRNP70
SNRPB
SNRPD1
SNRPD2
SNRPD3
SNRPF
SNRPN
SNTB2
SNTG1
SNTG2
SNUPN
SNX14
SNX15
SNX16
SNX18
SNX19
SNX2
SNX22
SNX24
SNX26
SNX27
SNX29
SNX31
SNX32
SNX33
SNX4
SNX6
SNX8
SNX9
SOAT1
SOAT2
SOBP
SOCS1
SOCS2
SOCS3
SOCS4
SOCS5
SOD3
SOHLH2
SOLH
SON
SORBS1
SORBS2
SORBS3
SORCS2
SORCS3
SORL1
SORT1
SOS1
SOS2
SOX1
SOX10
SOX12
SOX13
SOX14
SOX15
SOX17
SOX2OT
SOX3
SOX4
SOX5
SOX6
SP110
SP140
SP2
SP6
SP9
SPAG1
SPAG11A
SPAG11B
SPAG16
SPAG4
SPAG4L
SPAG6
SPAG7
SPANXN5
SPARC
SPAST
SPATA1
SPATA13
SPATA18
SPATA19
SPATA20
SPATA3
SPATA5L1
SPATC1
SPATS1
SPATS2
SPATS2L
SPC24
SPCS2
SPDEF
SPDYE4
SPEG
SPEM1
SPEN
SPG21
SPG7
SPHK1
SPI1
SPIN1
SPINK1
SPINK2
SPINK5L3
SPINK6
SPINK8
SPINT1
SPINT2
SPIRE2
SPN
SPNS1
SPNS2
SPNS3
SPO11
SPOCK1
SPOCK2
SPON2
SPP2
SPPL2A
SPPL2B
SPPL3
SPRED1
SPRED2
SPRED3
SPRR2B
SPRR2C
SPRR4
SPRY1
SPRY4
SPRYD3
SPRYD4
SPSB1
SPSB2
SPSB3
SPSB4
SPTA1
SPTB
SPTBN1
SPTBN2
SPTBN4
SPTBN5
SPTLC1
SPTLC2
SPTY2D1
SQLE
SQRDL
SR140
SRA1
SRBD1
SRC
SRCAP
SRCIN1
SRCRB4D
SRD5A1
SRD5A1P1
SRD5A2
SREBF1
SRF
SRFBP1
SRGAP1
SRGAP3
SRI
SRL
SRM
SRMS
SRP14
SRPK1
SRPK2
SRPX
SRPX2
SRRM1
SRRM3
SRRM4
SRRT
SS18L1
SS18L2
SSBP1
SSBP3
SSH1
SSH2
SSH3
SSPN
SSPO
SSR1
SSR2
SST
SSTR2
SSTR3
SSU72
SSX3
SSX7
ST14
ST18
ST3GAL1
ST3GAL2
ST3GAL3
ST3GAL5
ST3GAL6
ST5
ST6GAL1
ST6GALNAC2
ST6GALNAC4
ST7OT3
ST8SIA2
ST8SIA5
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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ST8SIA6
STAB1
STAC2
STAG1
STAG2
STAG3L2
STAM2
STAMBP
STAP1
STAR
STARD10
STARD3
STARD4
STARD7
STARD9
STAT1
STAT2
STAT4
STAT5A
STATH
STAU1
STC2
STEAP1
STEAP2
STEAP3
STEAP4
STIL
STIM1
STIM2
STK11
STK16
STK19
STK25
STK3
STK31
STK32A
STK32B
STK32C
STK35
STK38
STK39
STK4
STK40
STMN1
STMN2
STMN3
STOML1
STOML2
S T O N 1 -
GTF2A1L
STON2
STOX1
STOX2
STRA13
STRA6
STRA8
STRAP
STRN
STRN3
STRN4
STT3A
STT3B
STX11
STX12
STX18
STX1A
STX2
STX5
STXBP2
STXBP4
STXBP5L
STXBP6
STYK1
STYXL1
SUB1
SUCLG1
SUCLG2
SUFU
SUGT1P1
SULF1
SULF2
SULT1A3
SULT1C4
SUMF1
SUMF2
SUMO2
SUMO3
SUNC1
SUOX
SUPT3H
SUPT6H
SUSD1
SUSD3
SUV39H1
SUV420H1
SUV420H2
SUZ12
SV2B
SV2C
SVIL
SVOP
SVOPL
SYCE1
SYCE1L
SYCE2
SYCN
SYCP3
SYF2
SYN1
SYN2
SYN3
SYNE1
SYNE2
SYNGAP1
SYNGR1
SYNGR3
SYNJ1
SYNJ2
SYNPO
SYNPO2L
SYNPR
SYNRG
SYP
SYPL1
SYPL2
SYS1
SYT1
SYT10
SYT11
SYT13
SYT14
SYT15
SYT17
SYT2
SYT3
SYT6
SYT7
SYT8
SYT9
SYTL1
SYTL2
SYTL3
SYTL4
SYVN1
T
TAAR3
TAAR9
TAC1
TACC1
TACC2
TACC3
TACR1
TACR3
TACSTD2
TADA1
TADA2A
TADA2B
TADA3
TAF10
TAF12
TAF15
TAF1B
TAF1C
TAF2
TAF4
TAF4B
TAF5
TAF7
TAF7L
TAF8
TAF9
TAF9B
TAGAP
TAGLN
TAL1
TANC1
TANC2
TANK
TAOK1
TAOK2
TAOK3
TAP1
TAP2
TAPBP
TARBP2
TARS2
TAS1R1
TAS1R2
TAS1R3
TAS2R38
TAS2R8
TASP1
TATDN1
TATDN3
TBC1D1
TBC1D10B
TBC1D10C
TBC1D12
TBC1D13
TBC1D14
TBC1D15
TBC1D16
TBC1D2
TBC1D21
TBC1D22A
TBC1D22B
TBC1D23
TBC1D24
TBC1D26
TBC1D28
TBC1D2B
TBC1D4
TBC1D8
TBC1D9
TBC1D9B
TBCB
TBCC
TBCCD1
TBCD
TBCK
TBKBP1
TBL1X
TBL1XR1
TBL2
TBP
TBPL1
TBR1
TBRG4
TBX1
TBX10
TBX15
TBX18
TBX2
TBX20
TBX21
TBX3
TBX4
TBX5
TBXA2R
TBXAS1
TC2N
TCAP
TCEA1
TCEA3
TCEAL2
TCEAL5
TCEAL6
TCEB3
TCEB3B
TCERG1
TCERG1L
TCF12
TCF15
TCF19
TCF21
TCF23
TCF25
TCF3
TCF7
TCF7L1
TCF7L2
TCFL5
TCIRG1
TCOF1
TCP1
TCP10L2
TCP11L1
TCP11L2
TCTE1
TCTE3
TCTEX1D4
TCTN1
TDG
TDH
TDRD10
TDRD12
TDRD5
TDRD6
TDRD9
TEAD1
TEAD3
TEC
TECPR1
TECPR2
TECR
TEF
TEK
TEKT1
TEKT2
TEKT3
TEKT4
TELO2
TENC1
TEPP
TERC
TERF2
TERT
TES
TESC
TESK1
TESK2
TESSP1
TET1
TEX101
TEX13B
TEX14
TEX15
TEX19
TEX2
TEX261
TEX264
TEX9
TF
TFAM
TFAP2A
TFAP2B
TFAP2D
TFAP2E
TFAP4
TFCP2L1
TFDP1
TFDP3
TFE3
TFEB
TFF1
TFF2
TFG
TFIP11
TFPI2
TFPT
TFR2
TG
TGDS
TGFA
TGFB2
TGFBR2
TGFBR3
TGFBRAP1
TGIF1
TGM2
TGM5
TGM6
TGM7
TGOLN2
TGS1
TH
TH1L
THADA
THAP11
THAP3
THAP4
THAP5
THAP7
THAP9
THBD
THBS1
THBS2
THBS4
THEM5
THNSL1
THNSL2
THOC1
THOC4
THOC5
THOP1
THRA
THRAP3
THRB
THSD1
THSD1P
THSD4
THTPA
THUMPD1
THUMPD2
THY1
THYN1
TIAL1
TIAM1
TIAM2
TICAM1
TIE1
TIFAB
TIGD3
TIGIT
TIMELESS
TIMM17A
TIMM17B
TIMM44
TIMM50
TIMM8A
TIMM8B
TIMM9
TIMP2
TIMP4
TINAGL1
TINF2
TIPARP
TIPIN
TIPRL
TIRAP
TJP1
TJP2
TK1
TK2
TKTL2
TLCD2
TLE1
TLE2
TLE3
TLE4
TLL1
TLL2
TLR1
TLR2
TLR4
TLR5
TLR6
TLR9
TLX1
TLX2
TLX3
TM2D1
TM2D2
TM4SF5
TMBIM4
TMC1
TMC6
TMC8
TMCC1
TMCC3
TMCO1
TMCO3
TMCO6
TMCO7
TMED1
TMED10
TMED2
TMED4
TMED6
T M E D 7 -
TICAM2
TMEM100
TMEM101
TMEM102
TMEM106A
TMEM108
TMEM109
TMEM110
TMEM114
TMEM115
TMEM116
TMEM117
TMEM120A
TMEM120B
TMEM121
TMEM123
TMEM127
TMEM129
TMEM130
TMEM132A
TMEM132B
TMEM132C
TMEM132D
TMEM132E
TMEM134
TMEM135
TMEM138
TMEM139
TMEM140
TMEM146
TMEM14A
TMEM14C
TMEM150A
TMEM151A
TMEM151B
TMEM155
TMEM156
TMEM159
TMEM161A
TMEM163
TMEM165
TMEM167B
TMEM168
TMEM170B
TMEM171
TMEM173
TMEM174
TMEM175
TMEM178
TMEM179
TMEM18
TMEM181
TMEM183A
TMEM183B
TMEM185A
TMEM187
TMEM188
TMEM19
TMEM191A
TMEM192
TMEM194A
TMEM194B
TMEM195
TMEM196
TMEM2
TMEM200A
TMEM200B
TMEM200C
TMEM201
TMEM211
TMEM212
TMEM216
TMEM219
TMEM22
TMEM222
TMEM229B
TMEM231
TMEM233
TMEM25
TMEM39A
TMEM40
TMEM45A
TMEM48
TMEM49
TMEM5
TMEM51
TMEM53
TMEM57
TMEM59L
TMEM62
TMEM63A
TMEM63B
TMEM64
TMEM71
TMEM79
TMEM82
TMEM85
TMEM86B
TMEM88
TMEM89
TMEM8A
TMEM91
TMEM92
TMEM98
TMEM9B
TMF1
TMIGD2
TMLHE
TMOD1
TMOD3
TMOD4
TMPO
TMPRSS11D
TMPRSS11F
TMPRSS13
TMPRSS3
TMPRSS4
TMPRSS6
TMPRSS9
TMSB15A
TMSB15B
TMTC1
TMTC4
TMUB1
TMUB2
TMX1
TMX2
TMX4
TNC
TNF
TNFAIP1
TNFAIP3
TNFAIP8
TNFAIP8L2
TNFAIP8L3
TNFRSF10B
TNFRSF10D
TNFRSF11B
TNFRSF13C
TNFRSF18
TNFRSF1A
TNFRSF1B
TNFRSF25
TNFRSF8
TNFSF10
TNFSF13
TNFSF13B
TNFSF18
TNIK
TNIP1
TNIP2
TNK1
TNK2
TNKS
TNKS1BP1
TNKS2
TNN
TNNC2
TNNT3
TNP1
TNPO1
TNPO2
TNPO3
TNR
TNRC18
TNRC4
TNRC6B
TNRC6C
TNS1
TNS3
TNS4
TNXB
TOB1
TOLLIP
TOM1L2
TOMM20
TOMM20L
TOMM22
TOMM34
TOMM40
TOMM7
TOP1
TOP1MT
TOP2A
TOP3A
TOP3B
TOPBP1
TOPORS
TOR1AIP1
TOR1AIP2
TOR1B
TOR3A
TOX
TOX2
TP53
TP53AIP1
TP53BP1
TP53I11
TP53I13
TP53I3
TP53INP2
TP53RK
TP53TG5
TP63
TP73
TPBG
TPCN2
TPD52
TPD52L2
TPH2
TPK1
TPM3
TPM4
TPO
TPP1
TPPP
TPPP2
TPPP3
TPRA1
TPRKB
TPRXL
TPST1
TPTE
TPX2
TRADD
TRAF1
TRAF3
TRAF3IP1
TRAF3IP2
TRAF5
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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TRAF7
TRAIP
TRAK1
TRAM1L1
TRAM2
TRANK1
TRAP1
TRAPPC2
TRAPPC2L
TRAPPC3
TRAPPC4
TRAPPC5
TRAPPC9
TRDMT1
TREH
TREM2
TREML1
TREML2
TREML2P
TRERF1
TRH
TRHDE
TRHR
TRIB1
TRIB2
TRIB3
TRIL
TRIM10
TRIM13
TRIM15
TRIM17
TRIM2
TRIM24
TRIM25
TRIM26
TRIM27
TRIM28
TRIM29
TRIM3
TRIM31
TRIM33
TRIM35
TRIM36
TRIM37
TRIM38
TRIM39
TRIM40
TRIM41
TRIM42
TRIM44
TRIM46
TRIM47
TRIM50
TRIM52
TRIM53
TRIM54
TRIM56
TRIM59
TRIM62
TRIM63
TRIM65
TRIM66
TRIM6-
TRIM34
TRIM7
TRIM71
TRIM72
TRIM75
TRIM8
TRIM9
TRIML1
TRIO
TRIOBP
TRIP10
TRIP11
TRIP13
TRIP4
TRMT11
TRMT2B
TRMT61B
TRMU
TRNAU1AP
TRNP1
TROAP
TRPA1
TRPC3
TRPC4
TRPC4AP
TRPC7
TRPM2
TRPM4
TRPM5
TRPM8
TRPS1
TRPV3
TRPV4
TRRAP
TSC2
TSC22D1
TSC22D3
TSC22D4
TSEN2
TSEN54
TSG1
TSGA10IP
TSGA14
TSHR
TSHZ2
TSKS
TSKU
TSLP
TSNARE1
TSNAX-
DISC1
TSPAN1
TSPAN12
TSPAN13
TSPAN14
TSPAN17
TSPAN2
TSPAN31
TSPAN33
TSPAN4
TSPAN5
TSPAN6
TSPAN7
TSPAN9
TSPO
TSPYL3
TSPYL4
TSPYL5
TSPYL6
TSR2
TSSC1
TSSC4
TSSK6
TST
TSTA3
TSTD1
TTBK1
TTBK2
TTC12
TTC13
TTC15
TTC21B
TTC23
TTC25
TTC26
TTC28
TTC29
TTC3
TTC30A
TTC30B
TTC33
TTC35
TTC36
TTC38
TTC39A
TTC39C
TTC4
TTC7A
TTC7B
TTC8
TTF2
TTK
TTLL1
TTLL10
TTLL12
TTLL3
TTLL5
TTLL7
TTLL8
TTN
TTR
TTTY18
TTYH1
TTYH2
TTYH3
TUB
TUBA1B
TUBA1C
TUBA3D
TUBA3E
TUBA8
TUBB
TUBB2A
TUBB2C
TUBB3
TUBB4Q
TUBB6
TUBB8
TUBBP5
TUBE1
TUBGCP2
TUBGCP5
TUBGCP6
TUFT1
TUG1
TULP2
TULP3
TUSC3
TUSC4
TWF1
TWF2
TWISTNB
TXLNA
TXN
TXN2
TXNDC11
TXNDC17
TXNIP
TXNL1
TXNL4A
TXNRD1
TXNRD2
TYK2
TYMS
TYRO3
TYROBP
TYRP1
TYSND1
U2AF1
U2AF2
UACA
UAP1L1
UBA1
UBA3
UBA7
UBAC1
UBAC2
UBAP1
UBAP2L
UBASH3B
UBE2B
UBE2C
UBE2D1
UBE2E1
UBE2E2
UBE2E3
UBE2F
UBE2G1
UBE2G2
UBE2I
UBE2L3
UBE2M
UBE2MP1
UBE2O
UBE2Q2
UBE2R2
UBE2U
UBE2V1
UBE2Z
UBE3B
UBE3C
UBE4B
UBFD1
UBIAD1
UBL4B
UBN1
UBQLN2
UBQLNL
UBR1
UBR2
UBR5
UBTD1
UBTF
UBXN1
UBXN10
UBXN11
UBXN4
UCHL3
UCK2
UCN3
UCP1
UCRC
UEVLD
UGCG
UGDH
UGP2
UGT1A10
UGT2B15
UGT3A1
UHMK1
UHRF1
UHRF1BP1L
ULBP1
ULBP2
ULK1
ULK2
ULK4
UMODL1
UNC13A
UNC13B
UNC13D
UNC45B
UNC5A
UNC5B
UNC5CL
UNC5D
UNC80
UNC84A
UNC93A
UNC93B1
UNCX
UNG
UNK
UNKL
UPF1
UPF3A
UPF3B
UPK1A
UPK1B
UPK3A
UPP2
UQCC
UQCRC2
UQCRFS1
UQCRHL
URB1
URB2
URGCP
UROD
USF1
USF2
USO1
USP1
USP10
USP12
USP13
USP14
USP16
USP2
USP20
USP21
USP22
USP25
USP3
USP31
USP32
USP33
USP34
USP35
USP36
USP4
USP40
USP42
USP43
USP44
USP46
USP49
USP5
USP51
USP53
USP54
USP6NL
USP7
UST
UTP14A
UTP14C
UTP6
UTRN
UXS1
UXT
VAC14
VAMP2
VAMP3
VAMP4
VANGL1
VANGL2
VAPA
VARS
VARS2
VASH1
VASH2
VASP
VAT1
VAV1
VAV2
VAV3
VAX1
VAX2
VCAN
VCX2
VCX3B
VDAC1
VDAC3
VEGFA
VENTX
VENTXP1
VENTXP7
VEPH1
VGF
VGLL2
VGLL3
VGLL4
VIL1
VILL
VIP
VIPR1
VIPR2
VKORC1
VMO1
VN1R4
VOPP1
VPRBP
VPS13A
VPS13B
VPS13D
VPS16
VPS24
VPS29
VPS36
VPS37A
VPS37B
VPS37C
VPS39
VPS41
VPS45
VPS4A
VPS52
VPS53
VPS54
VPS72
VSIG8
VSNL1
VSTM2L
VSX2
VTCN1
VTI1A
VTI1B
VTN
VTRNA1-1
VTRNA1-3
VWA1
VWA2
VWA3A
VWA3B
VWA5B2
VWC2L
VWF
WAC
WASF1
WASF3
WBP2
WBP2NL
WBP4
WBSCR16
WBSCR17
WBSCR22
WDFY1
WDFY2
WDFY3
WDFY4
WDR1
WDR12
WDR13
WDR17
WDR20
WDR24
WDR25
WDR26
WDR27
WDR31
WDR33
WDR35
WDR37
WDR45
WDR45L
WDR46
WDR47
WDR52
WDR53
WDR5B
WDR60
WDR64
WDR65
WDR67
WDR69
WDR70
WDR73
WDR74
WDR8
WDR81
WDR86
WDR89
WDR93
WDTC1
WEE1
WFDC1
WFDC3
WFDC5
WFDC9
WFIKKN2
WFS1
WHAMM
WHAMML1
WHSC1L1
WHSC2
WIBG
WIPF3
WIPI1
WIPI2
WIZ
WNK1
WNK2
WNK3
WNT1
WNT10A
WNT10B
WNT11
WNT16
WNT2
WNT2B
WNT3
WNT4
WNT5A
WNT5B
WNT6
WNT7A
WNT7B
WNT8B
WNT9A
WNT9B
WRB
WRN
WRNIP1
WSB2
WSCD1
WSCD2
WT1
WTAP
WWC1
WWC2
WWOX
WWP1
WWP2
XAB2
XAF1
XAGE3
XIRP1
XIRP2
XK
XKR4
XKR5
XKR6
XKR7
XKR8
XKR9
XKRX
XPC
XPNPEP1
XPNPEP3
XPO6
XPOT
XRCC2
XRCC4
XRCC5
XRCC6
XRRA1
XYLT1
YAF2
YARS2
YBX2
YIF1A
YIPF1
YIPF3
YIPF4
YIPF5
YIPF7
YJEFN3
YOD1
YPEL1
YPEL2
YPEL4
YPEL5
YSK4
YTHDC1
YTHDF3
YWHAB
YWHAE
YWHAG
YWHAQ
YWHAZ
ZACN
ZADH2
ZAK
ZAR1
ZBED2
ZBED4
ZBED5
ZBTB11
ZBTB12
ZBTB16
ZBTB17
ZBTB2
ZBTB20
ZBTB22
ZBTB24
ZBTB25
ZBTB3
ZBTB38
ZBTB4
ZBTB40
ZBTB44
ZBTB46
ZBTB47
ZBTB48
ZBTB5
ZBTB7A
ZBTB7B
ZBTB8B
ZBTB9
ZC3H11A
ZC3H12A
ZC3H12C
ZC3H12D
ZC3H14
ZC3H15
ZC3H18
ZC3H3
ZC3H4
ZC3HAV1L
ZC3HC1
ZC4H2
ZCCHC12
ZCCHC14
ZCCHC24
ZCCHC6
ZCCHC8
ZCWPW1
ZDHHC1
ZDHHC11
ZDHHC14
ZDHHC15
ZDHHC16
ZDHHC17
ZDHHC19
ZDHHC2
ZDHHC21
ZDHHC3
ZDHHC4
ZDHHC5
ZDHHC7
ZDHHC8
ZDHHC9
ZEB2
ZFAND2A
ZFC3H1
ZFHX3
ZFHX4
ZFP1
ZFP3
ZFP30
ZFP36
ZFP36L1
ZFP41
ZFP62
ZFP64
ZFP91
ZFP92
ZFPM1
ZFPM2
ZFR
ZFYVE1
ZFYVE16
ZFYVE20
ZFYVE21
ZFYVE27
ZFYVE28
ZFYVE9
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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ZGLP1
ZGPAT
ZHX2
ZHX3
ZIC1
ZIC3
ZIC4
ZIC5
ZKSCAN1
ZKSCAN5
ZMIZ1
ZMIZ2
ZMPSTE24
ZMYM1
ZMYM2
ZMYM4
ZMYND11
ZMYND19
ZMYND8
ZNF10
ZNF117
ZNF12
ZNF121
ZNF136
ZNF138
ZNF14
ZNF143
ZNF146
ZNF148
ZNF16
ZNF167
ZNF169
ZNF174
ZNF181
ZNF182
ZNF185
ZNF187
ZNF192
ZNF193
ZNF2
ZNF20
ZNF200
ZNF204P
ZNF205
ZNF211
ZNF212
ZNF214
ZNF215
ZNF219
ZNF22
ZNF226
ZNF229
ZNF23
ZNF230
ZNF232
ZNF235
ZNF236
ZNF238
ZNF239
ZNF24
ZNF248
ZNF25
ZNF250
ZNF251
ZNF252
ZNF256
ZNF26
ZNF260
ZNF263
ZNF266
ZNF267
ZNF268
ZNF274
ZNF276
ZNF280B
ZNF280C
ZNF281
ZNF282
ZNF283
ZNF286B
ZNF295
ZNF296
ZNF3
ZNF311
ZNF317
ZNF318
ZNF322A
ZNF330
ZNF331
ZNF333
ZNF334
ZNF337
ZNF341
ZNF345
ZNF347
ZNF35
ZNF354C
ZNF362
ZNF382
ZNF385B
ZNF395
ZNF397
ZNF398
ZNF404
ZNF415
ZNF416
ZNF420
ZNF423
ZNF425
ZNF426
ZNF429
ZNF430
ZNF431
ZNF438
ZNF446
ZNF449
ZNF451
ZNF460
ZNF462
ZNF467
ZNF469
ZNF48
ZNF484
ZNF485
ZNF487
ZNF488
ZNF496
ZNF497
ZNF498
ZNF500
ZNF506
ZNF513
ZNF516
ZNF518B
ZNF524
ZNF525
ZNF527
ZNF528
ZNF530
ZNF532
ZNF536
ZNF540
ZNF542
ZNF543
ZNF547
ZNF551
ZNF552
ZNF566
ZNF568
ZNF57
ZNF574
ZNF575
ZNF576
ZNF578
ZNF580
ZNF583
ZNF584
ZNF585A
ZNF586
ZNF589
ZNF593
ZNF595
ZNF596
ZNF597
ZNF598
ZNF599
ZNF606
ZNF607
ZNF608
ZNF610
ZNF611
ZNF613
ZNF614
ZNF618
ZNF619
ZNF620
ZNF621
ZNF622
ZNF624
ZNF625
ZNF628
ZNF629
ZNF630
ZNF639
ZNF641
ZNF643
ZNF644
ZNF646
ZNF652
ZNF660
ZNF662
ZNF665
ZNF671
ZNF672
ZNF674
ZNF678
ZNF679
ZNF681
ZNF687
ZNF688
ZNF692
ZNF696
ZNF697
ZNF7
ZNF702P
ZNF703
ZNF704
ZNF709
ZNF710
ZNF711
ZNF713
ZNF714
ZNF718
ZNF721
ZNF737
ZNF740
ZNF749
ZNF75D
ZNF76
ZNF763
ZNF764
ZNF768
ZNF77
ZNF770
ZNF771
ZNF774
ZNF775
ZNF777
ZNF781
ZNF783
ZNF784
ZNF786
ZNF787
ZNF788
ZNF793
ZNF8
ZNF800
ZNF805
ZNF808
ZNF813
ZNF815
ZNF816A
ZNF823
ZNF827
ZNF828
ZNF829
ZNF83
ZNF830
ZNF831
ZNF835
ZNF836
ZNF837
ZNF843
ZNF844
ZNF845
ZNF85
ZNF860
ZNF862
ZNF879
ZNFX1
ZNHIT2
ZNHIT3
ZNHIT6
ZNRD1
ZNRF1
ZNRF2
ZNRF3
ZNRF4
ZP2
ZP3
ZPBP
ZPBP2
ZPLD1
ZSCAN10
ZSCAN12L1
ZSCAN20
ZSCAN21
ZSCAN22
ZSCAN23
ZSCAN4
ZSCAN5A
ZSCAN5B
ZSWIM2
ZSWIM4
ZSWIM5
ZSWIM6
ZSWIM7
ZW10
ZWILCH
ZXDC
ZYG11A
ZZEF1
ZZZ3
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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Supplementary Table 2. Top DNA methylation sites associated with depressive symptoms in the 
discovery EWAS: M2 is model additionally adjusted for antidepressant medication
CpG site ID Chr Location Gene symbol Direction 
M1$
p value
M1
Direction 
M2$
p value 
M2
cg04987734 14 103415873 CDC42BPB ++--+-+++ 4.93×10-8 ++--+-+++ 3.94×10-8
cg07012687 17 80195180 SLC16A3 +++-+++++ 3.47×10-7 +++-+++++ 4.51×10-7
cg08796240 16 70733832 VAC14 +++++++++ 7.43×10-7 ++-++++++ 4.06×10-6
cg06096336 2 231989800 PSMD1;HTR2B ++-++-+++ 8.06×10-7 +++++-+++ 2.11×10-6
cg16745930 10 100220809 HPSE2 --------- 1.34×10-6 --------- 2.19×10-6
cg09849319 5 1494983 LPCATI1 +++-+-+++ 1.81×10-6 +++-+-+++ 6.14×10-6
cg17237086 22 40814966 MKL1 +++++-+++ 3.44×10-6 ++-++-+++ 1.30×10-5
cg03985718 2 105924245 TGFBRAP1 +++-+-+++ 3.61×10-6 +++-+-+++ 1.28×10-5
cg21098005 20 44538605 PLTP +++++++++ 4.36×10-6 +++++++++ 7.86×10-6
cg16466652 19 6271960 MLLT1 +++-+++++ 4.39×10-6 +++-+++++ 7.08×10-6
cg07884764 11 64107517 CCDC88B +++-+++++ 5.03×10-6 +++-+++++ 1.50×10-5
cg01541347 7 4729920 FOXK1 ++++++++- 5.64×10-6 ++++++++- 6.66×10-6
cg02341197 21 34185927 C21or62 +++++-+++ 5.84×10-6 +++++++++ 8.57×10-6
cg01947751 3 196728969 - +++-+++++ 6.23×10-6 +++-+++++ 5.93×10-6
cg13747876 17 80195402 SLC16A3 +++++-+++ 6.32×10-6 +++++++++ 1.31×10-5
cg12764201 1 105101123 CORT;APITD1 +++++-+++ 7.15×10-6 +++++-+++ 1.33×10-5
cg08295111 5 133866097 PHF15 +++-+++++ 7.87×10-6 +++-+++++ 1.73×10-5
cg18030453 3 45506216 LARS2 +++-+-+++ 9.16×10-6 +++-+-+++ 2.44×10-5
cg12325605 3 56810151 ARHGEF3 +++++++++ 9.62×10-6 ++-++++++ 1.82×10-5
cg23282441 10 73533927 C10orf54;CDH23 ++--+++++ 9.69×10-6 ++-++++++ 5.30×10-6
$ Order of cohorts in the direction column: Discovery meta-analysis: CHS, FS, GS, HBCS, KORA, LBC1921, 
LBC1936, RS_BIOS, RS_III; Replication meta-analysis: WHI-EMPC, ARIC; Discovery and replication samples 
meta-analysis: CHS, FS, GS, HBCS, KORA, LBC1921, LBC1936, RS_BIOS, RS_III, WHI-EMPC, and ARIC; + 
hyper-methylation and – hypo-methylation.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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Supplementary Table 3. Top DNA methylation sites associated with depressive symptoms in the 
meta-EWAS (N = 11 256)
MarkerName Weight Zscore P value Direction$ HetPVal CHR MAPINFO UCSC_RefGene
cg12325605 11256 5.839 5.24×10-09 +++++++++++ 0.903 3 56810151 ARHGEF3
cg04987734 11256 5.653 1.57×10-08 ++--+-++++- 0.004874 14 103415873 CDC42BPB
cg14023999 11256 5.419 5.99×10-08 ++++++++-++ 0.1514 15 90543224
cg18030453 11253 5.293 1.20×10-07 +++-+-++++- 0.4738 3 45506216 LARS2
cg10829227 11254 5.1 3.40×10-07 +++++-+++++ 0.5651 19 47200595 PRKD2
cg07175797 11254 5.073 3.92×10-07 +++-+++-+++ 0.389 16 50317656
cg07012687 11251 5.048 4.46×10-07 +++-++++++- 0.2654 17 80195180 SLC16A3
cg12728588 11256 5.011 5.43×10-07 +++++++++++ 0.5798 1 36025489 NCDN
cg22069247 11253 4.93 8.23×10-07 +++-+-+++++ 0.7434 2 232393256 NMUR1
cg12526091 11256 4.912 9.00×10-07 +++-+-+++++ 0.8524 12 58245042
cg14012686 11253 4.89 1.01×10-06 ++-+++++++- 0.6241 2 74785750 C2orf65
cg00153395 11255 4.888 1.02×10-06 +++-+++++++ 0.8356 1 65327523 JAK1
cg04583842 10491 4.836 1.33×10-06 +++-+++?+++ 0.3046 16 88103117 BANP
cg03429645 11255 4.82 1.43×10-06 +++++++-+++ 0.666 3 100053188 NIT2
cg04286697 11256 4.78 1.75×10-06 +++-+++++++ 0.2851 2 232259623 B3GNT7
cg08796240 11256 4.775 1.80×10-06 ++++++++++- 0.2479 16 70733832 VAC14
cg19769147 11255 4.744 2.09×10-06 +++++-++++- 0.1715 14 105860954 PACS2
cg17822325 11253 4.722 2.33×10-06 +++++-+++++ 0.9251 1 31896462 SERINC2
cg06096336 11254 4.707 2.51×10-06 ++-++-+++++ 0.4324 2 231989800 PSMD1;HTR2B
cg10401362 11254 4.691 2.71×10-06 -++-+-+++++ 0.001998 7 157185402 DNAJB6
cg07467649 11256 4.689 2.75×10-06 +++-+-+++++ 0.3612 7 72856462 BAZ1B
cg13747876 11256 4.676 2.93×10-06 +++++-++++- 0.4857 17 80195402 SLC16A3
cg25392060 11256 4.664 3.10×10-06 +++-+++++++ 0.5181 8 142297121
cg22365240 11250 4.659 3.17×10-06 -++++++++++ 0.983 2 105374995
cg08631783 11253 4.62 3.83×10-06 -++-+-+-+++ 0.1325 15 89418456 ACAN
cg19269039 11255 4.62 3.84×10-06 ++++++++-++ 0.5069 1 111743200 DENND2D
cg03720762 11256 4.572 4.82×10-06 +++++++-+++ 0.08729 17 17604184 RAI1
cg21604136 11255 4.568 4.93×10-06 ++-++++++++ 0.1963 1 9910137 CTNNBIP1
cg11931558 11252 4.546 5.46×10-06 +++++++++++ 0.8237 7 11013742 PHF14
cg24550880 11255 4.531 5.88×10-06 +++-+-+++++ 0.4632 17 79420279 BAHCC1
cg07372520 11255 4.526 6.01×10-06 +++-+-+++++ 0.4239 1 180086434
cg05827190 11255 4.524 6.08×10-06 +++++-++-++ 0.2259 4 681440 MFSD7
cg19743103 11253 4.524 6.08×10-06 +++--++++++ 0.1436 1 6304220 HES3
cg17237086 11256 4.523 6.09×10-06 +++++-++++- 0.3516 22 40814966 MKL1
cg16745930 11254 -4.518 6.26×10-06 ----------- 0.1094 10 100220809 HPSE2
cg27305772 11256 4.507 6.57×10-06 +++++-+++++ 0.8274 11 65630355 MUS81
cg02341197 11256 4.5 6.80×10-06 +++++-+++++ 0.8595 21 34185927 C21orf62
cg23606718 11255 4.456 8.37×10-06 +++-+++++++ 0.8073 2 131513927 FAM123C
cg23282441 11254 4.449 8.63×10-06 ++--++++++- 0.4265 10 73533927 C10orf54;CDH23
cg17743381 11256 4.437 9.10×10-06 +++++-+++++ 0.7012 1 39024825
cg05251389 11254 4.424 9.67×10-06 +++-+++-+++ 0.7075 22 43525330 BIK
cg26610247 11255 4.424 9.70E-06 ++---++++++ 0.1656 8 142297175
 
$ Order of cohorts in the direction column: Discovery and replication samples meta-analysis: CHS, FS, GS, 
HBCS, KORA, LBC1921, LBC1936, RS_BIOS, RS_III, WHI-EMPC, and ARIC; + hyper-methylation and – hypo-
methylation.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
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Supplementary Table 7. Differentially expressed probes associated with methylation at cg14023999
probeID Effect SD p value p value FDR Gene Protein_Product Chr Cytoband
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CHAPTER 5
 
Physical health factors for depression

CHAPTER 5.1
 
Multiple episodes of late-life 
depression and cognitive decline
Jovanova Olivera, Wolters Frank, Ikram Arfan, Tiemeier Henning, Schmitz Norbert.
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ABSTRACT
Importance: Population-based studies consistently reported a cross-sectional but no prospective 
association between depression and cognitive decline. Clinical studies suggest that the number of 
depressive episodes a patient experienced, may explain the association between depression and 
cognitive decline. To date, no population-based study has investigated the prospective relation 
between single-episode and multiple-episode depression and subsequent cognitive decline.
Objectives: To determine the association between depressive episodes and cognitive change over 
a 12-year period.
Design, Settings and Participants: This study was embedded in the Rotterdam Study, a prospective 
population-based cohort of persons aged ≥ 55 years. 6 221 non-demented participants, with a 
mean (SD) age of 68.6 (8.1) years were enrolled between 1997 and 2001 and were followed for 
cognitive functioning until 2012.
Main outcomes and Measures: Depressive symptoms questionnaire and general practitioner 
records were used to detect 751 (12.1%) persons with single-episode and 350 (5.6%) persons 
with multiple-episode among 6 221 individuals (depression follow-up 1993 - 2004). Cognitive 
decline was determined during three consecutive examination rounds with a test-battery including 
a letter-digit-substitution test, Stroop test, verbal fluency test, and mini-mental state examination 
(cognition follow-up 1997 - 2011). The association between depressive episodes and cognitive 
decline was modelled with a latent growth curve adjusted for sociodemographic and lifestyle 
factors, and comorbidities.
Results: Severity of depressive symptoms at baseline was not related to cognitive decline during on 
average 12 years follow-up. Likewise, participants who experienced a single-episode depression 
had no excess decrease in cognitive functioning during follow-up (beta, -0.088; S.E., 0.12; p = 
0.45). In contrast, participants who experienced multiple-episodes of depression had a stronger 
decrease in the cognitive functioning than persons without depression (beta, -0.656; S.E., 0.16; 
p < 0.001).
Conclusions and relevance: In older adults, multiple-episode but not single-episode depression is 
associated with accelerated cognitive decline. This finding is in line with clinical studies showing 
that chronic psychiatric disease may have impact on brain resilience. Elderly persons suffering 
recurrent depression could be considered a target group for prevention and management of 
cognitive impairment.
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INTRODUCTION
Depression and cognitive decline are common chronic and disabling conditions affecting older 
people.1,2 Non-demented elderly diagnosed with depression often report cognitive complaints 
such as concentration loss, memory impairment, word-finding difficulties, or limitations in daily 
activities.2 Depression and cognitive impairment often co-occur1,3-9 and cognitive complaints 
frequently persist even after the remission of the depressive episode.2,7,10,11 Yet, whether 
depression-associated pathology contributes to the subsequent cognitive decline is uncertain.2
While it is often speculated that depression can negatively affect neurocognitive functioning, it 
is unclear whether depression truly contributes to subsequent cognitive decline.12 A substantial 
number of clinical and population-based studies addressed the prospective association between 
depression and cognitive complaints, but findings have been inconsistent.8,9,12-25 Clinical studies 
repeatedly reported greater cognitive decline following depression.12,19,20,22 In contrast, population-
based studies generally found no relation between depressive symptoms assessed at baseline and 
subsequent change in cognitive function.8,15-18,21 This discrepancy between epidemiological and 
clinical findings may relate to the variation in severity of depression between settings.
In order to reconcile these discrepant findings researchers have more recently studied persistent 
depressive symptoms in population-based studies.9,22,26 Persistent depression was defined as 
symptom ratings repeatedly assessed above a certain threshold. These studies showed that the 
persistence of symptoms across a 2 - 5 year follow-up period was paralleled by a decline in 
cognitive functioning.9,22,26 This essentially cross-sectional design of two repeatedly assessed 
measures suggests that multiple episodes23 of depressive symptoms rather than a single episode 
may be associated with cognitive decline. Against this background, a recent review argued that 
the relationship between severity of depression and cognitive disability is poorly understood and 
understudied.12
Longitudinal population-based studies that assess depressive episodes over a long period prior to 
cognitive decline are lacking.12 We aimed to investigate in an ongoing population-based study 
whether the frequency of exposure to depressive episodes in non-demented elderly is associated 
with cognitive decline if followed for many years. We hypothesized that persons with multiple 
episodes of depression have a faster cognitive decline over a 12 years follow-up period than 
individuals that experienced none or a single episode of depression.
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METHODS
Study population
This study was embedded in the Rotterdam Study, a prospective population-based cohort that 
started in 1990 among inhabitants aged ≥ 55 years living in the district Ommoord, Rotterdam, 
the Netherlands.27 The medical ethics committee approved the study according to the Population 
Study Act of the Dutch Ministry of Health (Wet Bevolkingsonderzoek). Written informed consent 
was obtained from all participants.
The first cohort of the Rotterdam Study included 7 983 participants and was expanded with an 
additional 3 011 participants, who had reached age of 55 years or moved into the study area, in 
the year 2000. The details of the objectives and the study design of the Rotterdam Study have 
been previously described elsewhere.27 In brief, all participants underwent home interview and 
an extensive set of examinations in a research centre during follow-up examination rounds that 
were conducted on average every 3 - 4 years.27 The current study included participants assessed 
for depressive episodes and cognitive functioning, during the 1997 - 1999 examination of the 
first cohort, and the 2000 - 2001 examination of the second cohort; this defines the baseline of 
the present study (Supplement 1 and Figure 1).
7 808 persons participated in this baseline examination of this study (Supplement 1). Of these, 
7 533 participants were screened for depressive symptoms (96.5% response rate). We excluded 
1 269 participants, who did not have full cognitive testing (at least two completed cognitive 
tests were required). The subjects with no cognitive assessment were on average older (74.9 
versus 69.0 years), more likely to be female (66.9% versus 56.7%) and had experienced more 
depression (20% versus 18%) than those participants with cognitive assessment. Additionally, we 
excluded 92 persons with prevalent dementia and 8 persons with bipolar disorder. This resulted 
in a cohort of 6 221 persons eligible for the study.
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Table 1. Study population by depressive episodes status (N = 6 221)
Depressive episodes
No depression
N = 5120
Single episode
N = 751
Multiple episodes
N = 350
Age, years 68.4 (8) 70.1 (8.5) 69.6 (7.9)
Sex, female 2757 (53.8) 495 (65.9) 270 (77.1)
Highest education attained
Primary 614 (12.0) 122 (16.2) 57 (16.3)
Lower/intermediate 2203 (43.0) 340 (45.3) 159 (45.4)
Vocational 1566 (30.6) 196 (26.1) 111 (31.7)
Higher 710 (13.9) 86 (11.5) 20 (5.7)
Smoking habits
Never smoker 1642 (32.1) 270 (36) 119 (34)
Current smoker 850 (16.6) 157 (20.9) 82 (23.4)
Past smoker 2628 (51.3) 324 (43.1) 149 (42.6)
Alcohol consumption
No consumption 484 (9.5) 88 (11.7) 51 (14.6)
Current consumers 4345 (84.9) 589 (78.54) 257 (73.4)
Past consumers 291 (5.7) 73 (9.7) 42 (12)
Body mass index, kg/m2 26.9 (3.9) 27.1 (4) 27.5 (4.5)
IADL* 15.6 (7.3) 15.3 (7.5) 15.3 (7.5)
Cardiovascular medication 2088 (40.8) 362 (48.2) 169 (48.3)
Psychotropic medication 631 (12.3) 217 (28.9) 156 (44.6)
Cancer 386 (7.5) 54 (7.2) 38 (10.9)
Diabetes mellitus 252 (4.9) 54 (7.2) 20 (5.2)
Myocardial infarctions 212 (4.1) 34 (4.5) 15 (4.3)
Stroke 152 (3.0) 38 (5.1) 20 (5.7)
Descriptive characteristics of study population were assessed at baseline and present the non-imputed data. 
The values represent counts (percentage) or means (standard deviations).*IADL – instrumental activity of 
daily living.
Assessment of depressive episodes
Participants were monitored for the occurrence of depressive episodes (including: depressive 
symptoms, depressive syndromes, dysthymia and major depressive disorders) during an average 
of 8 years. The time-lines for assessment of depressive episodes are illustrated in detail in Figure 1. 
The occurrence of depressive episodes was assessed continuously four years prior to baseline and 
before the first re-examination of the first cohort (first cohort 1993 - 2004). Likewise, depressive 
episodes were assessed prior to the first re-examination of the second cohort (second cohort 
1999 - 2004).
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Figure 1. Diagram of the timeline 
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In order to enhance case-findings of depressive episodes during the interval between examinations 
and at examination rounds the information was collected with different assessment methods.28 
First, we used information from the screening for depressive symptoms, performed at each 
examination. All participants were screened for depression with the validated Dutch versions of 
the Centre for Epidemiologic Studies Depression (CES-D) scale.29 The 20-item CES-D measure 
self-reported frequency of experienced depressive symptoms. Participants could score from 0 up 
to 60. A cut-off score of ≥ 16 defined participants with clinically relevant depressive symptoms, 
i.e., a depressive episode.29
To identify the depressive episodes that occurred and may have remitted in the intervals between 
follow-up examination rounds, we continuously monitored data on the occurrence of depressive 
episodes from the general practitioners (GP) records. The Netherlands have a primary health 
care system, thus all specialist must report to the GP. The GP records are elaborate and include 
diagnoses obtained from mental-health professionals substantiated by DSM-classification.28 The 
occurrences inferred from the different data sources were consistent.28
With this information, participants were either classified as persons with depressive episodes 
(single-episode (N = 751) and multiple-episode (N = 350) depression) and persons with no 
episodes of depression (N = 5 120). Only depressive episodes occurring before the first re-
assessment of cognitive functioning were included to minimize the overlap between depressive 
episode assessment and cognitive decline (Figure 1). Depression often has a chronic course and 
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only 60% of the persons suffering recover in the first year, 70 - 80% recover during the second 
year but remission of depression is not always well documented.28 Therefore, to distinguish 
between episodes we assumed that one depressive episode may last for a maximum of two years.
Cognitive functioning
Cognitive function was assessed during three consecutive examination rounds (Figure 1) with a 
battery of cognitive tests that included the Mini Mental State Examination (MMSE), Stroop test, 
a letter-digit substitution task (LDST), and a verbal fluency test (VF). On the MMSE, participants 
could score from 0 to 30 points.30 The 40-items Stroop test31 scored time needed to name the ink 
colour of incongruously printed name of colours. The LDST32 assessed the total number of correct 
digits assigned to letters according to a code key during 60 seconds. VF was assessed with the 
animal naming test.33 The total number of named animals within one minute were scored. Lower 
scores indicated worse performance on all tests, except for the Stroop test.
We used principal component analyses of the four cognitive test scores to derive a more robust 
summary test score (G-factor). The G-factor was calculated at each wave using a multiple 
indicator measurement model. The model was constrained by requiring corresponding loadings 
across waves to be equal in the assumption of measurement invariance (Supplement 3). For each 
participant, z-scores were calculated for the G-factor and each test separately by dividing the 
difference between individual test score and mean test score by the standard deviation.
Table 2. Descriptive of cognitive performance tests measured over time for depression
Depression status          Cognitive test
T1* T2* T3*
(1997-1999) (2002-2004) (2009-2011)
N Mean (SD) N Mean (SD) N Mean (SD)
Letter-digit substitution task
No depression 5036 28 (7.2) 3797 27.4 (7.5) 2480 26.5 (8.2)
Single episode 739 26.2 (7.5) 485 26.1 (7.5) 262 26.5 (9.4)
Multiple episodes 341 26.1 (7) 249 24.4 (7.4) 129 24.4 (9.3)
Verbal fluency test
No depression 5094 21.4 (5.7) 3888 20.7 (5.5) 2560 20.8 (6.3)
Single episode 747 20.8 (6.1) 502 20.5 (5.5) 274 20.9 (7.5)
Multiple episodes 347 20.6 (5.8) 261 19.8 (5.4) 138 19 (5.2)
Stroop test
No depression 4970 58.0 (27.3) 3 523 60.1 (29.9) 2466 61.8 (31.4)
Single episode 730 64.8 (34.9) 455 65.2 (37.8) 265 61.4 (29.4)
Multiple episodes 340 62.9 (29.7) 231 70.6 (38.5) 136 67.9 (40.4)
Mini–mental state examination
No depression 5119 27.8 (1.8) 3998 27.6 (2.2) 2718 27.4 (3)
Single episode 751 27.5 (2.1) 546 27.2 (2.7) 294 27.1 (3.1)
Multiple episodes 350 27.5 (2) 287 26.9 (3.1) 159 26.8 (2.9)
 
*T1: time point one; T2:  time point two; T3: time point three.
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Covariates
Data on socio-demographic background and life-style factors were assessed at baseline using 
standardized interview questions. Highest level of education was classified in four categories: low, 
intermediate-low, intermediate-high, and high education. Smoking and alcohol consumption 
habits were classifed as current, past and non-consumers. Presence of common chronic 
diseases (stroke, diabetes mellitus, myocardial infarction and cancer) was based on self-report, 
examination, medical record information, and drug utilization. Psychotropic and cardiovascular 
medications were self-reported during interview, and verifed by medication prescriptions. Height 
and weight were measured and body mass index (BMI) was calculated as weight divided by 
height squared (kg/m2). To assess physical self-maintenance, we used the instrumental-Activities 
of daily living scale (IADL).
DATA ANALYSIS
A descriptive analysis provided an overview of the study sample at baseline. Also, we assessed 
crude mean differences in cognitive test scores between persons with no depression, single-
episode, and multiple-episode depression at each of the three examination rounds, by using 
repeated measures analysis of variance.
In order to analyse the temporal relationship between depression and cognitive change we used 
a latent growth curve model (LGCM) approach. This approach models repeated measures into 
latent variables with a random intercept and random slope, allowing individual cases to have 
individual trajectories of change over time. This methodology permitted us to effectively study 
the within-person (intra-individual) and the between-person (inter-individual) change in cognitive 
functioning over time.
In the present study, a trajectory of cognition was modelled from the G-factor of cognitive 
functioning (constructed as described above). The trajectory was estimated by using an intercept 
(the average level of baseline scores) and a slope (linear rate of change over time). The time points 
for the slope growth factor were fixed at 0, 1, and 2 to define a linear growth model and the 
factor loadings were held constant across time to create an LGM process with latent slope and 
intercept.
This study examined the association of depression with the change rates (slope) of the G-factor 
of cognition measured at 3 time points (Figure 1). First, we evaluated the course of cognition 
over time while controlling for sex, age, education and cohort (Supplement 3). Second, we 
conditioned cognitive performance on baseline depressive symptoms and depressive episodes 
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status while controlling for sex, age, education and cohort. Third, we constructed a fully adjusted 
model were we additionally controlled the conditional models for other potential confounders; 
including various comorbidities, life-style, and demographic factors (Table 3).
Parameters were estimated using a maximum likelihood estimation, including estimating a 
random effect and estimator with robust standard errors. The general goodness of fit of each 
model was evaluated using the Comparative Fit Index (CFI) and the Root Mean Square Error of 
Approximation (RMSEA). Conventional rules suggest that a CFI ≥ 0.90 indicates adequate fit 
and CFI ≥ 0.95 indicates excellent fit; a RMSEA ≤ 0.08 indicates adequate fit (≤ 0.05 indicates 
excellent fit).34,35
Multiple imputations were used in to account for missing data on potential confounding 
variables (missing values: alcohol consumption 0.01%, BMI 0.5%, IADL 8.1%, cardiovascular 
and psycotropic medication 4.1%, cancer 0.01%, diabetes mellitus 0.2%, myocardial infarction 
8%, education 0.6%,). All analyses were run in the complete case and ten imputed data sets. In 
this manuscript we present results from the imputed data. Analyses were conducted in M-Plus 
(Version 7.3).
In a sensitivity analyses we conducted the analyses for the initial cohort and the extension cohort 
separately, to account for the slight discrepancy in the assessment of past depression (Supplement 
4).
RESULTS
Table 1 provides the demographics and clinical characteristics of the participants by depression 
status at baseline. Participants with single-episode (70.1 ± 8.5 years) and with multiple-episode 
(69.6 ± 7.9 years) were on average older than participants without depression (68.4 ± 8 years). 
Table 2 presents the mean cognitive status of the three depression groups at each assessment 
wave. The overall decline in all cognitive tests across follow-up in all three groups is shown. 
For example, persons with multiple episodes of depression had a lower MMSE score at all time 
points (27.5 at baseline and 26.8 at the end of follow-up) than those without depression (27.8 at 
baseline and 27.4 at the end of follow-up).
We first tested the association of depressive symptoms at baseline studied continuously with 
decline of cognitive functioning across follow-up (Supplement 2). Although persons with more 
depressive symptoms had worse cognitive function at baseline (see intercept, Supplement 2), we 
found no prospective association between depressive symptoms and cognitive decline (beta [B], 
-0.006; standard error [S.E.], 0.01; p = 0.28; see slope).
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Second, we investigated the association between frequency of depressive episodes and cognitive 
functioning (Table 3). All latent growth models had an excellent fit, with no CFI lower than 0.06 
and no RMCEA higher than 0.04. In line with the analysis of continuous depressive symptoms, 
we observed that a single or multiple episodes of depression were related to poor cognitive 
functioning at baseline (Table 3, see intercept). A single episode of depression was not associated 
with subsequent cognitive decline (B, -0.09; S.E., 0.12; p = 0.45; see slope), but persons with 
multiple-episode depression had faster cognitive decline than those without depression (B, -0.66; 
S.E., 0.2; p < 0.001). This finding was not significantly changed after adjustment for various 
potential confounders (Table 3).
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Table 3. Initial level and rate of change of cognitive functioning and single or multiple-episode 
depression using the Latent growth curve modelling (N = 6 221)
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.911 0.20 <0.001 -0.088 0.12 0.45
Multiple episodes -1.088 0.28 <0.001 -0.645 0.16 <0.001
Sex (female) 0.680 0.13 <0.001 0.198 0.07 0.007
Age -2.945 0.08 <0.001 -1.045 0.05 <0.001
Cohort -1.002 0.15 <0.001 0.075 0.08 0.36
Education 2.043 0.08 <0.001 0.091 0.04 0.034
Model fit indices: RMSEA* (95% CI) = 0.038 (0.036; 0.040); CFI** = 0.967
Fully adjusted model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.581 0.20 0.003 -0.088 0.12 0.45
Multiple episodes -0.545 0.28 0.053 -0.656 0.16 <0.001
Sex (female) 1.034 0.14 <0.001 0.153 0.08 0.051
Age -2.678 0.08 <0.001 -1.023 0.05 <0.001
Cohort -0.914 0.15 <0.001 0.094 0.08 0.25
Education 1.958 0.08 <0.001 0.090 0.04 0.036
Body mass index -0.022 0.02 0.18 -0.012 0.01 0.20
Cancer 0.506 0.24 0.033 -0.121 0.14 0.38
Diabetes mellitus -0.855 0.29 0.003 -0.541 0.17 0.002
Stroke -1.611 0.36 <0.001 -0.428 0.26 0.09
Myocardial infarction 0.258 0.33 0.47 -0.003 0.19 0.99
Psychotropic therapy -0.661 0.18 <0.001 0.061 0.11 0.57
Cardiovascular therapy -0.152 0.15 0.30 -0.173 0.08 0.030
IADL*** 1.318 0.12 <0.001 -0.063 0.08 0.44
Smoking habits 0.327 0.08 <0.001 -0.033 0.04 0.42
Alcohol consumption 0.050 0.16 0.75 -0.047 0.10 0.62
Model fit indices: RMSEA* (95% CI) = 0.028 (0.027; 0.030); CFI** = 0.965
* RMSEA: Root Mean Square Error of Approximation **CFI: Comparative Fit Index;***IADL instrumental 
activity of daily living.
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DISCUSSION
In this population-based cohort of older adults we investigated the impact of late-life depression 
on the change in cognitive functioning. We observed that increased baseline depressive symptoms 
(continuously assessed) did not predict cognitive decline over a 12 year follow-up. However, 
persons who had experienced multiple-episodes of depression were prone to faster cognitive 
decline during follow-up compared to those who experienced only one or no depressive episode. 
These results emphasise that the persistence or recurrence rather than the severity of depression 
at one time point relates to cognitive decline.
Depression and cognitive decline are two conditions consistently co-occurring more often than 
expected. Impaired cognition is an important symptom of depression and it is evident that 
clinical and community-dwelling individuals with depression have impaired cognitive functioning 
compared to non-depressed individuals.13,36,37
In contrast to the cross-sectional associations, the prospective association of depression and 
cognitive decline has been a challenge for both clinical and population based studies. Clinical 
studies mostly report prospective association in patients with depression7,12, while population-
based studies often did not find a prospective association.8,15,17,19 Consistent with previously 
published population-based studies, we also observed that depressive symptoms at baseline did 
not predict cognitive decline.8,14-18,20 The discordance in findings between clinical and population-
based studies is probably not a power problem, since these cohorts were sufficiently large and 
include many individuals with depressive symptoms. Rather, patients with more severe symptoms 
are typically selected in clinical studies due to referral patterns. Thus, in the general population 
studies persons screened positively for depressive symptoms may not have severe or chronic 
enough depressive problems to impact the cognitive functioning.
We continuously monitored persons over longer periods of time for the occurrence of depressive 
episodes and observed that not a single episode of depression but recurrent depression was 
associated with a stronger decline of cognitive functioning over the longer term. A few previously 
published studies support our results and suggest that persistent symptoms of depression are 
related to concurrent cognitive decline.9,21,26 For example, in the EVA study, the authors observed 
that more depressive symptoms at baseline were associated with lower MMSE scores only if the 
depressive symptoms persisted during the entire follow-up of 4 years.26 Also Kohler et al, reported 
a similar association between the co-occurring persistent depressive symptoms and the decline in 
cognition during 6 years follow-up.21 However, in these studies persistent depressive symptoms 
were defined during the same period as the cognitive functioning. In the present study, there is 
only a short overlap in the assessments periods of repeated depression and cognitive functioning 
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assessments. Hence, the longitudinal association reflects the decline of the cognitive function 
after the assessment of depression.
How does multiple-episode depression affect cognitive functioning?
The neuropsychological consequences of late-life depression are unclear. Various potential 
mechanisms may explain why multiple-episode but not single-episode depression is a risk factor 
for long-term cognitive decline. First, elderly people experience chronic stress due to age-related 
life-style, environmental, and health changes. Exposure to such a chronic stress increases the 
likelihood of developing mental disorders with a more chronic/recurrent course. Chronic stress 
can activate the hypothalamus-pituitary–adrenal (HPA) axis, which responds with cortisol release. 
This depression or stress-related prolonged hypercortisolemia is known to have adverse neurotoxic 
effect such as hippocampal neuronal degeneration and loss.38 Indeed, hyper-activation of the 
HPA axis with consequent hippocampal and hypothalamic atrophy were associated with both 
recurrent depression and cognitive decline.9,22,38-40 Importantly, other biological pathways also link 
depression and cognitive decline such as metabolic changes or inflammation.41,42 Studies have 
shown that severe or repeated depression is related to subsequent increase of interleukin-6 and 
other inflammatory markers.43
Second, depression and cognitive decline might reflect one shared underlying pathophysiological 
mechanism. For example, cerebrovascular disease causes disruption of prefrontal systems that 
can give rise to both mood and executive functions and thereby explain the relationship between 
depression and cognitive decline.44 This could be due to microvascular dysfunction which underlies 
amyloid-β formation, and white-matter changes.23 Indeed, a vascular hypothesis is supported 
by neuroimaging data showing that cerebrovascular lesions were related to both persistent 
depression and increased risk of dementia.45 Importantly, vascular small vessel disease can be 
both a cause and a consequence of depression, thus the two mechanisms above need not be 
exclusive. In this study we carefully adjusted for vascular morbidity at baseline including; stroke, 
diabetes mellitus, and myocardial infarction. Thus confounding by pre-existing vascular diseases 
is not very likely but this does not control for vascular change as a consequence of depression.
Limitations
We continuously monitored participants, both men and women, for depressive episodes for 
almost 12 years. This large population study combines a comprehensive follow-up of depression 
and detailed cognitive functioning assessments. Yet, several limitations need to be addressed. 
First, different aspects of severity of depression such as age of first onset, number and duration 
of the depressive episodes, duration of the illness, and treatment resistance might be more 
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meaningful for the subsequent cognitive functioning but are not easily measured in population-
based settings.12 Second, the cognitive battery assessment did not include all cognitive domains 
of interest. However, we constructed G-factor from four cognitive functioning measures which 
yields a good but not ideal proxy of the nominal five items G-factor.46 Third, persons with 
depression may have cognitive impairment prior to the occurrence of depression and a perception 
of cognitive decline can be precipitate depression.3,16 However, we excluded participants with 
prevalent dementia and controlled for baseline cognition function, thus reverse causality cannot 
easily explain our results. Fourth, the first cohort but not the second was assessed for history 
of depression four years prior to baseline (Figure). However, the sensitivity analysis stratified by 
cohort did not change the results (Supplement 4).
In conclusion, our study demonstrates that individuals who experienced multiple episodes of 
depression had accelerated decline in cognitive functioning over an average follow-up of 12 years 
compared to individuals without depression. In contrast, those who experienced a single episode 
of depression followed a similar trajectory of cognitive decline as those without depression. This 
result can help to reconcile the contrasting findings from clinical and population-based studies, 
and has implications for the prognosis and management of persons with chronic depression.
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ABSTRACT
Background: The association between myocardial infarction (MI) and depression is well described. 
Yet, the underlying mechanisms are unclear and the contribution of psychological factors is 
uncertain. We aimed to determine the risk of recognized (RMI) and unrecognized myocardial 
infarction (UMI) on depression, as both have a similar impact on cardiovascular health but differ 
in psychological epiphenomena.
Methods and results: Participants of the Rotterdam Study, 1 823 men aged ≥ 55, were followed 
for the occurrence of depression. RMI and UMI were ascertained using electrocardiography and 
medical history at baseline. We determined the strength of the association of RMI and UMI 
with mortality, and we studied the relation of RMI and UMI with depressive symptoms and the 
occurrence of major depression.
Results: The risk of mortality was similar in men with RMI (adjusted hazard ratio (HR): 1.71, 
95%CI: 1.45-2.03) and UMI (HR: 1.58, 95%CI: 1.27-1.97). Men with RMI had on average 
(unstandardized regression coefficient (B): 1.14, 95%CI: 0.07-2.21) higher scores for depressive 
symptoms. By contrast, we found no clear association between UMI and depressive symptoms 
(B: 0.55, 95%CI: -0.51-1.62) in men. Analysis including occurrence of major depression as the 
outcome were consistent with the pattern of association.
Conclusion: The discrepant association of RMI and UMI with mortality compared to depression 
suggests that the psychological burden of having experienced an MI contributes to the long-term 
risk of depression.
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INTRODUCTION
The increased occurrence of depression after myocardial infarction (MI) is well-recognized in 
clinical practice.1-3 In those that experienced MI, the prevalence of depression exceeds 30%.2,4 
Several biological and pathophysiological pathways including inflammation and endothelial 
dysfunction might link MI and depression5,6, but post-MI depression could also occur as a result of 
illness perception. Alterations in mood can be part of the coping process after surviving a cardiac 
event, treatment and recovery.4
MI is traditionally described as a clinical syndrome characterized with precordial discomfort and 
pain. Nevertheless, a substantial proportion of MIs are not clinically recognized by patients or 
treating physicians.7-9 The available epidemiological, clinical and basic science evidence provides 
support for a similar ischemic pathology underlying both recognized (RMI) and unrecognized 
(UMI) myocardial infarctions.10-14 Many studies demonstrated that UMI has a similar long-term 
impact on physical health as RMI. In men, and to a lesser extent in women, both RMI and UMI 
are associated with increased risk of all-cause mortality, heart failure and sudden death.14,15 In 
the Rotterdam Study, men with UMI were also at increased risk for dementia, stroke and cerebral 
small vessel diseases.16-19
Whether there is a common mechanism that engenders RMI and clinically UMI remains 
controversial.12 One theory suggests that the cardiac-pain mechanism is the main reason for the 
difference in the perception of the discomfort.20 A second theory suggests that various humoral 
and neurological factors together determine whether the symptoms arise from myocardial 
ischemia.21 Third, despite similar pathophysiology the size, location or duration of the myocardial 
ischemia could explain the absence of pain in UMI.10,14,21 There is a lack of empirical evidence to 
supporting any of the above theories and the reported long-term impacts of UMI on physical 
health suggests that differences in size and duration of ischemia are unlikely explanations. Finally, 
psychological factors regarding the recognition and willingness of the patient to seek medical 
attention have been discussed.12
To test the impact of RMI and UMI in the present study population, we first compared the 
association of RMI and UMI with mortality in men and women (note, mortality has been studied 
in a slightly different sample of the Rotterdam Study previously15). By definition, the awareness of 
having survived a life-threatening health event is absent in persons with UMI. This characteristic of 
UMI provides us with the opportunity to explore the potential role of psychological mechanisms 
underlying the relation between MI and depression, but only if the long-term impact can be 
established and if depression can be assessed independently of help seeking behavior. In this 
case our approach provides us with the unique opportunity to disentangle the pathophysiological 
from the psychological mechanisms in the association between MI and depression.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Myocardial infarction and the long-term risk for depression  |  227
5
The main aim of our study was to determine the relation of RMI and UMI with depression in older 
persons. If MI would cause depression mainly due to psychological mechanisms, we would expect 
that individuals, who are unaware of having had an MI, are not at risk of developing depression. 
Indeed we hypothesized that RMI but not UMI is associated with an increased risk of depression.
METHODS
The study was part of the Rotterdam Study, a population-based cohort designed to study the 
occurrence and determinants of diseases.22 In 1990, all residents aged ≥ 55 of Ommoord, a 
district in Rotterdam, the Netherlands, were invited to participate. Informed consent to retrieve 
information from treating physicians was obtained from all participants. The medical ethics 
committee approved the study according to the Wet Bevolkingsonderzoek-Population Study Act 
executed by the Ministry of Health, the Netherlands.
In the Rotterdam Study, four examination rounds have taken place. In each round, participants 
underwent home interviews and subsequent physical examinations at the research center. 
During the second examination (1993 - 1995), 4 940 persons were interviewed for depressive 
symptoms. This round constituted the baseline for the current study.23 We excluded 461 persons 
without electrocardiography, due to technical problems, or lack of personnel to operate the 
electrocardiography device. Another 23 persons were excluded because they withdrew the 
informed consent. We excluded persons with a Mini Mental State Exam (MMSE) score of ≤ 26 
at baseline (N = 287)24, no valid information on the MMSE (N = 129), and bipolar disorder (N = 
3). In total, 4 037 participants were eligible with a valid electrocardiography and evaluation of 
depressive symptoms. These participants were followed from baseline to occurrence of major 
depression (MDD), death, loss to follow-up, or the end of the study (January 1st, 2010).
History of myocardial infarction
MI status was assessed as described in detail previously.9 In short, at the research center visit, a 
10-second 12-lead electrocardiogram was recorded using an ACTA Gnosis IV-electrocardiography 
recorder (Esaote Biomedica, Florence, Italy) at a sampling frequency of 500 Hz and sored digitally.
Electrocardiograms were processed by the Modular electrocardiogram Analysis System (MEANS) 
to obtain electrocardiogram measurement and interpretation.25 Two research doctors blinded for 
other clinical information validated the electrocardiograms selected by MEANS. The diagnosis 
of MI using MEANS is mainly driven by pathological Q-waves and auxiliary criteria, such as QR 
ratio and R-wave progression. ST-T changes were not considered as criteria for MI by MEANS, 
but were taken into account by the clinicians validating and ascertaining the diagnosis of MI. 
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A senior cardiologist, ascertained the final diagnosis of MI. Assessment of clinically RMI was 
done as previously reported.9 A history of RMI was defined by self-reported MI confirmed by 
clinical data (GP records, and Nationwide Medical Registry), and confirmed or not confirmed with 
electrocardiogram characteristics matching MI.9 A history of UMI included all participants without 
documentation or self-reported MI, but with electrocardiogram characteristics matching MI.9 All 
UMIs were therefore Q-wave MIs. Persons without indication of MI on electrocardiography and 
no medical documentation of an earlier MI constituted the reference group.9
Vital status
The information on vital status is collected continuously, on a weekly basis from the Central 
Register of Population of Rotterdam. The follow-up for mortality started from the assessment of 
depression until loss to follow-up or September 5th, 2013 (mean follow-up 13.9 years).9,15
Depression
At baseline, all participants were screened for depression with the validated Dutch versions of 
the Centre for Epidemiologic Studies Depression (CES-D) scale26, or the Hospital Anxiety and 
Depression Scale (HADS-D).27 The reliability of these questionnaires was tested formally: the 
Cronbach alphas were 0.82 and 0.83, respectively. The CES-D consists of 20 items related to 
assess depressive symptoms. All symptoms were self-rated on a 0-3 scale, dependent upon the 
frequency of the experienced symptom.28 Participants could score from 0 up to 60. The HADS-D 
consists of 7 items measuring depressive symptoms. Again, participants rated the symptoms on a 
0 - 3 scale. Standardized Z-score of the CES-D and HADS-D scores at baseline was used to control 
for the severity of depressive symptoms and adjust for pre-existing depressive symptoms.
During first and second follow-up assessments (at the examination rounds in 1997 - 1999 and 
2002-2004) the CES-D scale was used to determine depressive symptoms.
From 1993 till 2010, participants were followed for the occurrence of MDD, which was 
determined from two sources of information as described previously.23 At follow-up examinations 
all participants who scored 16 or above on the CES-D scale, were invited to the research center 
for a semi-structured clinical interview to diagnose depressive disorders. A trained clinician 
diagnosed depression according to the Diagnostic and Statistical Manual of Mental Disorders, 
4th revised edition (DSM-IV) by using the Dutch version of the Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN).29 Second, medical records of general practitioners were continuously 
monitored for occurrence of an episode of MDD from baseline onward (mean follow-up 12.5 
years). Considering the information about possible MDD provided by the psychiatric interviews 
and medical records, we defined the occurrence of MDD episodes, as the first event that 
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chronologically occurred in one of the two data sources (note, all record retrievals were blinded 
for prior episodes). The occurrences inferred from the different data sources were consistent.23 
However, one assessment (SCAN) was repeatedly cross-sectional and the other assessment 
reflects continuous monitoring, thus such comparison must be interpreted carefully to account 
for the different assessment methods.
Covariates
Potential confounders were selected on the basis of prior knowledge.1,2 Marital status, education, 
smoking, and alcohol use were assessed at baseline during the home interview. Education was 
classified as low, intermediate, or high. Participants were classified as never married or divorced, 
married, and widowed. Smoking habits were classified as never, past, or current smoker and, 
similarly, alcohol consumption was classified as never, past, or current consumer. The MMSE was 
used to measure cognitive performance.24
Blood pressure was measured twice in the sitting position at the right upper arm with a random-
zero sphygmomanometer. The average of these consecutive measurements was calculated. 
Diabetes was considered present if fasting plasma glucose was 7.0 mmol/l or higher, non-fasting 
glucose or an oral glucose tolerance test result of 11.1 mmol/l or higher, or if the participant 
used blood glucose-lowering medication.30 A history of stroke was defined as a self-reported 
stroke verified by medical records.31 Height and weight were measured without heavy clothing to 
calculate body mass index (BMI).
DATA ANALYSIS
First we determined the relative mortality risk of participants with RMI and UMI using Cox 
proportional hazard regression analyses. These analyses were adjusted for age, level of education, 
smoking status, and alcohol consumption, history of stroke, diabetes, systolic blood pressure, 
and baseline depressive symptoms. Results of previous studies suggested sex difference in the 
prognosis of RMI and UMI.15 Also, the interaction term of history of MI with sex and mortality was 
statistically significant (p < 0.05). Therefore we stratified all analyses by sex.
Second, we studied whether RMI and UMI are associated with depressive symptoms with linear 
regression. The models were adjusted for baseline depressive symptoms in order to correct for 
pre-existing depression. Generalized Estimating Equation (GEE) approach was used to estimate 
the pooled effect of RMI and UMI on repeatedly assessed depressive symptoms. The interaction 
term of history of MI with sex and depressive symptoms was statistically significant (p < 0.05).
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All analyses related to the association between RMI/UMI and depressive symptoms were tested 
using two models. The first model was adjusted for age and baseline depressive symptoms. The 
second model was additionally adjusted for level of education, marital status, smoking status, 
alcohol consumption, BMI, history of stroke, diabetes mellitus, and systolic blood pressure.
Third, we assessed the association between RMI/UMI and MDD using Cox proportional hazard 
regression analyses. These analyses included two models with the same covariates in those 
testing depressive symptoms described above. The Breslow-Generalized Wilcoxon test was used 
to compare the hazard curves of RMI and UMI.
Multiple imputations were used in order to account for missing data on potential confounding 
variables. Smoking status was missing in 2.9%, marital status in 16.9%, BMI in 3.5%, alcohol 
consumption in 1.4%, systolic blood pressure in 1.5%, and education in 0.3% of the participants. 
All analyses were rerun in the complete case and five imputed data sets. In this paper we present 
results from the imputed data. All analyses were performed using IBM SPSS Statistics, version 21 
(IBM Corp., Somers, NY USA).
RESULTS
Baseline characteristics of 4 037 participants are presented in Table 1. The mean age of men was 
68.1 years (6.9 SD) and women were on average 68.5 years (7.7 SD). Of the men, 12.3% (N = 
220) had a RMI, 6.3% (N = 115) an UMI and 81.4% (N = 1 488) had no evidence of a MI. Of the 
women, 2.4% (N = 53) had had a RMI, 4.7% (N = 104) had had an UMI and 92.9% (N = 2 057) 
were free of MI. In total, 273 persons had a RMI, of these 138 had electrocardiography evidence 
of MI. The remaining 135 RMI cases were identified by clinical records and therefore represent 
non-Q-wave MIs.
First, we assessed the mortality risk of RMI and UMI (Table 2). In men, the average follow-up was 
13.1 years (23 846 person-years) during which 943 men died. RMI and UMI were associated 
with an increased risk of mortality: recognized MI (HR: 1.71, 95%CI: 1.45-2.03); UMI (HR: 1.58, 
95%CI: 1.27-1.97). In women, the average follow-up was 13.9 years (32 438 person-years) 
during which 825 women died. Women with RMI (N = 53) had a higher mortality risk (HR: 1.81, 
95%CI: 1.33-2.46). However, there was no association between UMI (N = 104) and mortality risk 
in women (HR: 0.99, 95%CI: 0.77-1.30).
Next, we studied the association between RMI and UMI and repeated assessments of depressive 
symptoms after a mean of 3.8 and 8.5 years The mean CES-D score at the first and second follow-
up assessment was 4.2 (6.7 SD) and 6.7 (7.7 SD), respectively. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Myocardial infarction and the long-term risk for depression  |  231
5
Ta
b
le
 1
. B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
o
f 
th
e 
st
u
d
y 
p
o
p
u
la
ti
o
n
 (
N
 =
 4
 0
37
)
H
is
to
ry
 o
f 
m
yo
ca
rd
ia
l i
n
fa
rc
ti
o
n
M
en
 (
N
=
1 
82
3)
W
o
m
en
 (
N
=
22
14
)
N
o
 M
I 
(N
=
14
88
)
R
ec
o
g
n
iz
ed
 M
I
(N
=
22
0)
U
n
re
co
g
n
iz
ed
 M
I
(N
=
11
5)
N
o
 M
I
(N
=
20
57
)
R
ec
o
g
n
iz
ed
 M
I
(N
=
53
)
U
n
re
co
g
n
iz
ed
 M
I
(N
=
10
4)
A
g
e,
 y
ea
rs
, m
ea
n
 (
SD
)
67
.6
 (6
.9
)
69
.8
 (6
.5
)
70
.1
 (7
.2
)
68
.2
 (7
.6
)
74
.3
 (8
.7
)
71
.8
(7
.9
)
D
ep
re
ss
iv
e 
sy
m
p
to
m
s 
at
 b
as
el
in
e,
 s
co
re
, m
ea
n
 (
SD
)*
4.
3 
(4
.7
)
4.
9 
(4
.9
)
4.
3 
(5
.6
)
5.
4 
(5
.9
)
7.
2 
(5
.7
)
6.
1 
(5
.9
)
Sm
o
ki
n
g
 s
ta
tu
s,
N
ev
er
 s
m
ok
er
, N
 %
13
2 
(8
.9
)
11
 (5
.1
)
7 
(6
.4
)
94
4 
(4
8)
23
 (4
6)
58
 (5
6.
9)
Pa
st
 s
m
ok
er
, N
 %
10
41
 (7
0.
6)
16
7 
(7
7)
78
 (7
1.
6)
65
8 
(3
3.
5)
21
 (4
2)
28
 (2
7.
5)
C
ur
re
nt
 s
m
ok
er
, N
 %
30
2 
(2
0.
5)
39
 (1
8)
24
 (2
2)
36
3 
(1
8.
5)
6 
(1
2)
16
 (1
5.
7)
A
lc
o
h
o
l c
o
n
su
m
p
ti
o
n
,
N
ev
er
 c
on
su
m
er
, N
 %
82
 (5
.5
)
26
 (1
1.
9)
3 
(2
.6
)
29
3 
(1
4.
5)
14
 (2
7.
5)
19
 (1
9)
Pa
st
 c
on
su
m
er
, N
 %
10
0 
(6
.8
)
23
 (1
0.
6)
11
 (9
.6
)
34
5 
(1
7.
1)
10
 (1
9.
6)
24
 (2
4)
C
ur
re
nt
 c
on
su
m
er
, N
 %
12
99
 (8
7.
7)
16
9 
(7
7.
5)
10
1 
(8
7.
8)
13
78
 (6
8.
4)
27
 (5
2.
9)
57
 (5
7)
M
M
SE
, s
co
re
, m
ea
n
 (
SD
) 
28
.2
 (1
.2
)
28
.2
 (1
.2
)
28
.1
 (1
.4
)
28
.1
 (1
.3
)
27
.9
 (1
.1
)
28
.2
 (1
.3
)
B
M
I, 
kg
/m
2,
 m
ea
n
 (
SD
)
25
.8
 (2
.9
)
26
.2
 (3
.1
)
26
.3
 (3
.2
)
26
.6
 (3
.9
)
27
.4
 (4
.5
)
27
.6
 (4
.5
)
Sy
st
o
lic
 b
lo
o
d
 p
re
ss
u
re
, m
m
H
g
, m
ea
n
 (
SD
)
13
9.
8 
(2
1.
6)
13
8.
4 
(2
0.
4)
14
6.
3 
(2
1)
14
0 
(2
1.
9)
13
4.
1 
(1
9.
2)
14
6.
3 
(2
3.
4)
B
lo
o
d
 p
re
ss
u
re
 lo
w
er
in
g
 m
ed
ic
at
io
n
, N
 %
27
4 
(1
9.
4)
81
 (3
9.
3)
22
 (2
0.
2)
52
1 
(2
6.
4)
18
 (3
7.
5)
30
 (3
0.
3)
H
is
to
ry
 o
f 
ca
rd
io
va
sc
u
la
r 
d
is
ea
se
s,
 N
 %
80
 (5
.4
)
20
5 
(9
3.
2)
99
 (8
6.
1)
61
 (3
)
50
 (9
4.
3)
86
 (8
2.
7)
H
is
to
ry
 o
f 
St
ro
ke
, N
 %
 
39
 (2
.6
)
13
 (5
.9
)
7 
(6
.1
)
32
 (1
.6
)
4 
(7
.5
)
3 
(2
.9
)
H
is
to
ry
 o
f 
C
A
B
G
, N
 %
 
36
 (2
.5
)
59
 (2
7.
6)
)
0 
(0
)
9 
(0
.4
))
8 
(1
5.
4)
)
0 
(0
)
H
is
to
ry
 o
f 
PC
I, 
N
 %
10
 (0
.7
)
12
 (5
.6
)
0 
(0
)
6 
(0
.3
)
4 
(7
.7
)
1 
(1
)
D
ia
b
et
es
 m
el
lit
u
s,
 N
 %
12
1 
(8
.1
)
40
 (1
8.
2)
17
 (1
6.
5)
16
2 
(7
.9
)
7 
(1
3.
2)
11
 (1
0.
6)
H
ig
h
es
t 
ed
u
ca
ti
o
n
 a
tt
ai
n
ed
,
Lo
w
 e
du
ca
tio
n,
 N
 %
28
2 
(1
9)
59
 (2
6.
78
)
26
 (2
3.
2)
72
9 
(3
5.
5)
27
 (5
0.
9)
35
 (3
4)
In
te
rm
ed
ia
te
 e
du
ca
tio
n,
 N
 %
93
5 
(6
3)
13
1 
(5
9.
5)
67
 (5
9.
8)
12
09
 (5
8.
9)
25
 (4
7.
2)
61
 (5
9.
2)
H
ig
h 
ed
uc
at
io
n,
 N
 %
26
8 
(1
8)
30
 (1
3.
6)
19
 (1
7)
11
3 
(5
.5
)
1 
(1
.9
)
7 
(6
.8
)
M
ar
it
al
 s
ta
tu
s,
N
ev
er
 m
ar
rie
d 
or
 d
iv
or
ce
d,
 N
 %
57
 (4
.6
)
9 
(5
.6
)
6 
(7
)
24
9 
(1
4.
3)
4 
(1
1.
1)
7 
(8
.1
)
M
ar
rie
d 
or
 li
vi
ng
 t
og
et
he
r, 
N
 %
10
55
 (8
4.
7)
14
0 
(8
6.
4)
66
 (7
6.
7)
97
0 
(5
5.
7)
14
 (3
8.
9)
41
 (4
7.
7)
 
W
id
ow
ed
, N
 %
13
3 
(1
0.
7)
13
 (8
)
14
 (1
6.
3)
52
2 
(3
0)
18
 (5
0)
38
 (4
4.
2)
Ta
bl
e 
pr
es
en
ts
 c
om
pl
et
e 
da
ta
, m
is
si
ng
 v
al
ue
s 
ar
e 
no
t 
im
pu
te
d 
he
re
.*
C
ES
-D
/H
A
D
S-
D
 z
-s
co
re
.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
232  |  Chapter 5.2
Table 2. Recognized and unrecognized MI and all-cause mortality risk with Cox regression (N = 4 
037)
All-cause mortality
  HR (95% CI) p value
Men (N = 1 823)
Recognized MI (N = 220)
Multivariate adjusted* 1.71 (1.45;2.03) <0.001
Unrecognized MI (N = 115)
Multivariate adjusted* 1.58 (1.27;1.97) <0.001
Women (N = 2 214)
Recognized MI (N = 53)
Multivariate adjusted* 1.90 (1.39;2.61) <0.001
Unrecognized MI (N = 104)
Multivariate adjusted* 0.99 (0.77;1.30) 0.99
1 768 (943 men) of 4 037 person died during 56 284 person-years of follow-up.
* Multivariate adjusted: additionally adjusted for age, level of education, smoking status, Alcohol consumption, 
history of stroke, diabetes mellitus and systolic blood pressure.
In men (Table 3), RMI predicted higher scores of depressive symptoms at the first (B: 1.05, 95%CI: 
0.16-1.95) and second assessment (B: 1.29, 95%CI: 0.07-2.52). UMI was not associated with 
depressive symptoms at the first (B: 0.79, 95%CI: −0.34-1.97), or second assessment (B: 0.54, 
95%CI: −1.14-2.21). In the combined analysis of the two assessments, we observed that RMI (B: 
1.14, 95%CI: 0.07-2.21) but not UMI (B: 0.55, 95%CI: −0.51-1.62) was associated with more 
depressive symptoms. In women (Table 4), RMI was not significantly associated with depressive 
symptoms in the first (B: -1.37, 95%CI: −3.64-0.90) or in the second assessment (B: 1.48, 95%CI: 
−1.94-4.89). Moreover, there were no significant associations in the combined analysis of the two 
depressive symptoms assessments (B: -0.86, 95%CI: −3.13-1.42). UMI was not associated with 
depressive symptoms in any analysis. For this reason we restricted the additional analysis on 
occurrence of MDD in men only.
In an additional sensitivity analysis we explored the relation of RMI and UMI with the occurrence 
of MDD. Men were followed up for 11.8 years ± 4.71 SD (21 664 person years). In total, 52 
men (10 of those with RMI but only 3 of those with UMI) developed MDD during follow-up. We 
calculated occurrence of MDD during follow-up and cannot present point prevalence data. Men 
with a history of RMI were at increased risk to develop MDD (HR: 2.18, 95%CI: 1.04-4.57), but 
not those with an UMI (HR: 0.99, 95%CI: 0.77-1.30). The difference between the risk of RMI and 
UMI was statistically significant (p = 0.024).
We repeated the analyses (see Supplementary material 1) excluding RMI cases that did not meet 
electrocardiography criteria for prior Q-wave MI, to reduce possible misclassification and bias 
by person (over) reporting symptoms. In these analyses, the effect estimates were very similar. 
However, due to loss of statistical power the effect was no longer statistically significant.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Myocardial infarction and the long-term risk for depression  |  233
5
Ta
b
le
 3
. T
h
e 
lo
n
g
it
u
d
in
al
 a
ss
o
ci
at
io
n
 o
f 
re
co
g
n
iz
ed
 o
r 
u
n
re
co
g
n
iz
ed
 M
I w
it
h
 d
ep
re
ss
iv
e 
sy
m
p
to
m
s 
in
 m
en
 (
N
 =
 1
 8
23
)
D
ep
re
ss
iv
e 
sy
m
p
to
m
s
Fi
rs
t 
as
se
ss
m
en
t§
(N
 =
 1
47
1)
Se
co
n
d
 a
ss
es
sm
en
t§
(N
 =
 1
11
3)
C
o
m
b
in
ed
 a
n
al
ys
is
(N
 =
 x
, w
ith
 2
58
4 
ob
se
rv
at
io
ns
)
Ex
p
o
su
re
N
B
 (
95
%
 C
I)
p
 v
al
u
e
N
B
 (
95
%
 C
I)
p
 v
al
u
e
B
 (
95
%
 C
I)
p
 v
al
u
e
R
ec
o
g
n
iz
ed
 M
I 
A
dj
us
te
d 
fo
r 
ag
e 
an
d 
ba
se
lin
e 
de
pr
es
si
ve
 s
ym
pt
om
s*
15
9
0.
92
 (0
.2
9;
1.
81
)
0.
04
3
10
2
1.
26
 (0
.0
4;
2.
48
)
0.
04
3
1.
06
 (-
0.
09
;2
.1
3)
0.
05
2
M
ul
tiv
ar
ia
te
 a
dj
us
te
d*
*
15
9
1.
05
 (0
.1
6;
1.
95
)
0.
02
1
10
2
1.
29
 (0
.0
7;
2.
52
)
0.
03
9
1.
14
 (0
.0
7;
2.
21
)
0.
03
7
U
n
re
co
g
n
iz
ed
 M
I 
A
dj
us
te
d 
fo
r 
ag
e 
an
d 
ba
se
lin
e 
de
pr
es
si
ve
 s
ym
pt
om
s*
84
0.
85
 (-
0.
33
;2
.0
4)
0.
16
51
0.
50
 (-
1.
18
;2
.1
8)
0.
56
0.
62
 (-
0.
44
;1
.6
7)
0.
25
M
ul
tiv
ar
ia
te
 a
dj
us
te
d*
*
84
0.
79
 (-
0.
40
;1
.9
7)
0.
19
51
0.
54
 (-
1.
14
;2
.2
1)
0.
53
0.
55
 (-
0.
51
;1
.6
2)
0.
31
A
na
ly
si
s 
w
er
e 
pe
rf
or
m
ed
 w
ith
 li
ne
ar
 r
eg
re
ss
io
n 
an
d 
ge
ne
ra
liz
ed
 e
st
im
at
in
g 
eq
ua
tio
ns
.
§ 
C
ES
-D
 m
ea
n 
sc
or
e 
(S
D
); 
Fi
rs
t 
as
se
ss
m
en
t:
 R
ec
og
ni
ze
d 
M
I 4
.2
 (7
.9
), 
U
nr
ec
og
ni
ze
d 
M
I 3
.8
 (6
.5
) a
nd
 N
o 
M
I 2
.9
 (5
.3
); 
Se
co
n
d
 a
ss
es
sm
en
t:
 R
ec
og
ni
ze
d 
M
I 6
.7
 
(8
.1
), 
U
nr
ec
og
ni
ze
d 
M
I 5
.4
 (5
.9
) a
nd
 N
o 
M
I 5
.1
 (6
.3
)
*M
od
el
 a
dj
us
te
d 
fo
r 
ag
e 
an
d 
ba
se
lin
e 
de
pr
es
si
on
 (c
or
re
ct
ed
 f
or
 b
as
el
in
e 
de
pr
es
si
ve
 s
ym
pt
om
s)
;
**
M
ul
tiv
ar
ia
te
 a
dj
us
te
d:
 a
dd
iti
on
al
ly
 a
dj
us
te
d 
fo
r 
le
ve
l 
of
 e
du
ca
tio
n,
 m
ar
ita
l 
st
at
us
, 
bo
dy
 m
as
s 
in
de
x,
 s
m
ok
in
g 
st
at
us
, 
al
co
ho
l 
co
ns
um
pt
io
n,
 a
nd
 h
is
to
ry
 o
f 
st
ro
ke
, d
ia
be
te
s 
m
el
lit
us
 a
nd
 s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
234  |  Chapter 5.2
Ta
b
le
 4
. T
h
e 
lo
n
g
it
u
d
in
al
 a
ss
o
ci
at
io
n
 o
f 
re
co
g
n
iz
ed
 o
r 
u
n
re
co
g
n
iz
ed
 M
I w
it
h
 d
ep
re
ss
iv
e 
sy
m
p
to
m
s 
in
 w
o
m
en
 (
N
 =
 2
 2
14
)
D
ep
re
ss
iv
e 
sy
m
p
to
m
s
Fi
rs
t 
as
se
ss
m
en
t§
(N
 =
 1
83
1)
Se
co
n
d
 a
ss
es
sm
en
t§
(N
 =
 1
50
6)
C
o
m
b
in
ed
 a
n
al
ys
is
(N
 =
 x
, w
ith
 3
33
7 
ob
se
rv
at
io
ns
)
Ex
p
o
su
re
N
B
 (
95
%
 C
I)
p
 v
al
u
e
N
B
 (
95
%
 C
I)
p
 v
al
u
e
B
 (
95
%
 C
I)
p
 v
al
u
e
R
ec
o
g
n
iz
ed
 M
I 
A
dj
us
te
d 
fo
r 
ag
e 
an
d 
ba
se
lin
e 
de
pr
es
si
ve
 
sy
m
pt
om
s*
36
-1
.1
1 
(-
3.
37
;1
.1
6)
0.
34
19
1.
24
 (-
2.
20
;4
.6
8)
0.
48
-0
.7
3 
(-
3.
0;
1.
54
)
0.
53
M
ul
tiv
ar
ia
te
 a
dj
us
te
d*
*
36
-1
.3
7 
(-
3.
64
;0
.9
0)
0.
24
19
1.
48
 (-
1.
94
;4
.8
9)
0.
40
-0
.8
6 
(-
3.
13
;1
.4
2)
0.
46
U
n
re
co
g
n
iz
ed
 M
I 
A
dj
us
te
d 
fo
r 
ag
e 
an
d 
ba
se
lin
e 
de
pr
es
si
ve
 
sy
m
pt
om
s*
84
0.
12
 (-
1.
38
3;
1.
62
)
0.
87
62
0.
57
 (-
1.
37
;2
.5
0)
0.
57
0.
23
 (-
1.
18
;1
.6
4)
0.
75
M
ul
tiv
ar
ia
te
 a
dj
us
te
d*
*
84
-0
.0
4 
(-
1.
54
;1
.4
6)
0.
96
62
0.
39
 (-
1.
54
;2
.3
3)
0.
69
0.
12
 (-
1.
30
;1
.5
4)
0.
87
A
na
ly
si
s 
w
er
e 
pe
rf
or
m
ed
 w
ith
 li
ne
ar
 r
eg
re
ss
io
n 
an
d 
ge
ne
ra
liz
ed
 e
st
im
at
in
g 
eq
ua
tio
ns
.
§ 
C
ES
-D
 m
ea
n 
sc
or
e 
(S
D
); 
Fi
rs
t 
as
se
ss
m
en
t:
 R
ec
og
ni
ze
d 
M
I 5
.2
 (8
.2
), 
U
nr
ec
og
ni
ze
d 
M
I 5
.9
 (8
.2
) a
nd
 N
o 
M
I 4
.9
 (7
.2
); 
Se
co
n
d
 a
ss
es
sm
en
t:
 R
ec
og
ni
ze
d 
M
I 1
0.
2 
(9
.2
), 
un
re
co
gn
iz
ed
 M
I 9
.1
 (8
.4
) a
nd
 N
o 
M
I 7
.6
 (8
.3
)
*M
od
el
 a
dj
us
te
d 
fo
r 
ag
e 
an
d 
ba
se
lin
e 
de
pr
es
si
on
 (c
or
re
ct
ed
 f
or
 b
as
el
in
e 
de
pr
es
si
ve
 s
ym
pt
om
s)
;
**
M
ul
tiv
ar
ia
te
 a
dj
us
te
d:
 a
dd
iti
on
al
ly
 a
dj
us
te
d 
fo
r 
le
ve
l 
of
 e
du
ca
tio
n,
 m
ar
ita
l 
st
at
us
, 
bo
dy
 m
as
s 
in
de
x,
 s
m
ok
in
g 
st
at
us
, 
al
co
ho
l 
co
ns
um
pt
io
n,
 a
nd
 h
is
to
ry
 o
f 
st
ro
ke
, d
ia
be
te
s 
m
el
lit
us
 a
nd
 s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Myocardial infarction and the long-term risk for depression  |  235
5
DISCUSSION
Men with RMI or UMI had an increased mortality risk in this population-based study, as 
demonstrated previously.15 However, the risks of RMI and UMI for depression did not correspond 
to the mortality risks. Whereas men with RMI had an increased risk to develop depression, men 
with UMI were at similar risk to develop depression compared to persons without MI. In line with 
other studies, we confirmed a much weaker association between unrecognized MI and survival in 
women.8 This has been attributed to the increased likelihood of lead-placement artefacts due to 
breast tissue.32 Therefore, the results of the association between unrecognized MI and depression 
in women are hard to interpret.
A history of UMI conveyed a long-term increased risk of both depressive symptoms and MDD in 
men. Many studies of cardiovascular disease and depression focused on the prognostic value of 
short-term incidence of depression in patients shortly after the diagnosis of MI.2,33,34 One such 
study reported that patients with heart disease have 45% more depressive symptoms compared 
to those without heart disease.35 The long-term risk of psychological distress in post-MI patients as 
well as depression in patients with cardiovascular disease have previously been studied for follow-
up periods of 5-8 years.35,36 The present study addresses a period of 11 years after experiencing 
MI. In men, RMI was associated with an increased risk of MDD that remained elevated even over a 
long period. However, in men UMI was not associated with depressive symptoms or occurrence of 
MDD, although it was a risk factor for mortality. This discrepancy in the risks of UMI for mortality 
and depression, when compared to RMI, can be explained in multiple ways.
First, previous studies have suggested that patients with UMI may have less severe symptoms 
and mostly do not consult physicians.12,37 Others have argued that, the size of myocardial tissue 
damage underlying UMI may also be less severe.38 Yet, our study showed that in men, UMI was 
almost as predictive of mortality as RMI. This suggests that the underlying pathology is of equal 
severity.
Second, it is conceivable that the mortality risk of RMI and UMI are similar only due to the medical 
interventions and behavioral changes occurring after RMI. Successful treatment of RMI certainly 
decreases mortality risk.39 However, it is questionable whether treating MI successfully has a 
strong impact on the risk of depression.40
Third, depression may also be an adverse effect of the treatment of RMI. Patients with RMI are 
more often treated with interventions such as percutaneous coronary intervention to restore the 
coronary blood flow and the tissue perfusion.39 These procedures have been associated with 
increased risk of depressive symptoms because of the intensity of the treatment procedure.3 
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Also, drugs used for blood pressure and heart rate control, such as beta-blockers, may worsen 
depressive symptoms.39 However, we accounted for antihypertensive use and previous cardiac 
interventions at baseline to control for this effect.
Fourth, our results suggest that in men psychological factors contribute to the development 
of depression after MI. Although it remains difficult to disentangle psychological mechanisms 
from the pathophysiological mechanism underlying both MI and depression, we argue that 
psychological mechanisms are key to the different risk patterns of RMI and UMI in men. Due to 
improved clinical management of clinical MI, the survival has improved substantially, yet patients 
with MI often experience the event as life threatening.41 Further, frightening events impact not 
only the survivors health, but also theirs families and working life.42 These resulting lifestyle 
changes contribute to the psychological reaction following the MI experience and often resulting 
in depression.43 Clinical studies of MI patients demonstrated that the psychological distress related 
to health problems makes men particularly vulnerable to depression.36
We did not observe any relation between RMI or UMI with depressive symptoms in women. Only 
53 women but 220 men had RMI at baseline, thus our analysis were underpowered in women. 
Moreover, we found no relation between UMI and mortality in women, suggesting that this 
event does not signal pathophysiological change or that there is possible misclassification of UMI 
in women. Some studies reported a low accuracy of electrocardiography diagnostics in older 
women.32 In this light the association of UMI with both mortality and depression was consistent.
Depression is an established risk factor for coronary heart disease44 and may thus contribute to 
the occurrence of MI. Although we correct for baseline depressive symptoms, reverse causality 
could in theory influence the observed association between RMI and depression.45 The Rotterdam 
Study started with screening for depression during 1993, this assessment constitutes the baseline 
of our study and no prior assessments were conducted.
A limitation of our study is the possible misclassification of UMI. The definition of UMI heavily relies 
on the presence of pathological Q-waves, therefore most non-Q-wave MIs remained undetected. 
Second, electrocardiogram evidence of a previous MI can disappear over time.20 This again could 
lead to misclassification of UMI and thereby lower the effect estimates. Third, the known history 
of RMI might introduce assessment bias towards MDD diagnosis. In contrast, individuals with UMI 
have less specific symptomatology and mostly seek no medical care thus may avoid MDD medical 
diagnosis. However, the systematic approaches we used to ascertain events of MDD minimize the 
possibility of these biases.23 Forth, due to the observational nature of the study design presence 
of residual confounding cannot be ruled out.
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Our study has several strengths. It is based on a large well-described population-based cohort with 
a long follow-up. Data were gathered prospectively and without prior knowledge of MI status. 
Participants were monitored continuously during follow-up for the occurrence of depression and 
diagnoses were made by clinical interviews according to the DSM criteria. We used different data 
sources and approaches to collect and validate MDD.23
Furthermore, detailed information on RMI was collected and validated from the medical 
records of the participants.9 Importantly, when we restricted the cases with RMI to those with 
electrocardiography-verified changes (excluding those with clinical symptoms only) results did not 
change. This suggest that possible misclassification cannot explain our findings. Possibly, persons 
(over)reporting more symptoms (without pathology) do not account for the observed association 
and did not bias the effect estimates (see (Macleod et al., 2002) for example).46
In conclusion, RMI and UMI are both associated with a higher mortality risk in men. However, only 
man with RMI had a higher likelihood of depression during follow-up. Although pathophysiological 
differences between UMI and RMI may also explain this discrepancy, our results are consistent 
with the hypothesis that the psychological burden of experiencing MI contributes to the long-
term risk of depression after MI. We can only carefully speculate about clinical implication as 
future studies must confirm this results and the underlying mechanisms but our findings suggest 
that effective long-term prevention of post-MI depression should address the psychological 
impact of experiencing an MI.
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APPENDIX of CHAPTER 5.1
Figure 1. Flow chart of study population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Flow chart of study population. 
RS = Rotterdam Study, Roman numbers denote cohorts and Arabic numbers examination 
waves, e.g. RS I-3 = third examination round of the first cohort MMSE= Mini Mental State 
Examination 
 N = 7 808                       
Persons participated in the 
baseline examination of this 
study (RS I-3 and RS II-1) 
N = 7 533                       
Persons assessed for 
depression 
 
N = 275 excluded                          
Missing data: not screened for CES-D 
depressive symptoms 
 
N = 8 excluded                         
Prevalent bipolar disorder 
 
 N = 92 excluded                     
Prevalent dementia 
 
N = 7 433                 
Participants free from 
prevalent bipolar disorder and 
dementia 
 
N = 1 212 excluded                
Missing data: cognition assessed 
only with MMSE 
 
N = 6 221                             
Total sample in analysis of 
depressive symptoms with 
cognitive decline 
 RS=Rotterdam Study, Roman numbers denote cohorts and arabic numbers examination waves, e.g. RS I-3 = 
third examination round of the first cohortMMSE= Mini Mental State Examination
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Baseline depressive symptoms analysis – Supplement 1.
Initial level and rate of change of cognitive functioning and single or multiple-episode depression 
using the Latent growth curve modelling (N = 6 221)
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive symptoms -0.080 0.01 <0.001 -0.007 0.01 0.18
Sex (female) 0.758 0.14 <0.001 0.180 0.07 0.015
Age -2.909 0.08 <0.001 -1.047 0.05 <0.001
Cohort -0.843 0.15 <0.001 0.098 0.08 0.28
Education 2.031 0.08 <0.001 2.043 0.08 0.028
Model fit indices: RMSEA* (95% CI) = 0.039 (0.037; 0.041); CFI** = 0.967
Fully adjusted model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive symptoms -0.050 0.01 <0.001 -0.006 0.01 0.28
Sex (female) 1.081 0.14 <0.001 0.139 0.08 0.078
Age -2.665 0.08 <0.001 -1.022 0.05 <0.001
Cohort -0.827 0.15 <0.001 0.120 0.08 0.14
Education 1.954 0.08 <0.001 0.090 0.04 0.037
Body mass index -0.022 0.02 0.17 -0.013 0.01 0.15
Cancer 0.548 0.24 0.021 -0.138 0.14 0.31
Diabetes mellitus -0.858 0.29 0.003 -0.529 0.17 0.002
Stroke -1.523 0.36 <0.001 -0.433 0.26 0.09
Myocardial infarction 0.272 0.33 0.40 -0.04 0.19 0.83
Psychotropic therapy -0.555 0.18 0.002 -0.004 0.11 0.96
Cardiovascular therapy -0.156 0.14 0.27 -0.159 0.08 0.044
IADL 1.289 0.11 <0.001 -0.046 0.08 0.58
Smoking habits 0.327 0.08 <0.001 -0.032 0.04 0.43
Alcohol consumption 0.064 0.16 0.68 -0.050 0.10 0.60
Model fit indices: RMSEA* (95% CI) = 0.029 (0.027; 0.030); CFI** = 0.965
* RMSEA: Root Mean Square Error of Approximation **CFI: Comparative Fit Index;***IADL instrumental 
activity of daily living.
Unconditional Model
Estimate S.E. p value
Factor loadings of latent variable cognition at T1 (baseline)
LDST 1.000
VF 0.571 0.010 <0.001
STROOP -3.629 0.062 <0.001
MMSE 0.215 0.004 <0.001
Intercept and slope of latent variable cognition
Intercept  0.000 0.000 /
Slope -2.812 0.143 0.001
Model fit indices: RMSEA* (95% CI) = 0.041 (0.039; 0.043); CFI** = 0.967
* RMSEA: Root Mean Square Error of Approximation **CFI: Comparative Fit Index;
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Stratified analysis in to the respect of cohort
Cohort 1 analysis
Flow chart of study population.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Flow chart of study population within the RS-I 
RS = Rotterdam Study, Roman numbers denote cohorts and Arabic numbers examination 
waves, e.g. RS I-3 = third examination round of the first cohort MMSE = Mini Mental St te
Examination 
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Table 1. Study population by depressive episodes status (N = 3 888)
Depressive episodes
No depression
N = 3143
Single episode
N = 499
Multiple episodes
N = 246
Age, years, mean (SD) 71.3 (6.8) 72.9 (7) 71.9 (6.4)
Sex*, female, N (%) 1726 (54.9) 326 (65.3) 192 (78)
Highest education attained,
Primary, N (%) 474 (15.2) 90 (18.3) 49 (20.2)
Lower/intermediate, N (%) 1324 (42.5) 219 (44.5) 107 (44)
Vocational, N (%) 970 (31.1) 142 (28.9) 76 (31.1)
Higher, N (%) 348 (11.2) 41 (8.3) 11 (4.5)
IADL**, score, mean (SD) 17.7 (0.6) 17.6 (0.9) 17.5 (0.8)
Smoking habits,
Never smoker, N (%) 1043 (33.2) 186 (37.3) 91 (37)
Current smoker, N (%) 470 (15.2) 98 (19.6) 51 (20.7)
Past smoker, N (%) 1622 (51.6) 215 (43.1) 104 (42.3)
Alcohol consumption,
No consumption, N (%) 316 (10.1) 57 (11.4) 40 (16.3)
Current consumers, N (%) 2642 (84.1) 391 (78.4) 175 (71.1)
Past consumers, N (%) 185 (5.9) 51 (10.2) 31 (12.6)
Body mass index, mean (SD) 26.8 (3.9) 27.1 (4) 27.2 (4.1)
Cardio vascular medication, N (%) 1413 (45) 261 (52.3) 130 (52.8)
Central nervous system medication, N (%) 426 (13.6) 141 (28.3) 107 (43.5)
Cancer, N (%) 167 (5.3) 30 (6) 22 (8.9)
Diabetes mellitus, N (%) 136 (4.3) 24 (4.8) 12 (4.9)
Myocardial infarction, N (%) 106 (3.4) 24 (4.8) 5 (2)
Stroke, N (%) 109 (3.4) 22 (4.4) 14 (5.7)
Descriptive characteristics of study population were assessed at baseline. Values represent percentage (%), or 
mean (SD). *Female; **IADL: Instrumental activity of daily leaving score.
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Table 2. Descriptive of cognitive performance tests measured over time for depression
Depressive episodes Cognitive test
Time point T1* T2* T3*
N Mean (SD) N Mean (SD) N Mean (SD)
Letter-digit substitution task
No depression 3088  27.9 (7) 2196 25.6 (6.8) 1127 25.1 (8.3)
Single episode 492 25.1 (7.4) 289 24.5 (7.3) 132 25.1 (11.4)
Multiple episodes 239 25.4 (6.5) 174 23.2 (7.1) 83 23.4 (10.2)
Verbal fluency test
No depression 3125 21 (5.4) 2264 20.4 (5.4) 1323 19.9 (6.4)
Single episode 497 20.1 (6.1) 302 19.8 (5.1) 140 19.3 (7.5)
Multiple episodes 245 20.4 (5.9) 184 19.4 (5.5) 91 18.5 (5.3)
Stroop test
No depression 3048 61.5 (29.1) 2069 64.1 (31.6) 1260 66.9 (35.1)
Single episode 481 68.8 (37.5) 273 69.7 (42.2) 133 69.5 (36.6)
Multiple episodes 239 65.7 (32.8) 165 73.8 (39.2) 88 74 (40.4)
The mini–mental state examination
No depression 3142 27.8 (1.8) 2329 27.5 (2.3) 1434 27 (3.4)
Single episode 499 27.4 (2.2) 336 26.9 (2.8) 154 26.6 (3.6)
Multiple episodes 246 27.5 (2) 200 27 (2.6) 108 26.6 (3)
 
*T1: time point one (1997-1999); T2: time point two (2002-2004); T3: time point three (2009-2011).
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Table 3. Initial level (intercept) and rate of change (slope) of cognitive performance and late-life 
depression using the Latent growth curve modelling (N = 3 888)
Unconditional Model
Estimate                     S.E. p value
Factor loadings of latent variable cognition
LDST T1 1.000
VF T1 0.592 0.013 <0.001
STROOP T1 -3.947 0.088 <0.001
MMSE T1 0.235 0.006 <0.001
Intercept and slope of latent variable cognition
Intercept  0.000 0.000
Slope -3.020 0.132 <0.001
Model fit indices: RMSEA* (95% CI) = 0.043 (0.040; 0.046); CFI** = 0.965
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -1.017 0.24 <0.001 -0.128 0.16 0.44
Multiple episodes -0.800 0.33 0.016 -0.661 0.21 0.001
Sex (female) 0.296 0.17 0.080 0.170 0.11 0.107
Age -2.608 0.08 <0.001 -0.850 0.06 <0.001
Education 1.988 0.10 <0.001 0.110 0.06 0.072
Model fit indices: RMSEA* (95% CI) = 0.038 (0.036; 0.040); CFI** = 0.965
Fully adjusted Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.836 0.24 <0.001 -0.155 0.17 0.35
Multiple episodes -0.364 0.33 0.276 -0.718 0.21 0.001
Sex (female) 0.725 0.18 <0.001 0.105 0.11 0.357
Age -2.375 0.09 <0.001 -0.832 0.07 <0.001
Education 1.901 0.10 <0.001 0.116 0.06 0.058
Body mass index -0.011 0.02 0.61 -0.007 0.01 0.62
Cancer 0.571 0.34 0.605 -0.291 0.24 0.21
Diabetes mellitus -0.755 0.39 0.050 -0.533 0.27 0.049
Stroke -1.718 0.43 <0.001 -0.058 0.35 0.87
Myocardial infarction 0.600 0.46 0.19 0.112 0.29 0.70
Psychotropic therapy -0.613 0.22 0.006 0.283 0.15 0.065
Cardiovascular therapy -0.030 0.17 0.861 -0.262 0.11 0.016
iADL 1.258 0.13 <0.001 -0.002 0.10 0.98
Smoking habits 0.291 0.10 0.003 -0.052 0.06 0.38
Alcohol consumption 0.153 0.19 0.43 -0.077 0.14 0.72
Model fit indices: RMSEA* (95% CI) = 0.027 (0.025;0.029); CFI** = 0.964
Model 1: Unconditional model; Model 2: Conditional model; Model 3: Fully adjusted model. * RMSEA: Root 
Mean Square Error of Approximation **CFI: Comparative Fit Index.
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Cohort 2 analysis.
Flow chart of study population.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Flow chart of study population within the RS-II 
RS = Rotterdam Study, Roman numbers denote cohorts and Arabic numbers examination 
waves, e.g. RS I-3 = third examination round of the first cohort MMSE = Mini Mental State 
Examination 
N = 3 011 
Persons participated in the 
baseline examination of these 
analyses (RS II-1) 
 
N = 2 932 
Persons assessed for 
depression 
N = 79 
Missing data: Not screened for 
depressive symptoms (CES-D) 
 
N = 3 excluded                         
Prevalent bipolar disorder 
 
 N = 17 excluded                     
Prevalent dementia 
 
N = 2 912                 
Participants free from 
prevalent bipolar disorder and 
dementia 
 
N = 579 excluded                    
Missing data: cognition assessed 
only with MMSE 
 
N = 2 333                             
Total sample in analysis of 
depressive symptoms with 
cognitive decline 
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Table 1. Study population by depressive episodes status (N = 2 333)
Depressive episodes
No depression
N = 1977
Single episode
N = 252
Multiple episodes
N = 104
Age, years, mean (SD) 63.6 (7.6) 64.6 (8.6) 64.1 (8.5)
Sex*, female, N (%) 1031 (52.1) 169 (67.1) 78 (75)
Highest education attained,
Primary, N (%) 140 (7.1) 32 (12.7) 8 (7.7)
Lower/intermediate, N (%) 879 (44.5) 121 (48) 52 (50)
Vocational, N (%) 596 (30.1) 54 (21.4) 35 (33.7)
Higher, N (%) 362 (18.3) 45 (17.9) 9 (8.7)
iADL**, score, mean (SD) 16.3 (6.3) 16.6 (5.3) 14.9(7.9)
Smoking habits,
Never smoker, N (%) 599 (30.3) 84 (33.3) 28 (26.9)
Current smoker, N (%) 372 (18.8) 59 (23.4) 31 (29.8)
Past smoker, N (%) 1006 (50.9) 109 (43.3) 45 (43.3)
Alcohol consumption,
No consumption, N (%) 168 (8.5) 31 (12.4) 11 (10.6)
Current consumers, N (%) 1703 (86.1) 198 (78.9) 82 (78.8)
Past consumers, N (%) 106 (5.4) 22 (8.8) 11 (10.6)
Body mass index, mean (SD) 27.1 (4) 27.1 (4.1) 28.2 (5.3)
Cardio vascular medication, N (%) 675 (34.1) 101 (40.1) 39 (37.5)
Central nervous system medication, N (%) 205 (10.4) 76 (30.2) 49 (47.1)
Cancer, N (%) 219 (11.1) 24 (9.5) 16 (15.4)
Diabetes mellitus, N (%) 116 (5.9) 30 (11.9) 8 (7.7)
Myocardial infarction, N (%) 106 (5.4) 10 (4) 10 (9.6)
Stroke, N (%) 44 (2.2) 16 (6.3) 6 (5.8)
Descriptive characteristics of study population were assessed at baseline. Values represent percentage (%), or 
mean (SD). *Female; **iADL: Instrumental activity of daily leaving score.
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Table 2. Descriptive of cognitive performance tests measured over time for depression
Depressive episodes Cognitive test
Time point T1* T2* T3*
N Mean (SD) N Mean (SD) N Mean (SD)
Letter-digit substitution task
No depression 1948 29.9 (7.2) 1601 29.3 (7.9) 1209 28 (7.8)
Single episode 247 28.5 (7.2) 196 28.5  (7.2) 130 27.9 (6.5)
Multiple episodes 102 27.8 (7.8) 75 27.1 (7.2) 46 26.3 (7.3)
Verbal fluency test
No depression 1969 22.2 (5.4) 1624 21.2 (5.6) 1237 21.7 (6.1)
Single episode 250 22.3 (6.1) 200 21.6 (5.8) 134 22.7 (5.7)
Multiple episodes 102 21.3 (5.7) 77 20.7 (5.1) 47 20 (4.8)
Stroop test
No depression 1922 52.6 (23.3) 1454 54.5 (26.3) 1260 56.5 (26)
Single episode 249 57.1 (27.7) 182 58.5 (29.1) 132 53.3 (16.2)
Multiple episodes 101 56.1 (19.4) 66 62.5 (35.7) 48 56.8 (22.9)
The mini–mental state examination
No depression 1977 27.8 (1.8) 1669 27.7 (2.1) 1284 27.7 (2.4)
Single episode 252 27.7 (1.9) 210 26.5 (2.4) 140 27.6 (2.2)
Multiple episodes 104 27.4 (2.1) 87 26.5 (3.9) 51 27.3 (2.5)
 
*T1: time point one (1997-1999); T2: time point two (2002-2004); T3: time point three (2009-2011).
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Table 3. Initial level (intercept) and rate of change (slope) of cognitive performance and late-life 
depression using the Latent growth curve modelling (N = 2 333)
Unconditional Model
Estimate                      S.E. p value
Factor loadings of latent variable cognition
LDST T1 1.000
VF T1 0.565 0.018 <0.001
STROOP T1 -3.161 0.093 <0.001
MMSE T1 0.208 0.007 <0.001
Intercept and slope of latent variable cognition
Intercept  0.000 0.000
Slope -2.075 0.131 <0.001
Model fit indices: RMSEA* (95% CI) = 0.040 (0.037; 0.045); CFI** = 0.974
Conditional model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.616 0.33 0.061 -0.026 0.15 0.87
Multiple episodes -1.619 0.50 0.001 -0.577 0.24 0.018
Sex (female) 1.330 0.22 <0.001 0.213 0.10 0.029
Age -2.526 0.11 <0.001 -1.057 0.06 <0.001
Education 2.039 0.13 <0.001 0.078 0.06 0.17
Model fit indices: RMSEA* (95% CI) = 0.037 (0.033; 0.041); CFI** = 0.973
Fully adjusted model Intercept Slope
Estimate S.E. p value Estimate S.E. p value
Depressive episodes
No depression reference reference
Single episode -0.106 0.33 0.747 0.039 0.16 0.80
Multiple episodes -0.865 0.50 0.083 -0.451 0.50 0.072
Sex (female) 1.465 0.22 <0.001 0.184 0.10 0.071
Age -2.280 0.11 <0.001 -1.034 0.06 <0.001
Education 1.951 0.13 <0.001 0.060 0.06 0.295
Body mass index -0.031 0.03 0.22 -0.017 0.01 0.16
Cancer 0.368 0.32 0.25 -0.040 0.15 0.79
Diabetes mellitus -1.092 0.41 0.008 -0.512 0.22 0.017
Stroke -1.460 0.63 0.021 -1.052 0.36 0.003
Myocardial infarction -0.080 0.46 0.86 -0.190 0.23 0.41
Psychotropic therapy -0.631 0.30 0.036 -0.304 0.14 0.035
Cardiovascular therapy -0.403 0.23 0.075 -0.045 0.11 0.674
iADL 1.339 0.21 <0.001 -0.112 0.12 0.36
Smoking habits 0.266 0.12 0.025 -0.003 0.05 0.95
Alcohol consumption -0.071 0.26 0.79 -0.003 0.13 0.98
Model fit indices: RMSEA* (95% CI) = 0.026 (0.024;0.029); CFI** = 0.973
Model 1: Unconditional model; Model 2: Conditional model; Model 3: Fully adjusted model. * RMSEA: Root 
Mean Square Error of Approximation **CFI: Comparative Fit Index. A
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Table 2. Recognized and unrecognized MI and all-cause mortality risk with Cox regression 
(N = 3 940)
All-cause mortality
  HR (95% CI) p value
Men (N = 1 747)
Recognized MI (N = 144)
Multivariate adjusted* 1.99 (1.64;2.42) <0.001
Unrecognized MI (N =115)
Multivariate adjusted* 1.59 (1.27;1.98) <0.001
Women (N = 2 193)
Recognized MI (N = 32)
Multivariate adjusted* 1.97 (1.32;2.94) 0.001
Unrecognized MI (N =104)
Multivariate adjusted* 1.00 (0.77;1.30) 0.97
2 148 (1087 men) of 3 940 persons died during 55,170 person-years of follow-up.
*Multivariate adjusted: additionally adjusted for age, level of education, smoking status, alcohol consumption, 
history of stroke, diabetes mellitus and systolic blood pressure.
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6
In this thesis I present evidence for the possible role of several biological factors and physical 
health problems in the aetiology of depression. The studies described in the previous chapters 
were performed mostly within the frame of the Rotterdam Study (RS), a prospective population-
based data-collection project. One of the studies in this thesis is a consortium based meta-analysis 
comprising eleven cohort studies from the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) consortium and another study comprises data from the Erasmus 
Rucphen Family Study. The details of the conducted research, methods, analysis, and results 
have already been described in detail. In this chapter, I would like to give an overview of the key 
findings and emphasize their possible clinical implications. Studying mental health diseases such 
as depression is a challenge and faces a series of concerns that were already discussed in some 
detail. In this chapter I will also elaborate on the most important methodological issues that I 
encountered conducting this work. Finally, I will conclude and describe some perspectives and 
strategies for future research.
Main findings
Potential biomarkers for depression
Clinically translatable biomarkers in psychiatry are crucial for efficient diagnosis, therapy, and 
prognosis of a psychiatric disease.1 Detection of biomarkers specific for depression is necessary for 
the psychiatric practice. Yet, validated clinically relevant biomarkers specific for depression have 
been very hard to identify.2 In other medical disciplines, such as endocrinology, conditions like 
diabetes mellitus3 are clinically diagnosed, predicted and the severity of the disease is defined by 
a well-established set of biomarkers. Unlike endocrinology, in psychiatry we lack such laboratory 
tools and non-invasive blood tests to diagnose and predict depression. All biological parameters 
that can be repeatedly measured with precision and are related to the occurrence of depression 
are considered potential biomarkers for depression.2 Yet, biomarkers could be factors that are 
causally related to depression or are good predictors of depression (Figure 1). They may also be 
biological markers that just allow a better discrimination between depressed and non-depressed 
patients, and thus constitute diagnostic biomarkers (Figure 1). Therefore, the full definition 
for biomarkers (biological markers) postulated by the World Health Organization includes any 
substances, structures, or processes that can be objectively measured in the body or its products 
and influence or predict the incidence of outcome or disease.4
Epidemiological longitudinal designs have a unique role in refining or rejecting causal hypotheses5 
on the relation of certain biological risk factors with depression. Longitudinal associations may 
thus imply or dismiss possible biomarkers for depression. In Chapter 2 we study whether 
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aetiological candidate markers, including blood extracted vitamin D serum levels (neuroendocrine 
factor), or three neuro-inflammatory markers (interleukin (IL)-6, alpha-1-antichymotrypsin (ACT), 
and C reactive protein (CRP)) are risk factors for depression.
In order to re-examine the extensively studied possible causal relation between vitamin D serum 
levels and depression, in Chapter 2.1 we addressed the association between these two factors. 
Both the cross-sectional and the prospective association between vitamin D serum levels and 
subsequent change of depressive symptoms or incident major depressive disorder (MDD) were 
explored. Few studies have tested these associations. Prior longitudinal analyses produced 
inconsistent results that were mostly explained by small sample size, incomplete definition of 
depression, confounding, and short length of follow-up.6-8 We observed no longitudinal association 
between vitamin D and depression after some of the limitations of previous studies, such as poor 
confounder control, were addressed. All authors should be careful when commenting on the 
presence or absences of causality, but our careful analysis sheds doubt on the causal relationship 
between vitamin D and depression. Yet, we observed a negative cross-sectional association 
between vitamin D and depression. Thus, we did speculate about a possible role of vitamin D 
serum levels as a biomarker of depression.
Biological factors need not be causally related to depression in order to be a biomarker for 
depression.2 A marker that differs between those with depression and those without depression 
need not to be involved in the causal pathway of depression to be a diagnostic biomarker (see 
Figure 1). To optimally establish a temporal relationship, the longitudinal design should include 
repeated assessments of the biomarker of interest over a significant period of time.9 Indeed, 
longitudinal designs such as the one we use, with a single measure of the biomarker at baseline 
are not ideal designs and are vulnerable to random measurement error.10 Moreover, the long 
follow-up (almost 12 years follow-up time in the current study) may additionally bias the results 
by introducing regression dilution bias.11 The longitudinal design we used is limited to determine 
the directionality of the association. Yet, I argue that the power of the cross-sectional analysis 
should also not be underestimated to capture two correlates. Vitamin D deficiency and depression 
are unquestionably correlated but vitamin D does not have the role of a long-term risk factor for 
depression.
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Figure 1 ®taken and adapted from Gadad at al.2 Types of Biomarkers for depression. 
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Figure 1 ®taken and adapted from Gadad at al.2 Types of Biomarkers for depression. Biomarkers can be defined as biomarkers used before diagnostics and treatment initiation, and are classified as diagnostic, predictive, or moderators. Diagnostic biomarkers classify an patient with depressive disorder, predictive biomarkers determine overall likelihood of response/remission, and moderators determine likelihood of response/remission with a particular treatment. Mediators are biomarkers collected soon after treatment initiation and help predict overall likelihood of response/remission. Long-term treatment response biomarkers are factors that may also be indicative of ultimate outcome.  
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Biomarkers can be defined as biomarkers used before diagnostics and treatment initiation, and are classified 
as diagnostic, predictive, or moderators. Diagnostic biomarkers classify an patient with depressive disorder, 
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likelihood of response/remission with a particular treatment. Mediators are biomarkers collected soon after 
tre tment initiation an  help predict over ll likelihood of response/remission. Long-term treatment resp nse 
biomarkers are factors that may also be indicative of ultimate outcome.
I doubt that vitamin D can be classified as a biomarker with clinical relevance for depression. 
Nowadays, depression is being diagnosed by self-reported depressive symptoms diagnosed by 
clinician’s criteria such as the DSM criterion.12 This nosologic method of depression diagnosis is an 
obstacle in further clinical validation of vitamin D as a predicting biomarker. Venkatasubramanian 
G. commented on biological factors with discriminating power but low or no predicting power: 
“If in heart research we look for characteristics that would help classify chest pain patients into 
those with and without coughing, we will get nowhere”.1 “On the other hand, testing specific 
enzymes elevations in persons with specific ECG changes compared to persons with no ECG 
changes is more informative and might bring more meaningful clinical discrimination”.1 In this 
notation, I rather see vitamin D deficiency as a biomarker of conditions such as skeletomuscular 
diseases, osteoporosis, increased risk of falls with subsequent fractures in patients with chronic 
psychiatric disease such as depression, than as a biomarker specific for depression.13
Biomarker research has focused and worked on identifying potential peripheral proteins of 
interest such as inflammatory markers.14 Tumor necrosis factor alpha (TNF-alfa), interleukin-6 
(IL-6), interleukin-1Beta (IL-1Beta), and C-reactive protein (CRP) are just some of the proteomic 
markers that have been associated with depression.14 In Chapter 2.2 we investigated both the 
cross-sectional and the longitudinal association between IL-6, alpha-1-antichymotrypsin (ACT), 
and CRP and depressive symptoms. As previously observed in other studies2,14, this study provides 
evidence for IL-6 and CRP as potential predictive biomarkers for depression. More specifically, we 
found that higher levels of IL-6 and CRP are longitudinally associated with incident depressive 
symptoms over five years follow-up. Even though many large epidemiologic studies reported 
cross-sectional associations between these inflammatory markers and depression15-17, we 
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observed no cross-sectional association in our study. This may be attributed to the small-sample 
size of the current study. The absence of the cross-sectional association in this study suggests that 
IL-6 and CRP are measures of a process or a product of key pathophysiological stages that lead to 
depression (Predictive biomarkers see Figure 1).2
The fact that we observed a longitudinal but no cross-sectional associations between these 
inflammatory proteins and depressive symptoms may also indicate that the brain-response with 
subsequent depression precipitated by inflammatory proteins occurs only if this inflammatory 
stimulus is chronic/persistent; and does not occur in an acute and transitional response of 
the inflammatory system.18 Indeed, ACT is a known acute phase plasma protein. If depressive 
symptoms occurred as a response to the present acute inflammation, we would expect that 
elevated levels are associated with more depressive symptoms. However, we observed neither 
a cross-sectional or a longitudinal association between elevated levels of ACT and depressive 
symptoms. Earlier clinical studies reported elevated ACT in depression, for example among 21 
male depressed patients compared to healthy control subjects.19 However, this study was based 
on clinical samples of severe cases of depression (often with other comorbidities). Alternatively, 
ACT could be a less sensitive inflammation marker in the general population and signal early 
inflammation.
To conclude, the results of this study confirm the hypothesis of depression occurring rather in 
response to chronic/persistent and not to acute inflammatory processes. It could have been 
interesting to investigate whether persistently elevated inflammatory markers contribute 
the occurrence of depressive symptoms. However, the data to explore this question were not 
available. Yet, previously published reports show that persistent elevation of inflammatory markers 
contribute to the development of subsequent common mental disease such as depression.20
Depression is a syndrome with a high recurrence rate21, more than a well-defined disease. Also, 
depression describes a heterogeneous population including those that experience depressive 
symptoms once and those that suffer depressive symptoms persistently. The association between 
inflammatory markers and specific subgroups of depression such as those with persistent 
depressive symptoms has not been established yet. Therefore, we also tested whether IL-6, 
CRP, and ACT may also have the power to predict the persistence of depressive symptoms. We 
found that IL-6 and CRP are not only predictive of the occurrence of depressive symptoms but 
are also independent predictors of the persistence of depressive symptoms. Therefore, these 
inflammatory biomarkers may be not only meaningful predictive biomarkers of depression but it 
should be tested whether they can be used to discriminate subtypes or the course of depression.2
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Epigenetic findings
Peripherally measured proteins and vitamin D were not the only candidate biomarker of 
depression I investigated. Variations in a gene, set of genes, and other molecular factors are 
other potential diagnostic and prognostic biomarkers of depression.1 Depression is a complex 
multifactorial disorder substantially affected by both environmental and genetic factors.22 The 
genetic contribution to the development of depression has been estimated to be almost 40% and 
environmental and other factors contribute the additional 60%.22 However, the knowledge of the 
interacting processes between the genetic and environmental factors is incomplete. A few studies 
suggest that epigenetic mechanisms might play an important role in the pathophysiology of 
depression and capture the genetic environment interection.22-25 DNA methylation is an epigenetic 
mechanism in which methyl groups are added to the DNA as a response to an environmental 
or genetic influence. DNA epigenetic markers may play important role in the pathophysiology 
of psychiatric diseases but are also interesting targets for clinically translatable biomarker of 
depression (see Figure 2).1 Yet, the epigenetic method is a novel genomic tool and whether the 
epigenetic alterations can be used as a biomarker is not yet clear and must be carefully studied. 
In an intense collaborative effort, we studied possible epigenetic markers of depressive symptoms 
in a population-based setting.2
The aim of Chapter 4 was to study and map gene-environment interaction in depression by 
identifying epigenetic alterations associated with depressive symptoms. We performed the first 
and largest (N = 11 256) epigenome-wide association population-based study of depressive 
symptoms to date. We found three epigenetic markers associated with depressive symptoms 
(hypermethylation of cg04987734 annotated on the CDC42BPB gene; cg12325605 annotated 
on the ARHGEF3 gene; and cg14023999 an intergenic epigenetic marker. The genes on which 
these epigenetic marks are located, are known to be involved in the regulation of serotonin and 
dopamine levels in the brain26, sphingolipid metabolism27, and immune response22. Moreover, 
the gene pathway analyses of our findings have shown that these genes are involved in synaptic 
plasticity, inflammatory mechanisms, regulation of monoamine levels in the brain, axon guidance, 
and growth factor signalling. These are all mechanisms previously associated with psychiatric 
disorders including depression.22,28-30 Certain expression mechanisms of these genes, RNA 
transcription, protein function and structures, could also be involved in the pathophysiological 
mechanisms underlying depression.22 Indeed, RNA expression analysis within the frame of our 
study have shown that differentially expressed genes reveal one significant pathway; the immune 
system (more specifically, expression of these genes was involved in the adaptive immune system).
This study was performed within a multi-ethnic population based sample of approximately 11 000 
individuals. This epidemiologic design has several strengths and limitations, which were already 
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discussed in Chapter 4. Here I would like to emphasize few considerations. Most importantly, 
the cross-sectional design of the study limits the interpretation of the associations. I speculate 
that that there are few possible ways to interpret these findings (Illustrated in Figure 2). First 
(Figure 2.(a)), blood DNA hypermethylation of cg04987734, cg12325605, and cg14023999 
may occur due to environmental influences, stress events, or early childhood trauma preceding 
the occurrence of depressive symptomes.22 Second (Figure 2.(b)), the epigenetic alterations 
may also be mediators of genetic risk for depressive symptoms. In this scenario, the epigenetic 
mark mediates the causal pathway from genes to depression. Many DNA methylation differences 
can be partially traced back to genetic variations, suggesting that differentially methylated CpG 
sites serve as evolutionarily established mediators between the genetic code and phenotypic 
variability.31 These epigenetic DNA imprinting’s may reflect genetic mechanisms such as silencing 
of the gene or gene expression22,32, that lead to depression. Third (Figure 2.(d)), depression itself 
could be the cause of the epigenetic changes. Via endocrinological, immune or other metabolic 
changes secondary to depression, methylation or demethylation of the DNA may occur.
These proposed pathophysiological mechanisms, however, could not be confirmed by the study 
presented in this thesis and describing both causality and the direction of causality should be a 
focus of future research. Finally, these epigenetic marks may not involve in the pathophysiological 
mechanism underlying or arising from depression and thus present “only” biomarkers of 
depression. The cross-sectional association between the epigenetic markers and depressive 
symptoms may also be confounded by large number of environmental factors (Figure 2.(c)). 
The analyses presented in this study were controlled for the effect of factors such as age, sex, 
smoking habits, and antidepressant medication. Yet, confounding by unmeasured environmental 
factors is possible. Therefore, if the association between the blood DNA methylation markers 
and depressive symptoms were explained by these unmeasured environmental factors, then such 
markers would present biomarker of exposure only.
Since we can only speculate about the directionality, this study is certainly only an indicator that 
blood methylation of the three identified CpG sites are a potential tool to discriminate individuals 
suffering from depression from those who do not. 
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Figure 2. Possible interpretations of the epigenetic epidemiologic findings. 
Genetic findings
Depression is a complex, heterogeneous, and common disease with modest heritability.22 A 
number of common single nucleotide polymorphisms were found to be associated with depression 
by DNA microarray-based whole genome-wide association studies (GWAS).33 However, it has 
been suggested that common variants have small effects and do not completely account for the 
heritability. Moreover, GWAS studies are non-informative of rare variants that outnumber the 
common variants.34 The next generation sequencing is a new method for identifying rare novel 
variants that might fulfil the genomic heritability gap.34 Rare variants in exonic or coding regions 
that affect protein function, are probably important for depression.34 Therefore, identifying rare 
variants opens new hopes for genetic research of depression and psychiatric research in general. 
In Chapter 3 we have performed exome sequencing studies to identify rare unknown variants 
with strong effects contributing to the development of depressive symptoms.
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In Chapter 3.1 we performed the first large-scale population-based high-coverage exome 
sequencing study. We found a significant association of depressive symptoms with a rare variant 
(rs77960347-G; MAF = 1%, N (carriers) = 60; β = 7.2; p value = 5.2 × 10-08) on chromosome 18. 
The large estimated effect of this variant on depressive symptoms suggesting that each allele yields 
an increase of depressive symptoms by 7.2 points. Rs77960347 is a highly conserved missense 
variant in the LIPG gene (Asn396Ser). Moreover, it is predicted to be damaging (polyPhen = 
1) for the LIPG gene. LIPG is a gene predicted to be involved in enzymatic function in steroid 
biosynthesis, cholesterol biosynthesis and thyroid hormone metabolic processes.35 These results 
were replicated in three independent samples. Also, within the Rotterdam Study, we observed 
that carriers of such missense non-synonymous variant have a higher risk of Alzheimer’s disease 
and more white matter lesions.
The heterogeneity and the complexity of depression is a challenge that genetic research constantly 
faces.36 To overcome heterogeneity of depression, enlarging the studied sample sizes is widely 
used as a methodological strategy.36 Indeed, the number of common variants with small effects 
identified by GWAS associated with depression increases by expanding the sample size.37 To 
identify rare variants associated with complex trait such as depression large sample sizes are 
required, like in studies of common variants.34 Using isolated cohorts with less genetic variance, 
and similar environmental, and cultural characteristics is another strategy to overcome the 
limited power inherent to this approach.38 Rare variants accumulated in isolated populations can 
counterbalance problems of studying heterogeneity. Therefore, in Chapter 3.2 we performed 
exome-sequencing and exome-chip genotyping in a genetically isolated European population to 
identify rare variants associated with depressive symptoms. We found an association of a rare 
non-synonymous variant in the NKPD1 gene with depressive symptoms (the missense variant that 
showed the strongest association within the NKPD1 gene was rs75291769/exm1479956, p value 
= 2.5 x 10-04 with a frequency of 4.6% in the discovery sample). These variants explained 0.9% 
of the age- and sex-adjusted variance and 3.8% of heritability of depressive symptoms in the 
isolated population. Importantly, these results were replicated in the Rotterdam Study. The NKPD1 
gene is involved in the biosynthesis of sphingolipids that was earlier proposed as a therapeutic 
target for depression.39
These two studies are among the first studies to use exome-sequencing on a large scale with a 
specific aim to discover novel risk genes for depressive symptoms and therefore uncover pathways 
that lead to the development of depression. The strengths of this approach have already been 
discussed in the previous chapters. However, the interpretation of the achieved results has to 
carefully consider several issues.
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First, a question that arises when looking in to the results of these studies is whether the observed 
depression-associated rare variants are really depression specific. Psychiatric disorders have a 
great overlap in their genetic architecture and it is known that many of the genetic associations 
are common to all schizophrenia, bipolar disorder and depression.37,40,41 The studies performed 
in Chapter 3 were performed in a population-based setting where the prevalence of diseases 
such as bipolar disorder and schizophrenia are low (< 2%).42,43 Thus, we were not able to test 
the independence of the reported associations from other mental disorders. Yet, in Chapter 3.1 
we tested the statistical difference between carriers of the Asn396Ser variant and non-carriers 
and their risk of suffering Alzheimer’s disease. We observed carriers of the Asn396Ser variant 
to be more likely to suffer from Alzheimer’s disease compared to non-carriers. Adjusting the 
association between this rare variant and depressive symptoms for prevalent Alzheimer disease 
did not change the results. Therefore, we speculate that depressive symptoms could mediate 
the pathway between this Asn396Ser variant and Alzheimer’s disease but we cannot reject the 
possibility that this variant contributes to the development of Alzheimer’s as well, i.e. it has 
pleotropic effects.
Second, the rare variants may be population specific.34 Rare variants identified in isolated 
populations such as the one we study in Chapter 3.2, could be extremely rare in other populations 
or absent.44 We replicated the results of our studies in one population-based sample; however, 
the samples we used for replication have a similar ancestry. Thus, replication in a more distinct 
population sample than the discovery sample might be more appropriate.34 This issue challenges 
the generalizability of the results to other populations. Yet, we argue that rare variants need not 
be population specific since rare variants associated with other phenotypes such as Alzheimer’s 
disease were replicated across populations successfully.45
Third, even though we used high coverage sequencing in the study presented in Chapter 3.2 
Exome-chip sequencing is not capable in detecting rare variants with a minor allele frequency 
lower than 0,004%.46 Exome-sequencing captures only the exomes (~1% of the entire genome) 
and hence does not capture all rare variation in the genome and that can be achieved using 
whole genome sequencing. Further other kinds of variants e.g. structural variants cannot be 
reliably detected using exome-sequencing. Thus, we cannot exclude the possibility that other rare 
coding variants contribute to depression as well.
Taking all the limitations in to consideration, the results of these two studies present strong 
evidence that the identified rare variants in the LIPG and the NKPD1 genes are involved in the 
occurrence of depressive symptoms. Although the variants are rare among populations, the 
estimated effect on the risk of depression was meaningful. This suggests that we discovered new 
risk factors for depression providing new insights in the biology of depression.
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Physical Health factors for depression
Living with chronic disability and disease such as cardiovascular disease or dementia is difficult, 
challenging, and decreases the quality of life significantly.47 These diseases develop slow, they 
are chronic, require constant treatment, and are perceived by the individual as life threatening.47 
In both, clinical and epidemiological settings high co-occurrence of such chronic diseases with 
depression was observed.48,49 Depression also often has a recurrent character and can take a 
chronic course. The relation between physical health problems and psychiatric disease is complex 
and the underlying biology is poorly understood. Whether depression is a cause or a consequence 
of other chronic conditions often remains questionable. Addressing the question of “the chicken 
or the egg” may help understand why depressed individuals have a substantial increased burden 
of diseases, physical disability, and mortality. An answer may improve BETTER management and 
therapy for depression.50 Moreover, studying the longitudinal relations between depression and 
diseases such as myocardial infarction and dementia may also elucidate the pathophysiology and 
provide clues to aetiological mechanisms. The Rotterdam Study setting allowed us to construct 
advanced longitudinal designs and address some of these questions. Therefore, In Chapter 5 we 
took the opportunity to study the impact of depression on neurodegenerative processes such as 
cognitive decline as well as the impact of chronic diseases such as myocardial infarction on the 
occurrence of depression.
In Chapter 5.1 we studied the longitudinal association between depression and cognitive decline. 
This subject was widely studied and produced contradictory results.49 Characteristics of depression 
like the age of first onset, chronicity, duration, number of episodes in the past may predict the 
longitudinal association between depression and subsequent cognitive decline. Therefore, we 
followed participants who experienced a single, multiple or no depressive episodes for their 
cognitive decline over, on average, 12 years to evaluate whether repeated episodes of depression 
predicted cognitive decline. The simple descriptive analysis showed that most persons experience 
cognitive decline over time in all the cognitive tasks irrespective of prior depression (See Table 2, 
Chapter 5.1 Mini-mental state examination). These results only confirmed the cognitive decline 
with aging. Moreover, we also observed that at baseline cognitive performance is worse among 
participants, who had had depression, compared to those with no past episodes of depression 
(See Table 2., Chapter 5.1). Next, we used three repeated measures of four different cognitive 
domains to construct a latent growth curve of cognitive change. With this advanced approach of 
modeling repeated measures we evaluated the course of cognitive decline. This approach accounts 
for the within-person and the between-person change in cognitive functioning over time and was 
additionally controlled for an extensive list of potential confounders such as age, sex, education 
and other life-style, demographic factors, and comorbidities that may affect the relation between 
depression and cognitive decline. As previously reported by others, we observed that depression 
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and cognitive decline are co-occurring conditions. However, our longitudinal analysis showed that 
depression contributes significantly to worse long-term cognitive performance only if experienced 
multiple times. Persons with single or those with no experience episodes of depression had similar 
cognitive decline.
This study provides evidence that only depression with a recurrent course contributes to a faster 
cognitive decline than the cognitive decline we normally experience due to aging. This is in line 
with studies that showed prominent neurological vulnerability among patients suffering recurrent 
depression.51,52 A previous study showed that persons with recurrent depressive symptoms 
have a higher risk of dementia and Alzheimer’s disease, reduce hippocampal volume, and are 
characterized by a cognitive deficit prodrome.53 We can only speculate that recurrent depression 
precedes cognitive deficits that eventually evolve into dementia or Alzheimer’s disease. Participants 
with prevalent dementia did not take part in this study. However, I argue that reversed causality 
could still explain our results. Dementia and Alzheimer’s disease are extremes that arise with 
minor cognitive deficits prior to the occurrence of depression. The baseline cognitive performance 
was lower among participants with multiple-episode depression compared to those with single-
episode or no depression across all cognitive domains. Indeed, there is a limited evidence that 
milder cognitive performance may precede the occurrence of consequent depression.54 However, 
such a scenario should be less likely since the tested models were corrected for baseline general 
cognitive performance. On the other hand, we were unable to explore whether trajectories with 
a steeper cognitive decline contributed to the occurrence of or the recurrence of depression. 
Overall, we conclude that depression and cognitive decline are comorbid conditions. Depression 
predicts a higher risk of worse long-term cognitive performance only if the experienced depression 
occurs multiple times.
In Chapter 5.2 we explored the long-term impact of experiencing health condition such as 
myocardial infarction (MI) on the occurrence of depression. We have contrasted the impact 
of a clinically recognized MI to that of a clinically unrecognized MI (without experience of any 
symptoms and absence of knowledge for the disease) on depression and compared both to the 
depression risk of persons with no MI experience. Comparing these three groups was an exclusive 
opportunity to distinguish the biological pathophysiological mechanisms behind the association of 
MI and depression from the psychological mechanism. The occurrence of depression in someone 
with an MI with a clear clinical presentation is the result of both psychological/reactive and 
biological/pathophysiological mechanism. In contrast, those having had a clinically unrecognized 
MI should develop depression only due to presence of a biological mechanisms linking MI to 
depression. We observed a discrepancy in the risk for depression among those with clinically 
recognized MI and those with unrecognized MI if compared to those without MI. We found that 
men with recognized MI were at a higher risk to develop depression than men without MI. In 
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contrast, men with unrecognized MI had similar risk to develop depression as those without MI. 
This suggests that in men the awareness of experiencing a life-threatening condition increased 
the risk of developing depression and not only the pathology related to MI. Interestingly, we 
did observe a similar impact of recognized and unrecognized MI on the mortality risk in this 
population. This confirms the serious pathophysiological impact both conditions had on the 
general health and life expectancy. Yet, clinically recognized and unrecognized MI seem to affect 
the mental health rather differently. We have to emphasize that due to low statistical power and 
possible measurement error we could not draw any conclusions from our data with regard to 
women. Thus, the evidence we provide should be interpreted carefully and is restricted to men.
In conclusion, Chapter 5 presents studies in which we see whether physical diseases are risk 
factors for the occurrence of depression and vice versa, how depression is a risk factor for the 
occurrence of physical diseases. More specifically, we provide evidence how MI contributes to 
the development of depression and how multiple-episode depression contributes to poor long-
term cognitive performance. The complexity of the interrelations between depression and its 
comorbidities requires well-designed epidemiological studies including repeated exposure and 
outcome measures to unravel bi-directional associations and the effect of chronic exposure. 
We have made an attempt to advance the epidemiological knowledge using epidemiological 
tools appropriate for the available data. Yet our results can only hint at the possible pathological 
mechanisms and factors that can help screen specific groups, or target to better manage or treat 
depressed individuals.
Methodological considerations
Analysing repeated measures in recurrent phenotypes
Traditionally, epidemiologists and statisticians advise that longitudinal population-based studies, 
even if observational, should be cautiously interpreted when referring to causality. Yet, recently 
advanced methodological tools have opened the possibility of a deeper and more complex 
understanding of disease initiation, course and progress. These methods were developed jointly 
by statisticians, social scientists, and epidemiologists to allow the possibility to disentangle the 
causal relationship between exposures and disease.5 As a result, we now have new and more 
diverse types of approaches to consider when analysing data beyond the traditional epidemiologic 
analyses.
The Rotterdam Study has a unique way of assessing depression, previously described in detail 
(see Chapter 1). We assessed depression with repeated measures at well-specified examination 
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rounds (on average every 4 to 5 years). In addition, to learn about the course of the disease 
and capture events that might have happened between examination rounds, we performed 
continuous monitoring for depression during 12 years of follow-up. This assessment strategy 
allows individuals to be followed for the course of the disease, the index occurrence of the 
observed events; but it also allows individuals to be assessed for the severity of the depressive 
events. The severity of the experienced depression (from depressive symptoms to MDD) was 
defined by well-specified and sensitive questionnaires, interviews, and information collected from 
general practitioners (GP) medical records. This approach is an attempt to assess mental disorders 
such as depression; disorder with a remitting course across time, and characterized duration and 
severity, in more detail. The Rotterdam Study depression data allows to conceptualize depression 
as both episodic (counting episodes of the disorder that occur over time), and persisting (to define 
whether the disorder persists across time or not), and finally to distinguish between different 
degrees of severity within a population-based sample. Most longitudinal designs on depression 
have limited validity37 due to the fact they conceptualize depression either by severity or by 
persistence only, but never combine or compare the two aspects. Our complex data avoids such 
limitation, yet collecting such a rich data is challenging and may introduce a number of limitations 
and obstacles that should be discussed.
In Chapters 2.1 and 5.2 two studies with almost identical study design are presented. We test the 
longitudinal association between an exposure of interest measured at baseline and depression as 
an outcome. In order to test the change of the depressive symptoms over time I used repeated 
measures of the outcome at a regular time points (two re-assessments). Such repeated measures 
of the outcome are correlated with each other and such correlation need to be treated cautiously. 
I used Generalized Estimating Equations (GEE) model.55 This model is more advanced than a 
traditional linear regression model and estimates a marginal population averaged effect that 
takes into account the within-subject correlation by using a covariance matrix.55 Our depressive 
symptoms data are balanced data and therefore such a method is appropriate. However, GEE is 
a marginal model and no conclusions about individual patterns can be drawn, especially patterns 
that occur across time such as trajectories.55 Indeed, depressive symptoms are not a normally 
distributed outcome variable and this may bias the within-subject correlation. To estimate the 
individual change of depressive symptoms across time we could have better used conditional 
model such as the generalized linear mixed model (GLMM).56 Conditional models are a more 
fundamental approach and estimate a random effect while holding other covariates constant. 
Also, from the estimated random effect we can easily draw conclusions about the population 
effect, which is estimated by the GEE models; but from the GEE model we cannot estimate the 
individual effect.56 Moreover, linear mixed models treat loss to follow-up more flexible than GEE 
models. GLMM are evidently better approach to analyse our data. However, the marginal GEE 
model is more straight forward and addresses the population-based effect we were particularly 
interested in.56
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Longitudinal analyses are considered biased if they do not take into account the duration of 
follow-up. Thus, in addition to the GEE analyses we estimated the survival risk using a Cox 
regression model.57 When compared to the GEE model, the Cox survival model takes into account 
time but does not fully address the course of the depressive disorder. Moreover, the survival 
model was used to estimate the effect of a one-time measure of the exposure at the baseline of 
the study. Such an approach is an important limitation given the type of exposure that changes 
over time such as vitamin D (Chapter 2.1).58,59 Therefore, I argue that longitudinal associations 
between exposure and outcome, both changeable across time, and with complex interrelations; 
should be tested by advanced models that would address this issue. Joint models where the 
exposure using GLMM and the outcome using Cox model with time varying exposure are possible 
solutions.60
In Chapter 2.2 we estimated the 5 year risk of increased depressive symptoms in persons with 
inflammatory measures such as CRP. Traditional linear and logistic models were used to analyse the 
longitudinal association between an exposure assessed at baseline and an outcome assessed at a 
fixed follow-up time. In order to test whether persistence of depressive symptoms can explain this 
longitudinal association we combined the baseline measure of the outcome depressive symptoms 
and defined persistence, as clinically relevant depressive symptoms at baseline and at follow-up. 
We tested both whether inflammatory factors were related to worsening depressive symptoms 
and persistent depressive symptoms. However, such model is incomplete and does not answer 
the question whether more depressive symptoms also increase the risk of increased inflammatory 
markers at follow-up. Prior depression and reverse causality may bias the reported results. Ideally, 
if data of two inflammatory markers assessments and depressive symptoms were available, we 
could have used cross-lagged structural equation modelling and address the directionality of the 
association and reduced the potential bias of reverse causality.61
Chapter 5.1 of this thesis uses a contemporary statistical method to estimate the contribution 
of depression to the long-term course of cognitive functioning using the latent growth curve 
modeling.62 First, in order to conceptualize depression as episodic disorder, the exposure of 
interest, we used repeated measures of depression. Second, in order to estimate individual curves 
of cognitive decline over 12 years’ time (the outcome of interest) we used repeated measures 
of four tests of cognitive functioning. Finally, to estimate the risk of a faster cognitive decline 
among persons with multiple episodes, a single episode compared to no episodes of depression, 
we regressed the exposure on the estimated latent growth curve of cognitive decline. This design 
appears ideal, however it was limited by a small overlap of the depression and the cognitive 
functioning assessments (see Figure 1, Chapter 5.1). Thus, our results only partially explain how 
the course of depression could predict the course of cognitive functioning. Most of the studies 
addressing similar hypothesis assessed depression in parallel to cognitive functioning assessment 
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(i.e. the periods of depressive symptoms and cognitive decline assessment overlap). The limitation 
of such a design increases the likelihood of reverse causality. Mixed modelling with depression 
assessment prior to the cognitive curve would be a possible solution to avoid this limitation of our 
design. One study assessed a trajectory of persistent depressive symptoms prior to the cognitive 
functioning assessments to avoid this limitation.63 However, such a design also has limitations as 
it might introduce bias by immortal time.64
The above-mentioned more advanced statistical methods would ideally fill the gaps and 
limitations of the traditional analysis we performed in this thesis. However, such analyses require 
data that were not yet available within the Rotterdam Study. Longitudinal cohort studies are 
time consuming and expensive designs. Financial and other methodological obstacles (such as 
data cleaning) sometimes result in incomplete measurements in a particular examination round. 
My decisions in terms of statistical designs were mostly based on the available data. Finally, we 
should also consider that advanced methodologies have difficult computations (require certain 
fits, are dependent on number of assumptions), require big sample sizes, and are mostly difficult 
to interpret. They are also a formidable challenge for PhD students; however, mastering these 
techniques certainly improves academic career prospects.
Time varying confounding
Population-based studies use observational data to study associations while trying to address 
causal questions. One of the fundamental problems of these studies is confounding bias. 
Confounding bias is a bias introduced by all factors considered to be common causes of both 
the exposure and the outcome of the study.65 Defining which are the factors that may bias 
the association between the exposure and outcome, to be addressed as potential confounders, 
requires prior knowledge on the causal assumption. In this thesis we control for confounding by 
using baseline adjustment. Based on prior knowledge we typically included all factors that may 
be related to both exposure and outcome in the tested model. This approach constitutes the most 
basic statistical method for treating confounding and it is called analysis of covariance.66
The Rotterdam Study has extensive measures of demographic, life-style and health factors 
across time. Therefore, this prospective cohort design allows us to adjust for numerous potential 
confounders and minimize the risk of residual confounding by unknown or unmeasured 
confounding. Yet, what remains a serious concern in using this methodology is omitting the 
effect that time-varying factors have on the observed association. For example, in the tested 
vitamin D depression association in Chapter 2.1 vitamin D is an exposure that is time varying and 
change of the exposure over time may have been caused by confounder factors. In the case that 
the change due to cofounders may have occurred independent of baseline vitamin D and prior to 
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the outcome the association may be biased. Due to limited data (repeated measures of vitamin D 
were not available in the Rotterdam Study) we could not account for time-varying exposure and 
confounding.
Ideally, we could have avoided time-varying confounding by using the methodology of inverse 
probability weighting and the Marginal Mixed models.66 As previously suggested, using Joint 
models are another strategy to treat both repeated measures of time-varying exposure and 
outcome under one model.60 These methodologies are more advanced and allow to test the 
interrelation and interaction between exposure and time. Such methods are also appropriate for 
recurrent outcomes and may answer potential causal relations better than traditional designs. 
However, as already discussed it is not always possible to implement such methods. Moreover, 
using such methods may also produce biased results. For example, similarly to traditional models 
they do not account for unmeasured confounding.
Broad phenotype of depression
Depression is a heterogeneous disease, and no established mechanism, risk factor, or features of 
the disease can explain all the aspects of this disorder. In my opinion, the biggest challenge of 
the work presented in this thesis and in psychiatric research in general is the definition and the 
characterization of the depressive phenotype. The question whether depression should be studied 
as a broad continuous phenotype (depressive symptoms) or as the narrow DSM-classification 
based phenotype of depression is what I have been asking myself most often. Indeed, the 
scientific world knows an endless discussion over the most appropriate depression phenotype 
to be used in research. This dilemma has not been solved yet and the decision to use one or the 
other depression phenotype brings advantages and disadvantages that should be discussed.
In epidemiologic research, both depressive symptoms phenotype but also DSM-categorizations 
phenotypes are widely used. The Rotterdam Study, as already discussed, performs assessment 
of both phenotypes; screening for depressive symptoms and establishment of DSM-criterion 
based depression diagnosis among those with clinically relevant depressive symptoms. Using the 
broad phenotype of depressive symptoms has helped identify numerous associations. Depressive 
symptoms were found to be associated with number of demographic factors67, comorbidities68, 
life style factors69, biological markers70, increased risk of disabilities71, chronic diseases72, and 
mortality73. Moreover, the recently developed neuroimaging technology has enabled us to 
relate depressive symptoms to various structural and functional brain measures.74-76 Obviously, 
epidemiologic research profited from using such a broad phenotype. Depressive symptoms are 
meaningful on the population-based level and for public health purposes in general. However, 
results from studies using depressive symptoms are not easily translatable to clinical practice. 
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Therefore, many population-based studies have attempted to study DSM-categorized diagnosis 
as their depression phenotype of interest. This work showed success as well and replicated 
almost all associations reported with depressive symptoms.77 For example, structural brain 
changes associated with MDD were also found to be associated with even mild depressive 
symptomes.75,77 In two of the studies we also observed consistent results regardless of the used 
depression phenotype (Chapter 2.1 and 5.2). However, we have to emphasize that assessment 
of DSM-categorized depression phenotypes within population-based studies is challenging. It 
requires more complicated semi-structured psychiatric interviews or/and retrieval of GP records 
data. Compared to this approach, screening questionnaires are easily assessable, cheap and more 
simple. Moreover, the prevalence of cases with depressive symptoms is much higher (around 
10 - 29%) than the low prevalence of MDD cases (around 6%) in population-based studies.77,78 
Therefore, the likelihood of detecting associations with low effect decreases when using DSM-
categorizes depression phenotypes and requires larger sample sizes although this may be partly 
counterbalanced by smaller effects if clinically relevant depressive symptoms are used as a 
categorical outcome.
In genetic-epidemiology research, however, we are not so successful in identifying associations 
and we are certainly far from replicating results using different phenotypes of depression as 
in non-genetic epidemiologic research. Early Genome wide association study (GWAS) failed to 
identify single nucleotide polymorphisms in association with MDD in almost 9 000 participants.79 
It was suggested, that the potential for discoveries in genetics is likely to increase if we use 
more broad and heterogeneous samples of depressive phenotypes without exclusions based on 
the DSM-diagnostic criteria and without constraining their measurement to consensus based 
categorize.37 Therefore, following GWAS investigated the depressive symptoms phenotype in 
30 000 individuals.80 However, this study also failed to identify genome-wide significant genetic 
associations. Genetic studies are based on the assumption that studying heterogenic, polygenic, 
complex, and common phenotypes such as depression requires studying bigger sample sizes or 
lowering the heterogeneity in order to find significant genetic associations.33,77 Indeed, restricting 
the definition of depression to a more severe type of recurrent disorder helped in identifying 
two genetic loci.33 Also, combining the phenotypes MDD and depressive symptoms to increase 
power at the expense of heterogeneity to detect loci associated with depressive symptoms.81 
However, such an approach may not unravel the effects of SNPs associated only with one 
phenotype, and therefore produce biased results towards the genetics of a broad phenotype.33 
Finally, the most successful published GWAS so far, by 23 and Me, identified 15 loci by using mild 
MDD phenotyping from a self-report of diagnosis.82 Although this phenotype strategy brought 
success in identifying depression associated SNPs, the possibility of misclassification bias is likely.33 
Therefore, using the most appropriate phenotype of depression in genetic research is crucial and 
again the same question emerges: “What is the most appropriate phenotype?”
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It is sometimes assumed that a smaller number of genes will be involved in the causality of 
more severe depressive illnesses than in depressive symptoms. Also, some genotype variations 
should be related to a specific subtype of depressive illness only.37 Thus, we may expect that the 
identified genetic loci of studying depressive symptoms and MDD will differ but a considerable 
overlap. Indeed, such overlap is likely and a recent GWAS has proven that by replicating genetic 
association between depressive symptoms and the FHIT gene in an independent sample of MDD 
cases.83 Yet, the rare variants located on the LIPG and NKPD1 gene (Chapter 3) we identify 
as associated with depressive symptoms may not be relevant to MDD or other more specific 
depression phenotypes. But that does not mean our results are biased or wrong.
In conclusion, epidemiology benefited from using broad depression phenotypes but these findings 
typically replicate when DSM-criterion based phenotypes were used. Whether we choose to use 
one or the other phenotype should mainly depend on the research question. Genetic research 
on the other hand, still attempts to learn which phenotype choice will bring success and, even 
more important, accurate results. So far it seems that combining phenotypes and using more 
flexible measures allows identifying more genetic associations. However, whether such findings 
have important theoretical meaning for an in-depth understanding of depression is questionable.
The depression phenotype issue was probably a good motivation for The National Institute of 
Mental Health (NIMH) to develop new criteria for research; the research domain criteria (RDoC).84 
The RDoC is a matrix based approach structured by specified functional constructs characterized 
by genes, molecules, cells, circuits, physiology, self-report, and paradigms. The constructs are 
finally grouped into five higher-level domains of functioning (negative valence systems, positive 
valence systems, cognitive systems, systems for social processes, and arousal/regulatory systems). 
The main aim of the RDoC is to provide an attempt for a deeper understanding of the biological 
and psychosocial basis of psychiatric disorders but also to help to improve current classification 
systems.77 Such an approach opens new possibilities for psychiatric research in general and may 
solve the current phenotyping issues.
Future perspectives and implications
Most of the suggestions for future research perspectives for and clinical implications of the studies 
included in this thesis were already discussed in the earlier sections of this discussion. However, 
here I would like to summarize and emphasize some of the most important points and draw a 
brief conclusion of this thesis.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
General discussion  |  275
6
The projects included in Chapter 2, Chapter 3, and Chapter 4 all provide evidence on biological 
factors related to depression. Vitamin D, inflammatory markers, blood DNA epigenetic markers, 
and the rare variants of the LIPG and NKPD1 gene are biological factors that may be used as 
biomarkers for depression. The reported studies suggest these biological factors as potential 
diagnostic markers of depression that might help differentiation between depressed and non-
depressed persons. However, future epidemiologic studies should prove their clinical validity and 
translate results to clinical practice. Moreover, some of these factors (for example the studied 
inflammatory markers IL-6 and CRP) could be used to identify specific subgroups of depressed 
individuals, for example individuals with persistent depression. They may therefore provide better 
screening of depressed individuals for specific subtypes and help to target more successful 
treatment for depression.
The studies presented in Chapter 2.1 and 5.2 have limited clinical implications. Both vitamin 
D serum levels and unrecognized MI are not related to the occurrence of depression. They may 
help targeting specific groups of individuals suffering from chronic diseases and conditions; 
for example, detecting depressed patients with lower vitamin D serum levels for osteoporosis 
preventing strategies. However, I doubt their clinical meaning as depression specific biomarkers.
The presented evidence is population-based; therefore, it is more relevant to populations than 
clinical samples. Policy makers can use these reports as direction for making future public 
health policies and strategies to improve people’s general health and quality of life. Yet, these 
studies also provide evidence for biological associations (for example between certain genes and 
depression) that have theoretical importance and may guide future basic research, which will 
hopefully confirm their clinical relevance and practical use.
In terms of future research perspectives, the literature lacks prospective studies with repeated 
measures of both depression and its determinants. Such designs will allow studying interrelations 
between depression and exposures of interest as well as address direction of the relations. Also, 
repeated assessment data will allow using more advance statistical methodology and thus yield 
more valid results.
Moreover, future psychiatric research should certainly address poly-causation by considering 
multiple genetic and environmental measures. Depression is a common disease, often with an 
adolescent first onset, and with a high prevalence through the entire life span. Elderly cohorts 
studying aging such as the Rotterdam Study are limited in studying first onset, childhood 
exposures, and life-course of depression. Exploring such a retrospective hypothesis within 
these setting is inaccurate and would produce biased results. Therefore, future epidemiological 
research requires prospective designs that start in childhood, at birth or even pregnancy and pre-
conception period.37
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Genetics is a field that has evolved and developed rapidly in the last years and scientists had high 
hopes that genetics will disentangle many mysteries. However, psychiatric genetics faced several 
challenges when studying depression: the definition of depressive phenotypes appeared to be the 
greatest obstacle for the scientists. In the future we will have to agree on concepts and definitions 
of the depressive phenotype and be open for implementing new concepts in psychiatric research 
such as RDoC.84 I believe overcoming the issue of defining depression will help genetic research 
but also the scientific knowledge of depression in general.
Finally, depression is a multifactorial disorder and in order to deeply understand the aetiology 
we need to address gene-environment interactions. Analyses of poly-causation including gene-
environment and environment-environment interactions can help in learning more about causal 
types and mechanisms that are also likely to generate new methods of prevention and therapy.37 
Yet, current studies of gene-environment interactions are flawed due to the lack of power and 
biological understanding.
In conclusion, this thesis uses epidemiologic and genetic tools to explore the associations between 
potential aetiological factors and depression. We have managed to partly fill a few of the many 
gaps in the knowledge of the pathophysiological mechanisms underlying depression and the 
biological markers for depression. Further, I have discussed the clinical importance of the findings 
in this thesis, as well as the methodological challenges I have faced during this work. Most of 
the evidence presented in this thesis will not directly influence clinical practice and the life of 
those suffering depression. However, I believe that this body of research will definitely be a good 
guidance for future research and will help the management of depression.
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SUMMARY
Depression is a complex multifactorial disease, it is the result of an interaction and accumulation of 
various different psychosocial, biological and environmental risk factors. Evidence on the aetiology 
of depression is mixed and important elements are still missing. In this thesis, we attempted to 
fill some of these knowledge gaps by studying the association of several biomarkers, genetic, 
epigenetic, and physical health factors with depression. Here we summarize the main findings 
that have been described in detail in chapters 2 to 5.
Chapter 2 presents two studies exploring the relation between serum extracted biomarkers and 
depression. In Chapter 2.1, we studied the cross-sectional and longitudinal relation between 
vitamin D serum levels and depression. All analyses were controlled for life-style factors, including 
sunlight exposure, socio-demographic factors, and general health factors. Although vitamin D 
deficiency co-occurred with depression, we found no evidence for an effect of vitamin D serum 
on the change in depressive symptoms or the long-term (12 year) occurrence of depression. In 
Chapter 2.2, we explored serum levels of inflammatory biomarkers in relation to depressive 
symptoms with a specific focus on the effect of inflammation on the persistence of depressive 
symptoms. Markers of inflammation, such as higher levels of interleukin-6 and C reactive protein, 
predicted both increase and persistence of depressive symptoms over 5 years. In contrast, markers 
of inflammation were not associated with depressive symptoms cross-sectionally. These results 
suggest that depression does not occur as an acute response to inflammation but rather as a 
reaction to chronic inflammation.
Chapter 3 employed exome-sequencing and exome-chip genotyping methodology to explore 
rare genetic variants that potentially had large effects on the risk of depression. In Chapter 3.1 
we demonstrated that depressive symptoms were associated with missense Asn396Ser mutation 
(rs77960347) located in the endothelial lipase (LIPG) gene in a general population setting. 
Chapter 3.2 identified rare non-synonymous variants located in the NKPD1 gene associated 
with more depressive symptoms in a genetically isolated European population. The LIPG and 
the NKPD1 genes are candidate genes for depression that require further genetic and functional 
investigation.
Chapter 4 presents the largest (N = 11,256) cross-ethnic epigenome-wide association study 
(EWAS) of depressive symptoms. Hypermethylation of cg04987734 (annotated to the CDC42BPB 
gene), cg12325605 (annotated to the ARHGEF3 gene), and cg14023999 (having an intergenic 
position) were all associated with depressive symptoms. The identified genes are involved in 
mechanisms such as axon guidance, nerve growth factor, regulation of serotonin and dopamine 
levels in the brain, and inflammation, yielding new insights into the molecular mechanisms 
potentially underlying the pathophysiology of depression.
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In Chapter 5 we explored the relation between depression and comorbid physical conditions 
such as cognitive decline and myocardial infarction. In Chapter 5.1 we tested whether cognitive 
function declines faster in older adults who had single or multiple depressive episodes than in 
older adults with no depression. We found that persons with multiple episodes of depression 
had a faster cognitive decline over a 12 years’ period than persons with a single or no depressive 
episode. This study suggests that the recurrence of depression, opposed to a single episode, 
contributes to subsequent cognitive decline. Chapter 5.2 aimed to distinguish the physiological 
and psychological impacts from myocardial infarction on depression. Therefore, we explored the 
risk of recognized (RMI) and unrecognized myocardial infarction (UMI) pose for depression. The 
results demonstrated that men with RMI had an increased risk to develop depression, while 
men with UMI were at similar risk to develop depression as persons without MI. However, RMI 
and UMI increased mortality risk similarly compared to those with no MI. We thus concluded 
that both RMI and UMI have evident physiological effects but that the psychological burden of 
experiencing MI contributes to the long-term risk of depression.
Finally, Chapter 6 of this thesis discusses the main findings and elaborates on the main 
methodological limitations of the presented work. In addition, this chapter gives an overview of 
some possible clinical implications and directions for future research.
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SAMENVATTING
Depressie is een complexe, multifactoriële ziekte die ontstaat door interactie tussen, diverse 
psychosociale, biologische en omgevingsfactoren. Hoewel er meer en meer bekend is over 
depressie, is de etiologie van depressie nog altijd onduidelijk. In dit proefschrift probeer ik 
enkele lacunes in kennis over de etiologie van depressie in te vullen door het bestuderen van 
de relatie van depressie met verschillende biomarkers, genetische, epigenetische en fysieke 
gezondheidsfactoren. De belangrijkste onderzoeksbevindingen van dit proefschrift zullen hier 
worden samengevat, een gedetailleerde beschrijving kan gevonden worden in de hoofdstukken 
2 tot en met 5.
Hoofdstuk 2 omvat twee studies die de relatie tussen depressie en serum biomarkers 
beschrijven. In hoofdstuk 2.1 bestudeerden we de cross-sectionele en longitudinale relatie 
tussen de concentratie van vitamin D in serum en depressie. We corrigeerden daarbij voor een 
uitgebreid aantal lifestyle factoren (waaronder blootstelling aan zonlicht), socio-economische en 
demografische factoren, en algemene gezondheidsfactoren. Alhoewel vitamine D deficiëntie 
vaak samen gaat met depressie, vonden we geen bewijs dat de vitamine D concentratie de 
verandering in depressieve symptomen beïnvloedt, noch dat vitamine D de ontwikkeling van 
depressieve episoden op de lange termijn (12 jaar) beïnvloedt. In hoofdstuk 2.2 onderzochten 
we de relatie van verschillende biomarkers voor inflammatie met depressieve symptomen, we 
richtten ons daarbij specifiek op de persistentie van de depressieve symptomen. Biomarkers van 
inflammatie, zoals verhoogde interleukine-6 en C reactieve proteïne waarden, voorspellen zowel 
de toename als de persistentie van depressieve symptomen over een periode van 5 jaar. De 
toename van inflammatoire markers was echter niet gerelateerd aan depressieve symptomen in 
cross-sectionele analyses, wat suggereert dat depressie waarschijnlijk niet een acute reactie is op 
inflammatie, maar een reactie op chronische inflammatie.
In hoofdstuk 3 kijken we met exome sequencing en exoom-chip genotypering naar zeldzame 
genetische variaties, waarvan bekend is dat ze samenhangen met een verhoogd risico op 
depressie. In hoofdstuk 3.1 demonstreerden we dat depressieve symptomen gerelateerd zijn aan 
een missense Asn396Ser mutatie (rs77960347), gelegen in het endothelial lipase (LIPG) gen in 
de algemene bevolking. In hoofdstuk 3.2 identificeren we zeldzame ‘niet-synonieme’ varianten, 
gelegen in het NKPD1 gen. Het NKPD1 gen was geassocieerd met verhoogde depressieve 
symptomen in een genetisch geïsoleerde Europese populatie. Onze resultaten geven aan dat 
zowel het LIPG als het NKPD1 gen mogelijk belangrijke kandidaat genen zijn voor depressie. 
Verder genetisch en functioneel onderzoek zal uit moeten wijzen hoe deze genen depressie 
beïnvloeden. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
286  |  Chapter 7
In hoofdstuk 4 presenteren we de grootste, multiculturele, epigenoom associatiestudie 
(‘EWAS’) van depressieve symptomen (N = 11,256). We identificeerden dat hypermethylatie van 
cg04987734, behorend bij het CDC42BPB gen, cg12325605, behorend bij het ARHGEF3 gen, en 
cg14023999, in een intergenic positie, allen gerelateerd zijn aan depressieve symptomen. Deze 
genen zijn betrokken bij mechanismen zoals axongeleiding, groeifactoren voor zenuwcellen, 
regulatie van serotonine en dopamine in het brein, en ontsteking. Mogelijk duiden deze 
bevindingen op moleculaire mechanismen die de ontwikkeling van depressie onderliggen.
In hoofdstuk 5 onderzochten we de complexe relatie tussen depressie en comorbide fysieke 
factoren zoals cognitie en hartfalen. In hoofdstuk 5.1 bestudeerden we of de cognitie van 
ouderen met één of meerdere depressieve episode sneller achteruit gaat dan ouderen zonder 
een historie van depressieve episoden. Ouderen met meerdere depressieve episoden hadden 
inderdaad een snellere cognitieve achteruitgang over een periode van 12 jaar dan ouderen met 
een historie zonder depressieve episoden of een enkele depressie episode. Dit suggereert dat niet 
een enkele episode, maar de terugkeer van depressieve episoden, een rol speelt in de cognitieve 
achteruitgang in ouderen. Hoofdstuk 5.2 probeert te achterhalen in hoeverre de fysiologische 
dan wel de psychologische gevolgen van een hartinfarct van belang zijn voor het ontwikkelen 
van depressie. Hiervoor onderzochten wij depressie in relatie tot gediagnosticeerde hartinfarcten, 
bekend bij de deelnemer, en zogenaamde ‘stille’ hartinfarcten, onbekend bij de deelnemer. 
Mannen met een gediagnosticeerd hartinfarct hadden een verhoogd risico op het ontwikkelen 
van depressie in vergelijking met mannen zonder hartinfarct. In contrast, mannen met ‘stille’ 
hartinfarcten hadden een vergelijkbaar risico op depressie als mannen zonder hartinfarct. Ter 
vergelijking, het risico op overlijden is verhoogd voor zowel mannen met gediagnosticeerde als 
‘stille’ hartinfarcten ten opzichte van mannen zonder hartinfarct. Zowel gediagnosticeerde als 
‘stille’ hartinfarcten hebben dus nadelige gevolgen voor de fysieke gezondheid, maar alleen de 
psychologische ervaring van een gediagnosticeerd hartinfarct draagt bij aan het ontwikkelen van 
een depressie.
Als laatste worden in hoofdstuk 6 de belangrijkste bevindingen en conclusie van dit proefschrift 
besproken. Daarnaast wordt verder ingegaan op de methodologische beperkingen, de betekenis 
van dit proefschrift voor de klinische praktijk en suggesties voor toekomstig onderzoek op het 
gebied van de etiologie van depressie.
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Research integrity 2014 2.0
Biomedical writing 2015 4.0
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Master of science in Health Sciences, Epidemiology 2012-2013 75
Study Design 2012 4.3
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Oh what a journey this was ! I am awaiting the birth of my son Aaron (who was supposed 
to arrive in this world 4 days ago) and completing this thesis by writing probably the most read 
section: the words of thanks. All of you who know me good enough, you know how important 
family and friends are to me. Private life is and it will be number one on my priority list. Without 
the love and support of the people I am surrounded with, I would have never achieved any of 
what I did today. You can imagine that the list of those who I have to thank will be a very long 
one; but I have to start somewhere. I will do it in an unconventional chronological way not to 
miss someone .
Taking risks and grabbing what life brings was somehow my expertise since I know myself. 
Coming in Rotterdam and doing my PhD training was more of an adventure to me rather than 
living my dreams. To be honest, I have never even dreamt that I will get a Master’s or a PhD 
Degree. Academic career was always a plan B for the old days. Yet, during my clinical work at 
Heliomedika, I realized I might need a change and I might have to try doing something new. I 
needed more knowledge, I simply wanted to study more. Thanks to my dear colleagues Dr. Vani, 
nurse Lile, Natka, and my ex-director and biggest motivator till this day Dr. Slavica; I decided 
to look for opportunities and challenged myself. I applied for Master’s study at the University 
of Erasmus in Rotterdam supported by the ERAWEB grant. Thank you Heliomedika ladies, the 
working experience I had with you and the support you gave me through the whole application 
procedure means a lot to me. You all have a big part in all the decisions I have made then and 
without you, I am not sure I would have discovered myself and what my needs were with such 
an ease.
My application was accepted and I got admitted not only to a Master’s program, but also got an 
opportunity to continue with PhD training. In August 2012, I was here in front of the Erasmus 
MC building yearning for all what this adventure would bring. The start was very difficult but I 
somehow managed it. For that, I would first like to thank the Ullmann Family. Mor, if it was not 
for you, I would have never came to the Netherlands at first. Thank you for that!! You were my 
start here, helping me integrate with the speed of light, supporting me during my beginner’s 
troubles and whenever it was needed. You are the best ex-boyfriend someone can have. Bella 
what can I say, your Dutch Integration expertise helped me go through the last years smoothly. 
Thanks to you, I make the best soup in the world and not even one word of this book would have 
been written if it was not for the laptop I got from you. In short family Ullmann; you are the kick 
off to this PhD adventure, I own one to you.
Prof. Henning Tiemeier was one of the first people I met at Erasmus MC. The first things I learnt 
from him was not to shake in front of people who have a title professor. Therefore, Henning I 
always say if you can choose your mentor than choose for Henning . You are a brilliant scientist 
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and a great teacher but for the most you are so human. Always down to earth, with a beautiful 
harsh German humor, it was a pleasure to have you as a leader in the working environment. I 
really appreciate that you always took in to account my personal circumstances when leading me 
through this PhD trajectory. You had that deep understanding and compassion for both work and 
private life and for that I give you all my credits. We are very different characters but somehow 
we managed working well together. Thank you for everything! I am happy to know you and 
even more happy to say that I have finish my PhD under your supervision. This thesis is a mutual 
product of both; your enthusiasm and stubbornness, and my patience and dedication.
Then, my co-promoter and mentor Najaf Amin. Dear Najaf, you are a role model to me. What 
Henning and I were missing to complete this project, was you. You were our balance and our 
tornado at the same time. Why tornado? I remember when you proposed to work together I 
thought: “Genetics, nooooo way I cannot do this.” So yes your ideas came to me as a tornado. 
But you also had another skill, the skill of reading my mind all the time and you motivated 
me by saying “Don’t worry genetics is not that difficult.” You brought the balance in this PhD 
project. Learning and working with genetic data was not easy at all but with your systematic, 
organized, efficient and friendly way of working, everything became possible. Thank you, you are 
an example of a strong women and we women scientists should all follow your example.
I will never forget the first course I took that first summer with prof. Albert Hofman. Prof. Hofman 
you approved my application and I have learned the basics of epidemiology from you. Thank you 
for that. But Oh g-d during your course, everything was so new to me that I did not understood a 
word of what you were teaching. However, with joint efforts with my ERAWEB-NIHES friends, we 
managed to learn all and pass the Master’s courses easily. Bibi, Dina, Kate, can you remember our 
long hours in the library? It was worth it. We have all managed to accomplish what we came here 
for and even better we have built friendships that will last forever. Thank you girls I am happy that 
these five years brought a lot of professional success but also extended family which you certainly 
are. Ana Maksimovic, Olja, Nasos, Gustavo, Ana Vitezova, and Janko you were my partners in 
crime from the very beginning. Owing to your presence, I did not forgot to smile, party and have 
fun during the first year of this PhD trajectory. Hope to meet you all once more and revive the 
memories we have built together.
During this PhD story, I was part of a great group: the PSYCH-EPI group. I had an opportunity to 
work with great colleagues, some of which I still work with even today and some will be marked 
as great friends whom I meet on regular basis. Annemarie you are such a friend! I have no words 
to explain it, but I can say you crashed my stereotype for Dutch friendship . I love to talk with 
you and even more to gossip with you. I am even more glad that you are coming back to the NL 
so we can continue seeing each other again regularly. Also, I have to mention that thanks to you 
and Tom I have nice Dutch summary of this thesis. Dank je wel jongens. 
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Lisette, even though I have lost you somewhere on the road of motherhood,  I can never forget 
our lunch moments in the park and the way you stress out every time I kiss you and hug you. Nese, 
my soulmate sister, you are the mini older me. Miss you a lot curly. Деси, сепак да останеме 
достоинствени на мајичниот Македонски јазик . Ти и Кате сте ми моја Македонска 
банда.  кога на балканот ќе кажеме крвта не  вода, не  за џабе кажано. Вие ми 
бевте најголема подршка и луѓе од доверба, другарки за се и сешто. Маките не споиа 
засекогаш . Ве обожавам секоја на свој начин најискрено, и ви благодарам за се.
Ayesha my paranymph, what are you “women”? Are you my group colleague, my office-mate, 
my soulmate, my pregnancy/motherhood trouble partner, my friend, my shrink? I would say you 
are all of that. Henning was testing if a Jew and a Muslim can share an office, but he did not 
know he matched the only two strong crazy women in this world that can actually adore and love 
each other for real. Thank you Henning you have connected me with someone I know I will have 
near me for a life-time! Dear Ayesha two years ago, I was supporting you during this moment of 
glory and now there you are supporting me in the same. But that is what we do for each other. 
No matter what or where we are, we will always be there one for another. Thank you my princess 
Jasmine, you know how much I love you and appreciate you and sorry that I am so useless at the 
moment because of living so far from you.
The colleagues’ circle is not small and there are some more people I have to thank. Saira, Heidi, 
Jelena, Marina, Akhghar, Mayara, Tom, Andrea, Else, Raluca, Nina, Ank, Rosanne, Jolien S, 
Irene, Dragan, Gogo, Ryan, Alex, Laura, Maartje B, Chantal, Roza, and Ingrid some of you I 
have worked with, some of you were my office-mates, some of you are just friends. What we 
have shared was Henning as a mentor, and thanks to all of you for making this period easier for 
me, since we have also shared our struggles that we faced during our scientific journeys. Fadila 
pa šta smo to nas dve preživele ? Kafa sa tobom mi je najdrža. Gde si sad našla da ideš tako 
daleko?! Nedostaješ jako jako. Frank, Vincent, Hieab, Hazel, Marileen, Rens, Renee, Natalie T., 
Trudy, Taulant, Olta, Jelena P., Clodian, Rene Sch., Emina, Jana N, Kozeta, Maarten B, Fjorda, and 
Sigi, sharing the elevator and the space with you which was a pleasure. Even better were all the 
chit-chat moments and all the taarten we shared these years.
This thesis is a product of joint work of many amazing people I have worked with. Prof. Oscar 
Franco, prof. Arfan Ikram, prof. Albert Hofman, prof. Cornelia van Duijn, prof. Wite Hoogendijk, 
prof. Norbert Schmitz, prof Miriam Fornage and the epigenetic group within CHARGE Consortium, 
Abbas, Maarten Leening, Wolters Frank, Carvalho Livia, Argita Zallili, Raymond Noordam, Nikkie 
Aarts, thank you for collaborating with me, I have learned a lot from all of you. Finally, I would 
like to thank Ivana Nedeljkovic. Ivana with joint forces we have finished my biggest and dearest 
project of this thesis. Thank you very much Ivana. I really appreciate your work, and want to let 
you know that you are very dear to me.
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All these years, a large number of people helped me grow in this process in a different way. Most 
of them were coming in my life and going out of my life; a real dynamic cohort. However, there is 
a cluster of people that were always by my side and I know they will stay that way. In last part of 
this word of thanks, I would like to especially thank THEM; my family and my friends.
Ana Tasevska, Dafina, Marija, Ive, Rushka, you are certainly the footprint of my Skopje life. But, 
even though we are separated physically (viva la Viber) you are still a big part of my daily life. 
I miss you always. Chris bedankt for de cover and the funny discussions that we have. Helena, 
Marlies, Rachel you are my only friends in Alphen thank you for all the nice coffee/tea moments.
My Jewish friends: Lela, Dina, Mina, Dunja, Mavro, Sale, Urosh, Vase, Jana Nichota, Ruben, Liza, 
Andrea Steiner, Beca, Gabor, Pidja, Bojana, Sandra, Poli, Deborah, and Martin Levi; writing your 
names reminds me that I am the richest person on this world. Some of you I know since I am 10, 
that is long . We all live in different parts of the world. Yet, our Jewish life connected us and 
made us who we all are today. You have shaped a big part of me and I am who I am also because 
of all of you. 
Лелка ти си ми другарица par-excellence! Толку сме исти, но спак толку различни, 
фала ти за сите долгочасовни разговори и што си дел од мојот живот. Дина и Мина 
другарице најдраже, па ви сте самном данас . Нама је заједно увек тако добро. Нема 
тих речи које могу описати колко сам захвална да сте данас самном и што сте тако 
добре праве другарице. Јако сам поносна што вас имам.
A special word in English for my second paranymph, Dina. In 1996 I met you in Szarvas, Hungary, 
during a camp. You were from Serbia, me from Macedonia, both from freshly separated 
Yugoslavia. I am sure our parents did not have a clue what a big favor they did to us by sending us 
to that camp. Here we are now, in 2018 and still together, sharing the best and the worst in our 
lives. Living the past, the present and the future. Dina dear, I don’t need you to be my paranymph 
to give you special place in my life, because you are so special to me. No one else in this world can 
be proud of such a friendship. Nothing can separate us because our lives are deeply connected. 
Thank you so much for being my paranymph and supporting me in this time of my life as you 
supported me in everything else so far (we should send JDC a copy of this book as a proof that 
their projects are not failures : Lela I will send you a second copy highlighting these sentences 
and so that you can present it to the board of directors LoL). Дики љубим те!
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My family Dedo Pero, Baba Vera, Dedo Ljupcho, Baba Tinche, Teta Lide, Tetin, Tea, Martin, Family 
Stojanovi, Family Shumkovski, Family Gligorovi, you are my roots and I am grateful that I have 
the opportunity to grow with so much love and as part of such a huge family. Дедо Перо 
биди горд на Оличка и сите твои внуци, ние сме твојата иднина и таа е светла. Баба 
Тинче ми фалиш најмногу и нема ден да не помислам на тебе. Хуморот и желбата за 
патувања ги наследив од тебе а тие нешта го чинат животот пресладок. Дедо Љупчо 
ти си непреболен, ама ете ја имам таа чест да те гледам повторно секој ден во очите 
на Арон. Баба Вера, фала ти на се а највеќе на тврдоглавоста што ја наследив од 
тебе. Да не беше таа немаше да постигнам волку многу. Тети, ти благодарам на сите 
моменти поминати со мене, знам дека ми се радуваш многу и ми е зал што не можеш 
да присуствуваш на одбраната на оваа теза. Бибе ти си ми единствена во Холандија и 
многу сум благодарна што те имам.
Mijn schoonfamilie: Opa Gerard, Oma Riek, Michael, Mariska, Sam, Nick en Jill Story. Ik ben trots 
dat ik een Story ben en dat ik deel mag uitmaken van jullie familie. Jullie zijn een grote steun in 
mijn dagelijks leven. Dank je wel voor alles. Opa, dank voor je onnavolgbare humor, dank je dat 
je zoveel van ons houdt. Oma dank je wel voor alle zorgen voor Ruth en alle hulp die je ons hebt 
geboden.
*
My Sister Eli. The biggest pain is that I am so far from you. Whatever I am busy with, I am 
constantly thinking: wish Eli would have been here. As I write this, I have tears in my eyes. Sorry 
if I was bothering you with my 100 daily calls. It is simply because I miss you so much. Thank you 
for being my sister, thank you for believing in me and always supporting me. Kufi thank you for 
taking care for my sister so much. Taking care for her means the same as if you have taken care 
for me. I am so sorry you are both not here for this day but it is for a good cause, awaiting another 
member of the Jovanov family.
Mama and Tato, I can write a whole book for you and it would still not be enough. You should 
be proud. Henning told me that he performed a research once, in which he was studying the 
offspring of couples that married in early age. The results of this research work were that no one 
that married at the age of 17 stayed happily married 33 years after with children that became 
doctors, master’s in science and certainly not PhD. Conclusion, you are an exception. Thank you 
for all that you have done and you still do for me. Thank you for teaching me to be human, 
to be a good friend, wife, doctor, and most importantly a good mother! I am a mirror of your 
wishes, expectations, and ambitions. И малку на македонски; ви се извинувам што сум 
неподнослива кога ми е тешко. Ве сакам најмногу и сигурна сум дека не постојат 
други родители како вас!
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And who shell I be grateful the most for all? My husband Egbert, of course.  No matter how 
much I think, I just do not get to the right words to thank you my love. You are the biggest 
surprise in my life. I know that If someone could have told me before I met you, that I will be so 
loved by a man I would not have believed it. Our story deserves another book, and this thesis is 
just a small chapter of it. Schat, if it was not you there would have certainly not be a PhD either. 
That unconditional love we share makes us both so strong that we can take every challenge and 
solve every problem. That small paradise we live in, our home, is reason enough for me to move 
mountains. We have mastered depression for sure. Ik hou van je! I believe in karma and I am sure 
I must have done something very good in my life previously to get the opportunity to share the 
rest of my life with you. Dank je wel!
Finally, this is the end of my PhD fairytale. I must admit it took me 4 months to write these 
words of thanks . It started when I was still pregnant with Aaron and here I am today 6th 
February,2018, and still writing it. It’s time to finish it for good!
My life is an adventure that I am super proud of and happy to be writing about it. On 4th April I 
will become a PhD most probably but to be honest the title I am the most happy with is being a 
MOTHER. During this period, I was pregnant two times and I have become a mother of two kids. I 
got Ruth in the second year of my PhD and Aaron 4 months ago. They have marked this period by 
large. Therefore, I must write a few words to my children: Dear Ruth and Aaron, you are now so 
little and you can’t read yet (Ruth knows the letter Н in Macedoninan only), but in a few years you 
can find these words and be even more proud of your mother. You are the best thing I have ever 
created. I am so proud of both of you. You are beautiful, sweet, funny, adorable and the biggest 
source of inspiration for me. You suck my energy out every day. I must admit that taking care of 
you is not easy. But those smiles and kisses gives me tremendous power to go further every day. 
Thank you for making my live meaningful and so happy. Ве сака мама!
Olivera Story Jovanova; 6th February 2018; Alphen
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